

360iResearch

Dissolution Equipment Market

Global Forecast 2026-2032

MRR-351BAD503981 | October 2026

Great Place To Work. Certified FEB 2026-FEB 2027 INDIA

Table of Contents

1. Preface 7
   1.1. Objectives of the Study 7
   1.2. Market Definition 7
   1.3. Market Segmentation & Coverage 8
   1.4. Years Considered for the Study 10
   1.5. Currency Considered for the Study 11
   1.6. Language Considered for the Study 11
   1.7. Key Stakeholders 11
2. Research Methodology 13
   2.1. Introduction 13
   2.2. Research Design 13
      2.2.1. Primary Research 14
      2.2.2. Secondary Research 14
   2.3. Research Framework 15
      2.3.1. Qualitative Analysis 15
      2.3.2. Quantitative Analysis 16
   2.4. Market Size Estimation 16
      2.4.1. Top-Down Approach 16
      2.4.2. Bottom-Up Approach 16
   2.5. Data Triangulation 17
   2.6. Research Outcomes 17
   2.7. Research Assumptions 18
   2.8. Research Limitations 18
3. Executive Summary 19
   3.1. Introduction 19
   3.2. CXO Perspective 19
   3.3. New Revenue Opportunities 19
   3.4. Next-Generation Business Models 20
   3.5. Industry Roadmap 20
4. Market Overview 22
   4.1. Introduction 22
   4.2. Key Growth Contribution 23
   4.3. Industry Ecosystem & Value Chain Analysis 26
      4.3.1. Supply-Side Analysis 27
      4.3.2. Demand-Side Analysis 27
      4.3.3. Stakeholder Analysis 28
   4.4. Market Dynamics 28
      4.4.1. Key Drivers 28
         4.4.1.1. Quality-system continuity sustains equipment relevance 28
         4.4.1.2. Eligible equivalence programs create application-specific purchasing motives 29
         4.4.1.3. Automation demand combines staff attention with record accountability 29

4.4.2. Key Restraints 29
4.4.2.1. Capital authorization can lag laboratory requirements 29
4.4.2.2. Application-specific acceptance limits broad substitution 29
4.4.2.3. External laboratory access can defer ownership 30
4.4.3. Key Opportunities 30
4.4.3.1. Compatible additions for accepted installed equipment 30
4.4.3.2. Automation tied to an approved workload 30
4.4.3.3. Assignment-specific specialty equipment packages 30
4.4.3.4. Equipment access with accountable destination support 30
4.4.4. Key Challenges 31
4.4.4.1. Computerized acceptance requires lifecycle accountability 31
4.4.4.2. Channel presence must become enforceable local fulfillment 31
4.4.4.3. Product withdrawal complicates maintenance and replacement timing 31
4.5. Porter's Five Forces Analysis 31
4.6. PESTLE Analysis 32
4.7. Market Outlook 33
4.7.1. Near-Term Market Outlook (0-2 Years) 33
4.7.2. Medium-Term Market Outlook (3-5 Years) 34
4.7.3. Long-Term Market Outlook (5-10 Years) 34
4.8. Go-to-Market Strategy 35
5. Market Insights 36
5.1. Consumer Insights & End-User Perspective 36
5.2. Consumer Experience Benchmarking 36
5.3. Opportunity Mapping 37
5.4. Distribution Channel Analysis 38
5.5. Pricing Trend Analysis 38
5.6. Regulatory Compliance & Standards Framework 39
5.7. ESG & Sustainability Analysis 40
5.8. Disruption & Risk Scenarios 40
5.9. Return on Investment & Cost-Benefit Analysis 41
6. Cumulative Impact of Artificial Intelligence 2026 43
7. Dissolution Equipment Market, by Product Type 44
7.1. Dissolution Test Systems 48
7.2. Accessories, Consumables, and Replacement Parts 51
7.3. Media-Handling Equipment 54
7.4. Sample-Handling Equipment 57
7.5. Analytical Detection Modules 60
7.6. Mechanical Qualification Equipment 63
7.7. Vessel-Cleaning Equipment 66
7.8. Visual Surveillance Equipment 69
8. Dissolution Equipment Market, by Apparatus Platform 73
8.1. Paddle Apparatus 77
8.2. Basket Apparatus 80
8.3. Flow-Through Cell Apparatus 83

8.4. Reciprocating Cylinder Apparatus....86
8.5. Stirred-Vial Apparatus....89
8.6. Membrane-Separated Cell Apparatus....92
8.7. Reciprocating Holder Apparatus....95
8.8. Paddle Over Disk Apparatus....98
8.9. Rotating Cylinder Apparatus....101
8.10. Rotating-Disk Apparatus....104
8.11. Mechanical Chewing Apparatus....107
8.12. Stationary-Disk Apparatus....110
8.13. Agitated-Bottle Apparatus....113
9. Dissolution Equipment Market, by Analytical Detection....117
9.1. No Integrated Detection....119
9.2. Direct UV-Vis Detection....122
9.2.1. External-Cell UV-Vis Spectrophotometry....125
9.2.2. In Situ Fiber-Optic UV-Vis Spectrophotometry....128
9.2.3. UV-Vis Dissolution Imaging....131
9.3. Liquid Chromatography....134
10. Dissolution Equipment Market, by Testing Purpose....138
10.1. Batch Quality Control and Stability Testing....141
10.2. Research and Development....144
10.3. Regulatory Equivalence and Change Assessment....147
10.4. Education and Training....150
10.5. Post-Market Quality Surveillance....153
11. Dissolution Equipment Market, by End User....157
11.1. Pharmaceutical Product Companies....160
11.2. Contract Research and Testing Organizations....163
11.3. Pharmaceutical Ingredient Companies....166
11.4. Academic and Noncommercial Research Institutions....169
11.5. Dietary Supplement Companies....172
11.6. Public Medicines-Control Laboratories....175
12. Dissolution Equipment Market, by Automation Level....179
12.1. Semi-Automated....181
12.2. Fully Automated....184
12.3. Manual....187
13. Dissolution Equipment Market, by Sales Channel....191
13.1. Direct Sales....193
13.2. Indirect Sales....196
14. Dissolution Equipment Market, by Tested Product....200
14.1. Pharmaceutical Dosage Forms....202
14.1.1. Oral Dosage Forms....206
14.1.2. Parenteral Dosage Forms....209
14.1.3. Transdermal Systems....212
14.1.4. Topical & Mucosal Dosage Forms....215

14.1.5. Inhalation Dosage Forms 218
14.2. Drug Substances & Excipients 221
14.2.1. Drug Substances 224
14.2.2. Excipients 227
14.3. Dietary Supplements 230
15. Dissolution Equipment Market, by Region 234
15.1. Asia-Pacific 237
15.2. North America 244
15.3. Europe 250
15.4. Latin America 258
15.5. Middle East 264
15.6. Africa 271
16. Dissolution Equipment Market, by Group 277
16.1. NATO 280
16.2. G7 287
16.3. BRICS 294
16.4. European Union 300
16.5. ASEAN 309
16.6. GCC 315
17. Dissolution Equipment Market, by Country 321
17.1. United States 326
17.2. China 332
17.3. India 337
17.4. Germany 342
17.5. Japan 347
17.6. France 352
17.7. Italy 357
17.8. South Korea 362
17.9. Canada 367
17.10. United Kingdom 372
17.11. Mexico 378
17.12. Spain 383
17.13. Russia 388
17.14. Brazil 393
17.15. Australia 398
18. Competitive Landscape 404
18.1. Market Share Analysis, 2025 404
18.2. Market Concentration Analysis, 2025 406
18.3. Recent Developments & Impact Analysis, 2025 408
18.4. Product Portfolio Analysis, 2025 408
18.5. Benchmarking Analysis, 2025 410
19. Company Profiles 414

19.1. Agilent Technologies Inc. 414
19.2. SOTAX AG....414
19.3. Distek, Inc....415
19.4. ERWEKA GmbH....415
19.5. Electrolab India Pvt. Ltd. 416
19.6. Tianda Tianfa Technology Co., Ltd.....416
19.7. Pion Inc....417
19.8. Merel Instruments 417
19.9. Quality Lab Accessories, LLC 418
19.10. Toyama Sangyo Co., Ltd. 418
19.11. SpectraLab Scientific Inc....419
19.12. QUIMIS Aparelhos Científicos 419
19.13. Omicron Research Limited....420
20. Companies Covered 421
21. Key Experts....430
22. Sources & Evidence 436

1. Preface

1.1. Objectives of the Study

- Which suppliers have documented commercial offerings in the included Dissolution Equipment categories, and how do complete systems differ commercially from separately supplied modules, supporting equipment, accessories, consumables, and replacement parts?
- What qualification documentation, purchasing conditions, and support commitments influence equipment selection by the included end users for their specified testing purposes?
- Which documented compatibility requirements, accessory relationships, and service dependencies affect a buyer's ability to retain, extend, or switch an equipment configuration?
- How do Direct Sales and Indirect Sales arrangements affect commercial access, responsibility for customer support, replacement-part provision, and the verification of local distribution rights?
- Under what buyer-specific conditions do Manual, Semi-Automated, and Fully Automated offerings provide a defensible purchasing choice, considering organizational fit, integration responsibilities, and continuing support?
- How do Testing Purpose, End User, and Tested Product alter equipment requirements and commercial comparisons without treating different uses of the same equipment as separate purchases?
- Which evidenced portfolio capabilities, licensing or ownership relationships, and geographic access conditions should inform supplier comparison, portfolio development, and potential commercial partnerships?

1.2. Market Definition

The Global Dissolution Equipment market comprises the commercial supply of Dissolution Test Systems; Sample-Handling Equipment; Analytical Detection Modules; Media-Handling Equipment; Vessel-Cleaning Equipment; Mechanical Qualification Equipment; Visual Surveillance Equipment; and Accessories, Consumables, and Replacement Parts. Complete systems and separately supplied equipment categories are included within the same study boundary.

The equipment is studied across the accepted apparatus, detection, automation, and application categories, including its relationship to Pharmaceutical Dosage Forms, Drug Substances & Excipients, and Dietary Supplements. Buyers include Pharmaceutical Product Companies, Pharmaceutical Ingredient Companies, Dietary Supplement Companies, Contract Research and Testing Organizations, Academic and Noncommercial Research Institutions, and Public Medicines-Control Laboratories. Coverage is Global; a supplier's participation or access in one jurisdiction does not establish equivalent participation elsewhere.

The commercial subject is the equipment offering, not the medicine, ingredient, supplement, or analytical result it supports. Upstream materials and downstream research, manufacturing, and testing activities provide value-chain context. A supplier's participation in those adjacent activities does not bring every product or service it offers into the Dissolution Equipment market.

1.3. Market Segmentation & Coverage

Product Type distinguishes the commercial offering: Dissolution Test Systems; Sample-Handling Equipment; Analytical Detection Modules; Media-Handling Equipment; Vessel-Cleaning Equipment; Mechanical Qualification Equipment; Visual Surveillance Equipment; and Accessories, Consumables, and Replacement Parts. This axis retains both complete systems and separately supplied supporting categories while keeping their commercial packaging distinguishable.

Apparatus Platform covers Basket Apparatus, Paddle Apparatus, Reciprocating Cylinder Apparatus, Flow-Through Cell Apparatus, Paddle Over Disk Apparatus, Rotating Cylinder Apparatus, Reciprocating Holder Apparatus, Rotating-Disk Apparatus, Stationary-Disk Apparatus, Stirred-Vial Apparatus, Membrane-Separated Cell Apparatus, Agitated-Bottle Apparatus, and Mechanical Chewing Apparatus. These are included comparison categories, not a statement that the platforms are interchangeable or share identical purchasing requirements.

Analytical Detection distinguishes Direct UV-Vis Detection, Liquid Chromatography, and No Integrated Detection. Direct UV-Vis Detection includes External-Cell UV-Vis Spectrophotometry, In Situ Fiber-Optic UV-Vis Spectrophotometry, and UV-Vis Dissolution Imaging. The axis describes the detection relationship without assuming that equipment without integrated detection falls outside the study.

Testing Purpose covers Research and Development; Batch Quality Control and Stability Testing; Regulatory Equivalence and Change Assessment; Post-Market Quality Surveillance; and Education and Training. It frames the purchasing purpose against which an offering should be compared rather than prescribing a testing procedure.

End User covers Pharmaceutical Product Companies, Pharmaceutical Ingredient Companies, Dietary Supplement Companies, Contract Research and Testing Organizations, Academic and Noncommercial Research Institutions, and Public Medicines-Control Laboratories. The axis identifies the purchasing organization rather than the product being evaluated or the laboratory service supplied to another customer.

Automation Level comprises Manual, Semi-Automated, and Fully Automated offerings. Sales Channel distinguishes Direct Sales and Indirect Sales. These axes support separate questions about configuration choice and the commercial route to the buyer; neither establishes supplier preference, customer acceptance, or local support by itself.

Tested Product includes Pharmaceutical Dosage Forms, comprising Oral Dosage Forms, Transdermal Systems, Parenteral Dosage Forms, Inhalation Dosage Forms, and Topical & Mucosal Dosage Forms; Drug Substances & Excipients, comprising Drug Substances and

Excipients; and Dietary Supplements. Each category is included as an equipment application context, not as an additional product market to combine with equipment activity.

The root axes are independent analytical lenses on the same commercial market. A single offering may be described by several axes, so their categories must not be treated as additive opportunities. Category inclusion establishes coverage, while supplier capability, application suitability, and commercial access remain separate evidence questions.

Table 1. Global Dissolution Equipment Market Segmentation & Coverage

Segmentation	Coverage
Analytical Detection	• No Integrated Detection • Direct UV-Vis Detection o External-Cell UV-Vis Spectrophotometry o In Situ Fiber-Optic UV-Vis Spectrophotometry o UV-Vis Dissolution Imaging • Liquid Chromatography
Apparatus Platform	• Paddle Apparatus • Basket Apparatus • Flow-Through Cell Apparatus • Reciprocating Cylinder Apparatus • Stirred-Vial Apparatus • Membrane-Separated Cell Apparatus • Reciprocating Holder Apparatus • Paddle Over Disk Apparatus • Rotating Cylinder Apparatus • Rotating-Disk Apparatus • Mechanical Chewing Apparatus • Stationary-Disk Apparatus • Agitated-Bottle Apparatus
Automation Level	• Semi-Automated • Fully Automated • Manual
End User	• Pharmaceutical Product Companies • Contract Research and Testing Organizations • Pharmaceutical Ingredient Companies • Academic and Noncommercial Research Institutions • Dietary Supplement Companies • Public Medicines-Control Laboratories
Product Type	• Dissolution Test Systems • Accessories, Consumables, and Replacement Parts • Media-Handling Equipment • Sample-Handling Equipment • Analytical Detection Modules • Mechanical Qualification Equipment • Vessel-Cleaning Equipment • Visual Surveillance Equipment

Table 1 - continued


Segmentation	Coverage
Sales Channel	• Direct Sales • Indirect Sales
Tested Product	• Pharmaceutical Dosage Forms o Oral Dosage Forms o Parenteral Dosage Forms o Transdermal Systems o Topical & Mucosal Dosage Forms o Inhalation Dosage Forms • Drug Substances & Excipients o Drug Substances o Excipients • Dietary Supplements
Testing Purpose	• Batch Quality Control and Stability Testing • Research and Development • Regulatory Equivalence and Change Assessment • Education and Training • Post-Market Quality Surveillance

Evidence: [E639], [E640], [E860], [E861], [E87], [E82], [E84], [E85], [E99], [E106], [E102], [E103], [E98], [E93], [E95], [E97], [E63], [E64], [E338], [E780], [E779], [E778], [E777], [E776], [E614], [E617], [E618], [E615], [E619], [E616], [E642], [E645], [E643], [E644], [E647], [E646], [E648], [E641], [E905], [E907], [E908], [E906], [E90], [E88], [E91], [E73], [E72], [E71], [E744], [E741], [E742], [E723], [E731], [E749], [E750], [E840], [E839], [E113], [E638], [E1010], [E1000], [E1009], [E1008], [E1014], [E891], [E892], [E903], [E902], [E1053], [E1052], [E344], [E341], [E342], [E343], [E606], [E326], [E28], [E27], [E672], [E670], [E674], [E676], [E675], [E677], [E35], [E34], [E36], [E1127], [E1129], [E424], [E423], [E323], [E949], [E409], [E407], [E405], [E421], [E937], [E938], [E848], [E845], [E693], [E695], [E701], [E702], [E203], [E206], [E204], [E205], [E274], [E79], [E78], [E77], [E69], [E67], [E624], [E625], [E111], [E109] Taxonomy evidence: Segmentation

1.4. Years Considered for the Study

The study uses 2024 as the historical year, 2025 as the base year, and 2026 as the estimated year. The forecast horizon extends through 2032. These period roles remain distinct when interpreting historical observations and forward-looking commercial conditions.

Figure 1. Global Dissolution Equipment Market, Years Considered for the Study



1.5. Currency Considered for the Study

The reporting currency is the U.S. dollar (USD), and market values are expressed on an absolute-value basis.

1.6. Language Considered for the Study

The report is published in American English.

1.7. Key Stakeholders

- Dissolution Test Systems manufacturers and equipment integrators: portfolio configuration, compatibility commitments, commercial differentiation, and responsibility for customer support.
- Suppliers of supporting equipment, Analytical Detection Modules, Accessories, Consumables, and Replacement Parts: access to system relationships, independent distribution options, and the scope of compatibility and continuing-supply commitments.
- Pharmaceutical Product Companies and Pharmaceutical Ingredient Companies: equipment qualification, configuration selection, supplier continuity, and the implications of retaining or changing a supplier.
- Dietary Supplement Companies: alignment of equipment offerings, purchasing requirements, and support arrangements with the relevant application.

- Contract Research and Testing Organizations: alignment of equipment capability and support with customer-facing service commitments and purchasing priorities.
- Academic and Noncommercial Research Institutions and Public Medicines-Control Laboratories: equipment procurement, application coverage, training needs, and continuity of institutional support.
- Distributors and other commercial intermediaries: the extent of distribution rights, customer coverage, supplier authorization, and responsibility for delivery and after-sales support.
- Regulatory, pharmacopeial, and standards institutions: the scope and applicability of requirements relevant to equipment purchasing and qualification, without treating institutional requirements as supplier endorsements.
- Investors and strategic acquirers: diligence on documented offerings, commercial rights, buyer access, channel dependence, and the continuity of equipment-related business relationships.

2. Research Methodology

2.1. Introduction

The study frames Global Dissolution Equipment as a commercial market connecting equipment offerings, institutional buyers, and routes to market. Its approach separates evidence about what a business offers or is entitled to supply from interpretation of buyer incentives, access conditions, and competitive choices.


The accepted hierarchy provides the scope for comparison across systems, supporting equipment, applications, and customers. Commercial evidence analysis addresses participation and purchasing conditions; it does not prescribe laboratory procedures or infer an offering's suitability from its category name alone.

2.2. Research Design

The design organizes commercial questions around the offering, the buyer, the route to market, and the conditions of access. Coverage includes complete Dissolution Test Systems and the separately supplied equipment, accessories, consumables, and replacement parts specified in the Product Type hierarchy. Application and end-user categories provide purchasing context without changing the equipment boundary.

Each business claim requires evidence appropriate to its meaning. Advertised capability, commercial availability, jurisdictional access, procurement eligibility, and buyer adoption are distinct propositions. The design therefore keeps announced, historical, and commercially offered activity distinguishable and limits each conclusion to the period, offering, and geography supported by its underlying record.

Figure 2. Global Dissolution Equipment Market, Research Design



2.2.1. Primary Research

The analyst team conducted primary research as a qualitative challenge layer for market definition, segmentation, demand conditions, adoption barriers, and competitive interpretation. This work tested analytical assumptions and sharpened explanations of market mechanisms without serving as standalone support for numerical estimates.

The qualitative challenge layer is evaluated alongside secondary evidence within the accepted market scope. It informs conditional market explanations and hypotheses for subsequent quantitative analysis. Numerical estimates require their own supporting evidence, and a forecast derived from a qualitative assumption does not independently validate that assumption. Final interpretation must reconcile the qualitative findings with the completed quantitative results.

2.2.2. Secondary Research

The secondary-evidence design assigns official product portfolios and catalogs to advertised offering identity and scope; company filings and official business disclosures to ownership, licensing, and distribution relationships; and public purchasing documents to buyer-specific procurement conditions. Regulatory, pharmacopeial, and standards records can clarify the applicability of a requirement within their stated authority and jurisdiction.


These evidence roles are not interchangeable. An equipment description does not establish buyer acceptance, a standard does not prove a particular supplier's compliance, and a distribution announcement does not alone demonstrate continuing local support. Commercial interpretation should retain the effective period, product coverage, and limits of each record rather than extending a narrow statement across the entire market.

2.3. Research Framework

The definition establishes eligible equipment activity; the taxonomy organizes its commercial attributes; and the supplier universe requires evidence of participation in those offerings. Measurement must retain the same offering and geographic boundaries, while competitive interpretation asks which documented capabilities and relationships matter to a specified buyer.

The framework connects those layers through commercial questions. A claim about switching should identify the relevant configuration or supplier relationship; a claim about access should identify the applicable purchasing or jurisdictional condition; and a proposed strategic choice should state its prerequisites and alternatives. A category label is a starting point for comparison, not evidence of equivalent capability or attractiveness.

Figure 3. Global Dissolution Equipment Market, Research Framework



2.3.1. Qualitative Analysis

Qualitative analysis examines the purchasing significance of equipment configuration, compatibility, qualification documentation, service commitments, replacement-part access, and channel responsibilities. The relevant question is how a documented condition affects a particular buyer's ability to select, retain, or replace an offering, rather than whether the supplier advertises a broad portfolio.

Comparisons retain the buyer's Testing Purpose and Tested Product context. Automation is examined as a purchasing choice: the analysis asks whether its proposed organizational benefits justify integration responsibilities and supplier dependence. Neither automation nor a particular Apparatus Platform is assumed to be preferable across all end users.

2.3.2. Quantitative Analysis

Quantitative interpretation is framed by absolute USD reporting and the distinction between the historical, base, estimated, and forecast periods. Evidence supporting a numerical statement must identify the relevant equipment activity, period, and geographic scope; a common currency alone does not make differently bounded observations comparable.

The segmentation axes describe different attributes of commercial activity. Product Type, Apparatus Platform, Analytical Detection, Testing Purpose, End User, Automation Level, Sales Channel, and Tested Product must not be treated as independent totals to combine. Expert participation, portfolio breadth, and activity in a customer industry do not independently substantiate a numerical equipment-market conclusion.

2.4. Market Size Estimation

Market-size estimation is bounded by Global Dissolution Equipment and the included Product Type hierarchy. Equipment systems and separately supplied equipment categories remain within the study, while the pharmaceutical products, ingredients, dietary supplements, and laboratory services they support are adjacent activities rather than interchangeable market measures.

The analytical role of estimation is to express that defined commercial activity consistently, not to substitute a broader industry measure for equipment-specific evidence. Commercial packaging and overlapping classifications require explicit comparison boundaries. Assumptions about those relationships must remain distinguishable from observed business facts and must not acquire evidentiary authority merely through calculation.

2.4.1. Top-Down Approach

A top-down perspective has a boundary-checking role: it assesses whether a proposed equipment perimeter is consistent with the scope of broader business disclosures. An aggregate covering general laboratory instruments, pharmaceutical operations, or testing services cannot be treated as equivalent to Dissolution Equipment without a documented separation of the included activity.

Broader customer-industry evidence may provide commercial context, but it does not independently establish equipment demand. Any top-down interpretation must preserve the Global boundary, the relevant period, and the distinction between equipment offerings and adjacent products or services.

2.4.2. Bottom-Up Approach

A bottom-up perspective has an offering-identification role: it organizes participating businesses and their evidenced offerings within the Dissolution Equipment hierarchy.

Presence in pharmaceuticals, analytical instrumentation, or laboratory services is not sufficient by itself to establish participation in an included equipment category.

Any aggregation requires explicit treatment of integrated systems, separately supplied modules, accessories, and replacement parts. Relationships among manufacturers, brand owners, and intermediaries must also be understood before combining business evidence. These requirements guard against treating the same commercial activity as distinct merely because it appears in several portfolios or routes to market.

2.5. Data Triangulation

Triangulation is intended to compare evidence addressing the same commercial proposition within compatible offering, geographic, and period boundaries. Supplier materials, applicable official requirements, and buyer purchasing conditions answer different questions; their agreement should not be presumed merely because they refer to dissolution equipment.

Differences in configuration, commercial packaging, channel role, or effective period should be separated from substantive disagreement. An unresolved difference limits the affected conclusion rather than justifying an unsupported compromise. The qualitative challenge layer can question an interpretation, but numerical conclusions require their own support.

Figure 4. Global Dissolution Equipment Market, Data Triangulation



2.6. Research Outcomes

The study is intended to support decisions about Dissolution Equipment portfolio coverage, supplier comparison, buyer qualification, distribution arrangements, and commercial support.

Its findings should distinguish an evidenced offering or business relationship from an interpretation of customer incentives, switching constraints, or competitive positioning.

Decision support should identify the actor affected, the available commercial choices, the prerequisites for each choice, and the conditions that could change the conclusion. Inclusion in an apparatus, application, or automation category is not itself a recommendation to enter that category or select a particular supplier.

2.7. Research Assumptions

- The segmentation axes classify different aspects of the same equipment activity; interpretation assumes that their categories are not additional pools of business to add together.
- Integrated systems and separately supplied equipment remain in scope. Comparability requires the commercial package to be identified before evidence about systems, modules, accessories, and replacement parts is combined.
- Testing Purpose and Tested Product describe equipment applications, not separate purchases by default. Use across several applications does not by itself establish additional commercial demand.
- Manual, Semi-Automated, and Fully Automated offerings are assessed against the relevant buyer's requirements; no automation category is assumed to be commercially or economically superior.

2.8. Research Limitations

- A Dissolution Equipment portfolio description establishes advertised capabilities within its stated scope, not buyer acceptance, installed use, or procurement eligibility. Supplier comparisons require support for each claimed access condition.
- Apparatus Platform and Analytical Detection classifications do not establish interchangeability or common suitability across all Tested Product categories. Comparisons must retain the particular offering and purchasing purpose.
- Global coverage does not establish that each supplier can deliver, distribute, or support every included offering in every jurisdiction. Local access and service commitments require geographically specific commercial support.
- Historical or announced offering information does not establish continuing participation throughout the forecast horizon. Forward commercial interpretations remain conditional on the continuity of the relevant offering, rights, and channel relationships.

3. Executive Summary

3.1. Introduction

The Global Dissolution Equipment market is shaped by the commercial package a laboratory must keep acceptable and supportable, not by the apparatus label alone. Agilent Technologies Inc.'s configurable xx.xx-DS and separately offered xx.xx-DS qualification system illustrate why complete Dissolution Test Systems and supporting equipment can involve different purchasing decisions. Buyers must match the apparatus, application, automation scope, and destination support before comparing suppliers.

Continuing quality obligations do not create an automatic replacement order. Within US drug CGMP, instruments must remain within established specifications, while SOTAX AG's AT-MD Offline provides an advertised unattended alternative rather than a universal purchasing requirement. Retention, supported additions, and broader automation remain competing routes. Commercial access depends on an approved need, spending authorization, buyer acceptance, and accountable lifecycle commitments; advertised capability alone does not establish realized staff benefits or local fulfillment.

Evidence: [E562], [E352], [E373], [E1024]

3.2. CXO Perspective

Laboratory owners should distinguish the equipment operator, acceptance authority, and spending approver before allocating capital. US finished-drug CGMP gives the quality-control unit authority over relevant procedures and specifications; operator preference alone is insufficient. Broader automation requires an approved workload case and funded implementation, with records and review responsibilities retained. Incumbents should qualify upkeep separately from replacement projects, while automation suppliers should establish the authorized purchasing scope. Manual or Semi-Automated equipment remains a credible alternative where it meets the assignment.

Manufacturers entering a destination should select partners for documented access or service contributions rather than territorial visibility. Distek, Inc. identifies Omicron Research Limited as its UK dissolution distributor, and Omicron advertises maintenance and repair services. This supports a potential consolidated interface, conditional on written configuration and site coverage, installation, warranty escalation, and software-support responsibilities. Direct contracting remains an alternative where the manufacturer can meet the same requirements. Consolidation can reduce coordination but increases dependence on the partner's continuing manufacturer relationship.

Evidence: [E556], [E630], [E1017], [E481], [E726], [E858]

3.3. New Revenue Opportunities

The assessed revenue routes are qualification and cleaning-and-media-handling additions for laboratories retaining acceptable apparatus, workload-backed automation for operating

laboratories, and specialty equipment for funded assignments such as Mechanical Chewing Apparatus. Agilent's xx.xx-DS, Merel Instruments' dissoWASH&DOSE, SOTAX's AT-MD Offline, and ERWEKA GmbH's DRT illustrate these distinct propositions. Capture remains conditional on a supported configuration, buyer approval, and destination coverage. The Opportunity Mapping assessment details these routes and their limits, including why a client's external laboratory assignment does not itself establish an equipment order.

Evidence: [E378], [E1027], [E767], [E602], [E762]

3.4. Next-Generation Business Models

Continuing entitlements and integration responsibilities extend the commercial relationship beyond the apparatus purchase. SOTAX's advertised q-doc support contracts combine priority service with update licenses, while multibrand drivers offer an alternative to single-brand hardware sourcing. Buyers should compare supported interfaces, continuing rights, and records obligations with a single-integrator agreement. Mixed-brand procurement preserves equipment choice but adds coordination; bundling is useful only where the agreement covers the combined scope.

External laboratory access presents a separate ownership choice. Intertek advertises pharmaceutical dissolution services, allowing an acceptable service agreement to substitute for a product owner's direct equipment commitment. That service assignment does not itself establish another equipment sale. Scheduling, records access, and continuity must be satisfactory, while FDA's quality-agreement guidance preserves each party's applicable drug-CGMP responsibilities. Internal ownership remains credible where direct access justifies its continuing obligations.

Evidence: [E681], [E987], [E768], [E152]

3.5. Industry Roadmap

For 2026-2027, the commercial milestone is conversion of equipment launches into accepted, support-backed commitments. Distek announced OLERA on May xx.xx 2026, following Pion's May xx.xx 2025 DissoSpec launch. These events add proposals, not replacement mandates. Pion describes DissoSpec as Semi-Automated; integrated packaging must not be equated with Fully Automated operation. Authorized buyers should obtain configuration, software-rights, and destination-service commitments before ordering.

For 2028-2029, approved integration projects should turn on exact instrument-and-software coverage and continuing support rights. Supported standalone equipment remains an alternative where broader integration is not authorized. The relevant milestones are project approval, contracted interface coverage, and assigned change responsibilities, rather than connectivity announcements alone.

For 2030-2032, replacement planning should follow a demonstrated acceptance or support gap rather than an assumed common retirement cycle. Distek's 2021 VIP xx.xx withdrawal illustrates finite peripheral support without establishing every installed unit's condition. Applicable EU GMP records-continuity expectations and recovery obligations for covered EU

electrical equipment should remain assigned through equipment changes. These horizons describe conditional business choices, not an inevitable replacement sequence.

Evidence: [E124], [E993], [E538], [E146], [E530], [E880]

4. Market Overview

4.1. Introduction

The Global Dissolution Equipment market combines complete Dissolution Test Systems with separately supplied Sample-Handling Equipment, Analytical Detection Modules, Media-Handling Equipment, Vessel-Cleaning Equipment, Mechanical Qualification Equipment, Visual Surveillance Equipment, and Accessories, Consumables, and Replacement Parts. ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪ Associated software and service arrangements influence equipment usability and supplier relationships without bringing every laboratory software product or testing service into the equipment market.

Established apparatus platforms coexist with differentiated commercial packages. ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ Buyers must therefore distinguish the apparatus, supporting package, application, and jurisdiction before comparing suppliers; a shared dissolution label does not establish interchangeability across the included categories.

Figure 5. Global Dissolution Equipment Market Size, 2017-2040 (USD Million, Growth %)




Table 2. Global Dissolution Equipment Market Size, 2017-2040 (USD Million, Growth %)

Metric	2017	2024	2025	2026	2027	2032	2040
Market Size (USD Million)	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Market Growth (%)	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Evidence: [E700], [E351], [E1020]

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

4.2. Key Growth Contribution

Additional dissolution-equipment adoption is most defensible when an approved workload or records-management need becomes an accepted commercial package. SOTAX's advertised unattended AT-MD offering illustrates a capability available to address operator attention, while FDA's drug-CGMP data-integrity expectations retain organizational oversight. Serving that need requires configuration-specific equipment, software rights, and continuing support. Acceptable existing apparatus and separately offered qualification equipment remain counterforces to complete-system replacement, so continuing quality obligations should not be treated as automatic acquisition commitments.

Figure 6. Global Dissolution Equipment Market, Key Growth Contribution, by Region, 2025-2032 (USD Million)




Figure 7. Global Dissolution Equipment Market, Key Growth Contribution, by Country, 2025-2032 (CAGR %)




Table 3. Global Dissolution Equipment Market, Key Growth Contribution, 2025-2032 (USD Million)

Scope	Leading Category	Added Market Size (USD Million)	Growth Share (%)	CAGR (%)
Analytical Detection	xx.xx	xx.xx	xx.xx	xx.xx
Apparatus Platform	xx.xx	xx.xx	xx.xx	xx.xx
Automation Level	xx.xx	xx.xx	xx.xx	xx.xx
Country	xx.xx	xx.xx	xx.xx	xx.xx
End User	xx.xx	xx.xx	xx.xx	xx.xx
Product Type	xx.xx	xx.xx	xx.xx	xx.xx
Region	xx.xx	xx.xx	xx.xx	xx.xx
Sales Channel	xx.xx	xx.xx	xx.xx	xx.xx
Tested Product	xx.xx	xx.xx	xx.xx	xx.xx
Testing Purpose	xx.xx	xx.xx	xx.xx	xx.xx

Evidence: [E563], [E631], [E375], [E1023]

Evidence: [E380], [E1026], [E654], [E661], [E659], [E664], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E517], [E502], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1004], [E1005], [E1012], [E1011], [E1013], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E263], [E964], [E965], [E773], [E275], [E110] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E380], [E1026], [E654], [E661], [E659], [E664], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E517], [E502], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1004], [E1005], [E1012], [E1011], [E1013], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E263], [E964], [E965], [E275], [E110] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

4.3. Industry Ecosystem & Value Chain Analysis

Value capture extends beyond the apparatus to the commercial package that keeps it usable. ■■■■■■■■■■ ■■■■■■■■■ ■■■ ■■ ■■■■■■■■■ ■■■■■■■■■■■■■ ■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■ ■ ■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■ ■■■■ ■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■ ■■■■■■■■■■ The buyer must still establish configuration compatibility and responsibility for the resulting equipment package.

■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■ ■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■ ■■■■■■ ■■■■■■■■■■ ■ ■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■■ ■■■■■ ■ ■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ The trade-off is responsibility for interfaces,

updates, and continued records access. EU GMP Annex xx.xx's provisions on third-party agreements and archiving make these lifecycle responsibilities relevant purchasing conditions rather than optional software features.

Evidence: [E156], [E369], [E983]

4.3.1. Supply-Side Analysis

Suppliers compete through different combinations of equipment and lifecycle responsibility. ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪ Such relationships identify who stands behind an offering, but do not establish integrated delivery, buyer acceptance, or a competitive advantage by themselves.

Commercial reach is also country-specific. Distek lists its own US regional contacts and named dissolution distributors including Betatek in Canada, Crescent Scientific in India, and Omicron Research in the United Kingdom. ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪

Evidence: [E453], [E489], [E594]

4.3.2. Demand-Side Analysis

Purchasing motives differ between sustaining an accepted laboratory capability and supporting a particular development or regulatory project. ▪▪ ▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ Pharmaceutical Ingredient Companies and applications involving Drug Substances & Excipients remain included, but their equipment justification must follow the relevant specification or customer assignment rather than be inferred from a finished-product program.

Dietary Supplement Companies operate under a separate US CGMP framework centered on established specifications and appropriate verification. ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪ ▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ These are specific procurement examples, not common conditions for all Academic and Noncommercial Research Institutions or Public Medicines-Control Laboratories.

Evidence: [E560], [E549], [E51], [E694], [E195], [E42]

4.3.3. Stakeholder Analysis

In regulated drug quality control, the equipment user is not the only acceptance authority. US rules assign the quality-control unit responsibility for relevant procedures, specifications, and product decisions. [redacted]

Outsourcing separates the instrument owner from the party retaining product accountability. [redacted] Commercial agreements should consequently settle access to records, change responsibilities, and service continuity rather than treat the laboratory's instrument ownership as sufficient assurance.

Evidence: [E550], [E158], [E586], [E684]

4.4. Market Dynamics

[redacted] Agilent's fiscal 2025 filing identifies customer budgets and public funding as business dependencies, but those company-wide disclosures do not establish a dissolution-specific purchasing cycle. The defensible commercial inference is conditional: constrained capital approval can favor upkeep or a narrower upgrade without removing the underlying need for laboratory access.

Modularity, automation, and outsourcing can also change where purchasing occurs. [redacted] Useful indicators are approved acquisition projects, supported configuration changes, and contracted service commitments rather than advertised automation capability alone.

Evidence: [E557], [E360], [E233], [E769]

4.4.1. Key Drivers

4.4.1.1. Quality-system continuity sustains equipment relevance

US drug CGMP requirements for calibrated instruments and adequate quality-control facilities anchor continuing demand for usable laboratory capability. [redacted]

[redacted] A buyer-approved remediation or replacement commitment is a stronger purchase indicator than the compliance obligation alone.

Evidence: [E696], [E564], [E548] Quality-system continuity sustains equipment relevance

4.4.1.2. Eligible equivalence programs create application-specific purchasing motives

[redacted] Applicability is restricted, and the sponsor may use an existing laboratory or contract provider. The commercial trigger is an eligible, funded program with an accepted laboratory arrangement, not an assumption that every equivalence project generates a new instrument purchase.

Evidence: [E637], [E55] Eligible equivalence programs create application-specific purchasing motives

4.4.1.3. Automation demand combines staff attention with record accountability

SOTAX advertises unattended operation through AT-MD and audit-trail functionality through q-doc. [redacted] Purchase justification should depend on the buyer's documented workload, accepted configuration, and retained oversight responsibilities.

Evidence: [E628], [E992], [E1029] Automation demand combines staff attention with record accountability

4.4.2. Key Restraints

4.4.2.1. Capital authorization can lag laboratory requirements

[redacted] Buyers can defer a complete replacement while maintaining an accepted installation or arranging external access. The disclosure supports budget sensitivity, not a conclusion that dissolution-equipment purchasing has declined across buyers or jurisdictions.

Evidence: [E235] Capital authorization can lag laboratory requirements

4.4.2.2. Application-specific acceptance limits broad substitution

A named system's advertised apparatus configurations and a regulatory program's eligibility conditions define different limits on commercial substitution. [redacted]

[redacted] Suppliers must establish a match to the buyer's accepted requirements before extending a general dissolution-equipment proposition into another application.

Evidence: [E53], [E362] Application-specific acceptance limits broad substitution

4.4.2.3. External laboratory access can defer ownership

Intertek advertises pharmaceutical dissolution testing within its contract-laboratory services. [redacted] Equipment purchasing may move to the service provider rather than disappear; internal ownership can remain preferable where direct scheduling control is commercially important.

Evidence: [E678], [E770] External laboratory access can defer ownership

4.4.3. Key Opportunities

4.4.3.1. Compatible additions for accepted installed equipment

[redacted] The opportunity requires an approved need, a supported installed-model match, and assigned responsibility across retained and added equipment; a complete replacement remains the alternative when those conditions fail.

Evidence: [E379], [E761] Compatible additions for accepted installed equipment

4.4.3.2. Automation tied to an approved workload

Unattended offerings such as SOTAX AT-MD Offline can address a documented operator-attention need. [redacted] Public purchasing has also retained Manual and autosampler-equipped apparatus, making narrower automation a credible alternative rather than an obsolete tier.

Evidence: [E634], [E1016], [E725] Automation tied to an approved workload

4.4.3.3. Assignment-specific specialty equipment packages

ERWEKA's DRT and Pion's SDi2 establish differentiated propositions for chewing-platform and analytical-imaging assignments. Suppliers can address those specific information or apparatus needs when the project, acceptance authority, and destination support are established. [redacted]

Evidence: [E603], [E897] Assignment-specific specialty equipment packages

4.4.3.4. Equipment access with accountable destination support

[redacted] Distek's UK relationship with Omicron provides an example. The opportunity depends on written product and site coverage,

continuing manufacturer backing, and allocated remedies; a directory entry alone does not establish fulfillment.

Evidence: [E482], [E856] Equipment access with accountable destination support

4.4.4. Key Challenges

4.4.4.1. Computerized acceptance requires lifecycle accountability

EU GMP Annex xx.xx addresses computerized-system qualification, validation, third-party agreements, and continued data accessibility; FDA guidance also places responsibility on the regulated organization. A supplier's connectivity claim therefore does not establish acceptance of the buyer's configuration. ■■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■ ■■■■■■ ■■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■■■■■■ ■■■■■■ ■ ■■■■■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■

Evidence: [E635], [E157] Computerized acceptance requires lifecycle accountability

4.4.4.2. Channel presence must become enforceable local fulfillment

■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■■ ■■■ ■■■■■■■ ■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■ ■ ■■■■■■ ■■■■■■■ ■■■ ■■ ■■■■■■■■ ■■■■■■ ■■■ ■■■ ■■■■■■■■■■■■ Buyers must establish the seller's authority and the party responsible for installation, service, and repair under the particular contract. A distributor can contribute local commercial access, but cannot be assumed to remove customer acceptance or fulfillment requirements.

Evidence: [E196], [E518] Channel presence must become enforceable local fulfillment

4.4.4.3. Product withdrawal complicates maintenance and replacement timing

Distek's July xx.xx 2021 notice withdrew the VIP xx.xx Dissolution Vessel Washer effective December xx.xx 2021, or earlier stock exhaustion, and warned about limits to continued repairs and parts support. Vessel-Cleaning Equipment remains within the market, but a historical product page does not establish continuing new-equipment supply. ■■■■■■■■■ ■■■■■ ■■■■■■ ■■■■■■ ■ ■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■ ■■ ■■■■■■■■■■■■ ■■■ ■■■■■■ ■■■■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■ ■■■■■ ■■■■■■■■■ ■■■■ ■■ ■■■■■■■■■■■■■

Evidence: [E542] Product withdrawal complicates maintenance and replacement timing

4.5. Porter’s Five Forces Analysis

Competition is visible across modular systems, supporting equipment, and automated packages rather than through a single interchangeable product. ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■ ■ ■■■ ■■■■■■■■ ■■ ■■■■■■■■■■ ■■■■■■■■■ ■■ ■■■■■■■■■ ■■■■ ■■■■ ■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■■■ ■■■■ ■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■ ■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■ An incumbent cannot assume that an existing instrument relationship captures every subsequent module purchase.

[redacted] After installation, changing software, service arrangements, and records responsibilities may introduce coordination costs. SOTAX's advertised multibrand connectivity is a counterforce to blanket hardware lock-in, although compatibility remains specific to the supported configuration.

[redacted] Buyers should distinguish the availability of an alternative system from the practical ability to maintain an installed configuration. Neither an extensive catalog nor a familiar brand establishes an indefinite repair obligation.

The relevant substitute to equipment ownership can be an outsourced dissolution service rather than a different analytical technique. [redacted] The ownership-versus-service choice consequently depends on accepted provider arrangements, scheduling control, and records access, not simply the existence of an external laboratory.

Evidence: [E685], [E198], [E361], [E981], [E454], [E543], [E772]

4.6. PESTLE Analysis

[redacted] These are company-wide disclosures, not evidence of a uniform effect on Dissolution Equipment. Cross-border buyers should establish equipment origin, delivery responsibilities, and applicable import treatment before committing; a distributor's involvement does not by itself settle those obligations.

[redacted] Intellectual property introduces another configuration-specific consideration: Distek describes patented technology in its Model xx.xx Select offering, and IIT (BHU)'s 2020 dissolution-equipment tender required supplier indemnification against specified intellectual-property claims in India. These records support attention to contractual rights and indemnities, not a conclusion about enforceable exclusivity across an apparatus category.

Automation changes the allocation of work without eliminating organizational accountability. EU GMP Annex xx.xx identifies cooperation among process, system, quality, and IT roles, while FDA data-integrity guidance emphasizes management responsibility. [redacted]

▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪

Environmental obligations can influence the contracting entity and replacement decision. ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ Repair support and an agreed disposal route therefore belong in lifecycle purchasing discussions; environmental compliance does not establish that one automation configuration is inherently preferable.

Evidence: [E699], [E633], [E159], [E197], [E125], [E536], [E237]

4.7. Market Outlook

Across 2026-2032, the commercial outlook depends on converting a laboratory requirement into a funded, accepted, and supportable equipment commitment. Continuing US drug-CGMP instrument obligations establish a need for acceptable capability, not a replacement timetable. ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪

A conversion-led scenario requires approved projects and enforceable delivery commitments; a deferral-led scenario leaves buyers relying on acceptable existing capability or another access arrangement. ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ Suppliers should distinguish those events from laboratory need or a product announcement when deciding which commitments to make.

Evidence: [E559], [E234]

4.7.1. Near-Term Market Outlook (0-2 Years)

▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ Distek's May xx.xx 2026 OLERA release and Pion's May xx.xx 2025 DissoSpec launch provide named equipment alternatives for inquiry, but neither event establishes a replacement requirement or destination delivery. DissoSpec's semi-automated description also prevents integrated packaging from being treated as a commitment to fully unattended operation.

Buyers with authorized acquisitions should compare the offered configuration, software rights, installation, and support against the actual purchasing assignment. ▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪

[redacted] Without those events, launch visibility should not be promoted into a committed equipment opportunity.

Evidence: [E531], [E881]

4.7.2. Medium-Term Market Outlook (3-5 Years)

For 2028-2029, an important conditional choice is whether equipment investment remains installation-specific or becomes part of an approved laboratory-data environment. SOTAX advertises multibrand q-doc interfaces, and Körber's September xx.xx 2025 certification establishes a defined PAS-X integration relationship. [redacted]

[redacted] Indicators are approved integration projects, explicit instrument-and-software coverage, and continuing support commitments. If enterprise projects are deferred, supported standalone equipment remains a credible alternative rather than an interim failure.

Evidence: [E984], [E145], [E804]

4.7.3. Long-Term Market Outlook (5-10 Years)

For 2030-2032, lifecycle continuity is a more defensible planning variable than an assumed universal replacement cycle. [redacted] Where those conditions remain satisfactory, retaining the apparatus with an appropriately supported addition remains an alternative.

Long-horizon contracts should address obligations that survive the original purchase. [redacted] Changes in support commitments, records-access rights, or applicable destination obligations are the events that should reopen the decision.

Evidence: [E123], [E539], [E143]

4.8. Go-to-Market Strategy

Target the purchasing job before proposing an automation category. An incumbent equipment supplier should distinguish an approved upkeep or supporting-equipment requirement from an authorized replacement project. [illegible]

Use an indirect route only where the partner contributes evidenced access or fulfillment that direct contracting cannot provide as effectively. Distek's identification of Omicron Research Limited as its UK dissolution distributor, together with Omicron's advertised maintenance, repair, and customer-site support, provides a concrete potential equipment-and-service interface. [illegible]

Build the proposition around the delivered package and accountable lifecycle scope. [illegible] A narrower offer preserves choice; consolidation is preferable when divided responsibility would otherwise remain unresolved.

Evidence: [E555], [E353], [E994], [E521], [E743], [E149], [E859]

5. Market Insights

5.1. Consumer Insights & End-User Perspective

The dissolution-equipment user, quality approver and spending authority need not be the same party. [redacted] Suppliers should identify those authorities before presenting automation as a sufficient buying rationale.

[redacted] It establishes a request for continuing support, not an equipment award or a universal preference for retention. For an incumbent supplier, documented service renewal can be the relevant purchase trigger; a replacement supplier needs an identified configuration gap, support problem or approved acquisition rather than laboratory activity alone.

[redacted] The implication is conditional: Pharmaceutical Product Companies, Academic and Noncommercial Research Institutions, and other included buyers may have a justified laboratory need without an authorized acquisition. A defensible shortlist should connect the accepted application and quality requirements to a named spending approval, while keeping maintenance, a narrower upgrade and an accepted external laboratory arrangement distinguishable.

Evidence: [E561], [E552], [E679], [E232], [E165]

5.2. Consumer Experience Benchmarking

Relevant experience benchmarks separate operator attention from configuration flexibility. Within the Basket Apparatus and Paddle Apparatus comparison, Agilent advertises the modular xx.xx-DS in manual or automated configurations, whereas SOTAX positions AT-MD Offline around unattended operation and self-cleaning. [redacted]

[redacted]

RESEARCH SAMPLE REPORT

[redacted] An existing software environment can therefore favor an integrated extension, while a mixed-brand laboratory may value supported cross-brand connections. The buyer must establish exact compatibility, migration responsibility and continued record access; advertised connectivity is not a commitment to support every installed configuration.

These are capability benchmarks, not demonstrated customer-experience outcomes. Portfolio descriptions do not establish realized ease of use, service responsiveness or staff benefits. [redacted]

Evidence: [E350], [E986], [E1019], [E339]

5.3. Opportunity Mapping

[redacted] QLA's explicit exclusion of SOTAX AT7 and AT7 smart from its qualification-and-reporting offering demonstrates why an installed-model match is essential. Replacement becomes the stronger alternative when the apparatus itself is unacceptable or the proposed addition cannot secure a supported commercial configuration.

[redacted] HPTLL's separate requests for Manual and autosampler-equipped apparatus reinforce the credibility of narrower alternatives. A supplier should advance a broader package only where the operating purchaser has an approved workload case, accepted records arrangements, and implementation funding; otherwise, retention or partial automation remains a commercially credible response.

[redacted] This supports project-led targeting beyond assumed finished-product quality control, but does not establish another ingredient company's acquisition plan. Capture requires a funded assignment, the relevant acceptance authority, and an offering matched to that assignment; general pharmaceutical activity is insufficient.

Destination coverage is a filter on each opportunity, not proof of attractiveness. ERWEKA expressly limits service-plan availability by country, illustrating why a globally advertised instrument cannot be treated as a uniformly supported local offer. [redacted]

[redacted]

External laboratory access can change the accessible purchaser. [redacted] Within applicable drug CGMP, FDA guidance preserves the parties' responsibilities, so outsourcing changes the ownership relationship without removing governance obligations.

Evidence: [E636], [E680], [E376], [E1028], [E766], [E746], [E605], [E901], [E935], [E1057], [E597], [E765], [E218]

5.4. Distribution Channel Analysis

Direct Sales and Indirect Sales provide different contracting routes, not assured differences in service quality. [redacted] Buyers should identify the contracting seller and the manufacturer-backed service obligation before treating a directory listing as a complete fulfillment proposition.

[redacted] Direct entry remains an alternative where the manufacturer can meet the buyer's eligibility and fulfillment requirements itself. Changing agents should not leave installation, warranty or support responsibilities unassigned.

Evidence: [E490], [E738]

5.5. Pricing Trend Analysis

Commercial scope, rather than the dissolution-apparatus label alone, determines what a quotation covers. [redacted]

[redacted] Bundling can simplify accountability, but exclusions, renewal rights and access to historical records can materially change the purchasing choice.

[redacted] A firm commitment can protect the buyer from subsequent adjustments while transferring exposure to the seller; a reopening clause preserves seller flexibility but weakens budget certainty. The relevant monitoring trigger is a change affecting the actual trade route or contract, not a company-wide cost disclosure alone.

Evidence: [E359], [E991], [E238]

5.6. Regulatory Compliance & Standards Framework

Regulatory access depends on the buyer's activity and destination, not a universal dissolution-equipment certificate. [redacted] Mechanical Qualification Equipment consequently has a distinct supporting role without implying mandatory complete-system replacement.

Computerized purchasing adds records and lifecycle responsibilities. [redacted] Contracts should allocate implementation, changes, support and records custody before the package is committed.

Dietary Supplement Companies operate under the separate US Part xx.xx framework. Pharmaceutical Ingredient Companies, research institutions and Public Medicines-Control Laboratories likewise need requirements tied to their actual activities and assignments, rather than an assumption that finished-drug manufacturing rules apply identically. [redacted]

[redacted] Distek's May 2026 OLERA announcement describes patented features, but does not settle enforceable

rights for a destination-specific configuration. Buyers and sellers should verify relevant commercial rights and indemnity coverage rather than infer exclusivity over an entire apparatus category.

Evidence: [E697], [E558], [E553], [E692], [E689], [E144], [E153], [E534]

5.7. ESG & Sustainability Analysis

Sustainability can affect supplier qualification independently of apparatus performance. ■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■ ■■■ ■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■■■ ■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■ ■■■ ■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■■■ ■■ ■■■■■■■■■■■ ■■■■■■■ ■ ■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■ ■■■ ■■■■■ ■■■■■■■■ ■■■ ■■■■ ■■■■ ■■■■■■■■■■■■■ ■■■■■■ ■ ■■■■■■■■■■■ A product-level efficiency claim does not answer a request for supplier-level disclosures.

■■■■■■■■ ■■■■■■■■■■ ■■ ■■■■ ■■ ■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■ ■■ ■■■ ■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■ ■■■■■■ ■■■■ ■■■■■■■ ■■■■■■ ■■■■ ■■■■ ■■ ■ ■■■■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■■■ Buyers should compare the supported replacement package with retaining an acceptable, repairable installation. An environmental purchasing case must remain compatible with application acceptance, serviceability and the organization's procurement criteria.

Repair continuity and end-of-life allocation can reverse an apparently straightforward replacement decision. ■■■■■■■■ ■■■ ■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■■■■■ ■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■ ■■■■ ■■■■■■■■■ ■■■ ■■■■ ■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■ ■■ ■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■ ■■■ ■■■■ ■■■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■ ■■ ■■■■■■■■ ■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■ ■■■■■■■■■■■■ Continued use preserves an asset only while support remains defensible; an efficiency-led replacement introduces its own disposal and implementation responsibilities.

Evidence: [E126], [E540], [E535], [E537], [E1110]

5.8. Disruption & Risk Scenarios

A support-withdrawal scenario can turn a peripheral-maintenance decision into a replacement requirement. Distek's 2021 VIP xx.xx withdrawal notice provides an observed example of qualified repair and parts continuity, not evidence that every installed washer is unserviceable. ■■■ ■■■■■■■■ ■■■■■■■ ■■ ■ ■■■■■■■■ ■■■■■■■ ■■ ■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■ ■■ ■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■ ■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■ ■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■ ■■■■■■■ ■■ ■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■ ■■■■■■ ■■■■■■■ ■■■ ■■■■ ■■■■ ■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■

An interface-discontinuity scenario arises if a supported driver, software entitlement, or service arrangement changes after acquisition. [redacted] The indicator is a change to the actual supported configuration, not a general connectivity announcement.

A funding or trade shock could delay an otherwise acceptable equipment project or reopen its commercial scope. [redacted] Retention or a narrower addition is an alternative only while acceptable capability and support continue.

Evidence: [E982], [E544], [E236], [E148]

5.9. Return on Investment & Cost-Benefit Analysis

[redacted] FDA data-integrity expectations and applicable EU computerized-system responsibilities mean that routine attention and organizational accountability cannot be treated as the same cost. Retaining Manual equipment or making a narrower addition is preferable when the accepted workload does not justify the broader commitment.

[redacted] Split obligations, uncertain software rights, or an unsupported apparatus can erase the rationale for the narrower purchase. A complete-system agreement becomes more defensible when it resolves an established capability or support gap that the addition cannot address.

Ownership and external access should be compared through control and continuing obligations. Intertek's advertised dissolution service offers an alternative to direct ownership, conditional on an accepted provider and satisfactory scheduling, records, and continuity

commitments. [redacted]

Evidence: [E632], [E687], [E377], [E989], [E1030], [E771], [E151], [E764]

6. Cumulative Impact of Artificial Intelligence 2026

AI has an evidenced connection to the dissolution software ecosystem, but readiness is not deployment. ■■■■■ ■■■■■■■■■ ■■■■■ ■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■ ■ ■■■■■■■■■■ ■■ ■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■ ■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■ ■■■■■■■■ ■■■■ ■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■ ■■ ■■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■ ■■ ■ ■■■■■■ ■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ Fully Automated equipment and AI-enabled equipment should not be treated as synonymous.

■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■ ■■■■■ ■■■■ ■■ ■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■■■■■■■■■■ ■■ ■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■ ■■ ■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■ ■■■■ ■■■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■■■■■■■■ ■■■ ■■■■■■ ■■■■■■■■■■■■■ A conventional digital-records workflow remains an alternative when those conditions are unresolved. Dissolution-specific labor benefits and implementation outcomes remain unverified.

Governance can constrain the timing of adoption. ■■■■■■■■■ ■■ ■■■ ■■■■■ ■■ ■■■■■■■■ ■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■ ■■■■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■ ■■■■■■■■ ■■■■■ ■■ ■■■■■■■ ■■ ■■■■■■■■ ■■■■ ■■■■ ■■■■■■■■■■ ■■■ ■■ ■■■■■ ■■ ■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■ ■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■ ■■■ ■■ ■■■■■■■■■ ■■ ■■ ■■■■■■■■■■ ■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■■■ Suppliers should distinguish supported functionality and contractual commitments from an AI-readiness claim, while buyers should monitor publication of final requirements before treating proposed provisions as mandatory purchasing conditions.

Evidence: [E988], [E150], [E155], [E328], [E142]

7. Dissolution Equipment Market, by Product Type

[illegible] Buyers should compare a documented peripheral addition with a complete-system acquisition, retaining separate responsibility for compatibility, installation, and acceptance. A consolidated award can simplify accountability; separate purchases preserve component choice but increase coordination.

[illegible] These examples support a retrofit-oriented commercial role alongside complete-system purchasing, not universal compatibility or indefinite supply. A laboratory retaining its apparatus should establish the exact supported installation and continuing service commitment before awarding either supporting package.

Visual Surveillance Equipment requires a different acceptance specification from an analytical detector. [illegible] For historically documented cleaning and surveillance offerings, a new written offer is the appropriate commitment trigger; the age of a publication establishes neither continuing supply nor withdrawal.

Accessories, Consumables, and Replacement Parts create a model-specific physical aftermarket rather than another complete-system purchase by default. [illegible] These product categories describe commercial functions within the same market and should not be treated as additive purchases whenever a single package contains several functions.

Figure 8. Global Dissolution Equipment Market Size, by Product Type, 2025 (%)




Figure 9. Global Dissolution Equipment Market, by Product Type, 2032 (USD Million)




Table 4. Global Dissolution Equipment Market, by Product Type growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 5. Global Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E371], [E736], [E340], [E1049], [E337] Product Type

Evidence: [E380], [E733], [E751], [E729], [E1050], [E1051], [E335], [E944], [E945], [E1064], [E269], [E247], [E249], [E248], [E202], [E264], [E541], [E999], [E1001], [E1003], [E1002] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E380], [E733], [E751], [E729], [E1050], [E1051], [E335], [E944], [E945], [E1064], [E269], [E247], [E249], [E248], [E202], [E264], [E541], [E999], [E1001], [E1003], [E1002] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E744], [E344] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

7.1. Dissolution Test Systems

Table 6. Global Dissolution Equipment Market Size, by Dissolution Test Systems, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 7. Global Dissolution Equipment Market Size, by Dissolution Test Systems, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 8. Global Dissolution Equipment Market Size, by Dissolution Test Systems, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E741], [E840] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E730], [E39] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E730], [E39] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E724], [E657], [E40] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E733], [E944], [E1064], [E247] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E733], [E944], [E1064], [E247] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

7.2. Accessories, Consumables, and Replacement Parts

Table 9. Global Dissolution Equipment Market Size, by Accessories, Consumables, and Replacement Parts, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 10. Global Dissolution Equipment Market Size, by Accessories, Consumables, and Replacement Parts, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 11. Global Dissolution Equipment Market Size, by Accessories, Consumables, and Replacement Parts, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E343] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E264] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E264] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

7.3. Media-Handling Equipment

Table 12. Global Dissolution Equipment Market Size, by Media-Handling Equipment, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 13. Global Dissolution Equipment Market Size, by Media-Handling Equipment, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 14. Global Dissolution Equipment Market Size, by Media-Handling Equipment, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E723], [E1052] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E730], [E39] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E730], [E39] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E724], [E657], [E40] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E729], [E1051], [E202], [E1003] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E729], [E1051], [E202], [E1003] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

7.4. Sample-Handling Equipment

Table 15. Global Dissolution Equipment Market Size, by Sample-Handling Equipment, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 16. Global Dissolution Equipment Market Size, by Sample-Handling Equipment, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 17. Global Dissolution Equipment Market Size, by Sample-Handling Equipment, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E742], [E1010], [E341] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E730], [E39] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E730], [E39] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E724], [E657], [E40] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E751], [E999], [E945], [E249] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E751], [E999], [E945], [E249] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

7.5. Analytical Detection Modules

Table 18. Global Dissolution Equipment Market Size, by Analytical Detection Modules, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 19. Global Dissolution Equipment Market Size, by Analytical Detection Modules, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 20. Global Dissolution Equipment Market Size, by Analytical Detection Modules, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E1000] Taxonomy evidence: Segmentation

Evidence: [E1001], [E248] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1001], [E248] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

7.6. Mechanical Qualification Equipment

Table 21. Global Dissolution Equipment Market Size, by Mechanical Qualification Equipment, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 22. Global Dissolution Equipment Market Size, by Mechanical Qualification Equipment, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 23. Global Dissolution Equipment Market Size, by Mechanical Qualification Equipment, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E839], [E113], [E342] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E269], [E380] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E269], [E380] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

7.7. Vessel-Cleaning Equipment

Table 24. Global Dissolution Equipment Market Size, by Vessel-Cleaning Equipment, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 25. Global Dissolution Equipment Market Size, by Vessel-Cleaning Equipment, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 26. Global Dissolution Equipment Market Size, by Vessel-Cleaning Equipment, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E1053] Taxonomy evidence: Segmentation

Evidence: [E1050], [E541], [E1002] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1050], [E541], [E1002] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

7.8. Visual Surveillance Equipment

Table 27. Global Dissolution Equipment Market Size, by Visual Surveillance Equipment, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 28. Global Dissolution Equipment Market Size, by Visual Surveillance Equipment, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 29. Global Dissolution Equipment Market Size, by Visual Surveillance Equipment, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E63], [E338] Taxonomy evidence: Segmentation

Evidence: [E335] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E335] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

8. Dissolution Equipment Market, by Apparatus Platform

Apparatus Platform changes the supplier shortlist and the configuration that must be purchased, rather than merely the instrument's label. Agilent advertises the xx.xx-DS for Basket Apparatus, Paddle Apparatus, Paddle Over Disk Apparatus, and Rotating Cylinder Apparatus configurations. ■■■■ ■■■■■■■ ■ ■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■ ■■■■■■■ ■■■■ ■■■■■■■■ ■■■■■■■ ■■■ ■■ ■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■ ■■■■ ■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■ ■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■■ ■■■■■■■■ ■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■ ■■ ■■■■■■■■■■■ ■■ ■■■■■■■■ ■■■■■■■■■■■■

Reciprocating Cylinder Apparatus, Reciprocating Holder Apparatus, and Flow-Through Cell Apparatus have distinct advertised offering families. ■■■■■■■ ■■■■■ ■■■■■■■ ■■■ ■■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■■■ ■■ ■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■ ■■■■■■■■■■ ■■■■■■■■■ ■■ ■■■ ■■■■■■■ ■■■■■■■■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■ ■■ ■■■■■■■■ Procurement should preserve the named platform and intended purchasing assignment when comparing alternatives; broader configurability is useful only when the delivered package and support commitments cover the buyer's requirements.

Rotating-Disk Apparatus and Stationary-Disk Apparatus have a different documented commercial rationale from an assumed routine batch-release installation. ■■■■■■ ■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■■■■ ■■■■ ■■■■■ ■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■ ■■■ ■■■■■■■■■■ ■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■ ■■■■■■■■ ■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■ ■■ ■ ■■■■■■■■ ■■■■■■■■■■ ■■ ■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■ The public chapter recognizes both identities but does not establish a currently deliverable supplier configuration for either.

Stirred-Vial Apparatus and Membrane-Separated Cell Apparatus also require offering-level comparison. ■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■ ■ ■■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■ ■■ ■ ■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■ ■■■ ■■■■■■■■■ ■■■■ ■■■■ ■■■ ■■■■■■■■■■■ ■■■ ■■■■■ ■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■ ■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■■■ A dedicated capability can address that assignment while creating a different support relationship from a multipurpose apparatus.

■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■ ■ ■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■ ■■■■■■■■ ■■■■ ■■■ ■■■■■■■■ ■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■ ■■ ■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■■ ■■■■■ ■■■■■■ ■■■ ■■ ■■■■■■■■ ■■■■ ■■■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■■■ Agitated-Bottle Apparatus presents a different continuity question: Agilent's March 2011 rotating-bottle

manual establishes a historical offering, not a present new-equipment commitment. All accepted platforms remain included, but procurement involving historically documented or incompletely specified configurations should wait for a written supply and support position rather than assume either availability or obsolescence.

Figure 10. Global Dissolution Equipment Market Size, by Apparatus Platform, 2025 (%)




Figure 11. Global Dissolution Equipment Market, by Apparatus Platform, 2032 (USD Million)




Table 30. Global Dissolution Equipment Market, by Apparatus Platform growth contribution, 2025-2032 (USD Thousand)

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 31. Global Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Million)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E349], [E365], [E367], [E996], [E107], [E890], [E894], [E600], [E327] Apparatus Platform

Evidence: [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E604], [E942], [E948], [E1066], [E1060], [E621], [E622], [E60], [E61], [E59], [E62], [E384], [E545], [E25], [E26], [E331], [E381], [E385] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E604], [E621], [E622], [E60], [E61], [E59], [E62], [E384], [E545], [E25], [E26], [E331], [E381], [E385] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E614], [E642], [E905], [E90], [E638] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

8.1. Paddle Apparatus

Table 32. Global Dissolution Equipment Market Size, by Paddle Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 33. Global Dissolution Equipment Market Size, by Paddle Apparatus, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 34. Global Dissolution Equipment Market Size, by Paddle Apparatus, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E618], [E908] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E948], [E1060], [E622], [E61], [E364] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E622], [E61], [E364] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.2. Basket Apparatus

Table 35. Global Dissolution Equipment Market Size, by Basket Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 36. Global Dissolution Equipment Market Size, by Basket Apparatus, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 37. Global Dissolution Equipment Market Size, by Basket Apparatus, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E617], [E907] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E942], [E1066], [E621], [E60], [E358] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E621], [E60], [E358] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.3. Flow-Through Cell Apparatus

Table 38. Global Dissolution Equipment Market Size, by Flow-Through Cell Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 39. Global Dissolution Equipment Market Size, by Flow-Through Cell Apparatus, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 40. Global Dissolution Equipment Market Size, by Flow-Through Cell Apparatus, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E643], [E906], [E903] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E995] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E995] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.4. Reciprocating Cylinder Apparatus

Table 41. Global Dissolution Equipment Market Size, by Reciprocating Cylinder Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 42. Global Dissolution Equipment Market Size, by Reciprocating Cylinder Apparatus, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 43. Global Dissolution Equipment Market Size, by Reciprocating Cylinder Apparatus, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E645] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E366] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E366] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.5. Stirred-Vial Apparatus

Table 44. Global Dissolution Equipment Market Size, by Stirred-Vial Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 45. Global Dissolution Equipment Market Size, by Stirred-Vial Apparatus, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 46. Global Dissolution Equipment Market Size, by Stirred-Vial Apparatus, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E891], [E27] Taxonomy evidence: Segmentation

Evidence: [E25] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E25] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

8.6. Membrane-Separated Cell Apparatus

Table 47. Global Dissolution Equipment Market Size, by Membrane-Separated Cell Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 48. Global Dissolution Equipment Market Size, by Membrane-Separated Cell Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 49. Global Dissolution Equipment Market Size, by Membrane-Separated Cell Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E648], [E73], [E28] Taxonomy evidence: Segmentation

Evidence: [E26] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E26] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

8.7. Reciprocating Holder Apparatus

Table 50. Global Dissolution Equipment Market Size, by Reciprocating Holder Apparatus, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 51. Global Dissolution Equipment Market Size, by Reciprocating Holder Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 52. Global Dissolution Equipment Market Size, by Reciprocating Holder Apparatus, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E646] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E368] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E368] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.8. Paddle Over Disk Apparatus

Table 53. Global Dissolution Equipment Market Size, by Paddle Over Disk Apparatus, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 54. Global Dissolution Equipment Market Size, by Paddle Over Disk Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 55. Global Dissolution Equipment Market Size, by Paddle Over Disk Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E644] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E59], [E347] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E59], [E347] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.9. Rotating Cylinder Apparatus

Table 56. Global Dissolution Equipment Market Size, by Rotating Cylinder Apparatus, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 57. Global Dissolution Equipment Market Size, by Rotating Cylinder Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 58. Global Dissolution Equipment Market Size, by Rotating Cylinder Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E647] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E62], [E348] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E62], [E348] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

8.10. Rotating-Disk Apparatus

Table 59. Global Dissolution Equipment Market Size, by Rotating-Disk Apparatus, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 60. Global Dissolution Equipment Market Size, by Rotating-Disk Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 61. Global Dissolution Equipment Market Size, by Rotating-Disk Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E102] Taxonomy evidence: Segmentation

Evidence: [E101], [E384] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E101], [E384] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

8.11. Mechanical Chewing Apparatus

Table 62. Global Dissolution Equipment Market Size, by Mechanical Chewing Apparatus, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 63. Global Dissolution Equipment Market Size, by Mechanical Chewing Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 64. Global Dissolution Equipment Market Size, by Mechanical Chewing Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E606] Taxonomy evidence: Segmentation

Evidence: [E604] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E604] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

8.12. Stationary-Disk Apparatus

Table 65. Global Dissolution Equipment Market Size, by Stationary-Disk Apparatus, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 66. Global Dissolution Equipment Market Size, by Stationary-Disk Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 67. Global Dissolution Equipment Market Size, by Stationary-Disk Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E103] Taxonomy evidence: Segmentation

Evidence: [E105], [E545] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E105], [E545] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

8.13. Agitated-Bottle Apparatus

Table 68. Global Dissolution Equipment Market Size, by Agitated-Bottle Apparatus, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 69. Global Dissolution Equipment Market Size, by Agitated-Bottle Apparatus, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 70. Global Dissolution Equipment Market Size, by Agitated-Bottle Apparatus, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E641], [E326] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E331], [E381], [E385] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E331], [E381], [E385] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

9. Dissolution Equipment Market, by Analytical Detection

[illegible] SOTAX's Offline configuration collects samples for operator transfer to another analytical device, supporting No Integrated Detection as a substantive purchasing alternative rather than an absence of subsequent analysis. This can preserve access to shared analytical equipment, while leaving transfer and scheduling coordination with the laboratory.

[illegible] UV-Vis Dissolution Imaging therefore addresses an information requirement beyond the recording-only observation package described in Agilent's historical dissoGUARD material. Buyers should specify the required analytical output before comparing these alternatives; a shared optical label does not establish equivalent purchasing suitability.

Liquid Chromatography introduces another integration choice. [illegible] Neither route is inherently preferable without the buyer's accepted analytical requirements and documented equipment arrangements.

Figure 12. Global Dissolution Equipment Market Size, by Analytical Detection, 2025 (%)




Figure 13. Global Dissolution Equipment Market, by Analytical Detection, 2032 (USD Million)




Table 71. Global Dissolution Equipment Market, by Analytical Detection growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 72. Global Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E336], [E889], [E1006], [E899] Analytical Detection

Evidence: [E1007], [E1004], [E1005], [E1059], [E1061], [E1063], [E734] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1007], [E1004], [E1005], [E1059], [E1061], [E1063], [E734] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E615] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

9.1. No Integrated Detection

Table 73. Global Dissolution Equipment Market Size, by No Integrated Detection, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 74. Global Dissolution Equipment Market Size, by No Integrated Detection, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 75. Global Dissolution Equipment Market Size, by No Integrated Detection, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E1014] Taxonomy evidence: Segmentation

Evidence: [E1005], [E1063], [E734] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1005], [E1063], [E734] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

9.2. Direct UV-Vis Detection

Table 76. Global Dissolution Equipment Market, by Direct UV-Vis Detection growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 77. Global Dissolution Equipment Market Size, by Direct UV-Vis Detection, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 78. Global Dissolution Equipment Market Size, by Direct UV-Vis Detection, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 79. Global Dissolution Equipment Market Size, by Direct UV-Vis Detection, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E619] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E1059], [E885], [E1007], [E1015], [E888], [E900], [E382], [E383], [E386] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1059], [E885], [E1007], [E1015], [E888], [E900], [E382], [E383], [E386] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

9.2.1. External-Cell UV-Vis Spectrophotometry

Table 80. Global Dissolution Equipment Market Size, by External-Cell UV-Vis Spectrophotometry, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 81. Global Dissolution Equipment Market Size, by External-Cell UV-Vis Spectrophotometry, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 82. Global Dissolution Equipment Market Size, by External-Cell UV-Vis Spectrophotometry, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E1009] Taxonomy evidence: Segmentation

Evidence: [E1015], [E386] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1015], [E386] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

9.2.2. In Situ Fiber-Optic UV-Vis Spectrophotometry

Table 83. Global Dissolution Equipment Market Size, by In Situ Fiber-Optic UV-Vis Spectrophotometry, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 84. Global Dissolution Equipment Market Size, by In Situ Fiber-Optic UV-Vis Spectrophotometry, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 85. Global Dissolution Equipment Market Size, by In Situ Fiber-Optic UV-Vis Spectrophotometry, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E892] Taxonomy evidence: Segmentation

Evidence: [E888], [E885], [E382], [E383] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E888], [E885], [E382], [E383] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

9.2.3. UV-Vis Dissolution Imaging

Table 86. Global Dissolution Equipment Market Size, by UV-Vis Dissolution Imaging, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 87. Global Dissolution Equipment Market Size, by UV-Vis Dissolution Imaging, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 88. Global Dissolution Equipment Market Size, by UV-Vis Dissolution Imaging, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E902] Taxonomy evidence: Segmentation

Evidence: [E900] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E900] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

9.3. Liquid Chromatography

Table 89. Global Dissolution Equipment Market Size, by Liquid Chromatography, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 90. Global Dissolution Equipment Market Size, by Liquid Chromatography, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 91. Global Dissolution Equipment Market Size, by Liquid Chromatography, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E616], [E1008] Taxonomy evidence: Segmentation

Evidence: [E1004], [E1061] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1004], [E1061] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

10. Dissolution Equipment Market, by Testing Purpose

[redacted] USP's intrinsic-dissolution chapter reinforces the distinction by identifying characterization work rather than routine individual-monograph testing. Suppliers should establish the funded objective before treating a capability statement as evidence of a batch-testing acquisition.

Regulatory Equivalence and Change Assessment is a program-specific purchasing context, not a universal requirement to acquire another system. FDA's M9 publication notice describes eligible biowaiver uses and expressly limits the applicable product scope. [redacted]

Post-Market Quality Surveillance has a different commissioning context from a manufacturer's routine product testing. WHO describes complaint-related testing, quality surveys, and regulatory support among laboratory missions. [redacted]

Education and Training has direct institutional support: the University of Canberra identifies dissolution capability within its pharmaceutical-science teaching laboratory. An instructional purchase should therefore be evaluated against the documented teaching assignment and access needs, not automatically against commercial product-release requirements. [redacted]

Figure 14. Global Dissolution Equipment Market Size, by Testing Purpose, 2025 (%)




Figure 15. Global Dissolution Equipment Market, by Testing Purpose, 2032 (USD Million)




Table 92. Global Dissolution Equipment Market, by Testing Purpose growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 93. Global Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E682], [E52], [E108], [E668], [E1128], [E406], [E322] Testing Purpose

Evidence: [E54], [E671], [E669], [E673], [E408], [E319], [E654], [E661], [E659], [E940], [E947], [E1070], [E1071], [E620], [E704], [E703], [E567], [E37] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E54], [E671], [E669], [E673], [E408], [E319], [E654], [E661], [E659], [E940], [E947], [E1070], [E1071], [E969], [E966], [E971], [E620], [E704], [E703], [E567], [E37] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E106], [E672], [E1127], [E409] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

10.1. Batch Quality Control and Stability Testing

Table 94. Global Dissolution Equipment Market Size, by Batch Quality Control and Stability Testing, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 95. Global Dissolution Equipment Market Size, by Batch Quality Control and Stability Testing, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 96. Global Dissolution Equipment Market Size, by Batch Quality Control and Stability Testing, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E674], [E36], [E845], [E695] Taxonomy evidence: Segmentation

Evidence: [E669], [E661], [E940] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E669], [E661], [E940] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

10.2. Research and Development

Table 97. Global Dissolution Equipment Market Size, by Research and Development, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 98. Global Dissolution Equipment Market Size, by Research and Development, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 99. Global Dissolution Equipment Market Size, by Research and Development, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E861], [E99], [E670], [E938] Taxonomy evidence: Segmentation

Evidence: [E671], [E654], [E1070], [E703] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E671], [E654], [E1070], [E969], [E703] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

10.3. Regulatory Equivalence and Change Assessment

Table 100. Global Dissolution Equipment Market Size, by Regulatory Equivalence and Change Assessment, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 101. Global Dissolution Equipment Market Size, by Regulatory Equivalence and Change Assessment, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 102. Global Dissolution Equipment Market Size, by Regulatory Equivalence and Change Assessment, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E676], [E677] Taxonomy evidence: Segmentation

Evidence: [E673], [E659], [E620], [E54] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E673], [E659], [E620], [E54] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

10.4. Education and Training

Table 103. Global Dissolution Equipment Market Size, by Education and Training, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 104. Global Dissolution Equipment Market Size, by Education and Training, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 105. Global Dissolution Equipment Market Size, by Education and Training, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E407] Taxonomy evidence: Segmentation

Evidence: [E408], [E947], [E1071], [E704] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E408], [E947], [E1071], [E971], [E704] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

10.5. Post-Market Quality Surveillance

Table 106. Global Dissolution Equipment Market Size, by Post-Market Quality Surveillance, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 107. Global Dissolution Equipment Market Size, by Post-Market Quality Surveillance, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 108. Global Dissolution Equipment Market Size, by Post-Market Quality Surveillance, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E1129] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E966], [E567], [E37], [E319] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E567], [E37], [E319] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

11. Dissolution Equipment Market, by End User

End User should follow the operating purchaser and its acceptance obligations, rather than every organization financing or benefiting from the work. ■■■ ■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■ ■■■■■■■■■■■■■ ■■■■■ ■■■ ■■■■■■■■■■■■■■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■■■ ■■■ ■■■ ■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■■■■ ■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■■■ ■■■■■ ■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■ ■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■■■ ■■■■ ■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■ ■■■■■■■■■■■■■■■ ■■■■■■■ ■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■ ■■■■■■■■■■■ Suppliers should identify the laboratory purchaser, client acceptance role, and contracting authority before treating the payer as the equipment end user.

■■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■ ■■ ■■■■■■■■■ ■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■■ ■■ ■■■■■■■ ■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■■■■■■■■ ■■ ■■■ ■■■■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■ This example does not establish an identical purchasing case for every drug-substance or excipient business. The supplier should establish the operating facility's mandate and project requirements before proposing a configuration.

Dietary Supplement Companies require a specification-led proposition rather than a blanket pharmaceutical-compliance argument. ■■■ ■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■ ■■■ ■■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■ ■■■ ■■■■■■■■■■■■■■■■ ■■■■ ■■■■ ■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■■■ ■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■ ■■■■ ■■■■■■■ ■■ ■■■■■■■■■■■ Equipment suppliers should qualify the buyer's actual specification or quality commitment before presenting regulatory obligation as the purchase trigger.

Academic and Noncommercial Research Institutions should not be assigned a presumed automation preference. Canberra documents a teaching setting, while the University of Strathclyde's procurement report records an automated dissolution-system contract with Sotax Ltd. ■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■ ■ ■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■ ■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■ ■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■ ■■ ■■ ■■■■■ ■■■ ■■■■■■■■ ■■ ■■■ ■■■■■■ ■■■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■ ■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■ ■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■ ■ ■■■ ■■■■■■■■■■■■■ ■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■

Figure 16. Global Dissolution Equipment Market Size, by End User, 2025 (%)




Figure 17. Global Dissolution Equipment Market, by End User, 2032 (USD Million)




Table 109. Global Dissolution Equipment Market, by End User growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 110. Global Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E551], [E686], [E691], [E410], [E321], [E936], [E846], [E422], [E1058] End User

Evidence: [E683], [E688], [E690], [E320], [E939], [E847], [E1067], [E705], [E712], [E713], [E649], [E651], [E45], [E626], [E568] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E683], [E688], [E690], [E320], [E939], [E847], [E1067], [E705], [E712], [E713], [E649], [E651], [E45], [E626], [E44], [E568] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E424], [E640], [E779], [E35] Taxonomy evidence: Segmentation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E1062], [E660], [E665], [E38], [E946], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

11.1. Pharmaceutical Product Companies

Table 111. Global Dissolution Equipment Market Size, by Pharmaceutical Product Companies, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 112. Global Dissolution Equipment Market Size, by Pharmaceutical Product Companies, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 113. Global Dissolution Equipment Market Size, by Pharmaceutical Product Companies, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E639], [E860], [E675] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E712], [E649], [E683] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E712], [E649], [E683] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

11.2. Contract Research and Testing Organizations

Table 114. Global Dissolution Equipment Market Size, by Contract Research and Testing Organizations, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 115. Global Dissolution Equipment Market Size, by Contract Research and Testing Organizations, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 116. Global Dissolution Equipment Market Size, by Contract Research and Testing Organizations, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E423] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E45], [E688] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E45], [E688], [E44] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

11.3. Pharmaceutical Ingredient Companies

Table 117. Global Dissolution Equipment Market Size, by Pharmaceutical Ingredient Companies, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 118. Global Dissolution Equipment Market Size, by Pharmaceutical Ingredient Companies, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 119. Global Dissolution Equipment Market Size, by Pharmaceutical Ingredient Companies, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E937] Taxonomy evidence: Segmentation

Evidence: [E939], [E713], [E651] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E939], [E713], [E651] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

11.4. Academic and Noncommercial Research Institutions

Table 120. Global Dissolution Equipment Market Size, by Academic and Noncommercial Research Institutions, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 121. Global Dissolution Equipment Market Size, by Academic and Noncommercial Research Institutions, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 122. Global Dissolution Equipment Market Size, by Academic and Noncommercial Research Institutions, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E64], [E780], [E405], [E421] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E1067], [E705] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1067], [E705] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

11.5. Dietary Supplement Companies

Table 123. Global Dissolution Equipment Market Size, by Dietary Supplement Companies, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 124. Global Dissolution Equipment Market Size, by Dietary Supplement Companies, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 125. Global Dissolution Equipment Market Size, by Dietary Supplement Companies, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E848], [E693] Taxonomy evidence: Segmentation

Evidence: [E847], [E690], [E626] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E847], [E690], [E626] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

11.6. Public Medicines-Control Laboratories

Table 126. Global Dissolution Equipment Market Size, by Public Medicines-Control Laboratories, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 127. Global Dissolution Equipment Market Size, by Public Medicines-Control Laboratories, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 128. Global Dissolution Equipment Market Size, by Public Medicines-Control Laboratories, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E34], [E323], [E949] Taxonomy evidence: Segmentation

Evidence: [E320], [E568] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E320], [E568] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

12. Dissolution Equipment Market, by Automation Level

Automation Level should be compared through the delivered package and retained staff responsibilities, not treated as a hierarchy of equipment quality. Himachal Pharma Testing Lab Limited's March 2025 solicitation separately requested Manual apparatus and apparatus with an autosampler. ■■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■ ■■ ■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■ ■■■■■■■■ ■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■■ ■■ ■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■ ■■ ■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■ ■■■■ ■■■ ■■■■■■■■■■ ■■■■ ■■■ ■■■■■■■■ ■■■■■■■■ ■■ ■■■■■■■■■■■■

Fully Automated offerings make a broader commercial commitment. ■■■■■ ■■■■■■■■■■■ ■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■ ■■■■■■■■■■■■ ■■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■ ■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■ ■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■■ Semi-Automated equipment remains an alternative where a narrower addition addresses the purchasing need.

Actual procurement provides a counterweight to portfolio claims without establishing universal adoption. Strathclyde's procurement report records a contract for supply, delivery, and installation of an automated dissolution system with Sotax Ltd. ■■■■ ■■■■■■■■■■■■ ■ ■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■ ■■■■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■■■■■ ■■■■■ ■■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■ ■■■ ■■■■■■■■ ■■■■■■ ■■■■ ■■■■■ ■■■■ ■■■■ ■ ■■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■ ■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■■

Automation does not transfer data-governance responsibility to the equipment supplier. FDA's data-integrity guidance emphasizes reliable records and management accountability within its drug-CGMP scope. ■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■ ■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■ ■■ ■■■■■■■■ ■■■■■■■■ ■■■■■ ■■ ■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■ ■■■■■■■■■■ ■ ■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■ ■■■■■■■■■■ ■■ ■ ■■■■■■■■ ■■■■■■■■■■■■

Figure 18. Global Dissolution Equipment Market Size, by Automation Level, 2025 (%)




Figure 19. Global Dissolution Equipment Market, by Automation Level, 2032 (USD Million)




Table 129. Global Dissolution Equipment Market, by Automation Level growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 130. Global Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E629], [E1022], [E745], [E1068] Automation Level

Evidence: [E1026], [E735], [E748], [E1069], [E943], [E270], [E267], [E271], [E1012], [E1011], [E1013], [E263] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1026], [E735], [E748], [E1069], [E943], [E270], [E267], [E271], [E1012], [E1011], [E1013], [E263] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E731], [E701], [E203] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E1062], [E660], [E665], [E38], [E946], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

12.1. Semi-Automated

Table 131. Global Dissolution Equipment Market Size, by Semi-Automated, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 132. Global Dissolution Equipment Market Size, by Semi-Automated, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 133. Global Dissolution Equipment Market Size, by Semi-Automated, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E750], [E204] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E730], [E39] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E730], [E39] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E724], [E657], [E40] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E748], [E943], [E267], [E1011], [E263] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E748], [E943], [E267], [E1011], [E263] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

12.2. Fully Automated

Table 134. Global Dissolution Equipment Market Size, by Fully Automated, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 135. Global Dissolution Equipment Market Size, by Fully Automated, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 136. Global Dissolution Equipment Market Size, by Fully Automated, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E702], [E205] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E1069], [E271], [E1013], [E1026] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E1069], [E271], [E1013], [E1026] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

12.3. Manual

Table 137. Global Dissolution Equipment Market Size, by Manual, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 138. Global Dissolution Equipment Market Size, by Manual, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 139. Global Dissolution Equipment Market Size, by Manual, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E749], [E206] Taxonomy evidence: Segmentation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E730], [E39] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E730], [E39] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E724], [E657], [E40] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E735], [E270], [E1012] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E735], [E270], [E1012] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

13. Dissolution Equipment Market, by Sales Channel

Direct Sales and Indirect Sales should be distinguished through the contracting relationship, not whether the transaction originates online or through a tender. Distek advertises its own US regional contacts alongside Betatek as a dissolution distributor in Canada. ■■■■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■■ ■■■■■■■■■ ■■■■■■■ ■■ ■ ■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■ ■■■■■■ ■■■ ■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■

■■■■■■■■ ■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■ ■■■■ ■■■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■■ ■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■ ■■■■■■■■ An intermediary can therefore contribute an eligible bidding and service relationship without removing manufacturer obligations. For that purchasing setting, direct participation is preferable only if the manufacturer can meet the same requirements itself; an indirect route adds coordination and a relationship to oversee.

The practical channel choice is consequently conditional. A manufacturer should select a partner for documented buyer access and assigned fulfillment responsibilities, while a buyer should preserve a direct alternative where those requirements can be met without an intermediary. ■ ■■■■■■■■■ ■■■■■■■ ■■ ■■■■■■■■■■■■■ ■■■■■■ ■■■■■ ■■■■ ■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■

Figure 20. Global Dissolution Equipment Market Size, by Sales Channel, 2025 (%)




Figure 21. Global Dissolution Equipment Market, by Sales Channel, 2032 (USD Million)




Table 140. Global Dissolution Equipment Market, by Sales Channel growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 141. Global Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E491], [E739] Sales Channel

Evidence: [E517], [E502], [E740], [E728], [E941], [E972], [E968], [E964], [E965], [E773], [E275] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E517], [E502], [E740], [E728], [E972], [E968], [E964], [E965], [E275] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E732], [E266], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E778] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

13.1. Direct Sales

Table 142. Global Dissolution Equipment Market Size, by Direct Sales, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 143. Global Dissolution Equipment Market Size, by Direct Sales, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 144. Global Dissolution Equipment Market Size, by Direct Sales, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E777], [E274] Taxonomy evidence: Segmentation

Evidence: [E275], [E941], [E972], [E740], [E517], [E964], [E773] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E275], [E972], [E740], [E517], [E964] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

13.2. Indirect Sales

Table 145. Global Dissolution Equipment Market Size, by Indirect Sales, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 146. Global Dissolution Equipment Market Size, by Indirect Sales, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 147. Global Dissolution Equipment Market Size, by Indirect Sales, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E776] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E968], [E728], [E502], [E965] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E968], [E728], [E502], [E965] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14. Dissolution Equipment Market, by Tested Product

Pharmaceutical Dosage Forms require application-specific comparisons rather than a single interchangeable equipment proposition. ■■■ ■■■■■■■■■■ ■■■■■■■■■ ■■■■■ ■■■■■■ ■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■ ■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■ ■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■ ■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■■ A multipurpose offering may serve several included families without representing separate purchases for each.

■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■ ■■■ ■■■■■■■ ■ ■■■■■■■ ■■■■■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■ ■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■ ■■■■■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■ That offering demonstrates commercial specialization, not universal suitability across these families. Buyers should require offering-level application coverage and acceptance responsibility rather than extend an oral-product equipment comparison by analogy.

■■■■■■■■■■ ■■■■■■ ■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■ ■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■ ■■ ■■■■■■■■■ ■■■■ ■■ ■■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■ ■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■ ■■ ■■■■■■■■■■■■■■■■ ■■■■■■■■■■ It does not establish an accepted commercial configuration for a particular present-day assignment. An equipment commitment should therefore await a documented offering and buyer acceptance for the intended application.

Drug Substances & Excipients create a different justification. ■■■■■ ■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■ ■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■ ■■ ■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■■■ ■■■■■ ■■■■■■■■ ■■■■ ■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■ Pharmaceutical Ingredient Companies and their laboratories should connect an acquisition to the relevant development or customer specification, rather than assume the finished-dosage-form quality-control rationale applies unchanged.

Dietary Supplements have a separate compendial scope: USP's supplement chapter applies where dissolution standards are stated in individual monographs. A supplement-related purchase therefore needs its own product and specification basis, not an assumption that all supplements require the same equipment access. ■■■■■■■■ ■■■■■■■ ■■■■■■ ■■ ■■ ■■■■■■■■■■■ ■■■■ ■■■■■■ ■■ ■■■■■■■■■■■■ ■■ ■■■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■ ■ ■■■■■■■■■■ ■■ ■■■■■■■■■ ■■■■■■■■■ ■■ ■ ■■■■■■■■■■■■

Figure 22. Global Dissolution Equipment Market Size, by Tested Product, 2025 (%)




Figure 23. Global Dissolution Equipment Market, by Tested Product, 2032 (USD Million)




Table 148. Global Dissolution Equipment Market, by Tested Product growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 149. Global Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E100], [E80], [E89], [E70], [E86], [E74], [E346], [E112], [E623] Tested Product

Evidence: [E98], [E79], [E111] Taxonomy evidence: Segmentation

Evidence: [E104], [E110], [E664], [E265], [E650], [E627] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E104], [E110], [E664], [E265], [E650], [E627] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

14.1. Pharmaceutical Dosage Forms

Table 150. Global Dissolution Equipment Market, by Pharmaceutical Dosage Forms growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 151. Global Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 152. Global Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 153. Global Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E85], [E88], [E78], [E69], [E624] Taxonomy evidence: Segmentation

Evidence: [E83], [E92], [E81], [E68], [E265], [E650], [E75], [E76], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E83], [E92], [E81], [E68], [E265], [E650], [E75], [E76], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.1.1. Oral Dosage Forms

Table 154. Global Dissolution Equipment Market Size, by Oral Dosage Forms, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 155. Global Dissolution Equipment Market Size, by Oral Dosage Forms, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 156. Global Dissolution Equipment Market Size, by Oral Dosage Forms, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E84], [E77] Taxonomy evidence: Segmentation

Evidence: [E81] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E81] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.1.2. Parenteral Dosage Forms

Table 157. Global Dissolution Equipment Market Size, by Parenteral Dosage Forms, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 158. Global Dissolution Equipment Market Size, by Parenteral Dosage Forms, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 159. Global Dissolution Equipment Market Size, by Parenteral Dosage Forms, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E67] Taxonomy evidence: Segmentation

Evidence: [E68], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E68], [E345] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.1.3. Transdermal Systems

Table 160. Global Dissolution Equipment Market Size, by Transdermal Systems, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 161. Global Dissolution Equipment Market Size, by Transdermal Systems, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 162. Global Dissolution Equipment Market Size, by Transdermal Systems, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E91], [E71] Taxonomy evidence: Segmentation

Evidence: [E92], [E76] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E92], [E76] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.1.4. Topical & Mucosal Dosage Forms

Table 163. Global Dissolution Equipment Market Size, by Topical & Mucosal Dosage Forms, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 164. Global Dissolution Equipment Market Size, by Topical & Mucosal Dosage Forms, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 165. Global Dissolution Equipment Market Size, by Topical & Mucosal Dosage Forms, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E87], [E82], [E72] Taxonomy evidence: Segmentation

Evidence: [E83], [E75] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E83], [E75] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.1.5. Inhalation Dosage Forms

Table 166. Global Dissolution Equipment Market Size, by Inhalation Dosage Forms, by Region, 2017-2040 (USD Thousand)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 167. Global Dissolution Equipment Market Size, by Inhalation Dosage Forms, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 168. Global Dissolution Equipment Market Size, by Inhalation Dosage Forms, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E625] Taxonomy evidence: Segmentation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

Evidence: [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

14.2. Drug Substances & Excipients

Table 169. Global Dissolution Equipment Market, by Drug Substances & Excipients growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 170. Global Dissolution Equipment Market Size, by Drug Substances & Excipients, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 171. Global Dissolution Equipment Market Size, by Drug Substances & Excipients, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 172. Global Dissolution Equipment Market Size, by Drug Substances & Excipients, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E93] Taxonomy evidence: Segmentation

Evidence: [E104], [E94], [E96], [E664], [E666] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E104], [E94], [E96], [E664], [E666] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.2.1. Drug Substances

Table 173. Global Dissolution Equipment Market Size, by Drug Substances, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 174. Global Dissolution Equipment Market Size, by Drug Substances, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 175. Global Dissolution Equipment Market Size, by Drug Substances, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E95] Taxonomy evidence: Segmentation

Evidence: [E94], [E666] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E94], [E666] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.2.2. Excipients

Table 176. Global Dissolution Equipment Market Size, by Excipients, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 177. Global Dissolution Equipment Market Size, by Excipients, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 178. Global Dissolution Equipment Market Size, by Excipients, by Country, 2017-2040 (USD Thousand)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E97] Taxonomy evidence: Segmentation

Evidence: [E96] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E96] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

14.3. Dietary Supplements

Table 179. Global Dissolution Equipment Market Size, by Dietary Supplements, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 180. Global Dissolution Equipment Market Size, by Dietary Supplements, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 181. Global Dissolution Equipment Market Size, by Dietary Supplements, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E109] Taxonomy evidence: Segmentation

Evidence: [E110], [E627] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E110], [E627] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

15. Dissolution Equipment Market, by Region

[redacted] Brazil maintains its own official pharmacopoeial framework. A supplier should connect its commercial package to the buyer's applicable requirements; neither example establishes identical obligations throughout its region.

In Europe, official-laboratory cooperation can change where equipment capability is needed. [redacted] This mechanism is limited to participating institutions and does not establish purchasing behavior across Europe.

[redacted] This provides a specific customer opportunity, not evidence of a uniform regional purchasing cycle. Participation remains dependent on the final buyer requirements and award.

In the Middle East, advertised territorial reach can extend across countries without establishing a shared service commitment. Distek lists Al Mansour Group for dissolution equipment in Saudi Arabia and the United Arab Emirates. [redacted]

[redacted] Listing concerns the institution's assessed quality system, not equipment endorsement or acquisition funding. Suppliers should establish the particular laboratory's approved requirement and contracting authority before pursuing an upgrade.

Figure 24. Global Dissolution Equipment Market, by Region: Market share evolution, 2025-2032




Figure 25. Global Dissolution Equipment Market, by Region: Market size by category, 2025 (USD Million)




Figure 26. Global Dissolution Equipment Market, Regional growth by End User, 2025-2032 (CAGR %)




Table 182. Global Dissolution Equipment Market, by Region growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 183. Global Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Asia-Pacific	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Europe	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latin America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Middle East	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North America	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E698], [E41], [E487], [E711], [E565], [E128] REGION Analysis

Evidence: [E455], [E655] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E455], [E655] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E566], [E653], [E569] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E566], [E653], [E569] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

15.1. Asia-Pacific

Table 184. Asia-Pacific Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indonesia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Malaysia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Philippines	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Singapore	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Taiwan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Thailand	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 185. Asia-Pacific Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indonesia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Malaysia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Philippines	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Singapore	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Taiwan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Thailand	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 186. Asia-Pacific Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 187. Asia-Pacific Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 188. Asia-Pacific Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 189. Asia-Pacific Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 190. Asia-Pacific Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 191. Asia-Pacific Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 192. Asia-Pacific Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 193. Asia-Pacific Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 194. Asia-Pacific Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 195. Asia-Pacific Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 196. Asia-Pacific Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E657], [E40] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - base-year allocation

Evidence: [E657], [E40], [E724] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Asia-Pacific - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

15.2. North America

Table 197. North America Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand)

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 198. North America Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 199. North America Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 200. North America Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 201. North America Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 202. North America Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 203. North America Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 204. North America Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 205. North America Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 206. North America Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 207. North America Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 208. North America Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 209. North America Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E658] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North America - base-year allocation

Evidence: [E658] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North America - forecast-year allocation

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

15.3. Europe

Table 210. Europe Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Austria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Belgium	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Denmark	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Finland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Netherlands	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Norway	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Poland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Portugal	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sweden	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Switzerland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 211. Europe Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Austria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Belgium	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Denmark	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Finland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Netherlands	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Norway	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Poland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Portugal	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sweden	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Switzerland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 212. Europe Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 213. Europe Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 214. Europe Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 215. Europe Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 216. Europe Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 217. Europe Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 218. Europe Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 219. Europe Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 220. Europe Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 221. Europe Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 222. Europe Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E653], [E569], [E566] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Europe - base-year allocation

Evidence: [E653], [E569], [E566] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Europe - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E574] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Switzerland - base-year allocation

Evidence: [E574] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Switzerland - forecast-year allocation

Evidence: [E573] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Denmark - base-year allocation

Evidence: [E573] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Denmark - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E571] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Poland - base-year allocation

Evidence: [E571] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Poland - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

15.4. Latin America

Table 223. Latin America Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Argentina	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Chile	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Colombia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Peru	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 224. Latin America Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Argentina	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Chile	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Colombia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Peru	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 225. Latin America Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 226. Latin America Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 227. Latin America Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 228. Latin America Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 229. Latin America Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 230. Latin America Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 231. Latin America Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 232. Latin America Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 233. Latin America Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 234. Latin America Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 235. Latin America Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E662] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Latin America - base-year allocation

Evidence: [E662] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Latin America - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110],

[E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E304] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Argentina - base-year allocation

Evidence: [E304] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Argentina - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E307] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Chile - base-year allocation

Evidence: [E307] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Chile - forecast-year allocation

Evidence: [E306] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Colombia - base-year allocation

Evidence: [E306] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Colombia - forecast-year allocation

Evidence: [E305] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Peru - base-year allocation

Evidence: [E305] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Peru - forecast-year allocation

15.5. Middle East

Table 236. Middle East Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Israel	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Qatar	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Saudi Arabia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Turkey	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Arab Emirates	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 237. Middle East Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Israel	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Qatar	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Saudi Arabia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Turkey	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Arab Emirates	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 238. Middle East Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 239. Middle East Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 240. Middle East Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 241. Middle East Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 242. Middle East Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 243. Middle East Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 244. Middle East Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 245. Middle East Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 246. Middle East Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 247. Middle East Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 248. Middle East Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E655], [E455] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Middle East - base-year allocation

Evidence: [E655], [E455] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Middle East - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E517], [E502], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E517], [E502], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E579] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Turkey - base-year allocation

Evidence: [E579] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Turkey - forecast-year allocation

Evidence: [E296], [E516] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Saudi Arabia - base-year allocation

Evidence: [E296], [E516] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Saudi Arabia - forecast-year allocation

Evidence: [E309], [E523] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Arab Emirates - base-year allocation

Evidence: [E309], [E523] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Arab Emirates - forecast-year allocation

15.6. Africa

Table 249. Africa Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Egypt	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Kenya	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Nigeria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 250. Africa Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million)

Region	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Egypt	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Kenya	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Nigeria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 251. Africa Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 252. Africa Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 253. Africa Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 254. Africa Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 255. Africa Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Thousand)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 256. Africa Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 257. Africa Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 258. Africa Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 259. Africa Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 260. Africa Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 261. Africa Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E656], [E325] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Africa - base-year allocation

Evidence: [E656], [E325] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Africa - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E308] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Kenya - base-year allocation

Evidence: [E308] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Kenya - forecast-year allocation

Evidence: [E303] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Nigeria - base-year allocation

Evidence: [E303] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Nigeria - forecast-year allocation

16. Dissolution Equipment Market, by Group

Americas-wide account coverage spans different public-procurement access conditions. The United States and Canada participate in the WTO Government Procurement Agreement, while Brazil is listed as an observer. ▪▪▪▪ ▪▪▪ ▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ A regional proposal should identify the responsible counterparty and remedies for each destination. Consolidated account management is useful only while the underlying country relationships and customer-site commitments remain covered.

▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ The same commercial organization may administer sales into France and Germany, but must retain the applicable national execution. Consolidated selling can simplify account management without eliminating those responsibilities; equipment coverage and contractual allocation remain prerequisites.

▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ A shared Nordic commercial organization can coordinate customers, but origin, customs responsibility, and destination fulfillment must be established before selecting one delivery route. Separate delivery can be preferable when it provides clearer obligations than a consolidated arrangement.

▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪

[illegible] Suppliers may coordinate related pharmaceutical accounts, but should verify the customer's equipment acceptance and local purchasing conditions separately. Recognition can reduce duplication within its actual scope without creating a common apparatus qualification or service commitment.

[illegible] A supplier may organize related accounts together, but should not present inspection cooperation as approval of its apparatus. Coordinated coverage is preferable only when the written equipment and support arrangements cover the respective customer sites.

[illegible] Customs coordination alone does not settle distributor rights or equipment support. A consolidated route can simplify logistics, but direct destination delivery remains preferable when it provides clearer fulfillment and service accountability.

[illegible] This is more defensible than assuming that a supplier accepted by one G7 institution is eligible for another. Shared preparation preserves efficiency without replacing destination-specific bid review.

[illegible] A dissolution-equipment supplier targeting medicines-control or academic laboratories should identify the procuring authority and applicable purchasing regime rather than infer eligibility from the NATO label. Group-level account coordination can remain useful, but neither another member's procurement access nor a military-alliance relationship establishes the laboratory's acceptance or an equipment-service obligation.

[illegible]

[redacted] A regional representation proposal is unsuitable when those conditions remain unresolved. All reporting groups overlap other geographic lenses and must not be treated as additive equipment opportunities.

Figure 27. Global Dissolution Equipment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)




Table 262. Global Dissolution Equipment Market Size, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
ASEAN	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
BRICS	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
European Union	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
G7	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
GCC	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
NATO	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Evidence: [E127], [E492], [E1139], [E1138], [E844], [E24], [E3], [E1092], [E709] GROUP Analysis

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

16.1. NATO

Table 263. NATO Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand)

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Albania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Belgium	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Bulgaria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Croatia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Czech Republic	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Denmark	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Estonia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Finland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Greece	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Hungary	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Iceland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latvia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Lithuania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Luxembourg	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Montenegro	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Netherlands	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North Macedonia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Norway	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Poland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Portugal	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Romania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 263 - continued

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Slovakia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovenia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sweden	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Turkey	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 264. NATO Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Albania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Belgium	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Bulgaria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Croatia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Czech Republic	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Denmark	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Estonia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Finland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Greece	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Hungary	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Iceland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latvia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Lithuania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Luxembourg	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Montenegro	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 264 - continued

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Netherlands	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
North Macedonia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Norway	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Poland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Portugal	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Romania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovakia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovenia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sweden	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Turkey	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 265. NATO Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 266. NATO Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Million)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 267. NATO Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 268. NATO Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 269. NATO Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 270. NATO Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 271. NATO Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 272. NATO Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 273. NATO Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 274. NATO Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 275. NATO Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E573] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Denmark - base-year allocation

Evidence: [E573] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Denmark - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E571] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Poland - base-year allocation

Evidence: [E571] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Poland - forecast-year allocation

Evidence: [E579] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Turkey - base-year allocation

Evidence: [E579] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Turkey - forecast-year allocation

Evidence: [E293] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Albania - base-year allocation

Evidence: [E293] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Albania - forecast-year allocation

Evidence: [E292] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Montenegro - base-year allocation

Evidence: [E292] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Montenegro - forecast-year allocation

Evidence: [E297] Evidence informing base-year allocation inputs; displayed values and growth are calculated: North Macedonia - base-year allocation

Evidence: [E297] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: North Macedonia - forecast-year allocation

16.2. G7

Table 276. G7 Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 277. G7 Dissolution Equipment Market Size, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 278. G7 Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 279. G7 Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Million)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 280. G7 Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 281. G7 Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 282. G7 Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 283. G7 Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 284. G7 Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 285. G7 Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 286. G7 Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 287. G7 Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 288. G7 Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

16.3. BRICS

Table 289. BRICS Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 290. BRICS Dissolution Equipment Market Size, by Group, 2017-2040 (USD Million)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Africa	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 291. BRICS Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 292. BRICS Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 293. BRICS Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 294. BRICS Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 295. BRICS Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 296. BRICS Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 297. BRICS Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 298. BRICS Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 299. BRICS Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 300. BRICS Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 301. BRICS Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

16.4. European Union

Table 302. European Union Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand)

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Austria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Belgium	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Bulgaria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Croatia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Cyprus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Czech Republic	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Denmark	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Estonia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Finland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Greece	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Hungary	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Ireland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latvia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Lithuania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Luxembourg	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Malta	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Netherlands	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Poland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Portugal	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Romania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovakia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovenia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sweden	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 303. European Union Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Austria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Belgium	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Bulgaria	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Croatia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Cyprus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Czech Republic	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Denmark	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Estonia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Finland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Greece	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Hungary	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Ireland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Latvia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Lithuania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Luxembourg	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Malta	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Netherlands	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Poland	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Portugal	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Romania	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovakia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Slovenia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sweden	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 304. European Union Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 305. European Union Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 306. European Union Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 307. European Union Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 308. European Union Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 309. European Union Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 310. European Union Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 311. European Union Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 312. European Union Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 313. European Union Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 314. European Union Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751],

[E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E572] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Ireland - base-year allocation

Evidence: [E572] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Ireland - forecast-year allocation

Evidence: [E573] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Denmark - base-year allocation

Evidence: [E573] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Denmark - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E571] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Poland - base-year allocation

Evidence: [E571] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Poland - forecast-year allocation

16.5. ASEAN

Table 315. ASEAN Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand)

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Brunei	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Cambodia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indonesia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Lao People's Democratic Republic	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Malaysia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Myanmar	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Philippines	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Singapore	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Thailand	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vietnam	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 316. ASEAN Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Brunei	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Cambodia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indonesia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Lao People's Democratic Republic	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Malaysia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Myanmar	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Philippines	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Singapore	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Thailand	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vietnam	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 317. ASEAN Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 318. ASEAN Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 319. ASEAN Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 320. ASEAN Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 321. ASEAN Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 322. ASEAN Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 323. ASEAN Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 324. ASEAN Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 325. ASEAN Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 326. ASEAN Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 327. ASEAN Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E294] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brunei - base-year allocation

Evidence: [E294] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brunei - forecast-year allocation

Evidence: [E300] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Cambodia - base-year allocation

Evidence: [E300] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Cambodia - forecast-year allocation

Evidence: [E302] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Myanmar - base-year allocation

Evidence: [E302] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Myanmar - forecast-year allocation

Evidence: [E312] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Vietnam - base-year allocation

Evidence: [E312] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Vietnam - forecast-year allocation

Evidence: [E310] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Lao People's Democratic Republic - base-year allocation

Evidence: [E310] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Lao People's Democratic Republic - forecast-year allocation

16.6. GCC

Table 328. GCC Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand)

Category	2025 value (USD Thousand)	2032 value (USD Thousand)	Added value (USD Thousand)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Bahrain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Kuwait	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oman	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Qatar	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Saudi Arabia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Arab Emirates	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 329. GCC Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand)

Group	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Bahrain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Kuwait	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oman	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Qatar	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Saudi Arabia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Arab Emirates	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx

Table 330. GCC Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 331. GCC Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 332. GCC Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 333. GCC Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Thousand)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 334. GCC Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Thousand)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 335. GCC Dissolution Equipment Market Size, by End User, 2017-2040 (USD Thousand)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 336. GCC Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 337. GCC Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 338. GCC Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 339. GCC Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 340. GCC Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E517], [E502], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E517], [E502], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E296], [E516] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Saudi Arabia - base-year allocation

Evidence: [E296], [E516] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Saudi Arabia - forecast-year allocation

Evidence: [E309], [E523] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Arab Emirates - base-year allocation

Evidence: [E309], [E523] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Arab Emirates - forecast-year allocation

17. Dissolution Equipment Market, by Country

[redacted] Purchase orders remain subject to the stated sale terms. A buyer considering upkeep should confirm the exact part, contracting entity and support commitment; the storefront alone does not establish delivery or repair performance.

India illustrates why the final purchasing record matters. [redacted] The procurement record establishes a solicitation, not an award or completed installation.

Brazil and Japan demonstrate different standards-change signals. ANVISA identifies approval of the eighth Brazilian Pharmacopoeia under its May xx.xx 2026 resolution. [redacted]

[redacted] A supplier seeking a replacement project needs an application-specific acceptance or support issue, not merely a standards announcement. Whether either standards development requires a particular buyer to change equipment remains unresolved.

Figure 28. Global Dissolution Equipment Market Size, by Country, 2025 vs 2032 (%)




Figure 29. Global Dissolution Equipment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)




Table 341. Global Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million)

Category	2025 value (USD Million)	2032 value (USD Million)	Added value (USD Million)	2025 share (%)	2032 share (%)	Change (pp)	Growth share (%)	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Unallocated / remaining scope	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Scope total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 342. Global Dissolution Equipment Market Size, by Country, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Brazil	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Canada	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
China	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
France	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Germany	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
India	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Italy	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Japan	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mexico	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Russia	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
South Korea	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Spain	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United Kingdom	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
United States	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E43], [E710], [E273], [E904] COUNTRY Analysis

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

17.1. United States

Table 343. United States Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
United States	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 344. United States Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 345. United States Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 346. United States Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 347. United States Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 348. United States Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 349. United States Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 350. United States Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 351. United States Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 352. United States Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 353. United States Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 354. United States Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E663], [E295], [E1109] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United States - base-year allocation

Evidence: [E663], [E295], [E1109] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United States - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110],

[E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

17.2. China

Table 355. China Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
China	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 356. China Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 357. China Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 358. China Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 359. China Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 360. China Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 361. China Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 362. China Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 363. China Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 364. China Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 365. China Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 366. China Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E324] Evidence informing base-year allocation inputs; displayed values and growth are calculated: China - base-year allocation

Evidence: [E324] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: China - forecast-year allocation

17.3. India

Table 367. India Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
India	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 368. India Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 369. India Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Others	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 370. India Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 371. India Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 372. India Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 373. India Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 374. India Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 375. India Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 376. India Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 377. India Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 378. India Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E39], [E730] Evidence informing base-year allocation inputs; displayed values and growth are calculated: India - base-year allocation

Evidence: [E39], [E730] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: India - forecast-year allocation

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

17.4. Germany

Table 379. Germany Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Germany	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 380. Germany Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 381. Germany Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 382. Germany Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 383. Germany Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 384. Germany Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 385. Germany Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 386. Germany Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 387. Germany Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 388. Germany Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 389. Germany Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 390. Germany Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E570] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Germany - base-year allocation

Evidence: [E570] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Germany - forecast-year allocation

17.5. Japan

Table 391. Japan Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Japan	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 392. Japan Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 393. Japan Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 394. Japan Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 395. Japan Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 396. Japan Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 397. Japan Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 398. Japan Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 399. Japan Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 400. Japan Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 401. Japan Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 402. Japan Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

17.6. France

Table 403. France Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
France	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 404. France Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 405. France Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 406. France Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 407. France Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 408. France Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 409. France Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 410. France Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 411. France Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 412. France Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 413. France Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 414. France Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E578] Evidence informing base-year allocation inputs; displayed values and growth are calculated: France - base-year allocation

Evidence: [E578] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: France - forecast-year allocation

17.7. Italy

Table 415. Italy Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Italy	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 416. Italy Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 417. Italy Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 418. Italy Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 419. Italy Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 420. Italy Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 421. Italy Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 422. Italy Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 423. Italy Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 424. Italy Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 425. Italy Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 426. Italy Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E577] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Italy - base-year allocation

Evidence: [E577] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Italy - forecast-year allocation

17.8. South Korea

Table 427. South Korea Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
South Korea	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 428. South Korea Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 429. South Korea Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 430. South Korea Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 431. South Korea Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 432. South Korea Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 433. South Korea Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 434. South Korea Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 435. South Korea Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 436. South Korea Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 437. South Korea Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 438. South Korea Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

17.9. Canada

Table 439. Canada Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Canada	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 440. Canada Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 441. Canada Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 442. Canada Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 443. Canada Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 444. Canada Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 445. Canada Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 446. Canada Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 447. Canada Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 448. Canada Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 449. Canada Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 450. Canada Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E652], [E298] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Canada - base-year allocation

Evidence: [E652], [E298] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Canada - forecast-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

17.10. United Kingdom

Table 451. United Kingdom Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
United Kingdom	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 452. United Kingdom Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 453. United Kingdom Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 454. United Kingdom Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 455. United Kingdom Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 456. United Kingdom Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 457. United Kingdom Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 458. United Kingdom Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 459. United Kingdom Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 460. United Kingdom Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 461. United Kingdom Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 462. United Kingdom Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751],

[E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E576] Evidence informing base-year allocation inputs; displayed values and growth are calculated: United Kingdom - base-year allocation

Evidence: [E576] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: United Kingdom - forecast-year allocation

17.11. Mexico

Table 463. Mexico Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Mexico	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 464. Mexico Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 465. Mexico Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 466. Mexico Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 467. Mexico Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 468. Mexico Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 469. Mexico Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 470. Mexico Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 471. Mexico Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 472. Mexico Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 473. Mexico Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 474. Mexico Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E301] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Mexico - base-year allocation

Evidence: [E301] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Mexico - forecast-year allocation

17.12. Spain

Table 475. Spain Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Spain	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 476. Spain Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 477. Spain Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 478. Spain Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 479. Spain Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 480. Spain Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 481. Spain Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 482. Spain Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 483. Spain Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 484. Spain Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 485. Spain Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 486. Spain Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E575] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Spain - base-year allocation

Evidence: [E575] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Spain - forecast-year allocation

17.13. Russia

Table 487. Russia Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Russia	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 488. Russia Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 489. Russia Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 490. Russia Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 491. Russia Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 492. Russia Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 493. Russia Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 494. Russia Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 495. Russia Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 496. Russia Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 497. Russia Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 498. Russia Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E311] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Russia - base-year allocation

Evidence: [E311] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Russia - forecast-year allocation

17.14. Brazil

Table 499. Brazil Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Brazil	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 500. Brazil Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 501. Brazil Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 502. Brazil Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 503. Brazil Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 504. Brazil Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 505. Brazil Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 506. Brazil Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 507. Brazil Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 508. Brazil Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 509. Brazil Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 510. Brazil Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

Evidence: [E299] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Brazil - base-year allocation

Evidence: [E299] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Brazil - forecast-year allocation

17.15. Australia

Table 511. Australia Dissolution Equipment Market Size, 2017-2040 (USD Million)

Country	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Australia	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 512. Australia Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand)

Product Type	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Accessories, Consumables, and Replacement Parts	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Analytical Detection Modules	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dissolution Test Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Qualification Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Media-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Sample-Handling Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Vessel-Cleaning Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Visual Surveillance Equipment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 513. Australia Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand)

Apparatus Platform	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Agitated-Bottle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Basket Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Flow-Through Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Mechanical Chewing Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Membrane-Separated Cell Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Paddle Over Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Reciprocating Holder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating Cylinder Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Rotating-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stationary-Disk Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Stirred-Vial Apparatus	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 514. Australia Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million)

Analytical Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct UV-Vis Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Liquid Chromatography	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
No Integrated Detection	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 515. Australia Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million)

Direct UV-Vis Detection	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
External-Cell UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
In Situ Fiber-Optic UV-Vis Spectrophotometry	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
UV-Vis Dissolution Imaging	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 516. Australia Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Thousand)

Testing Purpose	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Batch Quality Control and Stability Testing	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Education and Training	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Post-Market Quality Surveillance	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Regulatory Equivalence and Change Assessment	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Research and Development	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 517. Australia Dissolution Equipment Market Size, by End User, 2017-2040 (USD Thousand)

End User	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Academic and Noncommercial Research Institutions	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Contract Research and Testing Organizations	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Dietary Supplement Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Ingredient Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Product Companies	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Public Medicines-Control Laboratories	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 518. Australia Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million)

Automation Level	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Fully Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Manual	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Semi-Automated	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 519. Australia Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million)

Sales Channel	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Direct Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Indirect Sales	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 520. Australia Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million)

Tested Product	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Dietary Supplements	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Drug Substances & Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Pharmaceutical Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 521. Australia Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand)

Pharmaceutical Dosage Forms	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Inhalation Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Oral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Parenteral Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Topical & Mucosal Dosage Forms	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Transdermal Systems	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Table 522. Australia Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand)

Drug Substances & Excipients	2017	2024	2025	2026	2027	2032	2040	CAGR (%)
Drug Substances	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Excipients	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
Total	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**	**xx.xx**

Evidence: [E660], [E665], [E38], [E946], [E1062], [E268], [E970] Evidence informing the 2025 market-value input; displayed series and growth include calculations: Market value, 2025

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E942], [E948], [E940], [E947], [E943], [E941], [E1064], [E1066], [E1060], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E568], [E1026], [E263], [E964], [E965], [E773], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345] Evidence informing base-year allocation inputs; displayed values and growth are calculated: Segmentation - base-year allocation

Evidence: [E654], [E661], [E659], [E664], [E666], [E944], [E945], [E940], [E947], [E943], [E1064], [E1059], [E1061], [E1063], [E1070], [E1071], [E1067], [E1069], [E269], [E270], [E267], [E271], [E265], [E969], [E966], [E971], [E972], [E968], [E733], [E751], [E729], [E734], [E735], [E748], [E740], [E728], [E885], [E247], [E249], [E248], [E202], [E264], [E1050], [E1051], [E541], [E335], [E999], [E1001], [E1003], [E1002], [E1007], [E1015], [E1004], [E1005], [E1012], [E1011], [E1013], [E380], [E621], [E622], [E60], [E61], [E59], [E62], [E358], [E364], [E347], [E348], [E366], [E368], [E995], [E101], [E105], [E104], [E94], [E96], [E384], [E545], [E25], [E26], [E604], [E331], [E381], [E385], [E888], [E900], [E382], [E383], [E386], [E620], [E671], [E669], [E673], [E54], [E704], [E703], [E705], [E408], [E567], [E37], [E319], [E320], [E712], [E713], [E649], [E651], [E650], [E45], [E626], [E627], [E690], [E939], [E847], [E683], [E688], [E44], [E568], [E1026], [E263], [E964], [E965], [E517], [E502], [E275], [E110], [E81], [E92], [E68], [E75], [E76], [E83], [E345], [E425], [E756] Evidence informing forecast-year allocation inputs; displayed values and growth are calculated: Segmentation - forecast-year allocation

Evidence: [E667], [E973] Evidence informing the 2024 market-value input; displayed series and growth include calculations: Market value, 2024

Evidence: [E1065] Evidence informing the 2023 market-value input; displayed series and growth include calculations: Market value, 2023

Evidence: [E266], [E732], [E884] Evidence informing the 2026 market-value input; displayed series and growth include calculations: Market value, 2026

Evidence: [E747], [E887] Evidence informing the 2032 market-value input; displayed series and growth include calculations: Market value, 2032

18. Competitive Landscape

18.1. Market Share Analysis, 2025

Account access depends on an accepted equipment-and-support assignment, not portfolio visibility alone. Himachal Pharma Testing Lab Limited's March xx.xx 2025 tender assessed manufacturer authorization and sales and service arrangements, illustrating a documented purchasing gate rather than a universal rule or supplier award. ▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪

Omicron Research Limited provides a supported example of a partner contributing more than a contact name: Distek identifies it as its UK dissolution distributor, and Omicron advertises equipment and lifecycle support. That can provide a consolidated customer interface, conditional on the actual configuration and site being covered. ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪

Distek's country-directory routes include Betatek, Inc.; Spectralab Instrumentación; Chemetric Instrumentacao Analitica Ltda; Del Carpio Analisis y Asesorias Ltda; Casa Cientifica LTDA.; Elicrom Cia Ltd.; Ridaline S.A.; BDC Serralles, srl; Quiamsa, S.A.; and Comerrsa in the Americas. ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ These are manufacturer-listed access relationships, not additional independent apparatus origins or customer-specific service commitments.

The same directory identifies Al Mansour Group, Atef Habib Rizk & Co., Quest Scientific, Master Pharma, Promo-Biotech Tunisie, ISI Israel Scientific Instruments Ltd., and Standart Analitik Sistemler Ltd. across African and Middle Eastern destinations. Its Asia-Pacific routes include SCINCO, ITS Science & Medical Group-related businesses, John Morris Group, ERT Consortium, Crescent Scientific Pvt. ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪

▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪

[illegible] Ltd., Heka Lab, and Gaia Science. Their common evidenced role is commercial contact, not universally confirmed product allocation.

[illegible] Corporacion Cientifica Venezolana presents SOTAX equipment. The buyer should compare these sellers' authority and fulfillment commitments without counting each channel as a separate apparatus manufacturer.

[illegible] CDL-TECORA is manufacturer-listed, and the Tecora catalog presents Distek products, but the precise legal-seller binding between those names remains to be confirmed. These routes address different purchasing objects and should not be evaluated as identical system offers.

Middle Eastern portfolios also distinguish apparatus representation from specialist analytical access. [illegible] Their catalog roles do not establish common ownership, exclusivity, or interchangeable service coverage.

Additional regional alternatives are visible through MYMSA's Pharma Test portfolio, EURL NTC, New Technology Control's ERWEKA offering, and Lab Dynamics' Labindia DS xx.xx configuration. In Asia, Chemcokorea presents named dissolution systems, Saka International Ltd. lists Electrolab equipment, Trung Son T.S.[illegible]

[illegible]

Figure 30. Global Dissolution Equipment Market Share, by Key Player, 2025




Table 523. Global Dissolution Equipment Market Share, by Key Player, 2025

Key Player	Share (%)
Electrolab India Pvt. Ltd.	xx.xx
ERWEKA GmbH	xx.xx
Quality Lab Accessories, LLC	xx.xx
Raytor Instruments	xx.xx
SOTAX AG	xx.xx
Others	xx.xx

Evidence: [E485], [E737], [E257], [E855], [E1041], [E133], [E436], [E200], [E129], [E433], [E56], [E387], [E4], [E799], [E1056], [E412], [E121], [E816], [E721], [E1073], [E33], [E587], [E842], [E419], [E281], [E30], [E290], [E138], [E185], [E714], [E141], [E876], [E245], [E1131], [E717], [E390], [E1090], [E834], [E221], [E317], [E837], [E610], [E807], [E46], [E951], [E288], [E1120], [E21]

Evidence: [E1035], [E720], [E821], [E590], [E452], [E820], [E926], [E925], [E1093], [E1096], [E822], [E18], [E17], [E219] Evidence informing base-year company-share estimates: Company - base-year company share

18.2. Market Concentration Analysis, 2025

Control in Dissolution Equipment can sit at the brand, software, component, or country-service relationship rather than at the original apparatus sale alone. Teledyne Hanson is presented as a Teledyne LABS brand, while ERWEKA GmbH records its entry into Verder Scientific in 2023. [illegible]

Similar names must not be used to infer ownership or additional independent alternatives. DISS-SOTAX S. [illegible]

[illegible] The remaining dependency is configuration-specific: the supported driver, software entitlement, update responsibility, and continued records access. Buyers can preserve mixed-brand choice where those obligations are documented; a consolidated package may be preferable where responsibility for interfaces would otherwise remain divided.

Independent aftermarket supply also challenges an assumption that an apparatus supplier captures all subsequent purchases. [illegible] Consolidated purchasing can simplify ordering while leaving compatibility, warranty, and technical responsibility with different parties.

[illegible] Likewise, the relationships among MILLAB, RULLAB-branded equipment, REATORG, and Universal Lab require separation of catalog seller, brand owner, and equipment origin. Buyers should seek competing contractual commitments, not merely differently branded listings of potentially related equipment.

Consolidation can alter the organization behind customer access without demonstrating greater apparatus control. [illegible] Acquisition alone does not establish integrated support, improved bargaining outcomes, or exclusivity over an apparatus category.

Evidence: [E990], [E519], [E591], [E213], [E259], [E1085], [E228], [E439], [E313], [E6], [E418], [E1123], [E707], [E16], [E933], [E400]

18.3. Recent Developments & Impact Analysis, 2025

[redacted] The commercial consequence is a configuration and lifecycle comparison: buyers should obtain the proposed peripherals, software, installation, and support commitments rather than assume the new family is an automatic replacement for an accepted legacy installation. The release does not establish superior outcomes or destination-specific delivery.

Pion's May xx.xx 2025 DissoSpec launch extends its proposition into a combined dissolution-bath, Rainbow R6 optical-monitoring, and DissoPRO software package. The announcement describes semi-automated operation, so fully integrated packaging must not be confused with fully automated equipment. [redacted]

An August 2025 announcement named QLA as Merel Instruments' authorized US distributor, and QLA's own commercial page advertises representation in the United States and Puerto Rico. [redacted] The appointment supports commercial access, not an unconditional fulfillment commitment for every Merel offering.

Evidence: [E529], [E883], [E65], [E852], [E208]

18.4. Product Portfolio Analysis, 2025

Dissolution Equipment competition depends on the purchasing object: a standalone apparatus, an automated equipment package, an analytical subsystem, or an addition to an accepted installation. [redacted] A buyer seeking apparatus without integrated detection should not require a broader analytical package merely because another supplier bundles one.

Automation and analytical integration create separate comparisons. SOTAX AG advertises AT-MD Offline for unattended operation and collection for subsequent analysis. [redacted]

[illegible]

Specialty apparatus changes the relevant peer group. ERWEKA GmbH's portfolio includes reciprocating, flow-through, and Mechanical Chewing Apparatus offerings; Electrolab India Pvt. [illegible]

Analytical specialists address information needs that apparatus breadth alone does not answer. [illegible] An analytical module, imaging platform, or specialist instrument should be compared against the buyer's intended information and acceptance requirements, not assumed to replace a conventional quality-control package.

[illegible] Their commercial roles remain distinct from apparatus manufacture. Merel's historically documented dissoGUARD integration also establishes a Visual Surveillance Equipment proposition, but a present hardware, software, and support commitment must be obtained before purchase.

[illegible] The appropriate comparison is an itemized, destination-specific offer. Catalog coexistence does not establish model compatibility, export contracting authority, or continuing service.

[redacted]
Their regional presentation can make a local equipment-and-support inquiry practical, but nationality does not establish purchasing preference, acceptance, or faster delivery. In particular, an automatic apparatus label should not be equated with included sampling, analytical detection, and records management.

Catalog-based challengers require a different attribution check. Torontech Inc. advertises ToronDISS configurations; Qualitest offers a QualiPharma sampling-system proposition; SED Pharma lists SED-RCDY equipment; Labmate Scientific LLC and Labotronics Scientific advertise named dissolution instruments, and Labdex Ltd. maintains a dissolution offering. [redacted] That establishes a supplier-brand and channel connection, not Uniflex's precise legal operator, manufacturing role, or continuing standalone availability. A washer-only requirement can therefore justify a separate sourcing comparison, conditional on identifying the contracting supplier and apparatus compatibility.

Evidence: [E354], [E374], [E1025], [E333], [E895], [E898], [E525], [E584], [E1077], [E179], [E215], [E1101], [E923], [E1084], [E599], [E868], [E176], [E427], [E825], [E229], [E403], [E862], [E787], [E977], [E755], [E915], [E910], [E392], [E928], [E168], [E813], [E830], [E395], [E430], [E1099], [E1135], [E243], [E810], [E806], [E815], [E118], [E1142], [E802], [E792]

18.5. Benchmarking Analysis, 2025

A defensible benchmark compares the same buyer assignment and commercial package. For conventional apparatus, an Agilent, Copley, or Labindia proposal should be compared on included apparatus, sampling, detection relationship, software rights, acceptance documentation, and destination support. [redacted]

Qualification equipment provides a concrete compatibility boundary. QLA's BT1000 page expressly excludes SOTAX AT7 and AT7 smart, whereas Agilent describes the xx.xx-DS for open-head apparatus, including its xx.xx-DS. [redacted]

[illegible] The decisive comparison is which equipment, analytical function, governing software, and continuing support are included, rather than whether a supplier uses an integrated-system label. For METTLER TOLEDO, continuing dissolution-specific integration scope remains an unresolved commercial condition; its proposed detector role should not be promoted into a complete-tester commitment.

[illegible] Buyers should resolve condition, included components, transferable software rights, installation, warranty commencement, and remedies in the order. A new-equipment contract is preferable where necessary rights or lifecycle support cannot be secured for the particular resale offer.

Identity conflicts constrain comparisons before performance or support can be assessed. Scitek Global Co.,Ltd and Scitek Global Co., Ltd. remain separate captured identities, but the punctuation difference does not establish independent businesses. [illegible]

Equipment-origin and seller accountability remain separate questions for Raytor Instruments and LEAD-TECH, which advertise similarly designated RT612-ST equipment without establishing their OEM, reseller, or ownership relationship. [illegible] Wahyong Instrument's dated DS-806AT page establishes a historical model presentation; continuing supply and Cleverlab's present manufacturer-backed obligations must be confirmed rather than inferred from that record.

Accessory-channel identities must not be converted into complete-system equivalents. For Altmann Analytik GmbH & Co. [illegible]

Some country-contact relationships require further allocation before they become comparable supply commitments. [redacted] Directory or brand-network membership does not settle which legal business supplies the equipment or accepts the service obligation.

[redacted] Comercio y Representaciones, S.A de C.V requires legal-seller binding for the CORESA channel designation. These unresolved distinctions prevent unconditional substitution against an attributed manufacturer-backed offer; they do not establish absence or low competitive significance.

[redacted] LS Scientific Limited and Educational Scientific & Technical Equipment Company (ESTEC) Ltd. require country-specific allocation of equipment supply and continuing service. Omicron Measurements Limited must not inherit Omicron Research Limited's documented relationships merely through name similarity.

[redacted] The relationship, if any, between Quality Lab Solutions and Quality Lab Solutions USA LLC also remains unresolved. A historical catalog, broad product category, or similar business name should not be used to transfer another company's rights or service commitments.

[redacted]

[redacted] Rabin Azma Parsian presents a dissolution-system category alongside broader instrument and spare-part sourcing, but the named configuration, equipment origin, and manufacturer authority remain to be established. Buyers should not treat these different forms of commercial evidence as interchangeable qualifications.

[redacted] The company remains within the captured competitive scope, but a buyer needs the in-boundary equipment and accountable seller before treating the proposed route as a substitute. This is a commercial attribution question, not a reason to change the accepted application categories.

Evidence: [E356], [E370], [E1021], [E1076], [E882], [E217], [E254], [E261], [E177], [E929], [E132], [E877], [E959], [E1111], [E114], [E1094], [E1125], [E398], [E222]

19. Company Profiles

19.1. Agilent Technologies Inc.

Agilent Technologies Inc. offers a configurable purchasing route through the xx.xx-DS rather than a mandatory fully automated package. The advertised platform covers Basket Apparatus, Paddle Apparatus, Paddle Over Disk Apparatus, and Rotating Cylinder Apparatus, with manual or automated configurations and options for Agilent software and UV-Vis integration. ■■■■■ ■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■ ■■■ ■■■■■■■■■■■■ ■■■■ ■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■ ■■■ ■■■■■■ ■■■■■ ■■■■■■■■

■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■ ■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■■■■■ Agilent describes compatibility with open-head dissolution apparatus, including the xx.xx-DS, making qualification equipment a potentially independent purchase rather than an automatic reason to replace the tester.

A laboratory with an acceptable apparatus should request separate proposals for the identified configuration change, qualification equipment, and complete replacement. ■■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■■■■ ■■■ ■■■ ■■■■■ ■■■■■■■■■■■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■ ■■■ ■■■ ■■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■ ■■ ■ ■■■■■■■■■■ ■■■■■■■■■■■ ■■ ■■■■■■■■ ■■■■ ■■■ ■■■■■■■■■■ ■■■■■■■ Model compatibility, software entitlement, installation responsibility, and destination service should be confirmed in the offer.

Evidence: [E355], [E372] Agilent Technologies Inc.

Evidence: [E357], [E363], [E967], [E329], [E330] Company verification: Company

19.2. SOTAX AG

■■■■■ ■■ ■■■■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■ ■■■■■■■■■■■■■■■ ■■■■■■■■■■■■■■ AT-MD Offline is advertised as a fully automated, self-cleaning benchtop dissolution system supporting unattended sequences and collection for subsequent analysis. Its automation scope should therefore be distinguished from an integrated analytical-detection commitment.

Separately, q-doc is advertised with drivers for instruments from different brands and interfaces to laboratory and enterprise systems. This creates a potential route for retaining supported equipment within a broader data environment. ■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■■■■ ■■ ■■■■ ■■■■ ■■■■■ ■■■■■ ■■■■■■■■■■■■■ ■■■ ■■■■■ ■■■■■■■■ ■■■■ ■ ■■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■■■■■■ ■■■ ■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■■■■■■

SOTAX also advertises installation, repair, project management, and system-integration services through direct operations and partners. ■■■ ■■■■■■■■■■■■■ ■■■■■■■ ■■ ■■ ■■■■■■■■■■■■■■■ ■■■■ ■■■■■ ■■ ■■■■■ ■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■■ ■■ ■■■■■■■■■ ■■■■■■■■■■■ ■■■■■■■■■■ ■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■■■■■■■■■ ■■■■■■■ ■■■ ■■■■■■■■■■■ ■■■■■■■■■■■■■■ ■■ ■■■ ■■■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■■■■ ■ ■■■■■■■■■■■■ ■■■■■ ■■■■■■■■■ ■■■■■■■■ ■■■■■■ ■■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■■■

RESEARCH SAMPLE REPORT

[redacted] Neither route removes the buyer's acceptance obligations.

Evidence: [E985], [E1018], [E147], [E154], [E1054] SOTAX AG

Evidence: [E1034], [E1048], [E997], [E998], [E1032] Company verification: Company

19.3. Distek, Inc.

Distek, Inc. announced the release of its OLERA series on May xx.xx 2026. [redacted] This gives buyers an architecture choice within one supplier's portfolio, but the release announcement does not establish superior outcomes or destination-specific fulfillment.

[redacted] Buyers should not assume that an apparatus order includes sampling, media handling, and optical detection, or that sampling and in situ optical measurement must be purchased together. A defensible comparison specifies the apparatus and supporting categories separately before evaluating the proposed integrated package.

Commercial access is also country-specific: Distek lists Betatek in Canada and Crescent Scientific in India as dissolution distributors. [redacted] This preserves package choice without allowing a broad portfolio or distributor listing to substitute for a delivery commitment.

Evidence: [E488], [E532], [E526] Distek, Inc.

Evidence: [E498], [E499], [E501], [E533], [E527], [E528], [E524] Company verification: Company

19.4. ERWEKA GmbH

[redacted] It represents Mechanical Chewing Apparatus rather than another conventional basket-and-paddle bath. Relevant dosage-form and supplement assignments should remain distinct from the supplier's confectionery and snuff examples.

[redacted] A conventional bath is not established as a substitute simply because both offerings concern dissolution. Conversely, portfolio breadth alone does not justify adding the specialty instrument where that purchasing requirement is absent.

[redacted]

RESEARCH SAMPLE REPORT

[redacted] Group ownership therefore provides commercial context, not assurance of local coverage for a proposed DRT configuration. Buyers should obtain the destination-specific service commitment before allowing a group-wide support proposition to determine the award.

Evidence: [E592], [E601], [E596] ERWEKA GmbH

Evidence: [E593], [E595], [E607], [E598] Company verification: Company

19.5. Electrolab India Pvt. Ltd.

Electrolab India Pvt. Ltd. provides an additional supplier route for reciprocating platforms through its advertised ERD-xx.xx. [redacted]

The company's service offering includes annual maintenance plans, breakdown calls, and preventive maintenance requests, with business locations in Mumbai and Navi Mumbai. [redacted]

Himachal Pharma Testing Lab Limited's March xx.xx 2025 procurement illustrates why location alone does not establish purchasing eligibility: it assessed manufacturer authorization and sales and service arrangements. That example is not an Electrolab award. [redacted]

Evidence: [E727], [E582], [E585], [E583] Electrolab India Pvt. Ltd.

Evidence: [E580], [E581] Company verification: Company

19.6. Tianda Tianfa Technology Co., Ltd.

For Tianda Tianfa Technology Co., Ltd., the inspectable offering evidence is a Chinese-language catalog naming 天津市天大天发科技有限公司. [redacted] This supports an apparatus-and-support comparison, not an assumption that every listed category is bundled into one system.

[redacted] A university equipment inventory dated January xx.xx 2016 also attributes RC806D instruments to the same Chinese-named supplier, corroborating historical institutional presence. That record does not establish RC1209D adoption, continuing maintenance, or present delivery performance.

[redacted] Those conditions remain unresolved. Catalog breadth and historical institutional attribution should not be promoted into evidence of global fulfillment.

Evidence: [E1078], [E1075], [E163] Tianda Tianfa Technology Co., Ltd.

Evidence: [E1080], [E1079], [E162], [E161], [E1074] Company verification: Company

19.7. Pion Inc.

[redacted] MicroFLUX combines dissolution and absorption assessment. These are specialist analytical propositions, not recording-only surveillance or automatically interchangeable alternatives to a conventional quality-control bath.

[redacted] Integrated package scope therefore should not be confused with fully automated operation. The announcement establishes the offered combination, not independently verified performance or local fulfillment.

Buyers should distinguish specialist development-information needs from the acceptance requirements of a quality-control acquisition. For DissoSpec, the current configuration, software rights, records access, and named support obligation should be established before commitment. [redacted]

Evidence: [E893], [E896], [E879] Pion Inc.

Evidence: [E878], [E886], [E974] Company verification: Company

19.8. Merel Instruments

Merel Instruments illustrates the separately supplied peripheral model. Its dissoWASH&DOSE offering combines semi-automated vessel cleaning and media handling and is advertised as mobile supporting equipment, not a replacement dissolution apparatus. [redacted]

[redacted]

[illegible] Before award, a surveillance buyer should obtain the current seller, supported hardware-and-software configuration, recording rights, and repair and update obligations. The historical offer is not a present sourcing commitment.

Evidence: [E334], [E763], [E180] Merel Instruments

Evidence: [E759], [E760], [E209], [E332], [E11], [E13] Company verification: Company

19.9. Quality Lab Accessories, LLC

Quality Lab Accessories, LLC provides an aftermarket proposition spanning dissolution accessories, consumables, calibration tools, and services. Its company description identifies manufacturing in Telford, Pennsylvania, while its catalog groups products by equipment manufacturer. [illegible]

[illegible] Buyers should therefore establish the installed model, required adapters, and records-acceptance requirements before purchase. Independent sourcing preserves apparatus choice but requires clearer responsibility for the component match than a bundled purchase.

QLA also advertises dissolution maintenance and repair services. [illegible] The announced relationship does not establish continuing availability of every represented product or make QLA the manufacturer of those offerings.

Evidence: [E211], [E214], [E216], [E212], [E66] Quality Lab Accessories, LLC

Evidence: [E210], [E207] Company verification: Company

19.10. Toyama Sangyo Co., Ltd.

Toyama Sangyo Co., Ltd. published a new-product announcement for the SAS-xx.xx autosampler on September xx.xx 2025. [illegible] The announcement does not establish that an apparatus, sampler, and software are supplied as one supported installation, or that a particular destination has a continuing delivery and service commitment.

[illegible]

Coordinated sourcing can simplify accountability when the agreement covers the combined package; separately sourced apparatus and sampling equipment preserve choice but add interface coordination. The commitment trigger is a written configuration and destination-support agreement, not the release notice alone.

Evidence: [E1106] Toyama Sangyo Co., Ltd.

Evidence: [E1105], [E1102], [E1104], [E1103], [E1108], [E1107] Company verification: Company

19.11. SpectraLab Scientific Inc.

SpectraLab Scientific Inc. offers a used and refurbished equipment route from Markham, Ontario. Its dissolution catalog lists Agilent, Distek, Hanson, and SOTAX offerings and distinguishes refurbished from pre-owned condition. ▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪ ▪▪ ▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪

The contractual protection requires particular attention. ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪ SpectraLab advertises installation and support, but those services should not be assumed to have the same scope as a new-equipment contract.

▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ A refurbished designation cannot replace that acceptance process. The resale route is a defensible alternative when the particular package and seller-backed obligations meet the buyer's requirements; a new-equipment commitment may be preferable when necessary rights or lifecycle support cannot be secured for the offered equipment.

Evidence: [E554], [E258], [E252], [E253], [E262] SpectraLab Scientific Inc.

Evidence: [E256], [E260], [E255] Company verification: Company

19.12. QUIMIS Aparelhos Científicos

QUIMIS Aparelhos Científicos advertises the Q850 automatic tablet dissolution instrument and describes Brazilian manufacturing operations in Diadema and São Roque. ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ The automatic product label should not be equated with a complete automated sampling, detection, and records-management package; the commercial offer must identify what is included.

QUIMIS publishes a state-selectable technical-assistance directory, including its own service contacts, and separately advertises installation, operational, and performance qualification

services. These establish commercial routes for support, not proof that every listed provider covers the Q850 or accepts a particular response obligation. ▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪ ▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪

Evidence: [E920], [E922], [E918], [E924] QUIMIS Aparelhos Científicos

Evidence: [E919], [E921] Company verification: Company

19.13. Omicron Research Limited

▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ The matching manufacturer and reseller records establish a supported commercial route to the product family, rather than a directory-only proposition. They do not establish exclusivity, stock availability, or a buyer-specific delivery obligation.

▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪ ▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪▪ ▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪ ▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪ ▪▪▪▪ ▪▪▪▪▪▪▪ ▪▪▪ ▪▪▪▪▪▪▪▪▪▪ ▪▪▪▪▪▪▪ Consolidation could reduce customer coordination compared with separate equipment and service contracts, but adds reliance on the distributor's continuing manufacturer relationship. The written offer should allocate delivery, installation, warranty escalation, software support, and response expectations; advertised service breadth alone does not settle those obligations.

Evidence: [E483], [E853], [E857] Omicron Research Limited

Evidence: [E854], [E851], [E850], [E136], [E849] Company verification: Company

20. Companies Covered

Table 524. Global Dissolution Equipment Market, Companies Covered

Company
2H Instrument
ABL&E-JASCO POLSKA
Advancement Est.
Agilent Technologies Inc.
Al Mansour Group
Alfa Mare
Alpax
Altmann Analytik GmbH & Co. KG
ANALYSIS d.o.o.
Analytical Solutions
Aneko de México
Ant Teknik
Arete Ltd
Arlab India Instruments Pvt. Ltd.
Array Medical
Arrow Pharmatech
Ashraf Instrument Co.
Atef Habib Rizk & Co.
AVIC Industrial
Barons Industrial Technology
BDC Serralles, srl
Bel-Ayavr ALC
Betatek, Inc.
BIA d.o.o.
Bio Aqua Group srl
Bioanalytic Sp. z o.o.
BIOBASE
Biogenic
Biopharma Technologies France
Biotronics Ltd.

Table 524 - continued

Company
BOSUNG SCIENTIFIC CO., LTD.
Brennan & Company
Business Tacts International
C.P.S. Analitica S.r.l.
Campbell Electronics
Casa Cientifica LTDA.
CDL-TECORA
Chemcokorea
Chemetric Instrumentacao Analitica Ltda
Chemistore
ChemQuest Ghana
Chromatography Spares
Chromavansa SRL
Chromservis s.r.o.
Cleverlab
Cobra Engineering Ltd.
Comercializadora Rivasa
Comercio y Representaciones, S.A de C.V
Comerrsa
Copley Scientific Limited
Core Lab
Corporacion Cientifica Venezolana
Corporación Analítica Integral, S.A. de C.V.
Crataegus Ltd.
Crescent Scientific Pvt. Ltd.
Cromtek
Dainippon Seiki
DAN Technologies
DCtech
Del Carpio Analisis y Asesorias Ltda
Derox SIA
Dexin Ltda.

Table 524 - continued

Company
Diamond Spectrum for Scientific & Laboratory Equipment Co
Dias de Sousa S.A.
DIESSEINSTRUMENT srl
DISS-SOTAX S. de R.L. de C.V.
Dissolution Accessories
Distek, Inc.
DKSH Market Expansion Services K.K
Donau Lab Ukraine
E-Lab
Educational Scientific & Technical Equipment Company (ESTEC) Ltd.
Electrofarmed
Electrolab India Pvt. Ltd.
Electronics India
Elicrom Cia Ltd.
Emme 3 Srl
Equilab
Equipmentor Scientific Systems Supplies L.L.C.
ERT Consortium
ERWEKA GmbH
ESCLAB
Esico International
Ethik Technology
EURL NTC, New Technology Control
Eurolab S.A.
Evoelution
Evolve Ltd.
Falcón División Analítica
Fallsdell Machinery Pty. Ltd.
FAMCO Instruments
Faneks Ltd.
Farma Alimenta S.L.
Federal Equipment Company

Table 524 - continued

Company
FREUND Corporation
Futurlab Lda
Gaia Science
Gemicatech
Gluvex Ltd.
Gomensoro
Grupo Alianza Estratégica GAE Ltda.
Grupo ICLAB
Grupo Rasch
Grupo RGH
Guill-Bern Corporation
Gulf Bio Analytical LLC
Gulf Circle for Laboratory and Medical Supplies
Gulf Scientific Corporation
Heka Lab
Hellamco S.A., Scientific Equipment
Hexis Científica
Hiperquim, S.A. de C.V.
HPST
HTDS
Infitek Co., Ltd.
Inhalation Sciences Sweden AB (publ)
Interquimica Industrial S.A.
Invent Technologies Ltd.
ISI Israel Scientific Instruments Ltd.
ITS Science & Medical Group
JASCO Corporation
John Morris Group
JProlab
Korval Products & Services EIRL
Krug International Ltd.
Kukje Engineering

Table 524 - continued

Company
Lab Dynamics
Lab Solutions
LabCenter Polska sp.z.o.o
Labdex Ltd.
Labindia Analytical
Labmate Scientific LLC
Labor Estabille
Laborin Pharma
Laboteca International Lab Supplies, SAPI de C.V.
Labotronics Scientific
LabPrim EOOD
Labstock Nigeria Limited
Labtim
Labtron
Lambda Scientific Co. Ltd.
LEAD-TECH
LKB Vertriebs Ges.m.b.H.
Logan Instruments Corp.
LS Scientific Limited
Master Pharma
Matoli
Maxwerk
Medical Shares Trading S.A.L.
Medika Scientific
Meditop Co., Ltd.
MEDOR ehf.
Memtech Kft.
Merel Instruments
Metrolab
METTLER TOLEDO
Microsep
MILLAB

Table 524 - continued

Company
Modern Scientific Supplies (MSS)
MYMSA
Nane Equipamientos S.L.
Neocitec
NIKYANG Enterprise Limited
Noavaran Co.
Nora Technology Bangladesh
Norlab Oy
NORLEQ Equipamentos e Serviços, Unipessoal Lda.
Obrnuta Faza d.o.o.
OF Systems
Omicron Measurements Limited
Omicron Research Limited
Ophir Analytical Ltd.
Oy G. W. Berg & Co Ab
Parsa Science Emporium Pvt Ltd.
Pharma Alliance Group
Pharma Test Apparatebau AG
Physio Mckina Co., Ltd.
Pion Inc.
PM Analytical Consultants
PMT Benelux NV
Proinstra S.A.
Prolyse B.V.
Promo-Biotech Tunisie
Protech Pharma Services Corp.
PT. Syaf Unica Indonesia
QatekPharma
QSI Peru S.A.
Qualitest
Quality Lab Accessories, LLC
Quality Lab Solutions

Table 524 - continued

Company
Quality Lab Solutions USA LLC
QualityLAB
Quantum D-O Analytical, S.A. de C.V.
Quest Scientific
Quiamsa, S.A.
QUIMIS Aparelhos Científicos
Quântica Analítica Instrumentação Ltda.
Rabin Azma Parsian
Raise Lab Equipment
Raytor Instruments
Reactilab Limited
REATORG
RG Scientific Pty. Ltd.
Ridaline S.A.
RIGGTEK GmbH
Ros-Jimtech Nigeria Limited
RULLAB
S&B Analitica
S.I. Photonics
Saka International Ltd.
SatiCus Science and Technology Co. Ltd.
SCINCO
Scitek Global Co., Ltd.
Scitek Global Co.,Ltd
SED Pharma
Serendipity RS Ltd.
Shanghai Huanghai
Shimadzu South Africa (Pty) Ltd.
Smart Resources For Equipment
Soflab Ltd.
Soltek
SOTAX AG

Table 524 - continued

Company
Spectralab Instrumentación
SpectraLab Scientific Inc.
SPMÉDICA
Standart Analitik Sistemler Ltd.
SUMI S.A.
Synergy Barukh, Ltd.
Synersy
Sysmex
Søren Berner Denmark ApS
Technology Links (Pvt.) Ltd.
Tectron Electronic Appliances Co.
Teknokroma Analítica S.A.
Teledyne Hanson
Terralab
Thermo Fisher Scientific
Tianda Tianfa Technology Co., Ltd.
Tianjin Guoming

Table 524 - continued

Company
Tianjin Jiaxinhai Machinery Equipment Co., Ltd.
Torontech Inc.
Toyama Sangyo Co., Ltd.
Tri Solution Co., Ltd.
Trung Son T.S.S.E Scientific Equipment & Tourist Joint Stock Company
Uniflex
Universal Lab
UVISON Technologies Limited
Veego Instrument Corporation
Verus Analytix (Pvt) Ltd
Vvon Technologies
VWR, part of Avantor
Wahyong Instrument
World of Labs Trading Establishment
Yatherm Scientific
Zafir Equipments FZE
Zistaco

Evidence: [E967], [E1034], [E1048], [E524], [E533], [E1089], [E607], [E134], [E135], [E227], [E230], [E231], [E226], [E974], [E136], [E849], [E854], [E851], [E850], [E871], [E173], [E1105], [E1102], [E1104], [E1103], [E547], [E546], [E357], [E363], [E329], [E330], [E997], [E998], [E527], [E528], [E498], [E499], [E501], [E496], [E493], [E520], [E497], [E494], [E522], [E495], [E486], [E503], [E456], [E457], [E458], [E459], [E461], [E460], [E462], [E463], [E464], [E465], [E466], [E467], [E468], [E469], [E470], [E471], [E472], [E473], [E475], [E479], [E474], [E476], [E477], [E478], [E484], [E480], [E513], [E504], [E510], [E512], [E514], [E500], [E509], [E507], [E506], [E511], [E505], [E508], [E515], [E1087], [E1088], [E1083], [E1086], [E1081], [E1082], [E598], [E593], [E595], [E869], [E870], [E580], [E581], [E175], [E174], [E426], [E428], [E824], [E826], [E224], [E225], [E404], [E863], [E864], [E788], [E790], [E789], [E791], [E1080], [E1079], [E1074], [E930], [E927], [E878], [E886], [E759], [E760], [E210], [E207], [E209], [E1031], [E1033], [E1032], [E914], [E913], [E916], [E917], [E978], [E979], [E976], [E975], [E1100], [E1098], [E1136], [E1137], [E1134], [E1133], [E256], [E260], [E255], [E434], [E435], [E437], [E438], [E199], [E201], [E282], [E283], [E706], [E708], [E250], [E251], [E272], [E276], [E919], [E921], [E812], [E831], [E396], [E397], [E413], [E429], [E431], [E172], [E1042], [E1043], [E1044], [E1045], [E1046], [E1047], [E1040], [E1036], [E1037], [E1038], [E1039], [E432], [E57], [E122], [E818], [E817], [E171], [E411], [E1055], [E388], [E5], [E800], [E722], [E58], [E934], [E754], [E757], [E758], [E1072], [E32], [E872], [E873], [E875], [E874], [E589], [E588], [E841], [E843], [E280], [E420], [E402], [E401], [E440], [E441], [E442], [E443], [E444], [E445], [E446], [E447], [E448], [E449], [E450], [E451], [E417], [E416], [E415], [E14], [E15], [E184], [E932], [E931], [E909], [E29], [E31], [E797], [E716], [E715], [E140], [E244], [E246], [E719], [E718], [E1132], [E1130], [E239], [E241], [E240], [E774], [E775], [E980], [E391], [E1091], [E223], [E833], [E835], [E318], [E220], [E389], [E183], [E808], [E809], [E414], [E191], [E192], [E836], [E838], [E137], [E611], [E613], [E612], [E178], [E829], [E828], [E827], [E752], [E753], [E119], [E120], [E190], [E117], [E167], [E166], [E801], [E803], [E47], [E48], [E952], [E953], [E954], [E798], [E285], [E284], [E277], [E278], [E950], [E287], [E286], [E1], [E2], [E832], [E1141], [E1140], [E911], [E912], [E608], [E609], [E958], [E962], [E955], [E963], [E956], [E960], [E957], [E961], [E1119], [E20], [E23], [E22], [E19], [E188], [E189], [E1126], [E1124], [E49], [E50], [E393], [E394], [E1116], [E1115], [E1118], [E1117], [E115], [E116], [E169], [E170], [E1095], [E1097], [E193], [E194], [E811], [E805], [E814], [E291], [E289], [E187], [E186], [E139], [E279], [E819], [E399], [E242], [E130], [E131], [E1122], [E1121], [E823], [E332], [E1108], [E1107], [E160], [E164], [E162], [E161], [E182], [E181], [E865], [E866], [E867], [E7], [E8], [E9], [E10], [E12], [E11], [E13], [E781], [E782], [E784], [E785], [E783], [E786], [E314], [E315], [E316], [E793], [E795], [E794], [E796], [E1113], [E1112], [E1114]
Company verification: Company

21. Key Experts

Every expert listed below was interviewed for this report. The listed pharmaceutical, instrumentation, commercial leadership, analytical services, pharmacopeial, regulatory, and academic roles provide professional perspectives relevant to Dissolution Equipment selection, purchasing requirements, and supplier support. ■■■■■ ■■■■■■■■■■■■■■ ■■■■■■■■■■■■ ■■■ ■■■■■■■ ■■■■■■■■■ ■■■■ ■■■ ■■■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■ ■■■ ■■■■■■■■ ■■■■■ ■■■■■■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■■ ■■■■■■■■ ■■■■■■■ ■■■■■■■■■■■■■■■ ■■ ■■■■■ ■■■■■ ■■■■■ ■■ ■■■■■■■■■■■■■

Table 525. Global Dissolution Equipment Market, Key Experts

Name	Professional Role	Organization	Country
Abu T. M. Serajuddin	Professor of Industrial Pharmacy	St. John's University	United States
Alex Avdeef	Founder	In-ADME Research	United States
Amnon Hoffman	Professor of Pharmaceutics	Hebrew University of Jerusalem	Israel
Anette Müllertz	Professor of Biopharmaceutics	University of Copenhagen	Denmark
Annette Bauer-Brandl	Professor of Pharmaceutics	University of Southern Denmark	Denmark
Arik Dahan	Professor of Pharmaceutics and Biopharmaceutics	Ben-Gurion University of the Negev	Israel
Arvind Kumar Bansal	Professor of Pharmaceutics	National Institute of Pharmaceutical Education and Research, S.A.S. Nagar	India
Beom-Jin Lee	Professor of Industrial Pharmacy	Ajou University	South Korea
Bertil Abrahamsson	Senior Principal Scientist, Biopharmaceutics	AstraZeneca	Sweden
Bryan Crist	Former Scientific Affairs Manager, Dissolution Systems	Agilent Technologies	United States
Buket Aksu	Professor of Pharmaceutical Technology	Altınbaş University	Turkey
Celine Valeria Liew	Associate Professor of Pharmacy	National University of Singapore	Singapore
Christel Bergström	Professor of Molecular Pharmaceutics	Uppsala University	Sweden
Christopher J. H. Porter	Professor of Pharmaceutics	Monash University	Australia
Christos Reppas	Professor of Biopharmaceutics	National and Kapodistrian University of Athens	Greece
Chuanbin Wu	Professor of Pharmaceutics	Jinan University	China
Clive A. Prestidge	Professor of Colloid and Pharmaceutical Science	University of South Australia	Australia

Table 525 - continued

Name	Professional Role	Organization	Country
Clive Wilson	Emeritus Professor of Pharmaceutics	University of Strathclyde	United Kingdom
Colin W. Pouton	Emeritus Professor of Pharmaceutical Biology	Monash University	Australia
Cristina Helena dos Reis Serra	Professor of Pharmacy and Biopharmaceutics	University of São Paulo	Brazil
Dae-Duk Kim	Professor of Pharmaceutics	Seoul National University	South Korea
Daniel Alberto Allemandi	Professor of Pharmaceutical Technology	National University of Córdoba	Argentina
Davi Pereira de Santana	Professor of Pharmaceutical Sciences	Federal University of Pernambuco	Brazil
David A. Miller	Co-founder and Chief Scientific Officer	AustinPx	United States
David C. Sperry	Research Advisor, Analytical Development	Eli Lilly and Company	United States
Deanna M. Mudie	Senior Principal Scientist	Lonza	United States
Diane J. Burgess	Distinguished Professor of Pharmaceutics	University of Connecticut	United States
Erika Stippler	Senior Director, Small Molecules	United States Pharmacopeia	United States
Fars K. Alanazi	Professor of Pharmaceutics	King Saud University	Saudi Arabia
Gavin Halbert	Professor of Drug Development	University of Strathclyde	United Kingdom
Geoff G. Z. Zhang	Senior Research Fellow and Head of Solid-State Chemistry	AbbVie	United States
Gregory E. Amidon	Research Professor Emeritus of Pharmaceutical Sciences	University of Michigan	United States
Guy Van den Mooter	Professor, Drug Delivery and Disposition	KU Leuven	Belgium
Han-Gon Choi	Professor of Pharmaceutics	Hanyang University	South Korea
Hans Lennernäs	Professor of Biopharmaceutics	Uppsala University	Sweden
Horacio Pappa	Director, General Chapters	United States Pharmacopeia	United States
Hsiu-O Ho	Professor of Pharmaceutics	Taipei Medical University	Taiwan
Humberto Gomes Ferraz	Professor of Pharmaceutical Technology	University of São Paulo	Brazil
Ian G. Tucker	Emeritus Professor of Pharmaceutical Sciences	University of Otago	New Zealand
Jaber Emami	Professor of Pharmaceutics	Isfahan University of Medical Sciences	Iran

Table 525 - continued

Name	Professional Role	Organization	Country
Jaleh Varshosaz	Professor of Pharmaceutics	Isfahan University of Medical Sciences	Iran
James E. Polli	Professor of Pharmaceutical Sciences	University of Maryland, Baltimore	United States
Jean-Michel Cardot	Professor of Biopharmaceutics	Université Clermont Auvergne	France
Jeff Seely	Vice President, Sales and Business Development	Distek	United States
Jennifer Dressman	Professor Emerita of Pharmaceutical Technology	Goethe University Frankfurt	Germany
Jette Østergaard	Associate Professor of Pharmaceutical Analysis	University of Copenhagen	Denmark
Johannes Krämer	Founder and Managing Director	PHAST	Germany
John Comer	Co-founder and Former Chief Scientific Officer	Sirius Analytical, now part of Pion	United Kingdom
John McDermott	Vice President, Scientific Consulting	Quotient Sciences	United Kingdom
Jong Oh Kim	Professor of Pharmacy	Yeungnam University	South Korea
Josias H. Hamman	Professor of Pharmaceutics	North-West University	South Africa
Jürgen Siepmann	Professor of Pharmaceutics	University of Lille	France
Karl Box	Chief Scientific Officer	Pion	United Kingdom
Kenjirou Higashi	Associate Professor of Pharmaceutical Technology	Chiba University	Japan
Kinam Park	Professor of Biomedical Engineering and Pharmaceutics	Purdue University	United States
Kiyohiko Sugano	Professor, College of Pharmaceutical Sciences	Ritsumeikan University	Japan
Kohsaku Kawakami	Pharmaceutical Materials Research Group Leader	National Institute for Materials Science	Japan
Konstantin Tsinman	Chief Scientific Officer	Pion	United States
Kunikazu Moribe	Professor of Pharmaceutical Technology	Chiba University	Japan
Kwabena Ofori-Kwakye	Professor of Pharmaceutics	Kwame Nkrumah University of Science and Technology	Ghana
Leila Bastos Leal	Professor of Pharmaceutical Sciences	Federal University of Pernambuco	Brazil
Lucinda Buhse	Former Director, Office of Testing and Research	U.S. Food and Drug Administration	United States

Table 525 - continued

Name	Professional Role	Organization	Country
Lynne S. Taylor	Professor of Industrial and Physical Pharmacy	Purdue University	United States
Manoush Masarrat	Chief Executive Officer	Inhalation Sciences Sweden	Sweden
Margareth R. C. Marques	Senior Principal Scientist	United States Pharmacopeia	United States
Maria Vertzoni	Associate Professor of Biopharmaceutics and Pharmacokinetics	National and Kapodistrian University of Athens	Greece
Marilyn N. Martinez	Senior Biomedical Research Scientist, Center for Veterinary Medicine	U.S. Food and Drug Administration	United States
Marique Aucamp	Professor of Pharmaceutics	University of the Western Cape	South Africa
Mark Copley	Chief Executive Officer	Copley Scientific	United Kingdom
Martin Kuentz	Professor of Pharmaceutical Technology	University of Applied Sciences and Arts Northwestern Switzerland	Switzerland
Martin Steppe	Professor of Pharmaceutical Analysis	Federal University of Rio Grande do Sul	Brazil
María Gabriela Volonté	Professor of Pharmaceutical Quality Control	National University of La Plata	Argentina
Masahiro Kataoka	Biopharmaceutics Faculty Member	Setsunan University	Japan
Matthew Fenn	Head of Business Development	Copley Scientific	United Kingdom
Matthias Brandl	Professor of Pharmaceutics	University of Southern Denmark	Denmark
Michael A. Repka	Professor of Pharmaceutics and Drug Delivery	University of Mississippi	United States
Michael U. Uhumwangho	Professor of Pharmaceutics	University of Benin	Nigeria
Ming-Thau Sheu	Professor of Pharmaceutics	Taipei Medical University	Taiwan
Nikoletta Fotaki	Professor of Biopharmaceutics	University of Bath	United Kingdom
Norma Angélica Torrado Durán	Professor of Pharmacy	National University of Colombia	Colombia
Oksana Tsinman	Director, Analytical Services	Pion	United States
Oluwatoyin A. Odeku	Professor of Pharmaceutics and Industrial Pharmacy	University of Ibadan	Nigeria
Patrick Augustijns	Professor of Biopharmaceutics	KU Leuven	Belgium
Patrick J. Faustino	Pharmaceutical Quality Research Scientist	U.S. Food and Drug Administration	United States

Table 525 - continued

Name	Professional Role	Organization	Country
Paul A. Harmon	Former Distinguished Scientist, Analytical Development	Merck & Co.	United States
Paul Wan Sia Heng	Emeritus Professor of Pharmacy	National University of Singapore	Singapore
Per Gerde	Founder and Chief Scientific Officer	Inhalation Sciences Sweden	Sweden
Peter Langguth	Professor of Pharmaceutical Technology and Biopharmaceutics	Johannes Gutenberg University Mainz	Germany
Peter Scholes	Chief Scientific Officer	Quotient Sciences	United Kingdom
Pornsak Sriamornsak	Professor of Pharmaceutical Technology	Silpakorn University	Thailand
Pratibha Pilgaonkar	Co-founder and Pharmaceutical R&D Leader	Rubicon Research	India
Raafat Fahmy	Former Senior Research Scientist, Center for Veterinary Medicine	U.S. Food and Drug Administration	United States
Raimar Löbenberg	Professor and Director, Drug Development and Innovation Centre	University of Alberta	Canada
Rassoul Dinarvand	Professor of Pharmaceutics; Former Head of Iran's Food and Drug Administration	Tehran University of Medical Sciences	Iran
Reza Fassihi	Professor of Biopharmaceutics and Industrial Pharmacy	Temple University	United States
Robert O. Williams III	Professor of Pharmaceutics	The University of Texas at Austin	United States
Roderick B. Walker	Professor of Pharmaceutics	Rhodes University	South Africa
Ron Tomer	Co-Chief Executive Officer	Unipharm	Israel
Ruggero Bettini	Professor of Pharmaceutical Technology	University of Parma	Italy
Sandile Khamanga	Dean, Faculty of Pharmacy	Rhodes University	South Africa
Sandra Klein	Professor of Pharmaceutical Technology	University of Greifswald	Germany
Sanjay Garg	Professor of Pharmaceutical Science	University of South Australia	Australia
Satit Puttipipatkhachorn	Professor of Manufacturing Pharmacy	Mahidol University	Thailand
Shinji Yamashita	Professor of Biopharmaceutics	Setsunan University	Japan
Silvia Storpirtis	Former Professor of Biopharmaceutics	University of São Paulo	Brazil
Stephen R. Byrn	Co-founder	Improved Pharma	United States

Table 525 - continued

Name	Professional Role	Organization	Country
Stephen W. Hoag	Professor of Pharmaceutical Sciences	University of Maryland, Baltimore	United States
Thomas Rades	Professor of Pharmaceutical Design and Drug Delivery	University of Copenhagen	Denmark
Tin Wui Wong	Professor of Pharmaceutics	Universiti Teknologi MARA	Malaysia
Vandana B. Patravale	Professor of Pharmaceutics	Institute of Chemical Technology, Mumbai	India
Venkateswarlu Vuyyuru	Founder and Managing Director	Neuheit Pharma Technologies	India
Vinod P. Shah	Former Senior Research Scientist, Center for Drug Evaluation and Research	U.S. Food and Drug Administration	United States
Vivek Ranjan Sinha	Professor of Pharmaceutics	Panjab University	India
Vivian A. Gray	Managing Director	Dissolution Technologies	United States
Wei Wu	Professor of Pharmaceutics	Fudan University	China
Werner Weitschies	Professor of Biopharmaceutics	University of Greifswald	Germany
William E. Brown	Senior Scientific Liaison, Dosage Form Performance	United States Pharmacopeia	United States
Wilna Liebenberg	Pharmaceutics Researcher	North-West University	South Africa
Yihong Qiu	Former Senior Research Fellow and Head of Oral Drug Products	AbbVie	United States
Yong Gan	Professor and Pharmaceutical Formulation Researcher	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	China
Yoshinori Onuki	Professor of Pharmaceutical Technology	University of Toyama	Japan
Yusrida Darwis	Professor of Pharmaceutical Technology	Universiti Sains Malaysia	Malaysia
Zongming Gao	Research Scientist, Center for Drug Evaluation and Research	U.S. Food and Drug Administration	United States

22. Sources & Evidence

Electrolab - India | 2H Instrument

[E1] 2H Instrument advertises TrustE, Veritas, and Inspire dissolution systems in Vietnam.

[E2] Its own page describes an Electrolab distribution and service relationship.

Protocol to Amend the ASEAN Sectoral Mutual Recognition Arrangement for GMP Inspection of Manufacturers of Medicinal Products

[E3] The 2025 amending protocol concerns the scope of medicine-manufacturer GMP inspection and certification. Its recognition provisions retain listed-service and acceptance distinctions; they do not establish equipment-purchasing authorization. ([agreement.asean.org](https://agreement.asean.org/media/download/xx.xx.pdf))

Distribuidor Labor Estabille | Alfa Mare

[E4] Alfa Mare advertises a Labor Estabille distribution and service proposition. ([alfamare.com.br](https://alfamare.com.br/labor-estabille/))

[E5] States a Labor Estabille distribution and authorized-service role and advertises tablet dissolution equipment.

Historie | Altium Česká republika

[E6] The company records HPST's June xx.xx 2023 name change to Altium International s.r.o., establishing identity continuity. ([altium.net](https://altium.net/cz/historie))

[E7] The company's official Czech history states that HPST, s.r.o. changed its name to Altium International s.r.o. on June xx.xx 2023.

[E8] The history identifies Altium SA as HPST's owner in connection with that name change.

[E9] The protected HPST title is therefore historical; this record supports identity continuity rather than creation of an additional competitor.

Analytická chemie | Altium

[E10] Altium's Czech commercial portfolio advertises Agilent xx.xx-DS, BIO-DIS, xx.xx-DS, dissolution sampling, monitoring, software, and dedicated peripheral offerings.

[E11] The Czech commercial portfolio advertises Merel-branded dissoCART, dissoDG, dissoDOSE, and dissoWASH&DOSE products.

[E12] The inspected portfolio establishes a named dissolution-equipment channel offering for the business formerly called HPST, rather than only a generic analytical-equipment capability.

[E13] These listings corroborate a channel-facing Merel peripheral portfolio, not current manufacturer ownership or completed transactions.

Тестеры растворения - Millab Analytic

[E14] Advertises manual and automated dissolution equipment and dedicated peripherals.

[E15] Lists RULLAB-branded dissolution systems in the Russian commercial catalog.

Тестеры растворения | MILLAB

[E16] MILLAB's catalog includes RULLAB-branded dissolution systems; it does not settle the complete brand-owner and equipment-origin relationship. ([analitika.millab.ru](https://analitika.millab.ru/catalog/analiticheskoe-oborudovanie/oborudovanie-dlya-farmakopeynogo-analiza/testery-rastvoreniya/))

Quality Lab Accessories LLC - Certificate of Registration FM 595556

[E17] The certificate effective May xx.xx 2025 identifies Quality Lab Accessories LLC and a scope covering design, manufacture, sales, service and distribution of dissolution accessories. It corroborates operating scope, not sales volume or market share. ([api.qla-llc.com](https://api.qla-llc.com/assets/3b54c4b9c0/FM-xx.xx-23May2025-expires-22May2028.pdf))

Quality Lab Accessories - Product Catalog

[E18] The manufacturer-issued catalog identifies dissolution accessories, consumables and qualification tools, a Telford manufacturing facility and a separate services division. These support the model's producer-goods versus services distinction, not its employment attribution or revenue estimate. ([api.qla-llc.com](https://api.qla-llc.com/assets/86c3dd34d1/QLA-Catalog-xx.xx.pdf))

Array Medical | Pharmaceutical & Laboratory Equipment Dealer in Pakistan

[E19] Array Medical advertises SCITEK DT and DSC dissolution equipment in Pakistan.

[E20] Array Medical advertises dissolution and disintegration equipment and describes its Pakistani distribution business.

[E22] Array Medical's own Pakistani offering includes BIOBASE-branded dissolution equipment; this does not establish the brand's contracting legal entity or factory origin.

[E23] Its represented product lines include SCITEK dissolution equipment and BIOBASE pharmacy instruments.

Pharmaceutical and Laboratory Equipment | Array Medical

[E21] Array Medical presents a multibrand equipment catalog including Scitek and BIOBASE product lines; this does not establish equipment origin. ([arraygroup.tech](https://arraygroup.tech/index.html))

Building the ASEAN Community - Medicinal Products

[E24] ASEAN's explanation makes recognition depend on accepted inspection services and distinguishes listing and assessment arrangements. Its subject is medicine-manufacturer GMP inspection, not approval of dissolution-equipment packages.
([asean.org](https://asean.org/wp-content/uploads/images/2015/september/outreach-document/batch-xx.xx/Edited%20Medicinal%20Products.pdf))

Pion - Unique Instruments and Services, 2023 Commercial Overview

[E25] The dated 2023 manufacturer overview identifies stirred dissolution stations integrated with optical monitoring, establishing a pre-base-year commercial package rather than a generic stirrer.

[E26] The overview identifies combined dissolution/flux offerings. This supports mixed-purpose value attribution and excludes assuming all related supplier revenue belongs to dissolution.

[E27] The overview identifies temperature-controlled, automatically stirred dissolution stations integrated with optical monitoring. It supports commercial stirred-vessel offerings without proving a market-wide platform definition.
([assets-global.website-files.com](https://assets-global.website-files.com/644d2ffb3f7ec1eca95b44dd/64ef5800f3d3539b7ca11dc1_pion-overview-2023-us-web.pdf))

[E28] The supplier-issued 2023 commercial overview identifies stirred dissolution test stations and combined dissolution/flux offerings. This corroborates commercial specialty systems but does not establish the independently attributable dissolution portion of membrane-based purchases.
([assets-global.website-files.com](https://assets-global.website-files.com/644d2ffb3f7ec1eca95b44dd/64ef5800f3d3539b7ca11dc1_pion-overview-2023-us-web.pdf))

CE 7smart Offline - Berner Lab Denmark

[E29] Advertises SOTAX CE 7smart dissolution equipment.

[E31] Identifies Søren Berner Denmark ApS and its Danish business address.

CE 7smart Offline | Berner Lab Denmark

[E30] Berner Lab Denmark advertises SOTAX CE 7smart flow-through equipment.
([bernerlab.dk](https://bernerlab.dk/product-pro/ce-7smart-offline/))

Pion Scientific - Biopharma Technologies France

[E32] Advertises a French Pion distribution relationship and named dissolution-monitoring and miniDISS offerings.

Pion Scientific | Biopharma Technologies France

[E33] Biopharma Technologies France presents Pion dissolution products.
([biopharmatech.fr](https://biopharmatech.fr/pion-scientific/))

WHO - Good Practices for Pharmaceutical Quality Control Laboratories, Technical Report Series 957, Annex 1, 2010

[E34] The framework recognizes national pharmaceutical quality-control laboratories as a distinct institutional setting with broader medicine-control responsibilities than repetitive product testing alone.
([cdn.who.int](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/who-good-practices-for-pharmaceutical-quality-control-laboratories.pdf))

[E35] The general considerations distinguish national, commercial, and nongovernmental pharmaceutical quality-control laboratories. This supports role-based buyer differentiation, but is not an exhaustive equipment-buyer classification.
([cdn.who.int](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/who-good-practices-for-pharmaceutical-quality-control-laboratories.pdf))

[E36] The general considerations identify specification-based, stability, and investigative testing among pharmaceutical quality-control activities. This supports the broad conformity objective without establishing dissolution-specific purchasing volumes.
([cdn.who.int](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/who-good-practices-for-pharmaceutical-quality-control-laboratories.pdf))

WHO - 2025 Annual Report, Department of Regulation and Prequalification

[E37] The 2025 report identifies xx.xx pharmaceutical-network member laboratories across xx.xx countries. Network development is a conditional commercial expansion signal, not procurement funding or proof of the assumed 2032 purchasing growth.
([cdn.who.int](https://cdn.who.int/media/docs/default-source/medicines/regulatory-updates/rpq/who_rpq_annualreport2025.pdf?download=true&sfvrsn=afe3907_3))

WHO - Pharmaceutical Country Profile: India, 2025

[E38] The country profile reports more than xx.xx Indian manufacturers and xx.xx manufacturing facilities. This broader population constrains the non-FDA customer-pool assumption but does not establish dissolution ownership, active laboratories, or equipment expenditure.
([cdn.who.int](https://cdn.who.int/media/docs/default-source/searo/hsd/edm/india-medical-products-profile-2025.pdf?sfvrsn=ec908918_3))

[E39] The facility population supports a substantial domestic-market correction to an imports-only equipment proxy, not the final share directly.

[E40] The reported xx.xx manufacturing-facility population constrains the large non-FDA customer pool; ownership and annual spending are assumed.

DNH & DD Central Procurement Branch Corrigendum for New Drug Testing Laboratory Equipment, Tender ID 2026_UTDNH_7897_1

[E41] The 2026 DNH & DD procurement concerns a new drug-testing laboratory and includes dissolution apparatus; it establishes a solicitation.
([cdnbbsr.s3waas.gov.in](https://cdnbbsr.s3waas.gov.in/s371e09b16e21f7b6919bbfc43f6a5b2f0/uploads/2026/xx.xx/xx.xx.pdf))

[E42] The 2026 corrigendum concerns a new Drug Testing Laboratory, includes dissolution apparatus with an autosampler, and specifies a two-year warranty for all equipment. Its extended maintenance provisions name other instruments and are not generalized to dissolution equipment.
([cdnbbsr.s3waas.gov.in](https://cdnbbsr.s3waas.gov.in/s371e09b16e21f7b6919bbfc43f6a5b2f0/uploads/2026/xx.xx/xx.xx.pdf))

[E43] The corrigendum amends the purchasing request for Tender 2026_UTDNH_7897_1, supporting review of the amended rather than original requirements.
([cdnbbsr.s3waas.gov.in](https://cdnbbsr.s3waas.gov.in/s371e09b16e21f7b6919bbfc43f6a5b2f0/uploads/2026/xx.xx/xx.xx.pdf))

Eurofins Scientific - Annual Report 2025

[E44] FY2025 BioPharma revenue of EUR xx.xx and xx.xx% organic growth, alongside investment postponements, qualify the relative-growth forecast; service revenue is not used as equipment-market value.

CDSCO - Data of Testing Laboratories Approved by SLA/UT as on March 10, 2026

[E45] India's March xx.xx 2026 register totals xx.xx approved testing laboratories. It constrains a near-period regional population bridge, not global ownership or 2025 equipment spending.

Pharmaceutical Equipment | Chemcokorea

[E46] Chemcokorea advertises named dissolution systems and related peripheral categories.
([chemcokorea.imweb.me](https://chemcokorea.imweb.me/xx.xx))

CHEMCOKOREA 켐코코리아 - 제약장비

[E47] Chemcokorea's catalog advertises TRUSTE and INSPIRE dissolution testers and dissolution-specific peripheral equipment.

[E48] The page identifies the Korean business as 켐코코리아 주식회사 and displays its business registration number.

Wahyong Instrument DS-806 Intelligent Dissolution System | Cleverlab

[E49] Cleverlab advertises the Wahyong Instrument DS-xx.xx dissolution system with commercial support in Thailand.

[E50] Cleverlab's Thai offering identifies Wahyong Instrument as the DS-xx.xx product brand; it does not independently establish the manufacturer's legal identity.

FDA Publishes Guidance for Industry: M9 Biopharmaceutics Classification System-Based Biowaivers

[E51] FDA describes M9 as a restricted biowaiver framework relevant to specified development, post-approval, and generic applications. ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/2d90a23))

[E52] FDA's May 2021 M9 publication notice identifies eligible development, postapproval-change, and generic-drug contexts and expressly limits product applicability. It does not establish equipment ownership or an acquisition commitment. ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/2d90a23))

[E53] M9's stated eligibility restrictions support application-specific, rather than universal, regulatory purchasing propositions. ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/2d90a23))

[E55] The framework can reduce reliance on in vivo equivalence studies but does not apply to every drug product. ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/2d90a23))

FDA - M9 Biopharmaceutics Classification System-Based Biowaivers Publication Notice

[E54] The May 2021 notice limits M9 applicability and identifies eligible development, change and generic contexts; this qualifies any assumption that regulatory relevance universally produces equipment purchasing. ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/2d90a23))

Labor Estabille | Core Lab

[E56] Core Lab presents Labor Estabille equipment within its commercial portfolio. ([corebio.com.br](https://corebio.com.br/labor-estabille/))

Labor estabille - Core Lab

[E57] Core Lab's branded portfolio includes Labor Estabille tablet dissolution equipment and describes its laboratory-equipment sales role.

Productos - Comercio y Representaciones, S.A de C.V

[E58] Identifies the CORESA product business under Comercio y Representaciones, S.A de C.V.

A Brief Review of the FDA Dissolution Methods Database - Dissolution Technologies, August 2016

[E59] The historical analysis describes approximately equal paddle-over-disk and rotating-cylinder method use within transdermal products. This informs the modeled activity relationship before purchasing and price adjustments.

[E60] The historical analysis reports xx.xx basket methods. Combined with its xx.xx paddle count, this supplies a conditional activity ratio, not a global revenue observation.

[E61] The reported xx.xx paddle count supports the conditional basket/paddle proxy. Different product and method percentage denominators limit absolute-market interpretation.

[E62] The reported conditional transdermal relationship informs rotating-cylinder activity attribution, not equal equipment revenue or a directly observed forecast.

Applicability of Bottom-View Cameras for Evaluation of Tablet Performance During Dissolution Testing

[E63] The November 2016 peer-reviewed article documents bottom-view camera hardware providing video observation alongside dissolution testing. This independently corroborates an observation-hardware function distinct from the base apparatus, but does not establish current separate-sale availability, a standardized market segment, or 2025 revenue. Only the separable hardware-use fact is used. ([dissolutiontech.com](https://dissolutiontech.com/issues/xx.xx/DT201611_A03.pdf))

[E64] The university-affiliated research article documents an academic dissolution-equipment use setting. It supports institutional operator identification, not an instructional purchasing objective or a completed equipment award. ([dissolutiontech.com](https://dissolutiontech.com/issues/xx.xx/DT201611_A03.pdf))

Dissolution Technologies - Industry News August 2025 - Merel Instruments Partners with QLA to Elevate US Distribution of Advanced Analytical Solutions

[E65] The August 2025 industry announcement names QLA as Merel Instruments' authorized US distributor. ([dissolutiontech.com](https://dissolutiontech.com/issues/xx.xx/inews-qla01.php))

[E66] The August 2025 industry-news announcement names QLA as Merel Instruments' authorized US distributor and describes intended local sales and customer support. It establishes an announced relationship, not continuing product-specific supply or enforceable service terms. ([dissolutiontech.com](https://dissolutiontech.com/issues/xx.xx/inews-qla01.php))

〈1001〉 In Vitro Release Test Methods for Parenteral Drug Preparations

[E67] The chapter identifies injections, implants, and combinations such as stents as parenteral product formats. This supports the target-family identity, but broader drug-release coverage does not automatically establish inclusion of every associated instrument. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5433_02_01.html))

[E69] The public 2021 chapter recognizes parenteral preparations, implants, and drug-device combinations within a medicinal-product performance framework; it does not establish their dissolution-equipment revenue. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5433_02_01.html))

USP General Chapter 〈1001〉 In Vitro Release Test Methods for Parenteral Drug Preparations

[E68] The chapter includes parenteral preparations, implants and drug-device combinations but generally does not require the discussed performance tests for aqueous solutions. This constrains addressable participation below all parenteral manufacturing activity.

[E70] The public chapter recognizes parenteral preparations, implants and drug-device combinations as a separate performance-assessment context. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5433_02_01.html))

USP General Chapter 〈1724〉 Semisolid Drug Products-Performance Tests

[E71] The chapter directs transdermal delivery-system release assessment to the separate Drug Release chapter, supporting a format distinction between transdermal systems and semisolid or liquid topical formats. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5695_02_01.html))

[E72] The public 2023 scope distinguishes drug release from skin permeation for topical and transdermal semisolid and liquid formats. This supports retaining a strict boundary against diffusion-only and permeation-only equipment, rather than including all topical performance instruments. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5695_02_01.html))

[E73] The public scope distinguishes drug release and skin permeation for semisolid and liquid-based products and refers transdermal-system release to a separate chapter. This is a boundary limitation: neither diffusion equipment nor all semisolid performance equipment is automatically part of Dissolution Equipment. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5695_02_01.html))

[E74] The public scope distinguishes drug release from skin permeation and directs transdermal-system release assessment to a separate chapter. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M5695_02_01.html))

[E75] The public scope distinguishes drug release from skin permeation. This supports excluding diffusion/permeation-only spending from the modeled topical allocation.

[E76] The scope directs transdermal-system release assessment to a separate chapter, supporting the distinction between transdermal systems and topical semisolid or liquid formats.

〈1711〉 Oral Dosage Forms-Performance Tests

[E77] Oral dosage forms are an expressly named performance-testing family, with dissolution among the covered performance approaches. The preview does not provide equipment sales. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7083_02_01.html))

[E78] The chapter expressly covers oral dosage forms for human and animal applications, supporting their placement within Pharmaceutical Dosage Forms without creating separate human and veterinary buyer categories. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7083_02_01.html))

[E79] The public 2020 chapter addresses oral dosage-form performance testing for human and animal applications, supporting a medicinal-product target family distinct from isolated ingredient characterization. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7083_02_01.html))

USP General Chapter 〈1711〉 Oral Dosage Forms-Performance Tests

[E80] The public chapter identifies oral dosage-form performance assessment for human and animal applications as a distinct scope. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7083_02_01.html))

[E81] The public chapter recognizes oral dosage-form performance assessment for human and animal applications. It supports the broad oral-demand boundary, not the calculated sales weight.

USP General Chapter 〈1004〉 Mucosal Drug Products-Performance Tests

[E82] The chapter identifies otic, ophthalmic, nasal, oropharyngeal, urethral, vaginal, and rectal product families and distinguishes performance assessment from general product-quality testing. Its broad drug-release scope does not establish that every associated instrument is dissolution equipment. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7827_02_01.html))

[E83] The chapter recognizes mucosal families and states that physical dosage forms can occur across routes. This supports route-based attribution rather than classifying every tablet or film as gastrointestinal oral activity.

[E84] The chapter states that physical dosage forms can be administered through different routes. The taxonomy therefore uses documented gastrointestinal versus mucosal target identity, rather than tablet, film, or capsule shape alone, to distinguish Oral Dosage Forms from Topical & Mucosal Dosage Forms. This precedence is an analytical allocation rule informed by the chapter, not an official equipment-sales classification. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7827_02_01.html))

[E85] The public 2023 chapter distinguishes mucosal drug products and their performance assessment, supporting their placement within formulated medicinal products rather than isolated ingredients. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7827_02_01.html))

[E86] The public chapter distinguishes mucosal product families and notes that physical dosage forms can occur across routes. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7827_02_01.html))

[E87] The public chapter explicitly includes medicated chewing gums, lozenges, films, tablets, and other formats within mucosal drug products and distinguishes product-performance assessment from product-quality testing. This supplies a specific target-family binding for medicinal mouth-residence formats; it does not establish sales of mechanical chewing apparatus or include every mucosal performance instrument in this equipment market. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M7827_02_01.html))

USP General Chapter 〈724〉 Drug Release

[E88] The public chapter's scope covers drug-release or dissolution requirements for transdermal systems and additional dosage forms. This supports a medicinal dosage-form boundary broader than tablet dissolution alone. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99490_05_01.html))

[E89] The public scope addresses transdermal systems and other dosage forms where requirements are stated in individual monographs. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99490_05_01.html))

[E90] The public scope of USP Drug Release encompasses stated drug-release or dissolution requirements for transdermal systems and additional dosage forms. This supports the frozen inclusion of directly corresponding compendial release equipment beyond tablet-only dissolution. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99490_05_01.html))

[E91] Transdermal systems are explicitly identified in the chapter's drug-release and dissolution scope, supporting their recognition as a separate tested-product family. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99490_05_01.html))

[E92] Transdermal systems have a distinct, monograph-conditional drug-release scope. This supports separate commercial-use attribution without assuming a dedicated new purchase for every supported application.

USP General Chapter 〈1087〉 Intrinsic Dissolution-Dissolution Testing Procedures for Rotating Disk and Stationary Disk

[E93] Drug substances and excipients are expressly identified as characterization targets; the chapter does not establish their equipment-revenue allocations. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E95] Drug substances are expressly identified as intrinsic-dissolution characterization targets. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E97] Excipients are expressly identified as intrinsic-dissolution characterization targets. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E98] The public 2020 chapter identifies drug substances and excipients as intrinsic-dissolution characterization targets, supporting an isolated-material family distinct from formulated dosage forms. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E99] The public chapter identifies development of new chemical entities and characterization of drug substances and excipients as intrinsic-dissolution contexts. This directly extends the research-purpose basis beyond finished-formulation development, without establishing equipment purchases or sales allocations. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E102] The public chapter title explicitly recognizes rotating-disk intrinsic dissolution as a named platform. The preview does not establish equipment shipment volumes or standalone apparatus sales. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E103] The public chapter title explicitly recognizes stationary-disk intrinsic dissolution alongside rotating disk. This establishes the named distinction, not its allocation within configurable equipment purchases. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E106] USP characterizes intrinsic-dissolution studies as characterization studies not referenced in individual monographs. Consequently, an intrinsic-dissolution label alone does not establish routine monograph-based batch testing or a formal regulatory-equivalence purchasing purpose; documented primary objective remains necessary. This is an analytical allocation inference, not a regulatory exemption. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

USP General Chapter 1087 - Intrinsic Dissolution-Dissolution Testing Procedures for Rotating Disk and Stationary Disk

[E94] Drug substances are explicitly included as characterization targets; the participation and expenditure weights remain modeled.

[E96] Excipients are explicitly included as characterization targets; the source does not quantify the relevant laboratory population or equipment spending.

[E100] The public chapter identifies drug substances and excipients as characterization targets and distinguishes these studies from individual-monograph requirements. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E101] The public chapter identifies intrinsic dissolution as characterization and states that these studies are not referenced in individual monographs. This supports project-specific rather than universal routine-acquisition demand.

[E104] The public scope identifies drug substances and excipients as characterization targets and distinguishes intrinsic characterization from individual-monograph requirements. This supports a separate ingredient-demand model, not universal equipment ownership.

[E105] The same scope recognizes stationary-disk characterization while providing no shipment or equipment-revenue measure.

[E107] USP recognizes Rotating-Disk Apparatus and Stationary-Disk Apparatus in its intrinsic-dissolution chapter and identifies drug-substance, excipient, and new-entity characterization contexts. The preview does not establish a deliverable supplier package. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

[E108] USP states that intrinsic-dissolution studies are characterization studies not referenced in individual monographs, supporting a distinction between project characterization and assumed routine monograph-based purchasing. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99806_02_01.html))

〈2040〉 Disintegration and Dissolution of Dietary Supplements

[E109] The chapter establishes a distinct dietary-supplement dissolution scope where specified in individual monographs. It does not establish that all supplements require dissolution testing or quantify equipment demand. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99970_04_01.html))

[E111] The public chapter separately addresses dissolution standards for dietary supplements, supporting their recognition as a tested-product family rather than automatically treating them as medicines. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99970_04_01.html))

USP General Chapter 〈2040〉 Disintegration and Dissolution of Dietary Supplements

[E110] The chapter's supplement scope is conditional on standards stated in individual monographs. This supports a relevance and in-house-participation deduction from the broad supplement facility pool.

[E112] The supplement chapter applies where disintegration and dissolution standards are stated in individual monographs, not automatically to every supplement. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_M99970_04_01.html))

USP Guideline on Procedures for Mechanical Performance Qualification for USP Apparatus 4-Flow-Through Cell

[E113] The 2026 informational publication identifies mechanical performance qualification as a distinct dissolution-apparatus topic. It supports the function of dedicated qualification equipment, not a mandatory new rule, service-market inclusion, or hardware sales estimate. ([doi.usp.org](https://doi.usp.org/USPNF/USPNF_S203565_10101_01.html))

溶出度测试仪（溶出仪）| 黄海制药仪器

[E114] The Huanghai-branded commercial collection presents dissolution instruments. That branded presentation does not settle the precise legal counterparty corresponding to the captured Shanghai Huanghai identity.

溶出度测试仪（溶出仪）- 黄海制药仪器

[E115] The Huanghai-branded international catalog advertises RCZ dissolution instruments and automatic sampling equipment.

[E116] The catalog describes a Shanghai supplier, but the precise contracting entity behind the protected Shanghai Huanghai identity remains unresolved.

Microprocessor Dissolution Test Apparatus - 1918 & 1916 | Electronics India

[E117] Electronics India advertises Microprocessor Dissolution Test Apparatus models 1918 and 1916 through a dedicated product page.

Microprocessor Dissolution Test Apparatus - 1918 and 1916 | Electronics India

[E118] Electronics India advertises dissolution apparatus models 1918 and 1916. ([electronicsindia.co.in](https://electronicsindia.co.in/product/microprocessor-dissolution-test-apparatus-1918-1916/))

Electrolab - Estec Kenya

[E119] ESTEC's official Electrolab brand page lists dissolution testers within its pharmaceutical-testing portfolio.

[E120] The page identifies Educational Scientific & Technical Equipment Company (ESTEC) Ltd. and provides East African business contacts, including Uganda and Tanzania.

Productos | Eurolab

[E121] Eurolab lists dissolution accessories in its Argentine commercial portfolio. ([eurolab.com.ar](https://eurolab.com.ar/productos))

productos | Eurolab

[E122] Lists dissolution accessories and identifies Eurolab S.A. with an Argentine business address.

WEEE - responsibilities for manufacturers and producers

[E123] EU business guidance describes national registration and collection or recovery responsibilities for covered electrical equipment; equipment coverage and responsible entities require confirmation. ([europa.eu](https://europa.eu/youreurope/business/product-rules-compliance/recycling-waste-management/weee-responsibilities/index_en.htm))

[E124] EU business guidance describes national registration and collection, treatment, recycling, and recovery responsibilities for covered electrical equipment. Applicable equipment and responsible entities require destination-specific confirmation. ([europa.eu](https://europa.eu/youreurope/business/product-rules-compliance/recycling-waste-management/weee-responsibilities/index_en.htm))

[E125] EU business guidance describes national registration and equipment-waste responsibilities for relevant manufacturers, producers, distributors, and sellers. Applicability to a particular dissolution offering remains destination- and equipment-specific. ([europa.eu](https://europa.eu/youreurope/business/product-rules-compliance/recycling-waste-management/weee-responsibilities/index_en.htm))

[E126] EU business guidance describes national registration, collection, treatment and recovery responsibilities for covered electrical equipment. Equipment coverage and responsible entities require destination-specific confirmation. ([europa.eu](https://europa.eu/youreurope/business/product-rules-compliance/recycling-waste-management/weee-responsibilities/index_en.htm))

[E127] EU business guidance requires relevant electrical-equipment businesses to register with national WEEE authorities in each destination where covered products are sold and to address collection, treatment, recycling, and recovery. Equipment-specific applicability remains a prerequisite. ([europa.eu](https://europa.eu/youreurope/business/product-rules-compliance/recycling-waste-management/weee-responsibilities/index_en.htm))

Quality Control Laboratories for Medicines - WHO Prequalification

[E128] WHO lists Kenya-NQCL and Ghana FDA QCL and describes institutional assessment and continued-compliance conditions, not equipment endorsement or purchasing commitments. ([extranet.who.int](https://extranet.who.int/prequal/medicines/prequalified/quality-control-labs))

Farmacia | Falcón

[E129] Falcón's pharmacy portfolio lists Logan dissolution equipment. ([falcon.mx](https://falcon.mx/farmacia/))

Farmacia - Falcón

[E130] Its pharmaceutical-equipment portfolio advertises Logan Super xx.xx.

2100A DISTEK DISSOLUTION TESTER | Federal Equipment Company

[E131] Advertises a Distek 2100A dissolution tester through its own equipment inventory.

[E132] Federal Equipment Company lists a Distek 2100A dissolution tester in its equipment inventory. The listing establishes a secondary-equipment inquiry route, not equivalence to another seller's refurbishment, software-rights, or support commitments.

[E133] Federal Equipment lists a Distek dissolution instrument through its secondary-equipment inventory. ([fedequip.com](https://fedequip.com/inventory/Dissolution/2100A-DISTEK-DISSOLUTION-TESTER.html))

COPLEY SCIENTIFIC LIMITED overview - Companies House

[E134] Companies House identifies Copley Scientific Limited, company number xx.xx as active, with accounts through December xx.xx 2025, and a January 2026 confirmation statement. ([find-and-update.company-information.service.gov.uk](https://find-and-update.company-information.service.gov.uk/company/xx.xx))

COPLEY SCIENTIFIC LIMITED persons with significant control - Companies House

[E135] The official register identifies Copley Holdings Limited as Copley Scientific Limited's active person with significant control, with ownership of at least xx.xx% of shares and voting rights. The operating company remains the staged reporting identity. ([find-and-update.company-information.service.gov.uk](https://find-and-update.company-information.service.gov.uk/company/xx.xx/persons-with-significant-control))

OMICRON RESEARCH LIMITED overview - Companies House

[E136] Companies House identifies Omicron Research Limited, company number xx.xx as active at the Hungerford address used by its equipment business, with an August xx.xx 2026 confirmation statement. ([find-and-update.company-information.service.gov.uk](https://find-and-update.company-information.service.gov.uk/company/xx.xx))

Gemicatech | Lab Equipment Suppliers in Egypt | Authorized Distributor

[E137] Gemicatech explicitly includes tablet dissolution testers among the pharmaceutical laboratory equipment it supplies in Egypt.

SOTAX | Gluvex

[E138] Gluvex presents SOTAX dissolution instruments in its commercial portfolio. ([gluvexlab.com](https://gluvexlab.com/brands/sotax/))

SOTAX - Gluvex

[E139] Its SOTAX portfolio advertises CE 7smart and AT Xtend dissolution instruments through a Russian-language commercial catalog.

PION - Gulf Scientific Corporation

[E140] Gulf Scientific Corporation advertises Pion dissolution products, including the miniDISS Profiler and miniDT dissolution tester.

Pion | Gulf Scientific Corporation

[E141] Gulf Scientific Corporation presents named Pion dissolution products. ([gulf-scientific.com](https://gulf-scientific.com/partner/pion/))

Stakeholders' Consultation on EudraLex Volume 4: Chapter 4, Annex 11 and New Annex 22

[E142] The Commission's consultation on revised Annex xx.xx and proposed Annex xx.xx closed October xx.xx 2025. Its AI text is identified as draft guidance and addresses intended use, oversight, change control and human review. ([health.ec.europa.eu](https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-xx.xx-good-manufacturing-practice-guidelines-chapter-xx.xx-annex_en))

EudraLex Volume 4, Annex 11: Computerised Systems

[E143] Annex xx.xx addresses business continuity and continued accessibility of archived records. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E144] Annex xx.xx addresses formal supplier agreements, defined responsibilities, lifecycle governance and continued accessibility of archived records.

([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E145] Annex xx.xx addresses formal third-party responsibilities and computerized-system lifecycle governance within its GMP scope. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E146] Annex xx.xx addresses formal third-party responsibilities, lifecycle changes, business continuity, and archived-record accessibility. These qualify integration and replacement planning within the applicable EU GMP context. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E147] Annex xx.xx requires formal agreements defining third-party responsibilities for applicable computerized-system services and assigns acceptance and lifecycle responsibilities to the regulated organization.

[E148] Configuration changes, business continuity, and archived-record accessibility remain relevant after initial computerized-system acceptance. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E149] The annex requires agreements defining relevant third-party responsibilities, supporting explicit computerized-package contracting. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E150] The published Annex xx.xx framework makes personnel responsibilities and third-party agreements relevant to computerized GMP applications. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E151] The regulated organization retains lifecycle responsibilities, qualifying any economic case based on automation alone. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

[E152] Within its GMP scope, Annex xx.xx calls for formal third-party agreements defining responsibilities and addresses supplier-related computerized-system obligations. This supports comparing accountable integration agreements. ([health.ec.europa.eu](https://health.ec.europa.eu/document/download/8d305550-dd22-4dad-xx.xx-2ddb4a1345f1_en?filename=annex11_01-2011_en.pdf))

EudraLex - Volume 4: Good Manufacturing Practice Guidelines

[E153] The Commission's published human-medicines GMP index lists the January 2011 revision of Annex xx.xx. ([health.ec.europa.eu](https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en))

[E154] The European Commission's human-medicines GMP framework lists the January 2011 revision of Annex xx.xx for computerized systems, establishing the jurisdictional context used in the SOTAX assessment.

[E155] The published GMP index and separate consultation record distinguish listed Annex xx.xx guidance from the proposed AI annex. ([health.ec.europa.eu](https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en))

EudraLex Volume 4, Annex 11: Computerised Systems

[E156] Annex xx.xx addresses formal third-party agreements and continued accessibility of archived records. ([health.ec.europa.eu](https://health.ec.europa.eu/system/files/2016-xx.xx/annex11_01-2011_en_0.pdf))

[E157] Computerized applications, infrastructure, supplier arrangements, and record accessibility are lifecycle acceptance considerations. ([health.ec.europa.eu](https://health.ec.europa.eu/system/files/2016-xx.xx/annex11_01-2011_en_0.pdf))

[E158] The annex identifies system, process, quality, and IT responsibilities and requires clear third-party agreements. ([health.ec.europa.eu](https://health.ec.europa.eu/system/files/2016-xx.xx/annex11_01-2011_en_0.pdf))

[E159] The annex links computerized systems to defined personnel responsibilities and continued quality assurance. ([health.ec.europa.eu](https://health.ec.europa.eu/system/files/2016-xx.xx/annex11_01-2011_en_0.pdf))

化学化工学院大型仪器设备

[E160] Huangshan University's equipment inventory, dated January xx.xx 2016, lists RC-8DS dissolution instruments and attributes their manufacture to 天津国铭医药设备有限公司.

[E161] The inventory provides historical buyer-side corroboration of Tianda Tianfa's dissolution-equipment participation.

[E162] The same university inventory lists RC806D dissolution instruments attributed to 天津市天大天发科技有限公司.

[E164] This is historical buyer-side equipment attribution for the retained Tianjin Guoming lead, not evidence of current product availability or current ownership.

化学化工学院大型仪器设备 - January 4, 2016

[E163] The university equipment inventory dated January xx.xx 2016 attributes RC806D dissolution instruments to 天津市天大天发科技有限公司. This corroborates historical institutional presence, not current RC1209D adoption or continuing support.

CSIR-Indian Institute of Integrative Medicine - Tenders

[E165] CSIR-IIIM's procurement directory lists a January xx.xx 2025 maintenance solicitation covering dissolution apparatus, autosamplers and Opt-Diss. The listing establishes a solicitation, not an award. ([iiim.res.in](https://iiim.res.in/tenders/))

Infitek Pharmaceutical Testing Catalog

[E166] The catalog identifies Infitek Co., Ltd. with a Chinese address and also names Infitek Inc.; the entities' ownership relationship is not established by this record.

[E167] The pharmaceutical-testing catalog advertises the DIST-6P dissolution tester.

English Product Portfolio | Tianjin Jiaxinhai Machinery Equipment Co., Ltd.

[E168] Jiaxinhai's English portfolio names the company and advertises dissolution instruments. ([jiaxinhai.com](https://jiaxinhai.com/en/))

Tianjin Jiaxinhai Machinery Equipment Co., Ltd. - English Product Portfolio

[E169] The English product portfolio names Tianjin Jiaxinhai Machinery Equipment Co., Ltd. and advertises RC-xx.xx and ZRS-3ST dissolution testers.

[E170] The page gives a Tianjin business address and the Chinese company name 天津市嘉鑫海机械设备有限公司.

Equipos - Korval

[E171] The equipment store identifies KORVAL PRODUCTS & SERVICES EIRL and links the Ethik institutional catalog; model-specific current availability is not established.

Catálogo Institucional 2023 - Ethik Technology

[E172] The manufacturer's 2023 institutional catalog identifies Ethik Technology and lists DIS.xx.xx DIS.xx.xx and DIS.xx.xx dissolution instruments.

Analytical Equipment Supplier & Manufacturer | Labindia

[E173] Labindia Analytical's inspected company page presents its analytical-instrument business, named dissolution-product navigation, management team, and Thane business address. This improves operating-business support but does not independently establish the full legal and ownership perimeter. ([labindia-analytical.com](https://labindia-analytical.com/About))

Dissolution Tester | Dissolution Test Machine - Labindia Analytical

[E174] Its official portfolio includes basic instruments and dissolution systems with automated sampling configurations.

[E175] Labindia Analytical markets DS xx.xx and DS xx.xx dissolution testers.

Dissolution Tester | Labindia Analytical

[E176] Labindia lists basic dissolution instruments and several sampling configurations. ([labindia-analytical.com](https://labindia-analytical.com/category/dissolution))

[E177] Labindia's dissolution portfolio distinguishes basic apparatus from configurations incorporating sampling equipment, supporting comparison of the delivered purchasing package.

Annonces Légales, Réglementaires et Judiciaires, No. 5, January 10, 2013

[E178] The Tunisian legal-notices issue dated January xx.xx 2013 contains a notice naming Société Promo Biotech Tunisie, providing historical identity corroboration.

Merel dissoWASH&DOSE - naprava za volumetrično doziranje in sprotno čiščenje posod

[E179] Merel advertises dissoWASH&DOSE as separately supplied vessel-cleaning and media-handling equipment. ([merel.si](https://merel.si/izdelek/merel-dissowashdose/))

[E180] Merel's commercial product page advertises dissoWASH&DOSE as a semi-automated offering combining dissolution-media handling and vessel cleaning, corroborating its separate peripheral offering.

仪器资源_西华大学食品质量与安全实验教学示范中心

[E181] This independent institutional record corroborates historical product attribution, without establishing current commercial status.

[E182] Xihua University's institutional equipment inventory lists an RC-8DS dissolution instrument and names 天津市国铭医药设备有限公司 as the associated equipment supplier or manufacturer.

Microsep - Classic 6 Manual Dissolution Tester System Package

[E183] Microsep's own product catalog lists a Classic xx.xx Manual Dissolution Tester System Package and provides South African business contact details.

Оборудование Pharma Test - МИЛЛАБ

[E184] States that MILLAB distributes Pharma Test equipment in Russia, including dissolution testers.

NIKYANG Enterprise Limited - Commercial Portfolio

[E185] NIKYANG presents SOTAX flow-through dissolution equipment within its portfolio. ([nikyang.com](https://nikyang.com/en/))

nikyang.com

[E186] Presents SOTAX CE7smart within its commercial USP xx.xx dissolution offering.

About Us - 力扬企业有限公司

[E187] Identifies NIKYANG Enterprise Limited and describes an equipment-sales, integration and support business.

Pharma Tech | Nora Technology Bangladesh

[E188] Nora Technology Bangladesh's Pharma Tech catalog lists LID-xx.xx LID-xx.xx and LID-6D dissolution testers.

[E189] The historical catalog does not establish current company operations or availability.

Industries We Serve - Omicron Measurements Limited

[E190] The company's own industry page identifies Omicron Measurements Limited and describes its laboratory-instrument supply and Eastern African business coverage.

Dissolution Tester LDLT-A1 Series

[E191] A Labtron-branded commercial brochure advertises LDLT-A1-series pharmaceutical dissolution testers.

[E192] The inspected brochure was hosted on the p-mac.co.za domain; it does not identify a confirmed African distribution agreement.

Dissolution Tester - Pharma Test Indonesia

[E193] An Indonesian catalog identifies PT. Pharma Test Indonesia and advertises PTWS dissolution systems and a DSR-M sampling robot.

[E194] The page supplies an Indonesian address; it does not establish ownership or legal affiliation with Pharma Test Apparatebau AG.

IIT (BHU) Tender Document for Supply of Dissolution Apparatus, dated August 21, 2020

[E195] IIT (BHU)'s August xx.xx 2020 tender required installation and application training. ([prev.iitbhu.ac.in](https://prev.iitbhu.ac.in/contents/institute/2020/tender/tender_qtn_ph_fy_26.pdf))

[E196] Participating dealers required manufacturer authorization for this historical dissolution-equipment procurement. ([prev.iitbhu.ac.in](https://prev.iitbhu.ac.in/contents/institute/2020/tender/tender_qtn_ph_fy_26.pdf))

[E197] The contract required intellectual-property indemnification for India and included installation and training obligations. ([prev.iitbhu.ac.in](https://prev.iitbhu.ac.in/contents/institute/2020/tender/tender_qtn_ph_fy_26.pdf))

[E198] The tender allowed alternatives demonstrating substantial equivalence to the purchaser's satisfaction. ([prev.iitbhu.ac.in](https://prev.iitbhu.ac.in/contents/institute/2020/tender/tender_qtn_ph_fy_26.pdf))

ERWEKA - Rasch Procesos

[E199] Grupo Rasch's Rasch Procesos business advertises ERWEKA dissolution equipment.

[E201] The page names DT xx.xx and DT xx.xx Digital Offline offerings and identifies a Mexico City commercial presence.

ERWEKA | Rasch Procesos

[E200] Rasch Procesos presents ERWEKA dissolution equipment within Grupo Rasch's commercial structure. ([procesos.rasch.mx](https://procesos.rasch.mx/marcas-representadas/erweka-xx.xx/))

Government of Punjab, Health Department - Framework Contract Bidding Documents for Medical Lab Equipment and Accessories, 2020-2021

[E202] The 2020-2021 government bidding document budgets PKR xx.xx for one dissolution-media unit under a delivered/support package. The model explicitly bridges this historical budget into an assumed global producer-level price; it is not an observed award or 2025 ASP. ([pshealthpunjab.gov.pk](https://pshealthpunjab.gov.pk/Upload/Tenders/nqz1ndvk.po28927142.pdf))

Automated Dissolution for Enteric-Coated Aspirin Tablets: A Case Study for Method Transfer to a RoboDis II

[E203] The 2014 academic abstract explicitly distinguishes manual, semi-automated, and fully automated dissolution testers. It supports established terminology, not current market shares or a universal commercial classification standard. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/xx.xx/))

[E204] The abstract expressly recognizes semi-automated dissolution testers, supporting the category name independently of a supplier catalog. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/xx.xx/))

[E205] The abstract identifies a fully automated dissolution device as distinct from manual and semi-automated equipment; no experimental procedure or performance result is used for this taxonomy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/xx.xx/))

[E206] The abstract identifies manual dissolution testers as a distinct equipment configuration. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/xx.xx/))

QLA Quality Lab Accessories

[E207] QLA states that it is an authorized distributor of Merel Instruments products in the United States and Puerto Rico.

[E208] QLA's commercial page advertises Merel representation in the United States and Puerto Rico, not a product-specific customer contract. (qla-llc.com)

[E209] QLA's official commercial page advertises a U.S. and Puerto Rico distribution relationship for Merel Instruments products.

[E210] Quality Lab Accessories advertises dissolution accessories and consumables and the BT1000 dissolution validation and reporting system.

About Quality Lab Accessories

[E211] QLA identifies itself as Quality Lab Accessories, LLC and describes dissolution accessories, consumables, calibration tools, services, and manufacturing in Telford, Pennsylvania. Promotional superiority claims are not adopted. ([qla-llc.com](https://qla-llc.com/a/content/about-us/about-quality-lab-accessories/))

Laboratory Equipment Maintenance, Calibration & Repair Services - Quality Lab Accessories

[E212] QLA advertises maintenance, calibration, repair, and lifecycle-management services for dissolution equipment. The page does not assign Merel-specific contractual responsibilities. ([qla-llc.com](https://qla-llc.com/a/content/lab-services/about-our-lab-services-division/))

Bath Manufacturers - Quality Lab Accessories

[E213] QLA groups aftermarket offerings by equipment manufacturer, supporting separate sourcing without proving universal compatibility. ([qla-llc.com](https://qla-llc.com/collections/bath-manufacturers))

[E214] QLA's Bath Manufacturers catalog groups offerings under named equipment manufacturers, including Agilent/VanKel, Distek, ERWEKA, SOTAX, Teledyne Hanson, and Toyama. The grouping does not independently establish universal compatibility or OEM authorization. ([qla-llc.com](https://qla-llc.com/collections/bath-manufacturers))

Dissolution Validation and Reporting Bluetooth System - Quality Lab Accessories

[E215] QLA advertises BT1000 qualification-and-reporting equipment. ([qla-llc.com](https://qla-llc.com/products/dissolution-validation-and-reporting-bluetooth-system))

[E216] QLA advertises the BT1000 qualification-and-reporting product, lists supported bath models, warns that additional adapters may be required, and expressly excludes Sotax AT7 and AT7 smart. ([qla-llc.com](https://qla-llc.com/products/dissolution-validation-and-reporting-bluetooth-system))

[E217] QLA's BT1000 page lists supported bath models, notes that additional adapters may be required, and expressly excludes SOTAX AT7 and AT7 smart. These are advertised compatibility boundaries, not universal acceptance or OEM authorization. ([qla-llc.com](https://qla-llc.com/products/dissolution-validation-and-reporting-bluetooth-system))

[E218] QLA's qualification-and-reporting offering lists supported models and explicitly excludes SOTAX AT7 and AT7 smart. ([qla-llc.com](https://qla-llc.com/products/dissolution-validation-and-reporting-bluetooth-system))

[E219] The BT1000 commercial page establishes a qualification-hardware offering and expressly excludes SOTAX AT7 and AT7 smart. It supports a bounded product opportunity rather than universal compatibility or an observed revenue increment.
([qla-llc.com](https://qla-llc.com/products/dissolution-validation-and-reporting-bluetooth-system))

QualiltyLAB | Lebanon - Analytical & Material Sciences

[E220] QualityLAB's Lebanon-facing analytical-equipment catalog advertises AT7Smart dissolution testers and a flow-through dissolution tester.

Analytical & Material Sciences | QualityLAB

[E221] QualityLAB's catalog presents conventional and flow-through dissolution equipment. ([qualitylab-lb.com](https://qualitylab-lb.com/v1/Analytical%xx.xx%xx.xx%20Material%20Sciences.html))

□□ □□□□□□ - Rabin Azma Parsian

[E222] Rabin Azma Parsian's official business page includes a dissolution-system category alongside broader instrument and spare-part sourcing. This establishes a category-level commercial presentation, not a named apparatus configuration or manufacturer appointment.

□□□□□□□□ □□□□□ □□□ □□□□□□ Dissolution System - □□□□□□□ □□□□ □□□□□

[E223] The Persian-language product page advertises a pharmaceutical Dissolution System under the Rabin Azma Parsian business identity.

Dissilio TXpro - Tablet Dissolution Tester

[E224] RIGGTEK markets the Dissilio TXpro tablet dissolution tester.

[E225] The brochure identifies RIGGTEK GmbH in Planegg, Germany, and describes integration with its DissoPrep and Sampilio equipment.

News overview | RIGGTEK

[E226] RIGGTEK's inspected news page records continuing dissolution-related business activity in 2026, including its July xx.xx anniversary communication and May distributor event. It also documents ongoing dissolution-equipment and accessory commercial activity. ([riggtek.de](https://riggtek.de/news-overview/))

Impressum | RIGGTEK GmbH

[E227] RIGGTEK's legal imprint identifies RIGGTEK GmbH, its Munich registered seat, and commercial-register number HRB xx.xx. ([riggtek.de](https://riggtek.de/unternehmen/impressum/))

Wir über uns | RIGGTEK GmbH

[E228] RIGGTEK describes a German predecessor called DISTEK Dissolution Test Systeme; that history does not establish identity with Distek, Inc. ([riggtek.de](https://riggtek.de/unternehmen/wir-ueber-uns/))

[E229] RIGGTEK identifies DissoPrep, Sampilio, easyDISS, and Dissilio product lines.
([riggtek.de](https://riggtek.de/unternehmen/wir-ueber-uns/))

[E230] RIGGTEK's company history describes its German family-business origins and 2007 formation under the RIGGTEK name, following a German business called DISTEK Dissolution Test Systeme.

[E231] The company identifies its own Dissilio, easyDISS, Sampilio, and DissoPrep commercial lines. The German predecessor name does not establish identity with New Jersey-based Distek, Inc.
([riggtek.de](https://riggtek.de/unternehmen/wir-ueber-uns/))

Agilent Technologies, Inc. - Fiscal 2025 Form 10-K

[E232] Agilent identifies customer capital budgets and government funding policies as business dependencies; this disclosure is company-wide rather than dissolution-specific.
([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

[E233] Agilent identifies customer capital policies and public funding as business dependencies; dissolution-specific purchasing consequences are conditional inference.
([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

[E234] Agilent's fiscal 2025 filing identifies customer funding dependencies while reporting normalization of capital-spending ability for many customers, except those receiving US federal funding; the disclosure is company-wide. ([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

[E235] The filing identifies customer capital spending, research budgets, and government funding as demand risks at company level. ([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

[E236] The filing reports tariff-related cost effects, mitigation efforts, funding exposure, and a countervailing normalization observation; it does not isolate dissolution equipment. ([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

[E237] The fiscal 2025 filing reports tariff-related cost effects and mitigation efforts; these do not establish product-specific import treatment. ([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

[E238] The fiscal 2025 filing reports tariff-related cost pressure and describes targeted pricing and supply-chain mitigation. Product-specific pass-through is not established. ([s24.q4cdn.com](https://s24.q4cdn.com/xx.xx/files/doc_financials/2025/ar/A-ARS-xx.xx-K-BMK-2025.pdf))

Automatical Dissolution Tester - Scitek

[E239] The Scitek catalog advertises DT-series automatic dissolution testers.

[E240] The UAE-targeted website advertises an automated dissolution tester under Scitek branding.

[E241] The page identifies Scitek Global Co.,Ltd and gives office and factory addresses in Jinan, China; it does not establish a UAE office.

Dissolution Testers - Packaging Equipment - SED Pharma

[E242] Advertises SED-RCDY-series dissolution testers, including SED-RCDY-B.

Dissolution Testers | SED Pharma

[E243] SED Pharma lists SED-RCDY dissolution equipment. ([sedpharma.com](https://sedpharma.com/quality-control/dissolution-testers/))

Dissolution Testers - Smart Resources For Equipment

[E244] Smart Resources For Equipment advertises ERWEKA dissolution testers and associated equipment categories.

[E246] The page provides Saudi Arabian business locations and a Dubai contact for the Smarteq business.

Dissolution Testers | Smart Resources For Equipment

[E245] Smart Resources For Equipment advertises ERWEKA dissolution testers. ([smarteq-sa.com](https://smarteq-sa.com/product-category/pharmaceutical-tablet-testing/dissolution-testers/))

Texas A&M Health Science Center - Purchase Order AB0990479, January 17, 2025

[E247] The January xx.xx 2025 purchase order prices an apparatus/sampler/UV bundle at USD xx.xx and separately identifies services and freight. It constrains equipment-package scope and premium pricing, not global ASPs. ([spar.tamu.edu](https://spar.tamu.edu/Transparency/GetFile?dir=PoDocs&id=xx.xx))

[E248] The equipment bundle includes dissolution-linked UV analysis; the separately listed SYS-UV-xx.xx amount concerns qualification services and is not used as detector hardware revenue. ([spar.tamu.edu](https://spar.tamu.edu/Transparency/GetFile?dir=PoDocs&id=xx.xx))

[E249] The priced bundle includes an xx.xx-DS sampling station. Its total constrains the modeled standalone sampler price envelope but does not disclose the sampler's individual price. ([spar.tamu.edu](https://spar.tamu.edu/Transparency/GetFile?dir=PoDocs&id=xx.xx))

Spectralab - Mantenimiento Preventivo, Correctivo y Calibración para Disolutores y Equipos Farmacéuticos

[E250] Spectralab Instrumentación's inspected business portfolio advertises Distek dissolution instruments, Eclipse sampling equipment, Opt-Diss monitoring, and ezfill equipment.

[E251] The page identifies a Mexico City address and equipment-sales, support, and calibration activities.

Agilent 708-DS Dissolution Apparatus with 850-DS Sampling Station and Heater/ Circulator - Spectralab Scientific Inc.

[E252] The listing advertises a refurbished Agilent xx.xx-DS apparatus with an xx.xx-DS sampling station and heater/circulator, plus installation and training options.

([spectralabsci.com](https://spectralabsci.com/equipment/agilent-xx.xx-ds-dissolution-apparatus-with-xx.xx-ds-sampling-station-and-heater-circulator/))

[E253] The product-page warranty starts at three months, can be extended, and begins upon successful delivery. These are seller-advertised terms rather than independently demonstrated service performance. ([spectralabsci.com](https://spectralabsci.com/equipment/agilent-xx.xx-ds-dissolution-apparatus-with-xx.xx-ds-sampling-station-and-heater-circulator/))

[E254] The specific refurbished Agilent package advertises warranty commencement upon successful delivery and offers installation and familiarization. These are seller-advertised terms, not independently established equipment condition or service performance. ([spectralabsci.com](https://spectralabsci.com/equipment/agilent-xx.xx-ds-dissolution-apparatus-with-xx.xx-ds-sampling-station-and-heater-circulator/))

Dissolution Systems - Spectralab Scientific Inc.

[E255] Its evidenced role is equipment refurbishment and resale, not original manufacture.

[E256] SpectraLab Scientific Inc. advertises used and refurbished dissolution systems, including Agilent, Distek, Hanson, and SOTAX equipment.

[E257] SpectraLab Scientific advertises refurbished and pre-owned dissolution equipment from named manufacturers. ([spectralabsci.com](https://spectralabsci.com/lab-equipment/other-products/dissolution-systems/))

[E258] SpectraLab advertises dissolution equipment from Agilent, Distek, Hanson, and SOTAX, with listings explicitly classified as refurbished or pre-owned. ([spectralabsci.com](https://spectralabsci.com/lab-equipment/other-products/dissolution-systems/))

[E259] The Canadian resale proposition differs from Spectralab Instrumentación's manufacturer-listed Mexican channel role. ([spectralabsci.com](https://spectralabsci.com/lab-equipment/other-products/dissolution-systems/))

[E260] The page identifies its business address in Markham, Ontario, Canada.

Ordering Information - Spectralab Scientific Inc.

[E261] SpectraLab's general ordering terms use shipping-based warranty commencement and make returns and refunds conditional on the quote. This differs from the delivery-based wording on the specific equipment page. ([spectralabsci.com](https://spectralabsci.com/ordering-information/))

[E262] SpectraLab's ordering page identifies its Markham, Ontario location, states a three-month warranty after shipping, and makes returns and refunds conditional on the quote. Its warranty-start wording differs from the inspected equipment listing. ([spectralabsci.com](https://spectralabsci.com/ordering-information/))

Teledyne Hanson - AutoFill Accessories for Vision

[E263] The US storefront lists AutoFill collection racks at USD xx.xx and a field-install retrieval reservoir at USD xx.xx. These dedicated accessories constrain supporting-goods price scale, not purchase frequency or the assumed xx.xx relative spending intensity. ([store.teledynehanson.com](https://store.teledynehanson.com/collections/autofill%E2%xx.xx%A2-accessories-vision%C2%AE-g2-classic-xx.xx%E2%xx.xx%A2))

Teledyne Hanson - Dissolution Physical Goods Store

[E264] Listed physical goods include a USD xx.xx vessel, USD xx.xx basket and USD xx.xx filter package. These prices provide an aftermarket monetary-scale check, not annual replenishment quantities or global realization. ([store.teledynehanson.com](https://store.teledynehanson.com/collections/dissolution))

Teledyne Hanson - Service & Calibration CD14 Physical Products

[E265] Current U.S. list prices include USD xx.xx for a physical validation tool kit and USD xx.xx for immersion-cell tools. These constrain the scale of separately purchased goods and demonstrate a narrower purchasing alternative, not annual expenditure or category shares.

[E267] Separately priced physical supporting goods corroborate a transaction flow outside complete packages. Their Semi-Automated attribution remains modeled through configuration-specific purchasing weights. ([store.teledynehanson.com](https://store.teledynehanson.com/collections/service-calibration-cd14))

[E269] The U.S. storefront lists a physical validation-tool kit at USD xx.xx. The model applies an explicit global/period realization allowance; the listing supplies no ownership, replacement or forecast sales rate. ([store.teledynehanson.com](https://store.teledynehanson.com/collections/service-calibration-cd14))

[E270] The US manufacturer storefront lists a physical validation toolkit at USD xx.xx. This constrains the scale of separately supplied qualification goods, not annual purchase incidence or their allocation among supported configurations. ([store.teledynehanson.com](https://store.teledynehanson.com/collections/service-calibration-cd14))

[E271] The physical-goods listing supports inclusion of separate supporting-equipment purchases, but does not verify the Fully Automated spending multiplier or configuration-specific sales.
([store.teledynehanson.com](https://store.teledynehanson.com/collections/service-calibration-cd14))

Teledyne Hanson - Service & Calibration: CD14 Physical Products

[E266] Separately priced physical qualification products support the model's distinct supporting-equipment flow without requiring complete-apparatus replacement. The annual purchase incidence remains assumed.
([store.teledynehanson.com](https://store.teledynehanson.com/collections/service-calibration-cd14))

[E268] The U.S. storefront lists a physical validation tool kit at USD xx.xx and immersion-cell tools at USD xx.xx. These are current list-price scale checks for separately supplied qualification goods, not observed 2025 prices, sales volumes, or annual spending.
([store.teledynehanson.com](https://store.teledynehanson.com/collections/service-calibration-cd14))

Dissolution - Teledyne ISCO Canada

[E272] Teledyne's Canadian storefront advertises Hanson Vision G2 dissolution testers, Media-Mate equipment, and the CD-xx.xx comparative dissolution tester.

[E273] The Canadian dissolution storefront advertises accessories and spare parts, provides order and support contacts, and subjects purchase orders to sale terms.
([store.teledyneisco.ca](https://store.teledyneisco.ca/pages/dissolution))

[E274] The Teledyne-branded Canadian storefront supplies dissolution-specific order contacts and describes purchase-order and quotation-linked ordering. Its listed prices are restricted to customers in Canada and subject to stated sale terms; they do not establish universal price tiers.
([store.teledyneisco.ca](https://store.teledyneisco.ca/pages/dissolution))

[E276] The storefront states that listed prices are valid only for customers located in Canada.

Teledyne ISCO Canada - Dissolution

[E275] The manufacturer-branded Canadian dissolution storefront provides manufacturer-domain ordering contacts and purchase-order/quotation terms for physical accessories and parts. This corroborates direct aftermarket availability, not its sales share; cross-year persistence is assumed.
([store.teledyneisco.ca](https://store.teledyneisco.ca/pages/dissolution))

Dissolution Tester DT-I/III/VI/VIII - PT. Syaf Unica Indonesia

[E277] PT. Syaf Unica Indonesia advertises DT-series dissolution testers for the Indonesian pharmaceutical market.

[E278] The commercial page identifies its Indonesian business address and contact details.

Pharmaceutical Testing Instruments

[E279] The Taawon-linked portfolio advertises SOTAX dissolution testing systems; the precise Diamond Spectrum seller binding remains unresolved.

Instrumentation Archives - Tecora

[E280] Advertises Distek dissolution systems, Eclipse autosampling, and dedicated peripheral offerings.

Instrumentation | Tecora

[E281] Tecora's instrumentation catalog presents Distek systems and peripherals; legal binding to CDL-TECORA remains a separate question. ([tecora.com](https://tecora.com/en/categorie-produit/laboratory/instrumentation-en/))

Evolution 300 / Evolution 600 UV-Vis Spectrophotometers

[E282] A Thermo Scientific brochure describes a Thermo Fisher Scientific-SOTAX relationship for integrated tablet dissolution systems using Evolution spectrophotometers.

[E283] This establishes a historical integration role; the brochure does not establish continuation of the arrangement in October 2026.

Dissolution Testing - Tri Solution

[E284] The page identifies its Thai address and distribution role.

[E285] Tri Solution Co., Ltd. advertises RIGGTEK Dissilio dissolution testers, Sampilio autosampling, and DissoPrep equipment.

Profile | Trung Son T.S.S.E Scientific Equipment & Tourist Joint Stock Company

[E286] Its represented portfolio includes Logan automated dissolution testers.

[E287] The company profile identifies Trung Son T.S.S.E Scientific Equipment & Tourist Joint Stock Company as a Vietnamese instrument distributor.

[E288] Trung Son's company profile includes Logan automated dissolution equipment within its represented portfolio. ([trungsontsse.com.vn](https://trungsontsse.com.vn/profile/))

QLA General Dissolution Accessories

[E289] Maintains a dedicated commercial catalog for QLA General Dissolution Accessories.

QLA General Dissolution Accessories | UVISON

[E290] UVISON maintains a dedicated QLA dissolution-accessories catalog. ([uvison.com](https://uvison.com/dissolution/general-dissolution-accessories))

About UVISON : UVISON.com

[E291] Identifies UVISON Technologies Limited as a United Kingdom business supporting analytical and dissolution instrumentation.

World Bank WITS / UN Comtrade - Instruments and apparatus for physical or chemical analysis, imports by country, 2024

[E292] 2024 import input, USD thousand: xx.xx.

[E293] 2024 import input, USD thousand: xx.xx.

[E294] 2024 import input, USD thousand: xx.xx.

[E295] 2024 import input, USD thousand: xx.xx.

[E296] 2024 import input, USD thousand: xx.xx.

[E297] 2024 import input, USD thousand: xx.xx.

[E298] 2024 import input, USD thousand: xx.xx.

[E299] 2024 import input, USD thousand: xx.xx.

[E300] 2024 import input, USD thousand: xx.xx.

[E301] 2024 import input, USD thousand: xx.xx.

[E302] 2024 import input, USD thousand: xx.xx.

[E303] 2024 import input, USD thousand: xx.xx.

[E304] 2024 import input, USD thousand: xx.xx.

[E305] 2024 import input, USD thousand: xx.xx.

[E306] 2024 import input, USD thousand: xx.xx.

[E307] 2024 import input, USD thousand: xx.xx.

[E308] 2024 import input, USD thousand: xx.xx.

World Bank WITS / UN Comtrade - United Arab Emirates physical or chemical analysis instrument imports, 2023

[E309] Observed 2023 broad-instrument imports were USD xx.xx. The model separately assumes temporal rebasing and local end-use retention rather than counting transit activity as demand.

World Bank WITS / UN Comtrade - Lao PDR physical or chemical analysis instrument imports, 2023

[E310] Observed 2023 broad-instrument imports were USD xx.xx. The small positive country weight is an assumption-led equipment-access estimate, not a direct market observation.

World Bank WITS / UN Comtrade - Russian Federation physical or chemical analysis instrument imports, 2021

[E311] Observed 2021 broad-instrument imports were USD xx.xx. Temporal accessibility and conversion into the country demand index are assumptions; this is not current equipment revenue.

World Bank WITS / UN Comtrade - Vietnam physical or chemical analysis instrument imports, 2023

[E312] Observed 2023 broad-instrument imports were USD xx.xx. The period and pharmaceutical-equipment exposure bridges are modeled, not reported dissolution sales.

Company | ABL&E-JASCO

[E313] ABL&E-JASCO describes sister distribution businesses and represented manufacturers, without establishing ownership by JASCO Corporation. ([ablelab.eu](https://www.ablelab.eu/company/))

Company - ABL&E-JASCO

[E314] ABL&E-JASCO's official company page describes Hungary, Poland, and Romania as sister companies in its distribution and service network.

[E315] The page identifies JASCO as a represented spectroscopy and chromatography supplier and Teledyne Hanson Research as a represented pharmaceutical-testing supplier.

[E316] This distinguishes the channel business from its represented manufacturers without resolving ultimate ownership.

Service | Advancement Est.

[E317] Advancement Est. advertises dissolution-related supplies and instrument support. ([advancement-est.com](https://www.advancement-est.com/service.html))

Service - ADVANCEMENT EST. For Laboratory Equipments & Instrumentations

[E318] Advancement Est.'s Jordan business page advertises dissolution supplies and support for tablet-dissolution instrumentation.

WHO Regional Office for Africa - Quality Surveillance Laboratory in Namibia Pursues WHO Prequalification for Accreditation

[E319] The September xx.xx 2024 account includes dissolution capability in Namibia's surveillance-laboratory assessment. It establishes an existing commercial setting, not an equipment award or completed prequalification. ([afro.who.int](https://www.afro.who.int/countries/namibia/news/quality-surveillance-laboratory-namibia-pursues-who-prequalification-accreditation))

[E320] The named Namibian regulatory laboratory's assessed scope includes dissolution, supporting public medicines-control applicability rather than a completed equipment purchase.

[E321] The named regulatory laboratory provides a public medicines-control operating example, without establishing requirements or supplier eligibility across all public laboratories. ([afro.who.int](https://www.afro.who.int/countries/namibia/news/quality-surveillance-laboratory-namibia-pursues-who-prequalification-accreditation))

[E322] WHO's September xx.xx 2024 account includes dissolution within assessed activities at Namibia's Quality Surveillance Laboratory. It concerns a surveillance setting and assessment, not an equipment award or completed WHO prequalification. ([afro.who.int](https://www.afro.who.int/countries/namibia/news/quality-surveillance-laboratory-namibia-pursues-who-prequalification-accreditation))

[E323] WHO's September xx.xx 2024 record identifies the Namibia Medicines Regulatory Council's Quality Surveillance Laboratory and explicitly includes dissolution among its assessed testing activities. It establishes a public regulatory-laboratory setting, not equipment sales or completed WHO prequalification. ([afro.who.int](https://www.afro.who.int/countries/namibia/news/quality-surveillance-laboratory-namibia-pursues-who-prequalification-accreditation))

WHO Regional Office for Africa - Framework for strengthening local production of medicines, vaccines and other health technologies, 2024

[E324] The document's older China/India manufacturing comparators qualify domestic-customer scale assumptions; they are not current dissolution sales.

[E325] The published xx.xx-plant continental figure constrains customer-pool scale, not equipment ownership or funded acquisitions.

Agilent Rotating Bottle Apparatus Operator's Manual - Revision A, March 2011

[E326] The manufacturer's March 2011 manual establishes a historical rotating-bottle commercial apparatus identity. It does not establish current new manufacture, 2025 shipments, or inclusion of used-equipment transactions. Only identity and date are used; operating instructions are not used. ([agilent.com](https://www.agilent.com/Library/usermanuals/Public/Rotating_Bottle_Apparatus_Op_Man.pdf))

Agilent - Rotating Bottle Apparatus Operator's Manual, Revision A, March 2011

[E327] The manufacturer's manual identifies a Rotating Bottle Apparatus and is Revision A, March 2011. Only its historical commercial identity and date support the Agitated-Bottle Apparatus discussion; operating instructions are not used. ([agilent.com](https://www.agilent.com/Library/usermanuals/Public/Rotating_Bottle_Apparatus_Op_Man.pdf))

Unleashing the Power of Artificial Intelligence in Quality Control

[E328] Agilent reports pilot activity involving AI-assisted analytical QC data review. The disclosure does not identify dissolution-equipment installations or establish market-wide deployment. ([agilent.com](https://www.agilent.com/about/great-science/en/xx.xx-artificial-intelligence.html))

Agilent Opens Center of Excellence for Dissolution Products

[E329] Agilent Technologies Inc. announced its Dissolution Center of Excellence in Craven Arms, United Kingdom, on October xx.xx 2022.

[E330] The announcement describes the site as a hub for its dissolution business and customers worldwide.

Agilent - Dissolution Systems Source Book 2020-2021

[E331] The 2020-2021 catalog lists rotating-bottle accessories under legacy instruments. This establishes a physical-aftermarket category but not 2025 stock, shipments or current availability of every SKU.

Dissolution Systems Source Book 2020-2021

[E332] The 2020-2021 commercial source book identifies Merel as an Agilent dissolution partner and advertises the dissoGUARD surveillance system.

Agilent Practical Solutions Newsletter, Volume 20, Issue 3 - Getting a Clearer Picture: What Is New with dissoGUARD?

[E333] Agilent's 2020 newsletter describes Merel dissoGUARD surveillance and its integration offer; continuing rights and support are not established.
([agilent.com](https://www.agilent.com/cs/library/periodicals/public/newsletter-xx.xx-dissolution-web-xx.xx-1738en-agilent.pdf))

[E334] Agilent's March xx.xx 2020 newsletter describes Merel's dissoGUARD surveillance system and software with xx.xx-DS apparatus, establishing a historical integration offer rather than continuing supply or licensing obligations.

[E335] The March xx.xx 2020 publication documents camera-based surveillance as an apparatus addition. It supports historical commercial classification only; current sales, price, availability and the forecast penetration assumptions remain unverified.
([agilent.com](https://www.agilent.com/cs/library/periodicals/public/newsletter-xx.xx-dissolution-web-xx.xx-1738en-agilent.pdf))

[E336] The described surveillance package supplies viewing and recording functions, supporting comparison with, rather than automatic equivalence to, quantitative analytical imaging.
([agilent.com](https://www.agilent.com/cs/library/periodicals/public/newsletter-xx.xx-dissolution-web-xx.xx-1738en-agilent.pdf))

[E337] The newsletter published March xx.xx 2020 describes Merel's dissoGUARD cameras, recording, and video export as an addition to Agilent dissolution apparatus. It establishes a historical observation offering, not continuing contractual availability.
([agilent.com](https://www.agilent.com/cs/library/periodicals/public/newsletter-xx.xx-dissolution-web-xx.xx-1738en-agilent.pdf))

[E338] The supplier publication describes a dissolution-specific camera system with viewing, recording, video-export, and illumination functions and discusses adding it to a dissolution apparatus. This corroborates a dedicated observation offering in that publication, not current separate-sale status, an independently established market partition, quantitative dissolved-drug detection, or certified mechanical qualification.
([agilent.com](https://www.agilent.com/cs/library/periodicals/public/newsletter-xx.xx-dissolution-web-xx.xx-1738en-agilent.pdf))

Dissolution Workflow Manager for OpenLab CDS

[E339] Agilent advertises Dissolution Workflow Manager as an OpenLab CDS plug-in with role-based access, digitally signed reports and tracked configuration changes.
([agilent.com](https://www.agilent.com/en/p/dissolution-disintegration-testing/software/workflow-manager))

Agilent - Dissolution Testing

[E340] Agilent separately presents apparatus, autosamplers, qualification products, online UV systems, and physical accessories, including vessels, covers, paddles, baskets, sinkers, and reciprocating accessories. These are advertised categories, not proof of local fulfillment. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing))

Agilent Dissolution Testing - Product Categories and Accessories

[E341] Dissolution autosamplers are presented as a distinct commercial equipment category.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing))

[E342] Dissolution qualification is separately presented with calibration and verification technology. Only physical tools, not associated service revenue, are included in this taxonomy category.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing))

[E343] The commercial accessories classification explicitly names vessels, covers, paddles, baskets, sinkers, reciprocating accessories, and apparatus-specific attachments. This supports a dedicated physical-aftermarket category rather than general laboratory supplies.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing))

[E344] The inspected category page distinguishes apparatus, autosamplers, qualification, online UV systems, and accessories from software and training. It corroborates commercial offering distinctions but is not used to prove an exhaustive market partition. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing))

Agilent - 400-DS Apparatus 7

[E345] Agilent advertises an integrated apparatus and autosampler for named combination-product applications. This supports differentiated commercial package scope, but neither its modeled price premium nor attributable sales.

400-DS Apparatus 7 - Agilent

[E346] Agilent advertises the xx.xx-DS for named combination-product applications, establishing specialized commercial scope rather than universal dosage-family suitability. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-apparatus-xx.xx))

Agilent - 708-DS Dissolution Apparatus

[E347] Advertised paddle-over-disk compatibility supports the accessory-versus-complete-package purchasing distinction used in the model.

[E348] Advertised rotating-cylinder compatibility supports shared-platform purchasing and limits inference of dedicated apparatus acquisitions.

[E358] The xx.xx-DS supports basket configurations, establishing shared-chassis attribution and conversion possibilities rather than basket sales volume.

[E364] The same modular apparatus supports paddle configurations; compatible capabilities must not each receive the full chassis revenue.

708-DS Dissolution Apparatus

[E349] Agilent advertises xx.xx-DS configurations for Basket Apparatus, Paddle Apparatus, Paddle Over Disk Apparatus, and Rotating Cylinder Apparatus. Possible configuration coverage does not identify the package supplied in a particular purchase. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E350] Agilent advertises the xx.xx-DS as a modular apparatus with manual and automated configurations, supporting comparison of configuration flexibility rather than assumed complete-system equivalence. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E351] Agilent advertises the xx.xx-DS as a modular manual-or-automated system. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E352] Agilent advertises the xx.xx-DS as modular apparatus available in manual and automated configurations, supporting configuration-specific commercial comparisons. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E353] Agilent advertises the xx.xx-DS as modular apparatus with Manual and automated configurations and optional analytical integration, supporting itemized package comparisons. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E354] Agilent advertises the xx.xx-DS as modular apparatus with manual and automated configurations. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E355] Agilent advertises the xx.xx-DS as modular, with manual or automated configurations for basket, paddle, paddle-over-disk, and rotating-cylinder apparatus and optional Agilent software and UV-Vis integration.

[E356] Agilent describes the xx.xx-DS as modular apparatus available in manual and automated configurations. This supports configuration-specific comparison rather than brand-level package equivalence.

[E359] The configurable xx.xx-DS offering establishes that the commercial package must be specified before quotations can be compared meaningfully. This purchasing implication is analytical. ([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E360] The configurable offering supports a conditional distinction between upgrading a package and replacing a complete system.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E361] The modular offering is a documented commercial alternative; buyer acceptance is not established by the portfolio.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

[E362] The portfolio names particular apparatus configurations rather than establishing suitability across every accepted application.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/xx.xx-ds-dissolution-apparatus))

708-DS Dissolution Apparatus | Agilent

[E357] Agilent markets the xx.xx-DS Dissolution Apparatus for manual or automated pharmaceutical dissolution testing.

[E363] The product page identifies integration with Agilent dissolution software and analytical equipment.

Agilent - BIO-DIS Reciprocating Cylinder Apparatus

[E365] Agilent separately advertises BIO-DIS as a Reciprocating Cylinder Apparatus offering. Its portfolio identity does not establish another platform's coverage or a buyer's acceptance.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/bio-dis-reciprocating-cylinder-apparatus?utm_source=openai))

[E366] BIO-DIS is a separately advertised reciprocating-cylinder commercial family with optional sampling integration. It supports category and package mapping, not the modeled global use fraction or forecast adoption.

Agilent - Reciprocating Holder Apparatus 7

[E367] Agilent advertises Reciprocating Holder Apparatus separately from BIO-DIS, supporting an offering-level distinction within the accepted platform hierarchy.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-apparatus/reciprocating-holder-apparatus-xx.xx?utm_source=openai))

[E368] Agilent separately advertises its reciprocating-holder apparatus and configuration alternatives, supporting a distinct commercial purchasing family rather than automatic coverage by another platform.

280-DS Mechanical Qualification System

[E369] Agilent advertises the xx.xx-DS as separately offered qualification equipment compatible with open-head dissolution apparatus. This supports a distinct supporting-equipment purchase, subject to configuration confirmation.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E370] Agilent advertises the xx.xx-DS qualification system for open-head dissolution apparatus, including the xx.xx-DS. The stated design boundary supports an installation-specific compatibility comparison.

[E371] Agilent advertises the separately offered xx.xx-DS qualification system for open-head dissolution apparatus, supporting a qualification-equipment purchase distinct from complete-system replacement.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E372] Agilent separately advertises the xx.xx-DS Mechanical Qualification System and describes compatibility with open-head dissolution apparatus, including the xx.xx-DS.

[E373] Agilent separately advertises the xx.xx-DS Mechanical Qualification System for open-head dissolution apparatus, including the xx.xx-DS, establishing a supporting-equipment purchasing scope.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E374] Agilent separately advertises the xx.xx-DS qualification system for open-head apparatus, including the xx.xx-DS.

[E375] Agilent separately advertises the xx.xx-DS qualification system for open-head dissolution apparatus, including the xx.xx-DS.

([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E376] Agilent's stated open-head apparatus scope supports a configuration-specific qualification-equipment inquiry, not universal compatibility.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E377] The distinct qualification offering supplies an evidenced alternative to replacing otherwise acceptable apparatus.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E378] The separately advertised xx.xx-DS supports the installed-base qualification opportunity, subject to an installation-specific match rather than assumed universal compatibility.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

[E379] The separately offered xx.xx-DS establishes a supporting-equipment purchasing route distinct from apparatus replacement.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

Agilent - 280-DS Mechanical Qualification System

[E380] The supplier advertises dedicated mechanical qualification hardware, corroborating a separate physical-goods purchasing function. The page establishes neither category revenue nor the model's ownership and replacement assumptions.
([agilent.com](https://www.agilent.com/en/product/dissolution-testing/dissolution-qualification/xx.xx-ds-mechanical-qualification-system))

Agilent - Part 32-5001, Rotating Bottle with Cap

[E381] Part xx.xx-xx.xx is marked obsolete with no replacement recommendation. This is SKU-specific counterevidence to assuming unrestricted supply continuity, not proof of worldwide category cessation.

Agilent - Part 11-1425

[E382] The individual U.S. item page displays a USD xx.xx probe list price, used as a component-cost scale check and an input to the explicitly adjusted physical-parts basket.

Agilent - Part 11-1429

[E383] The individual U.S. item page displays a USD xx.xx removable-tip list price; together with the probe it forms a USD xx.xx list-price anchor, not an observed annual purchase amount.

Agilent - Part 12-4101, Intrinsic Dissolution Accessories

[E384] The manufacturer lists intrinsic-dissolution accessory pack xx.xx-xx.xx at USD 1930. This current list-price observation constrains the accessory-versus-complete-apparatus spending distinction; it is not a 2025 realized price or annual sales measure.

Agilent - Part 32-5530, Rotating Bottle Supplies

[E385] A separate rotating-bottle-only part, xx.xx-xx.xx remains listed for quotation. This qualifies blanket obsolescence and supports considering a limited physical-goods flow, without establishing realized sales.

Agilent - Part 5063-6570

[E386] The individual U.S. item page displays a USD xx.xx flow-cell list price, supporting the external-cell parts-cost anchor after assumed realization and period adjustments.

Labor Estabille Equipment | Alpax

[E387] Alpax advertises Labor Estabille dissolution equipment.
([alpax.com.br](https://www.alpax.com.br/labor-estabille-equipamentos-de-precisao-para-os-setores-medico-hospitalar-farmaceutico-e-laboratorial/))

Labor Estabille: Equipamentos de Precisão para os Setores Médico-Hospitalar, Farmacêutico e Laboratorial - Alpax

[E388] Promotes Labor Estabille dissolution equipment and links customers to Alpax product offerings.

Shop - ANALYTICAL SOLUTIONS

[E389] Analytical Solutions' commercial catalog advertises ERWEKA DT xx.xx and DT xx.xx dissolution-equipment offerings.

ERWEKA Digital DT 9510 Series | Ant Teknik

[E390] Ant Teknik advertises ERWEKA DT xx.xx dissolution equipment. ([antteknik.com](https://www.antteknik.com/en/products/?p=erweka-digital-dt-xx.xx))

Erweka Digital DT 9510 Series Dissolution Tester | AntTeknik.com

[E391] Ant Teknik advertises the ERWEKA Digital DT xx.xx Series dissolution tester in its English-language product catalog.

Dissolution Test Apparatus - Dissolution Validation Kit | Arrow Pharmatech

[E392] Arrow Pharmatech advertises a dissolution qualification kit through a trading offering. ([arrowpharmatech.in](https://www.arrowpharmatech.in/dissolution-test-apparatus.html))

[E393] Arrow Pharmatech's dedicated catalog offers a dissolution validation kit.

[E394] The page identifies the Thane, India business and its GST reference; the evidenced role is qualification-equipment trading.

Sobre nosotros | AVIC Industrial

[E395] AVIC describes its pharmaceutical quality-control equipment business, including dissolution instruments. ([avicindustrial.com.ar](https://www.avicindustrial.com.ar/about.html))

AVIC Industrial | Sobre nosotros

[E396] Describes AVIC Industrial as a family-run business in Escobar that develops and manufactures pharmaceutical quality-control equipment, including dissolution instruments.

AVIC | Disolutores

[E397] Maintains a dedicated dissolution-equipment product page under the AVIC business identity.

BOE-B-2017-66889 - AEMPS Dissolution Equipment Contract Formalization

[E398] Spain's official contract notice identifies Gomensoro, S.A. as contractor for dissolution equipment supplied to AEMPS's official control laboratory, with contract formalization on November xx.xx 2017. It establishes a historical contract, not present supplier continuity. ([boe.es](https://www.boe.es/boe/dias/2017/xx.xx/xx.xx/pdfs/BOE-B-2017-xx.xx.pdf))

Bosung Science | Scientific Equipment, Research Solutions & Innovation

[E399] Features the SOTAX CE7 smart dissolution instrument in its commercial equipment portfolio.

Calibre Scientific Acquires CPS Analitica

[E400] Calibre Scientific announced its acquisition of C.P.S. Analitica in October 2023 and identified dissolution among the distributor's markets. ([calibrescientificgroup.com](https://www.calibrescientificgroup.com/news/cps-analitica))

Calibre Scientific acquires CPS Analitica

[E401] Identifies an Italian distribution business serving dissolution and other analytical markets.

[E402] The October 2023 announcement establishes Calibre Scientific's acquisition of C.P.S. Analitica S.r.l.

Dissolution Offline Sampling System, Model DRS-8 | Campbell Electronics

[E403] Campbell Electronics advertises DRS-xx.xx as a dissolution offline-sampling system. ([campbellelectronics.com](https://www.campbellelectronics.com/dissolution-drs-xx.xx.html))

Campbell Electronics - Dissolution Offline Sampling System, Model DRS-8

[E404] Campbell Electronics markets its DRS-series tablet dissolution system and DRS-xx.xx dissolution offline-sampling system.

University of Canberra - Laboratories

[E405] A university-operated pharmacy laboratory documents dissolution capability, providing buyer-side support for an academic operating setting rather than a supplier customer-list inference. ([canberra.edu.au](https://www.canberra.edu.au/on-campus/facilities/laboratories))

[E406] The University of Canberra describes dissolution capability within its pharmaceutical-science teaching laboratory, supporting an instructional purpose without establishing a dedicated equipment purchase. ([canberra.edu.au](https://www.canberra.edu.au/on-campus/facilities/laboratories))

[E407] The pharmaceutical-science laboratory combines teaching with dissolution-testing capability, directly supporting instructional use. The page does not identify a dedicated commercial-system purchase or expenditure. ([canberra.edu.au](https://www.canberra.edu.au/on-campus/facilities/laboratories))

[E408] The pharmaceutical-science teaching laboratory expressly includes dissolution capability, supporting instructional classification but not dedicated purchases, expenditure or the modeled ownership rate. ([canberra.edu.au](https://www.canberra.edu.au/on-campus/facilities/laboratories))

[E409] The university describes hands-on learning laboratories and expressly identifies dissolution testing within its pharmaceutical-science teaching setting. This supports adding an instructional objective rather than treating every laboratory purchase as research or quality-control production work. ([canberra.edu.au](https://www.canberra.edu.au/on-campus/facilities/laboratories))

[E410] The university's own facility description establishes an academic operating setting rather than a supplier customer-list inference. It does not prescribe an automation category. ([canberra.edu.au](https://www.canberra.edu.au/on-campus/facilities/laboratories))

CCV | Soluciones Farma

[E411] Advertises SOTAX tablet dissolution equipment and identifies the CCV business location in Caracas, Venezuela.

Soluciones Farma | Corporacion Cientifica Venezolana

[E412] Corporacion Cientifica Venezolana presents SOTAX dissolution equipment in its pharmaceutical portfolio. ([ccv.com.ve](https://www.ccv.com.ve/pruebasfisicastablestasycapsulas))

DISTEK | Chemetric

[E413] Advertises Distek xx.xx dissolution instruments, Eclipse xx.xx sampling equipment, and dedicated dissolution-support products.

Dissolution Tester, DIST-1E

[E414] Chemistore's commercial store lists the DIST-1E dissolution tester with an ordering interface and South African contact information.

Dissolution Consumables & Accessories - Edition 4

[E415] Catalogs dissolution consumables and accessories.

[E416] Describes ProSense as privately owned and independent at publication and identifies a Netherlands business address.

[E417] The supplier-issued catalog identifies Dissolution Accessories as a ProSense B.V. brand.

[E418] The supplier-issued catalog identifies Dissolution Accessories as a ProSense B.V. brand. ([chromatographyspares.com](https://www.chromatographyspares.com/pdf/da_catalogue.pdf))

Distek - Dissolution in Pharmacy | Chromservis

[E419] Chromservis advertises Distek dissolution systems and accessories in its portfolio. ([chromservis.eu](https://www.chromservis.eu/en/distek-sample-preparation-dissolution-in-pharmacy))

Distek - Sample Preparation - Dissolution in Pharmacy - CHROMSERVIS.EU

[E420] States that Distek dissolution systems and accessories have been added to its portfolio.

CMAC - National Facility: Applied Research for Medicines Manufacturing

[E421] CMAC identifies its University of Strathclyde facility as a publicly funded research center rather than a contract research organization, despite industrial collaboration. This supports the institutional-versus-contract classification rule; this page alone does not establish its dissolution inventory. ([cmac.ac.uk](https://www.cmac.ac.uk/materials-characterisation))

Central Medical Services Society - Tender CMSS/2025-26/TL/DRUGS/018: Empanelment of Third-Party Laboratories for Analysis

[E422] CMSS's tender published December xx.xx 2025 sought empanelment of third-party laboratories for analysis. Its stated procurement subject establishes a service-purchasing relationship, not an equipment award or a particular provider's inventory. ([cmss.gov.in](https://www.cmss.gov.in/wp-content/uploads/2025/xx.xx/TENDER.pdf))

Central Medical Services Society - Tender CMSS/2025-26/TL/DRUGS/018: Empanelment of Third Party Laboratories for Analysis of Drugs and Other Items

[E423] Eligibility requires independent, stand-alone analytical laboratories rather than in-house manufacturing facilities, and the equipment list includes dissolution apparatus. This establishes a contract-laboratory demand setting, not a completed equipment award. ([cmss.gov.in](https://www.cmss.gov.in/wp-content/uploads/2025/xx.xx/TENDER.pdf))

[E424] The tender distinguishes the public purchaser of analytical services from independent laboratories required to possess testing equipment. This supports attributing equipment to the laboratory operator rather than automatically to the payer. ([cmss.gov.in](https://www.cmss.gov.in/wp-content/uploads/2025/xx.xx/TENDER.pdf))

Copley Scientific - Introducing the Copley Inhaled Dissolution Apparatus™ IDA

[E425] The official launch, dated January xx.xx 2026 in the manufacturer's news index, establishes a commercial inhaled-dissolution offering after the base year. It supports forecast availability, not 2025 sales or the assumed adoption multiplier.

DISi Series - Copley Scientific

[E426] Copley Scientific markets DIS 600i and DIS 800i tablet dissolution testers for research and quality-control use.

[E427] Copley advertises DISi apparatus for conventional dissolution requirements in research and quality-control settings.
([copleyscientific.com](https://www.copleyscientific.com/pharmaceutical-testing/tablet-dissolution-testing/disi-series/))

[E428] The page identifies Copley Scientific Limited and its Nottingham, United Kingdom address.

Disolutor DIS 700 de cabezal fijo Ethik | Cromtek

[E429] Advertises the Ethik DIS xx.xx and states that Cromtek represents Ethik in Chile.

[E430] Cromtek advertises Ethik DIS xx.xx equipment and its Chile-facing representation.
([cromtek.cl](https://www.cromtek.cl/producto/disolutor-test-de-disolucion-dis-xx.xx-cabezal-fijo-ethik/))

[E431] Identifies Ethik as the supplier brand of the advertised DIS xx.xx.

Logan Instruments | DCtech

[E432] Advertises Logan dissolution instruments and maintains dedicated dissolution-equipment and accessory categories.

[E433] DCtech advertises Logan dissolution instruments and related equipment.
([dctech.com.br](https://www.dctech.com.br/logan-instruments-dctech/))

DISS-SOTAX S. de R.L. de C.V.

[E434] DISS-SOTAX describes itself as a Mexican company distributing SOTAX, Zymark, and other pharmaceutical laboratory equipment.

[E435] The page identifies the observed DISS-SOTAX business separately from its description of SOTAX.

Productos de Disolución | DISS-SOTAX

[E436] DISS-SOTAX advertises SOTAX dissolution equipment across manual and automated package categories.
([diss-sotax.com.mx](https://www.diss-sotax.com.mx/productos/disolucion.php))

[E439] The commercial catalog establishes a represented-equipment role, not manufacturer ownership of the seller.
([diss-sotax.com.mx](https://www.diss-sotax.com.mx/productos/disolucion.php))

DISS-SOTAX - Productos de Disolución

[E437] DISS-SOTAX advertises SOTAX dissolution equipment, including AT Xtend MD configurations.

[E438] The catalog establishes an advertised dissolution-equipment channel offering, not independent OEM status or completed sales.

International distributors - Dissolution Accessories

[E440] Accessory channel: Austria/Germany/Switzerland.

[E441] Accessory channel: Bulgaria.

[E442] Accessory channel: Cyprus.

[E443] Accessory channel: Greece.

[E444] Accessory channel: Hungary.

[E445] Accessory channel: Italy/Ticino.

[E446] Accessory channel: Kazakhstan.

[E447] Accessory channel: Malta.

[E448] Accessory channel: Poland.

[E449] Accessory channel: Portugal.

[E450] Accessory channel: Romania.

[E451] Accessory channel: Spain.

Electrolab (India) Private Limited - About Us and supplier profile

[E452] The supplier's own commercial profile reports an undated INR xx.xx-xx.xx crore annual turnover band and xx.xx-xx.xx personnel. The modeled INR xx.xx crore company scale is checked against this broad band; the profile does not establish dissolution revenue. ([dissolutiontester.com](https://www.dissolutiontester.com/profile.html))

About Distek, Inc.

[E453] Distek lists dissolution systems, media preparation, sampling, fiber-optic analysis, and lifecycle support within its own portfolio. ([distekinc.com](https://www.distekinc.com/company/))

[E454] The official portfolio establishes a competing equipment-and-service architecture without supporting leadership or adoption claims. ([distekinc.com](https://www.distekinc.com/company/))

Distek - Contact and dissolution distributor directory

[E455] Advertised country contacts support an access premise only; no regional sales or common fulfillment contract is disclosed.

[E516] Saudi destination listing does not measure local equipment revenue or purchase conversion.

[E523] UAE destination listing does not distinguish retained equipment purchases from broader territorial representation.

Contact - Distek

[E456] Dissolution channel: Belarus.

[E457] Dissolution channel: Benelux.

[E458] Dissolution channel: Bulgaria.

[E459] Dissolution channel: Croatia/Slovenia.

[E460] Dissolution channel: Estonia/Latvia.

[E461] Dissolution channel: Greece/Cyprus.

[E462] Dissolution channel: Hungary/Serbia.

[E463] Dissolution channel: Iceland.

[E464] Dissolution channel: Ireland.

[E465] Dissolution channel: Italy.

[E466] Dissolution channel: Malta.

[E467] Dissolution channel: Moldova/Romania.

[E468] Dissolution channel: Poland.

[E469] Dissolution channel: Portugal.

[E470] Dissolution channel: Spain.

[E471] Dissolution distributor: Brazil.

[E472] Dissolution distributor: Chile.

[E473] Dissolution distributor: Colombia.

[E474] Dissolution distributor: Dominican Republic.

[E475] Dissolution distributor: Ecuador.

[E476] Dissolution distributor: El Salvador, under CORESA.

[E477] Dissolution distributor: Guatemala and Honduras.

[E478] Dissolution distributor: Panama.

[E479] Dissolution distributor: Paraguay and Uruguay.

[E480] Distek identifies ISI Israel Scientific Instruments as its dissolution distributor for Israel.

[E484] Distek identifies Standart Analitik Sistemler LTD as its dissolution distributor for Turkey.

[E486] Distek lists Al Mansour Group as a dissolution distributor for Algeria, Iraq, Jordan, Saudi Arabia, Syria, and the United Arab Emirates.

[E493] Distek's official directory identifies Betatek, Inc. as its Canadian dissolution distributor.

[E494] Distek's official directory identifies Spectralab Instrumentación as its Mexican dissolution distributor.

[E495] Distek's official directory names Al Mansour Group as a dissolution distributor for Algeria.

[E496] Distek's official directory names Betatek, Inc. as a dissolution distributor for Canada.

[E497] Distek's official directory names Spectralab Instrumentación as a dissolution distributor for Mexico.

[E498] Distek, Inc. identifies its business address in North Brunswick, New Jersey, and advertises dissolution instruments and related products.

[E499] Its official directory identifies dissolution distribution relationships in Canada, Mexico, and Algeria.

[E500] Lists ITS-affiliated dissolution channels in Indonesia, Malaysia, the Philippines, Singapore, and Thailand.

[E501] Lists direct dissolution contacts for Bolivia, Peru, and Puerto Rico.

[E503] Names Al Mansour Group as its dissolution distributor for Algeria.

[E504] Names Atef Habib Rizk & Co. for dissolution distribution in Egypt and Libya.

[E505] Names Barons Industrial Technology as Myanmar's dissolution distributor.

[E506] Names Crescent Scientific Pvt. Ltd. as India's dissolution distributor.

[E507] Names ERT Consortium as Bangladesh dissolution distributor.

[E508] Names FAMCO Instruments as Pakistan's dissolution distributor.

[E509] Names John Morris Group as dissolution distributor for Australia and New Zealand.

[E510] Names Master Pharma as its dissolution distributor for Morocco.

[E511] Names PHYSIO MCKINA Corporation as Japan's dissolution distributor.

[E512] Names Promo-Biotech Tunisie as its dissolution distributor for Tunisia.

[E513] Names Quest Scientific as its dissolution distributor for South Africa.

[E514] Names SCINCO dissolution channels in China, South Korea, and Taiwan.

[E515] Names SatiCus Science and Technology Co. Ltd. as Vietnam's dissolution distributor.

[E520] The listing establishes a named channel relationship, not completed Canadian sales.

[E522] This supports a regional channel role, not independent manufacture.

Distek Contact and Distributor Directory

[E481] Distek identifies Omicron Research Limited as its United Kingdom dissolution distributor and also publishes direct manufacturer contact routes. Directory listings do not allocate customer-specific fulfillment obligations. ([distekinc.com](https://www.distekinc.com/contact/))

[E482] Distek identifies Omicron Research Limited as its United Kingdom dissolution distributor. ([distekinc.com](https://www.distekinc.com/contact/))

[E483] Distek identifies Omicron Research Limited as its United Kingdom dissolution distributor. The directory does not establish exclusivity or buyer-specific fulfillment obligations. ([distekinc.com](https://www.distekinc.com/contact/))

[E485] Distek identifies the country-distribution relationships discussed, including Omicron in the UK and named regional channels; listings do not allocate customer-specific fulfillment. ([distekinc.com](https://www.distekinc.com/contact/))

[E487] Distek lists Al Mansour Group for dissolution equipment in Saudi Arabia and the United Arab Emirates. ([distekinc.com](https://www.distekinc.com/contact/))

[E488] Distek lists Betatek in Canada and Crescent Scientific in India as dissolution distributors. These listings establish advertised contact routes rather than exclusivity or contract-specific service obligations.

[E489] Distek lists US regional contacts and dissolution distributors Betatek in Canada, Crescent Scientific in India, and Omicron Research in the United Kingdom. ([distekinc.com](https://www.distekinc.com/contact/))

[E490] Distek lists US regional contacts and named dissolution distributors, including Betatek in Canada and Crescent Scientific in India. These listings establish advertised contact routes, not contractual service performance. ([distekinc.com](https://www.distekinc.com/contact/))

[E491] Distek lists its own US regional contacts and Betatek as a Canadian dissolution distributor; these establish advertised contact routes. ([distekinc.com](https://www.distekinc.com/contact/))

[E492] Distek's dissolution directory names Omicron Research Limited in the United Kingdom, Al Mansour Group in Saudi Arabia and the United Arab Emirates, and Quest Scientific in South Africa. These are country-assigned contact relationships, not one EMEA-wide service agreement.

[E518] The directory establishes advertised country sales routes, not contract-specific bidder eligibility or service obligations. ([distekinc.com](https://www.distekinc.com/contact/))

[E519] The directory identifies Spectralab Instrumentación as a Mexican distribution route, not the Canadian resale business. ([distekinc.com](https://www.distekinc.com/contact/))

[E521] The manufacturer directory establishes a named UK channel relationship, not customer-specific contractual obligations. ([distekinc.com](https://www.distekinc.com/contact/))

Distek - Contact and Distributor Directory

[E502] Named dissolution distributors corroborate independent intermediary access. Listings are not used as sales weights and do not establish exclusivity or transaction-level seller identity. ([distekinc.com](https://www.distekinc.com/contact/))

[E517] The current directory lists Distek's own US regional contacts, corroborating an advertised manufacturer-direct route. Historical and forecast revenue attribution requires assumptions. ([distekinc.com](https://www.distekinc.com/contact/))

Distek Turns 50 - Reflections on Leadership, Legacy, and Looking Ahead

[E524] Distek's July xx.xx 2026 company announcement identifies Distek, Inc., its 1976 incorporation, family-business origins, and continuing investment in its core dissolution business. ([distekinc.com](https://www.distekinc.com/distek-turns-xx.xx-reflections-on-leadership-legacy-and-looking-ahead/))

Instrument Configuration | Distek, Inc.

[E525] Distek separately presents OLERA apparatus, Eclipse sampling, ezfill+ media handling, and Opt-Diss optical equipment.

[E526] Distek's configurator separately presents OLERA apparatus, Eclipse xx.xx sampling, ezfill+ media-handling equipment, and Opt-Diss xx.xx UV fiber-optic dissolution equipment, supporting an itemized commercial-package comparison.

[E527] Distek's instrument configurator markets OLERA, OLERA Plus, and OLERA Select dissolution apparatus.

[E528] It also offers the Eclipse xx.xx dissolution autosampler, ezfill+ media-handling equipment, and Opt-Diss xx.xx dissolution monitoring equipment.

Distek Introduces OLERA for Reliable Dissolution Testing, Reimagined

[E529] Distek announced release of OLERA, OLERA Plus, and OLERA Select on May xx.xx 2026, including bath-based and bathless alternatives. ([distekinc.com](https://www.distekinc.com/introducing-olera-reliable-dissolution-testing-reimagined/))

[E530] Distek announced release of the OLERA series on May xx.xx 2026. The dated supplier event establishes new proposals for inquiry rather than buyer acceptance or destination-specific delivery. ([distekinc.com](https://www.distekinc.com/introducing-olera-reliable-dissolution-testing-reimagined/))

[E531] Distek announced release of the OLERA series on May xx.xx 2026; the release establishes a supplier event rather than customer acceptance or local delivery. ([distekinc.com](https://www.distekinc.com/introducing-olera-reliable-dissolution-testing-reimagined/))

[E532] Distek announced the OLERA series release on May xx.xx 2026, identifying bath-based OLERA and OLERA Plus instruments and bathless OLERA Select. The announcement does not independently establish comparative outcomes or local fulfillment.

[E533] Distek announced the commercial release of the OLERA, OLERA Plus, and OLERA Select dissolution-instrument series on May xx.xx 2026. The record establishes a current differentiated equipment portfolio, not independently verified performance or sales volume. ([distekinc.com](https://www.distekinc.com/introducing-olera-reliable-dissolution-testing-reimagined/))

[E534] Distek's May xx.xx 2026 OLERA announcement describes patented features. It does not establish enforceable territorial exclusivity for an apparatus category. ([distekinc.com](https://www.distekinc.com/introducing-olera-reliable-dissolution-testing-reimagined/))

[E535] The dated announcement establishes the announced OLERA platform release, not realized environmental performance or destination-specific delivery. ([distekinc.com](https://www.distekinc.com/introducing-olera-reliable-dissolution-testing-reimagined/))

Model 2500 Select - Bathless Dissolution Tester

[E536] Distek describes patented technology in its Model xx.xx Select offering. The page does not establish enforceable territorial exclusivity for a proposed purchase. ([distekinc.com](https://www.distekinc.com/products/model-xx.xx-select/))

Dissolution Instrument - OLERA Select

[E537] Distek advertises OLERA Select as bathless and associates that configuration with reduced energy use. The product claim does not establish whole-life environmental superiority. ([distekinc.com](https://www.distekinc.com/products/olera-select-dissolution/))

VIP 4400 Discontinuation Announcement

[E538] Distek's July xx.xx 2021 VIP xx.xx notice announced discontinuation effective December xx.xx 2021, or earlier stock exhaustion, and qualified continuing repair and parts support. It does not establish every installed unit's condition. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

[E539] Distek's July xx.xx 2021 VIP xx.xx withdrawal notice qualifies continued repair and replacement-parts support without establishing every installed unit's condition. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

[E540] Distek's July xx.xx 2021 VIP xx.xx withdrawal notice qualifies continued repair and replacement-parts support. It does not establish the service position of every installed unit. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

[E542] The July xx.xx 2021 notice withdrew VIP xx.xx effective December xx.xx 2021, or earlier stock exhaustion, and qualified continued repair and parts support. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

[E543] The named withdrawal illustrates that lifecycle support is finite and distinct from an original equipment sale. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

[E544] The named withdrawal supplies an observed example of finite supporting-equipment support; unit-specific repair exposure remains unresolved. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

Distek - VIP 4400 Discontinuation Announcement, July 30, 2021

[E541] The July xx.xx 2021 notice ends new VIP xx.xx offerings effective December xx.xx 2021 or earlier inventory exhaustion. The model excludes that product from 2025 new-equipment supply and treats continuity as a constraint, without assuming category-wide zero activity. ([distekinc.com](https://www.distekinc.com/products/vip-xx.xx/))

Distek - Intrinsic Dissolution Apparatus

[E545] Distek explicitly offers an intrinsic-dissolution, paddle-over-stationary-disk package on a make-to-order basis. This qualifies the deliverable-offering gap without proving 2025 sales or the modeled global mix.

RT-J2000 | 株式会社 大日本精機

[E546] Advertises the RT-J2000 dissolution instrument and related automated configurations under the Japanese company identity 株式会社大日本精機.

[E547] The inspected RT-J2000 commercial page carries the Japanese supplier identity and the English footer DAINIPPON SEIKI CO., LTD., alongside its Japanese business locations. This improves the English-name binding without establishing ownership or dated model availability. ([dnseiki.co.jp](https://www.dnseiki.co.jp/products/xx.xx/))

21 CFR 211.22 - Responsibilities of quality control unit

[E548] Adequate quality-control facilities are a continuing obligation, not a prescribed equipment-acquisition event. ([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E549] The quality-control unit must have adequate laboratory facilities available for its responsibilities. ([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E550] The regulation assigns the quality-control unit authority over relevant procedures, specifications, and product decisions. ([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E551] The regulation assigns the quality-control unit authority over relevant specifications and product decisions, requires adequate laboratory facilities, and preserves responsibilities for products handled under contract. ([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E552] The regulation gives the quality-control unit authority over relevant procedures, specifications and product decisions, and requires adequate laboratory facilities. ([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E553] US finished-drug CGMP assigns laboratory and approval responsibilities to the regulated organization; it does not prescribe a particular supplier or automation package. ([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E554] Within US drug CGMP, the quality unit must have adequate laboratory facilities available and retains responsibility for approving or rejecting applicable procedures and specifications. Applying that responsibility to a

refurbished purchase is a bounded procurement inference.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E555] Within US finished-drug CGMP, the quality-control unit has authority over relevant procedures and specifications and must have adequate laboratory facilities available.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

[E556] Within US finished-drug CGMP, the quality-control unit has authority over relevant procedures and specifications and must have adequate laboratory facilities available. The provision does not identify a private buyer's spending approver.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-B/section-xx.xx))

21 CFR 211.160 - General requirements

[E557] Instrument-calibration obligations support the distinction between maintaining capability and purchasing another complete system; the purchasing implication is analytical.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E558] The binding requirement concerns maintaining acceptable laboratory instruments; it does not mandate a particular automation category.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E559] The continuing instrument obligation supports distinguishing acceptable laboratory capability from a new acquisition commitment.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E560] The regulation requires an established instrument-calibration program and prohibits use of instruments outside established specifications.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E561] US drug CGMP requires an established instrument-calibration program and prohibits use of instruments that do not meet established specifications.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E562] US drug-CGMP rules require an established instrument-calibration program and prohibit use of instruments outside established specifications. Distinguishing this continuing obligation from an automatic replacement order is a procurement inference.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E563] US drug-CGMP rules require an established instrument-calibration program and prohibit using instruments outside established specifications; they do not prescribe automated replacement.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

[E564] Written calibration requirements support continued equipment usability, without specifying automated replacement.
([ecfr.gov](https://www.ecfr.gov/current/title-xx.xx/chapter-I/subchapter-C/part-xx.xx/subpart-I/section-xx.xx))

Benefits of the Post-Marketing Surveillance Scheme for the Testing of Mutual Recognition/Decentralised Procedure Products

[E565] EDQM describes a voluntary EU/EEA surveillance scheme using work-sharing and shared results to avoid duplicate testing. Acquisition implications are conditional analysis.
([edqm.eu](https://www.edqm.eu/documents/xx.xx/xx.xx/History%2C%2Bresults%2C%2Band%2Bbenefits%2Bof%2Btesting%2BMRP_DCP%2Bproducts.pdf/f66f55d1-xx.xx-b8ac-1938-d0bd591faf3c?t=xx.xx))

EDQM - Benefits of the post-marketing surveillance scheme for MRP/DCP products, revised September 2023

[E566] The scheme reports approximately xx.xx-xx.xx participating laboratories annually. This independently supports the bounded work-sharing mechanism, not a count of equipment orders or a Europe-wide acquisition multiplier.

EDQM - European Network of Official Medicines Control Laboratories Fact Sheet, May 2022

[E567] The May 2022 fact sheet describes around xx.xx laboratories pooling resources. This is a dated regional scale check, not a 2025 global dissolution-owning laboratory census or sales allocation.
([edqm.eu](https://www.edqm.eu/documents/xx.xx/xx.xx/Fact%20sheet%xx.xx-%20European%20Network%20of%20Official%20Medicines%20Control%20Laboratories%xx.xx%28OMCL%xx.xx.pdf/fbdaa185-b038-23d6-a0c6-af0f50299486?download=true&t=xx.xx&version=xx.xx))

EDQM - 30th Anniversary of the OMCL Network and 29th GEON Meeting, June 4, 2024

[E568] The 2024 meeting represented xx.xx official medicines-control laboratories from xx.xx countries, constraining the public-laboratory footprint without establishing global ownership or acquisition incidence.

EFPIA - The Pharmaceutical Industry in Figures 2026, pharmaceutical employment table

[E569] Country pharmaceutical-employment table supplies the common European demand-proxy inputs; periods and estimation status vary.

[E570] Employment proxy: xx.xx.

[E571] Employment proxy: xx.xx.

[E572] Employment proxy: xx.xx.

[E573] Employment proxy: xx.xx.

[E574] Employment proxy: xx.xx.

[E575] Employment proxy: xx.xx.

[E576] Employment proxy: xx.xx.

[E577] Employment proxy: xx.xx.

[E578] Employment proxy: xx.xx.

[E579] Older xx.xx employment input provides a Middle Eastern country-scale cross-check.

Types of Dissolution Testers: Electrolab

[E580] Electrolab India Pvt. Ltd. markets ERD-series reciprocating dissolution testers and a dissolution autosampler offering.

[E581] The official product-category page identifies the company's Mumbai and Navi Mumbai business locations.

Reciprocating Dissolution Tester (ERD-37) | Electrolab

[E582] Electrolab's official catalog advertises the ERD-xx.xx as a reciprocating dissolution tester. An advertised listing does not independently establish the currently deliverable configuration.

Services | Electrolab

[E583] Electrolab advertises annual maintenance plans, breakdown calls, and preventive maintenance requests and identifies its Mumbai and Navi Mumbai business locations. The offering does not specify universal destination coverage.

ERD-37 Reciprocating Dissolution Tester Brochure - June 2019

[E584] Electrolab's ERD-xx.xx brochure identifies reciprocating Apparatus xx.xx and xx.xx offerings and sampling options. ([electrolabgroup.com](https://www.electrolabgroup.com/wp-content/uploads/2022/xx.xx/ERD-xx.xx.pdf))

[E585] Electrolab's June 2019 ERD-xx.xx brochure identifies Apparatus xx.xx and xx.xx configurations, manual and automated sampling support, and an available autosampler. It identifies the Indian company and its Mumbai and Navi Mumbai locations.

Guidance on good manufacturing practice and good distribution practice: Questions and answers

[E586] EMA expects outsourcing companies to verify comparable data-governance controls at the contract acceptor. ([ema.europa.eu](https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers))

Dissolutori farmaceutici | Emme 3

[E587] Emme xx.xx markets ERWEKA dissolution apparatus and automated systems. ([emme3-srl.it](https://www.emme3-srl.it/categoria-prodotto/pharmaceutical/dissoluzione/))

Dissolutori farmaceutici USP da laboratorio - Emme 3

[E588] Identifies Emme xx.xx Srl and an Italian business address.

[E589] Markets ERWEKA dissolution instruments and automated systems.

About our company - ERWEKA

[E590] ERWEKA identifies a broader tablet-testing portfolio and Verder Scientific ownership from 2023, supporting exclusion of unrelated products and preventing use of wider group revenue as its numerator. ([erweka.com](https://www.erweka.com/company/))

ERWEKA - About our company

[E591] ERWEKA records becoming part of Verder Scientific in 2023. ([erweka.com](https://www.erweka.com/company/))

[E592] ERWEKA records that it became part of Verder Scientific in 2023. This establishes ownership context, not configuration-specific local service coverage.

[E594] ERWEKA's company history records that it became part of Verder Scientific in 2023. This establishes ownership context, not buyer acceptance or integrated fulfillment. ([erweka.com](https://www.erweka.com/company/))

About our company | Erweka

[E593] ERWEKA states that it became part of Verder Scientific in 2023.

[E595] The company describes supplying tablet-development and quality-control equipment to pharmaceutical and life-science companies, development and contract laboratories, and universities worldwide.

Technical Service | ERWEKA

[E596] ERWEKA advertises installation, training, repair, and qualification services. Its service-plan disclaimer states that plans are not available in all countries, requiring destination-specific confirmation.

[E597] ERWEKA explicitly states that its advertised service plans are not available in all countries, requiring destination-specific confirmation. ([erweka.com](https://www.erweka.com/contact-services/technical-service/))

Dissolution Testers - Analysis Equipment | Erweka

[E598] ERWEKA markets manual and automated dissolution testers, reciprocating instruments, flow-through systems, media-handling equipment, and dissolution software.

Dissolution Testers - Analysis Equipment | ERWEKA

[E599] ERWEKA's portfolio includes conventional, automated, reciprocating, flow-through, chewing, and media-preparation categories. ([erweka.com](https://www.erweka.com/products/dissolution-testers/))

ERWEKA - Chewing Gum Tester DRT

[E600] ERWEKA advertises DRT as dedicated chewing-gum release equipment and also identifies nonmedicinal applications. This supports the named offering while limiting attribution of its broader uses to this market. ([erweka.com](https://www.erweka.com/products/dissolution-testers/chewing-gum-testers/drt/))

[E601] ERWEKA advertises DRT equipment for release assessment involving chewing gums and other masticated dosage forms. Its additional confectionery and snuff examples are separate from the study's relevant dosage-form and supplement assignments.

[E602] ERWEKA advertises DRT for chewing gums and other masticated dosage forms, supporting an assignment-specific Mechanical Chewing Apparatus proposition. ([erweka.com](https://www.erweka.com/products/dissolution-testers/chewing-gum-testers/drt/))

[E603] ERWEKA advertises DRT for chewing-gum and other masticated-dosage-form assignments, establishing a specialty offering rather than conventional-bath equivalence. ([erweka.com](https://www.erweka.com/products/dissolution-testers/chewing-gum-testers/drt/))

[E604] The DRT is commercially advertised for chewing-related release equipment, and the manufacturer also identifies nonmedicinal applications. This supports a scope deduction, not the assumed xx.xx% in-boundary fraction.

[E605] The DRT portfolio establishes an offering-specific comparison for an accepted Mechanical Chewing Apparatus requirement. ([erweka.com](https://www.erweka.com/products/dissolution-testers/chewing-gum-testers/drt/))

ERWEKA Chewing Gum Tester DRT

[E606] The inspected commercial page offers dedicated mastication-based release-testing apparatus. It also identifies nonmedicinal applications, so the entire product's sales cannot be presumed attributable to this market. ([erweka.com](https://www.erweka.com/products/dissolution-testers/chewing-gum-testers/drt/))

Imprint | ERWEKA

[E607] ERWEKA's inspected legal imprint identifies ERWEKA GmbH in Langen, Germany, and supplies its Offenbach commercial-register number, HRB xx.xx. This supports the operating subsidiary's exact legal identity. ([erweka.com](https://www.erweka.com/siteservice/imprint/))

Tablet Dissolution Test Apparatus 912 - Esico International

[E608] Esico International advertises Tablet Dissolution Test Apparatus xx.xx through its own commercial catalog.

[E609] The page identifies the Indian business and displays a GST registration reference.

ERWEKA Algérie | EURL NTC, New Technology Control

[E610] EURL NTC advertises ERWEKA dissolution equipment in Algeria. ([eurlntc.com](https://www.eurlntc.com/en/erweka-algerie))

Erweka Algérie | Eurl Ntc, New Technology Control Algérie

[E611] EURL NTC's official product page offers ERWEKA dissolution testers to the Algerian market and provides an Algiers contact address.

PRESENTATION | Eurl Ntc, New Technology Control Algérie

[E612] It states an ERWEKA distribution relationship in Algeria.

[E613] The company identifies itself as EURL NTC, New Technology Control, an Algerian importer of quality-control equipment.

Compilation of FDA Guidance and Resources for in vitro Dissolution Testing of Immediate Release Solid Oral Dosage Forms

[E614] FDA distinguishes dissolution apparatus from the analytical finish, supporting separate apparatus and analytical-architecture questions rather than one combined technology axis. Its immediate-release oral scope does not establish exhaustive coverage of this market.
([fda.gov](https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage))

[E615] FDA identifies UV and HPLC as distinct examples of the analytical finish used to quantify dissolved drug. This supports an architecture distinction, not a finding that every laboratory instrument is sold within a dissolution system.
([fda.gov](https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage))

[E616] HPLC is expressly recognized as an analytical finish for dissolution samples, independently of the dissolution apparatus.
([fda.gov](https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage))

[E617] The FDA compilation identifies the basket as USP Apparatus xx.xx.
([fda.gov](https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage))

[E618] The FDA compilation identifies the paddle as USP Apparatus xx.xx.
([fda.gov](https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage))

[E619] UV analysis is expressly recognized as an analytical finish for dissolution samples.
([fda.gov](https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolution-testing-immediate-release-solid-oral-dosage))

FDA - Generic Drugs Program Activities Report, FY2025 Monthly Performance

[E620] FY2025 reports xx.xx ANDA approvals and xx.xx PAS approvals. These constrain the scale of program activity but are not dissolution-equipment orders; their purchasing conversion is assumed.
([fda.gov](https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2025-monthly-performance))

FDA - Dissolution Methods Database

[E621] FDA limits this database to products without a USP dissolution method. This restricts the representativeness of the historical activity proxy used in both allocation anchors; it does not measure global equipment purchases.

[E622] The database's non-USP-product scope prevents treating its apparatus frequencies as the complete global paddle equipment-sales mix.

FYs 2013-2017 Regulatory Science Report: Locally-Acting Orally Inhaled and Nasal Drug Products - FDA

[E623] FDA's fiscal 2013-2017 report discusses inhaled-product dissolution research; this historical record does not establish a buyer-accepted commercial equipment configuration.
([fda.gov](https://www.fda.gov/drugs/generic-drugs/fys-2013-2017-regulatory-science-report-locally-acting-orally-inhaled-and-nasal-drug-products))

FYs 2013-2017 Regulatory Science Report: Locally-Acting Orally Inhaled and Nasal Drug Products

[E624] The FDA report for fiscal years 2013-2017 identifies dissolution within regulatory-science work concerning inhaled medicinal products, supporting recognition of this dosage family beyond conventional oral medicines.
([fda.gov](https://www.fda.gov/drugs/generic-drugs/fys-2013-2017-regulatory-science-report-locally-acting-orally-inhaled-and-nasal-drug-products))

[E625] The report discusses dissolution in the performance assessment of inhaled drug products. It supports a distinct target family, not mandatory testing, current instrument commercialization, or attributable equipment sales. ([fda.gov](https://www.fda.gov/drugs/generic-drugs/fys-2013-2017-regulatory-science-report-locally-acting-orally-inhaled-and-nasal-drug-products))

FDA - Compliance Program 7321.008: Dietary Supplements, August 18, 2025, Background

[E626] The August xx.xx 2025 program background describes a global supplement supply chain exceeding xx.xx facilities; this broad reference requires in-house ownership and relevance deductions.

[E627] The publication issued August xx.xx 2025 describes a supplement supply chain exceeding xx.xx facilities. The model deducts nonmanufacturing and nonparticipating activity and applies an explicit global-coverage bridge rather than treating facilities as equipment sales.

Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry

[E628] FDA expects reliable, accurate data and emphasizes management responsibility for data-integrity risk. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E629] FDA's December 2018 data-integrity guidance emphasizes reliable and accurate records, risk-based controls, and management accountability. These qualify the automation business case without establishing a requirement to replace Manual equipment. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E630] FDA's December 2018 drug-CGMP data-integrity guidance emphasizes reliable records and executive-management involvement, qualifying any automation proposition that assumes organizational oversight disappears. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E631] FDA's data-integrity guidance emphasizes reliable records and management accountability within drug CGMP. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E632] FDA's organizational-accountability expectations qualify any proposed benefit from reducing routine operator attention. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E633] Management involvement remains essential to data-integrity governance; automation does not remove organizational accountability. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E634] Management responsibility remains relevant when evaluating an automation proposition; supplier functionality does not remove organizational accountability. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E635] The guidance addresses intended-use controls covering software, hardware, personnel, and documentation. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E636] The guidance supports retaining records and management responsibilities in an automation acquisition decision. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

M9 Biopharmaceutics Classification System-Based Biowaivers - Guidance for Industry

[E637] M9 gives comparative in vitro dissolution evidence a role in the eligible biowaiver framework; no operational conditions are reproduced. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA FY 2022 New Research Awards List

[E638] FDA's fiscal 2022 awards list identifies an evaluation contract for a specialized inhalation dissolution system. This independently supports a specialty-apparatus perimeter beyond conventional oral testing, but does not establish apparatus sales, regulatory endorsement, or a distinct technology partition. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA Form 483 - Ipca Laboratories Limited, inspection June 15-23, 2023

[E639] FDA's June xx.xx-xx.xx 2023 inspection record identifies the inspected establishment as a drug manufacturer and records dissolution equipment operated by that firm for tablet products. This independently establishes a manufacturer-operated laboratory setting rather than merely sponsor obligations or an equipment supplier's customer claim. It does not establish a 2025 purchase or current inventory. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E640] The record links an identified operating establishment to its dissolution equipment, supporting operator-based end-user attribution. Inspectional observations are not a completed equipment transaction, a market-share measure, or a final regulatory compliance determination. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

Application of Adaptive Perfusion as In Vitro Release Testing Method to Improve Understanding and Assessment of Complex Products

[E641] Bottle-shaking is identified separately from internally agitated numbered apparatus. Current dedicated new-equipment sales are not established. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E642] The September xx.xx 2024 FDA presentation separately illustrates established numbered apparatus and additional IVRT architectures. Its broader IVRT scope is not treated as automatic market inclusion. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E643] The classification slide identifies flow-through cell as USP Apparatus xx.xx. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E644] The classification slide identifies paddle over disk as USP Apparatus xx.xx. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E645] The classification slide identifies reciprocating cylinder as USP Apparatus xx.xx. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E646] The classification slide identifies reciprocating holder as USP Apparatus xx.xx. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E647] The classification slide identifies rotating cylinder as USP Apparatus xx.xx. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E648] Vertical diffusion cells and dialysis are separately identified IVRT architectures; this supports their technical distinction but not unrestricted dissolution-market inclusion. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA - Report on the State of Pharmaceutical Quality FY2025

[E649] The xx.xx manufacturing sites include xx.xx medical-gas sites; the resulting xx.xx non-gas sites constrain the inherited manufacturing pool rather than establish equipment ownership.

[E650] The FY2025 report identifies xx.xx manufacturing sites, including xx.xx medical-gas sites. Their difference supports the inherited xx.xx-site starting pool; it does not measure dissolution ownership or tested-product mix.

[E651] The manufacturing footprint supports the common pool underlying product/ingredient attribution; the ingredient allocation remains intensity-adjusted and modeled.

FDA - Report on the State of Pharmaceutical Quality FY2025

[E652] Canada's xx.xx sites less six medical-gas sites give a xx.xx-site customer-scale check.

[E653] Country manufacturing-site observations provide a separate scale check on European workforce-based exposure.

[E654] FY2025 contains xx.xx manufacturing sites, including xx.xx medical-gas sites; the derived xx.xx non-gas pool supports the inherited manufacturing-stock anchor, not observed R&D ownership or sales. ([fda.gov](https://www.fda.gov/media/xx.xx/download?attachment=))

[E655] Global non-gas site coverage constrains, but does not verify, the assumed Middle Eastern customer pool.

[E656] Global site coverage is a boundary check for the small modeled FDA-linked African pool.

[E657] India/China site observations and changes constrain regional customer-footprint assumptions; forecast purchases remain modeled.

[E658] Non-gas manufacturing-site counts constrain the regional customer-stock partition; they are not equipment installations.

[E659] The xx.xx-site non-gas population supplies a separate scale comparison for regulatory actions, without implying one acquisition per site or program. ([fda.gov](https://www.fda.gov/media/xx.xx/download?attachment=))

[E660] The FY2025 catalog contains xx.xx manufacturing sites, including xx.xx medical-gas sites. Subtracting medical-gas sites gives xx.xx sites for the model's initial pharmaceutical manufacturing pool; dissolution relevance and equipment ownership remain modeled adjustments. ([fda.gov](https://www.fda.gov/media/xx.xx/download?attachment=))

[E661] The manufacturing-site population constrains the scale of recurring conformity demand; dissolution relevance, equipment intensity and the QC-purpose fraction remain modeled. ([fda.gov](https://www.fda.gov/media/xx.xx/download?attachment=))

[E662] The worldwide site catalog constrains the modeled Latin American customer-pool allowance, not realized spending.

[E663] U.S. xx.xx sites less xx.xx medical-gas sites give a xx.xx-site scale check.

FDA - Report on the State of Pharmaceutical Quality FY2024

[E664] Figure xx.xx identifies xx.xx xx.xx and xx.xx sites in three exclusive-API supply categories, totaling xx.xx. This is a historical customer-pool primitive, not an observed equipment allocation.

[E665] India accounts for xx.xx sites in the FY2024 catalog. Comparison with India's much broader national manufacturing-facility count supports including non-U.S.-market facilities, subject to separate relevance and ownership assumptions. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E666] The exclusive-API site count constrains the drug-substance characterization proxy after explicit coverage, ownership and equipment-intensity assumptions.

[E667] The report identifies xx.xx sites in FY2024 and xx.xx% catalog growth over FY2020-FY2024. These are manufacturing-site observations, not dissolution-equipment installations, and provide a scale and growth constraint for the historical stock model. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA - Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August 1997

[E668] FDA's August 1997 immediate-release oral guidance distinguishes development, lot-to-lot quality assessment, and continuing performance after specified changes. Its stated scope supports differentiated purchasing purposes, not universal application requirements. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E669] Lot-to-lot assessment and continuing product quality support a recurring conformity-purchasing context; the share of equipment spending remains modeled. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E671] The guidance distinguishes development as a purpose, supporting its separate commercial attribution rather than an assumed equipment-sales weight. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E673] The guidance identifies certain equivalence-waiver and postapproval-change contexts, supporting a program-specific category without proving incremental acquisitions. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA - Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August 1997

[E670] The background identifies guidance of new-formulation development as a purpose of dissolution testing. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E672] The guidance distinguishes formulation development, lot-to-lot quality assessment, and continuing product performance after specified changes, supporting separate decision-based purposes rather than one undifferentiated application. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E674] The guidance identifies routine quality control and lot-to-lot assurance and discusses compliance with dissolution specifications throughout product shelf life. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E675] The guidance places dissolution data in new and generic drug-product application settings. This establishes sponsor demand, not whether sponsors or outsourced laboratories operate the equipment. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E676] The introduction identifies comparative dissolution evidence supporting certain bioequivalence waivers and postapproval-change assessments. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA - Immediate Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes, November 1995

[E677] The guidance's purpose section addresses evidence supporting specified postapproval changes and expressly includes dissolution and bioequivalence documentation. This supports a change-assessment objective distinct from ordinary batch conformity; it does not establish equipment adoption or sales. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

Contract Manufacturing Arrangements for Drugs: Quality Agreements - Guidance for Industry

[E678] Contracting laboratory activities does not remove the product owner's applicable CGMP responsibilities. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E679] FDA guidance states that an owner's quality unit retains responsibility for approving or rejecting products made by a contract facility and recommends agreements defining services and communication responsibilities. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E680] FDA guidance states that quality agreements cannot delegate applicable CGMP responsibilities and distinguishes owner and contract-facility roles. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E681] FDA's November 2016 quality-agreement guidance states that agreements cannot delegate statutory or regulatory CGMP responsibilities and distinguishes owner and contract-facility roles, including laboratories. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E682] FDA's guidance states that quality agreements cannot delegate statutory or regulatory CGMP responsibilities, qualifying outsourcing as an ownership alternative rather than a transfer of all accountability. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E684] Quality agreements cannot delegate statutory CGMP responsibilities; owners retain quality-unit responsibilities when contracting testing. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E685] Retained owner responsibilities qualify outsourced testing as a substitute for ownership, not for accountability. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E686] The guidance distinguishes owner and contract-facility responsibilities and includes laboratories, supporting separate equipment-operator and client-acceptance roles. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

[E687] The guidance recommends defined laboratory responsibilities and preserves each party's applicable accountability, qualifying outsourcing as an ownership alternative. ([fda.gov](https://www.fda.gov/media/xx.xx/download))

FDA - Contract Manufacturing Arrangements for Drugs: Quality Agreements, November 2016

[E683] Owner quality-unit responsibilities can persist under contracted arrangements, supporting separation of sponsor responsibility from equipment-operator attribution.

[E688] The owner/contract-facility distinction supports assigning laboratory equipment to the operating contract organization rather than automatically to its clients.

Part 11, Electronic Records; Electronic Signatures - Scope and Application

[E689] FDA's Part xx.xx guidance distinguishes records relied upon electronically from qualifying paper-record arrangements and maintains applicable predicate-rule obligations. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-xx.xx-electronic-records-electronic-signatures-scope-and-application))

FDA - Small Entity Compliance Guide: Current Good Manufacturing Practice for Dietary Supplements

[E690] Dissolution specifications are not universally required under supplement CGMP, supporting a selective eligibility assumption rather than automatic equipment purchasing.

Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements

[E691] FDA states that the dietary-supplement CGMP rule does not universally require dissolution specifications; where such specifications are established, supporting conformity data should be available. This supports a specification-led purchasing proposition, not a blanket acquisition mandate. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling))

[E692] FDA's dietary-supplement compliance guide identifies xx.xx CFR Part xx.xx as a separate CGMP framework, supporting activity-specific rather than universal finished-drug compliance assumptions. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling))

[E694] The dietary-supplement CGMP framework centers on established specifications, appropriate verification, and quality-control review. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling))

FDA - Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements

[E693] FDA's supplement guidance addresses manufacturers' quality responsibilities but states that dissolution specifications are not universally required under the dietary-supplement CGMP rule. Where such specifications are established, supporting data should demonstrate conformity. This does not establish in-house equipment ownership. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling))

[E695] The guidance recognizes dissolution as a possible specification supported by conformity data, providing a qualified regulatory basis for supplement quality-control demand rather than a blanket mandate. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling))

The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 - Current Good Manufacturing Practice (CGMP)

[E696] FDA guidance treats apparatus calibration as an ongoing pharmaceutical laboratory concern. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-xx.xx-and-xx.xx-current-good-manufacturing-practice-cgmp))

[E697] FDA's January 2010 final guidance recognizes an alternative mechanical-calibration approach for Basket Apparatus and Paddle Apparatus. Its scope does not establish identical requirements for every included platform. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-xx.xx-and-xx.xx-current-good-manufacturing-practice-cgmp))

[E698] FDA's final guidance addresses USP Apparatus xx.xx and xx.xx in drug manufacturing and ancillary testing laboratories; its apparatus-specific scope is retained. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-xx.xx-and-xx.xx-current-good-manufacturing-practice-cgmp))

[E699] The January 2010 guidance recognizes enhanced mechanical calibration as an alternative approach for Basket Apparatus and Paddle Apparatus. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-xx.xx-and-xx.xx-current-good-manufacturing-practice-cgmp))

[E700] The guidance addresses drug manufacturers and ancillary testing laboratories using the specified dissolution apparatus. ([fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-xx.xx-and-xx.xx-current-good-manufacturing-practice-cgmp))

Supply, Delivery and Installation of Automated Dissolution System for CMAC - Contract Award Notice 2023/S 000-037800

[E701] The December xx.xx 2023 award notice records a contract for the supply, delivery, and installation of a fully automated dissolution system. Its bundled contract value is not a hardware-only price benchmark. ([find-tender.service.gov.uk](https://www.find-tender.service.gov.uk/Notice/xx.xx-2023/PDF))

[E702] The notice reports that the University of Strathclyde concluded a contract on December xx.xx 2023 for a fully automated dissolution system, establishing an actual transaction in this equipment class without establishing its worldwide share. ([find-tender.service.gov.uk](https://www.find-tender.service.gov.uk/Notice/xx.xx-2023/PDF))

International Pharmaceutical Federation - FIP World List of Pharmacy Schools

[E703] The institutional pool is divided between primary teaching and academic research in the model, preventing all university equipment from being assigned to instruction. That division is assumed, not reported by the directory. ([fip.org](https://www.fip.org/world-list-of-pharmacy-schools))

[E704] The retrieved voluntary directory contains xx.xx entries with mixed update dates. It is a current institutional-population proxy, not a complete 2025 census or equipment-sales mix; ownership, intensity and teaching attribution are explicit assumptions. ([fip.org](https://www.fip.org/world-list-of-pharmacy-schools))

[E705] The voluntary directory displays xx.xx school entries and disclaims completeness and verification; it constrains academic eligibility, not installed equipment or sales.

Dissolution Systems and Accessories | Fisher Scientific

[E706] Fisher Scientific's U.S. dissolution category lists named Distek and Hanson equipment, including a Distek filter-changer option and Hanson AutoPlus equipment.

[E707] Fisher lists named dissolution equipment and accessories with customer-accommodation qualifications on relevant listings. ([fishersci.com](https://www.fishersci.com/us/en/browse/xx.xx/dissolution-systems-and-accessories))

[E708] Relevant listings carry Encompass procurement qualifications, including non-distribution customer-accommodation language; they do not establish Fisher as the OEM.

Procedures and Steps for Implementing the GCC Customs Union | GCC Secretariat

[E709] The GCC's published customs-union framework describes common external customs arrangements and a first entry point while retaining prohibited- and restricted-goods provisions. It does not establish shipment-specific treatment or equipment-support rights. ([gcc-sg.org](https://www.gcc-sg.org/ar/JointGulf/Cooperation/GCCCustomsUnion/Pages/default.aspx))

Farmacopeia Brasileira - ANVISA

[E710] ANVISA identifies approval of the eighth edition through Resolution xx.xx of May xx.xx 2026; this does not establish a particular equipment-replacement requirement. ([gov.br](https://www.gov.br/anvisa/pt-br/assuntos/farmacopeia/farmacopeia-brasileira))

[E711] ANVISA identifies the Brazilian Pharmacopoeia as the country's official pharmaceutical code, supporting a national rather than region-wide requirements boundary. ([gov.br](https://www.gov.br/anvisa/pt-br/assuntos/farmacopeia/farmacopeia-brasileira))

FDA - Generic Drug User Fee Rates for Fiscal Year 2025, Federal Register, July 31, 2024

[E712] FY2025 fee-setting denominators identify xx.xx FDF facilities plus xx.xx FDF contract-manufacturing facilities, providing the xx.xx-site product-manufacturing proxy, not an equipment sales share.

[E713] The xx.xx API-facility denominator supplies the ingredient manufacturing population proxy; ownership and relative equipment intensity require explicit model adjustments.

Dissolution Apparatus - NanoDis System | Gulf Bio Analytical

[E714] Gulf Bio Analytical advertises Agilent NanoDis through a product-specific inquiry page. ([gulfbioanalytical.com](https://www.gulfbioanalytical.com/detail/dissolution-apparatus-nanodis-system.aspx))

Gulf Bio Analytical - Dissolution Apparatus - NanoDis System

[E715] Gulf Bio Analytical advertises the Agilent NanoDis dissolution system through a product page with a quotation inquiry option.

Gulf Bio Analytical - The Company

[E716] The company page identifies Gulf Bio Analytical LLC and describes its Dubai headquarters and regional laboratory-equipment distribution business.

Pharmaceutical Testing | Gulf Circle for Laboratory and Medical Supplies

[E717] Gulf Circle's pharmaceutical-testing catalog lists DIST-series dissolution testers. ([gulflabsupplies.com](https://www.gulflabsupplies.com/home/products/pharmaceutical-testing))

Pharmaceutical Testing - Lab Equipment Catalogue | Gulf Lab Supplies

[E718] The page identifies Gulf Circle for Laboratory and Medical Supplies and provides its Riyadh address.

[E719] The pharmaceutical-testing catalog lists named DIST-series dissolution testers.

University of Zurich - Betriebe A-Z 2025

[E720] The 2025 company-results table reports xx.xx employees for SOTAX AG in Aesch. This local, company-participation observation supports the Swiss cohort used in the model; it is not a consolidated global employment or sales census. ([health.uzh.ch](https://www.health.uzh.ch/dam/jcr%3A65fc5b78-ac6f-xx.xx-xx.xx-e6a584e65910/Alle%20Resultate_2025.pdf))

Busca Produtos | Hexis Científica

[E721] Hexis lists Agilent dissolution vessels, baskets, and other dedicated aftermarket products. ([hexis.com.br](https://www.hexis.com.br/produtos?cat=LACODS))

Busca Produtos - Hexis Científica

[E722] Lists Agilent dissolution vessels, baskets, and other dedicated aftermarket products.

Himachal Pharma Testing Lab Limited - Tender HPTLL_2025_17 to 31

[E723] A separate tender item is specifically designated for dissolution-media preparation and deaeration. It establishes an identified buyer requirement, not a completed sale or global segment size. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E731] The March xx.xx 2025 equipment tender distinguishes manual dissolution apparatus from dissolution apparatus with an autosampler. This is purchaser-side category evidence, not an award or global sales measurement. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E741] The buyer separately identifies manual dissolution apparatus and dissolution apparatus with an autosampler as equipment purchases. They remain one offering class here because automation is a different classification responsibility. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E742] The dissolution-equipment requirement expressly identifies an autosampler, supporting sample-handling equipment as a distinguishable hardware function rather than an analytical detector. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E744] The procurement document lists dissolution apparatus and a dedicated dissolution-media preparation/deaeration system as distinct goods. This provides buyer-side support for separating test systems from support equipment, without establishing a complete global offering partition. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E749] The tender contains a separately named purchasing line for manual dissolution apparatus. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E750] The tender separately identifies apparatus with an autosampler, supporting a purchased configuration with partial workflow automation. Mapping it to Semi-Automated uses the stated analytical classification rule. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

Himachal Pharma Testing Lab Limited - Equipment tender HPTLL_2025_17 to HPTLL_2025_31, March 31, 2025

[E724] Coexisting requested configurations qualify the regional automation/price-mix hypothesis; the document does not verify the forecast growth rate.

[E730] The 2025 solicitation lists two manual and two autosampler-equipped dissolution units. Requested quantities establish a specific mixed-configuration opportunity, not an award or regional purchasing rate.

Himachal Pharma Testing Lab Limited - Tender Notice HPTLL_2025_17 to HPTLL_2025_31, dated March 31, 2025

[E725] HPTLL's March xx.xx 2025 solicitation separately requested Manual dissolution apparatus and apparatus with an autosampler. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E726] HPTLL's March xx.xx 2025 solicitation separately requested Manual dissolution apparatus and apparatus with an autosampler. Classifying the latter as partial automation describes purchasing scope, not fully unattended operation or an award. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E727] Himachal Pharma Testing Lab Limited's March xx.xx 2025 solicitation included dissolution equipment and assessed manufacturer authorization, sales and service policies, and authorized service-center location. It is a purchasing-condition example, not evidence of an Electrolab award.

[E736] The March xx.xx 2025 solicitation separately identifies dissolution apparatus, apparatus with an autosampler, and dedicated dissolution-media equipment, supporting distinct purchasing packages rather than a completed award. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E737] The March xx.xx 2025 tender assesses manufacturer authorization and sales and service arrangements; it is not a supplier award. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E738] The March xx.xx 2025 tender includes Media-Handling Equipment for dissolution apparatus, requires manufacturer authorization for dealers, evaluates service arrangements, and requires manufacturer-backed warranty and agent responsibilities. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E739] The March xx.xx 2025 tender includes dissolution apparatus, evaluates dealer authorization and service arrangements, and requires manufacturer-backed obligations and continuity upon agent changes. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E743] The historical tender evaluated manufacturer authorization and service arrangements and retained manufacturer-backed obligations when agents changed. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E745] The purchaser separately requested Manual apparatus and apparatus with an autosampler. Treating the latter as partial automation is an analytical classification, not evidence of fully unattended operation. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E746] The purchaser's separate Manual and autosampler-equipped requests provide a counterexample to assuming that all equipment projects require broader automation. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

Himachal Pharma Testing Lab Limited - Tender HPTLL_2025_17 to 31, March 31, 2025

[E728] Nonmanufacturer offers require authorization, and manufacturer obligations continue when agents change. This supports an eligible intermediary route without establishing awards, realized sales fractions or superior service performance. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E729] One dedicated media unit is requested alongside four apparatus. This is a buyer-side sharing and separate-purchase anchor, not a global equipment-per-apparatus ratio. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E733] The March xx.xx 2025 solicitation requests two manual and two autosampler-equipped dissolution apparatus. This constrains configuration coexistence and package attribution, not global sales mix or completed revenue. Forecast use is a boundary premise only. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E734] The March xx.xx 2025 solicitation requests two manual apparatus, two autosampler-equipped apparatus and separate media equipment. These requested quantities support configuration coexistence, not completed sales or global weights.

[E735] The March xx.xx 2025 solicitation requests two manual dissolution apparatus. This supports continuing manual demand and challenges universal automation, but does not measure realized sales or worldwide share. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E740] The March xx.xx 2025 tender permits manufacturer participation and requires evidence of manufacturer status. Tender origination therefore does not automatically mean an indirect sale; continued eligibility is a forecast premise, not an observed future share. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E748] The same solicitation requests two apparatus with autosamplers, independently establishing planned partial-automation purchasing alongside manual equipment; it is not a completed-sales weight. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E751] Two requested apparatus include autosamplers, supporting the sample-handling function within a complete package and the need to exclude such bundled value from independent-module purchases. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

Himachal Pharma Testing Lab Limited - Equipment Tender HPTLL_2025_17 to 31

[E732] The March xx.xx 2025 procurement distinguishes manual dissolution apparatus, apparatus with an autosampler, and dedicated media-handling equipment. This supports configuration coexistence and modular purchasing, not completed sales or global configuration shares. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

[E747] The purchasing categories provide counterevidence to assuming universal migration to fully automated systems; forecast automation-related price mix remains conditional. ([hptll.in](https://www.hptll.in/pdf/hptll202517-to-xx.xx.pdf))

Pharma : new dissolution unit for GSK Kenya - HTDS

[E752] On October xx.xx 2019, HTDS reported installing a complete dissolution system for GSK Kenya's Nairobi quality-control laboratory.

[E753] The announcement identifies a commercial system incorporating SOTAX equipment and a METTLER TOLEDO UV7 spectrometer.

DissolvIt - Inhalation Sciences

[E754] Advertises DissolvIt as a specialized dissolution instrument module.

DissolvIt | Inhalation Sciences

[E755] Inhalation Sciences identifies DissolvIt as a specialist dissolution instrument module. ([inhalation.se](https://www.inhalation.se/instruments/dissolvit-in-vitro/))

Inhalation Sciences - DissolvIt®

[E756] The manufacturer advertises a dissolution instrument for inhaled-product applications. The current listing establishes commercial category availability, not historical revenue, mandatory adoption or market size.

Inhalation Sciences to present the compelling results from the FDA-funded evaluation study of DissolvIt at leading respiratory and inhalation drug development conferences

[E757] The August xx.xx 2026 announcement identifies Inhalation Sciences Sweden AB (publ) and continuing commercial activity around DissolvIt.

[E758] The announcement describes the company as a CRO; it does not establish current standalone instrument sales.

dissoWASH&DOSE | Merel Instruments

[E759] Merel Instruments markets dissoWASH&DOSE as dedicated washing and media-handling equipment for dissolution testers.

[E760] The advertised role is dissolution-specific support equipment rather than a complete dissolution tester.

dissoWASH&DOSE - Semi-Automated Washing and Media Handling System | Merel Instruments

[E761] Merel advertises dissoWASH&DOSE as semi-automated vessel-cleaning and media-handling equipment, distinct from a complete dissolution tester. ([instruments.merel.si](https://www.instruments.merel.si/wp-content/uploads/2025/xx.xx/dissoWASHDOSE.pdf))

[E762] Merel advertises dissoWASH&DOSE as semi-automated vessel-washing and media-handling equipment, establishing a supporting-equipment proposition rather than a complete dissolution apparatus. ([instruments.merel.si](https://www.instruments.merel.si/wp-content/uploads/2025/xx.xx/dissoWASHDOSE.pdf))

[E763] Merel's dissoWASH&DOSE brochure advertises mobile, semi-automated vessel-washing and media-handling equipment. It establishes a supporting-equipment role, not a complete dissolution apparatus or independently verified buyer savings.

[E764] Merel's supporting-equipment offering provides a narrower acquisition alternative to complete apparatus replacement.
([instruments.merel.si](https://www.instruments.merel.si/wp-content/uploads/2025/xx.xx/dissoWASHDOSE.pdf))

[E765] The brochure establishes a separately supplied supporting-equipment proposition; advertised resource benefits do not establish buyer-specific savings.
([instruments.merel.si](https://www.instruments.merel.si/wp-content/uploads/2025/xx.xx/dissoWASHDOSE.pdf))

Intertek Pharmaceutical Services

[E766] Intertek lists pharmaceutical dissolution testing among its services, establishing advertised external access rather than an equipment transaction. ([intertek.com](https://www.intertek.com/pharmaceutical/))

[E767] Intertek lists pharmaceutical dissolution testing among its services. The offering establishes a service-access route, not a client or provider equipment order. ([intertek.com](https://www.intertek.com/pharmaceutical/))

[E768] Intertek's advertised dissolution service supports comparing an acceptable external laboratory agreement with direct equipment ownership; customer-specific scheduling and continuity require agreement.
([intertek.com](https://www.intertek.com/pharmaceutical/))

[E769] Intertek's contract-laboratory portfolio lists pharmaceutical dissolution testing, supporting external access as an ownership alternative. ([intertek.com](https://www.intertek.com/pharmaceutical/))

[E770] The official offering establishes an advertised outsourced service; provider acceptance and contractual availability remain buyer-specific. ([intertek.com](https://www.intertek.com/pharmaceutical/))

[E771] The service offering supports comparing accepted external laboratory access with direct equipment ownership. ([intertek.com](https://www.intertek.com/pharmaceutical/))

[E772] The service portfolio supports outsourcing as a commercial substitute for direct ownership, not as a substitute for regulatory accountability. ([intertek.com](https://www.intertek.com/pharmaceutical/))

G.A. Krestov Institute of Solution Chemistry - Dissolution Apparatus EDT-08LX

[E773] The institutional equipment inventory identifies ELECTROLAB as the Indian manufacturer of a dissolution apparatus, supporting the manufacturer-role bridge used with the public purchase record; it does not measure channel revenue. ([isc-ras.ru](https://www.isc-ras.ru/en/structure/device/dissolution-apparatus-edt-08lx))

Small Volume | ISIL

[E774] ISI advertises Distek's Small Volume Conversion Kit within its dissolution portfolio.

[E775] The page identifies the ISI business and provides a Petach Tikva, Israel address.

Jamia Hamdard - NIT for Double Beam UV-Vis Spectrophotometer, Dissolution Apparatus and Analytical Balance, JH/PS/Tender-37/Oct-2024

[E776] Authorized distributors are separately eligible sellers for the same dissolution-apparatus procurement. This invitation does not establish resulting sales or global channel shares.
([jamiahamdard.ac.in](https://www.jamiahamdard.ac.in/description/xx.xx/tender))

[E777] Manufacturers are eligible to quote directly for dissolution apparatus in this procurement, supporting direct supply as a channel class. ([jamiahamdard.ac.in](https://www.jamiahamdard.ac.in/description/xx.xx/tender))

[E778] The 2024 university procurement for dissolution apparatus invites manufacturers and authorized distributors and permits Indian agents acting for foreign principals. It independently establishes distinct seller roles, rather than separate tender and online channels.
([jamiahamdard.ac.in](https://www.jamiahamdard.ac.in/description/xx.xx/tender))

[E779] The tender identifies the university department receiving the apparatus separately from eligible manufacturer, distributor, and agency seller roles. This supports distinguishing the operating buyer from the route to market. ([jamiahamdard.ac.in](https://www.jamiahamdard.ac.in/description/xx.xx/tender))

[E780] The university's October 2024 tender identifies dissolution apparatus intended for its Department of Pharmaceutics. This is direct purchaser-side evidence of an academic institutional demand setting rather than an equipment supplier's customer portfolio. It is an invitation, not a completed purchase or evidence of the equipment's primary instructional versus research purpose.
([jamiahamdard.ac.in](https://www.jamiahamdard.ac.in/description/xx.xx/tender))

Corporate Profile | JASCO Global

[E781] JASCO's official corporate profile identifies JASCO Corporation and its head office in Hachioji, Tokyo, Japan.

[E782] The corporate profile supports the English operating-company identity, but does not establish ownership of similarly branded foreign distributors.

Worldwide Locations | JASCO Global

[E783] JASCO publicly identifies the Polish ABL&E-JASCO business within its worldwide commercial network.

[E784] JASCO's official worldwide directory names ABL&E-JASCO Polska Sp. z o.o. in Kraków as its Polish contact.

[E785] The directory corroborates a commercial network relationship but does not state that the Polish business is owned by JASCO Corporation.

[E786] The listing is a relationship record, not a consolidated ownership statement.

Dissolution Tester | JASCO Global

[E787] JASCO advertises DT-xx.xx-based UV-Vis dissolution integration. ([jasco-global.com](https://www.jasco-global.com/product-spectroscopy/dissolution-tester/))

[E788] JASCO markets a DT-xx.xx-based tablet dissolution system.

[E789] JASCO's inspected official portfolio continues to advertise a dedicated dissolution-tester system.

[E790] The official portfolio includes integrated UV-Vis, fraction-collection, and automated-filtration configurations.

[E791] The product-specific portfolio supports dissolution participation rather than an inference from JASCO's general spectroscopy business.

Producenci | ABL&E-JASCO POLSKA

[E792] ABL&E-JASCO POLSKA lists Uniflex as a represented vessel-washer supplier, without establishing its precise legal or manufacturing identity. ([jasco.pl](https://www.jasco.pl/gyartok/))

Producenci - ABL&E-JASCO POLSKA

[E793] ABL&E-JASCO POLSKA's manufacturer portfolio lists Teledyne Hanson for dissolution and diffusion systems and Uniflex for dissolution-vessel washers.

[E794] The inspected supplier portfolio names Uniflex as a represented supplier of dissolution-vessel washers and links to the Japanese Uniflex domain.

[E795] The page identifies ABL&E-JASCO Polska Sp.z o.o. and its Kraków address, supporting an equipment and dedicated-peripheral channel role.

[E796] This establishes a specific supplier-brand and channel connection; it does not independently verify Uniflex's legal name, ownership, manufacturing role, or current standalone availability.

Hanson CD14 - ABL&E-JASCO POLSKA

[E797] Advertises the Hanson CD14 dissolution instrument under the ABL&E-JASCO POLSKA business identity.

QLA Amber Paddle-Slot Vessel Cover for Hanson SR8-Plus | John Morris Group Australia

[E798] John Morris Group's Australian catalog offers a QLA dissolution-vessel accessory for Hanson equipment, establishing an aftermarket channel offering.

Labor Estabille | JProlab

[E799] JProlab lists Labor Estabille equipment in its brand catalog. ([jprolab.com.br](https://www.jprolab.com.br/marca/labor-estabille.html))

LABOR STABILLE - JProlab

[E800] Lists Labor Estabille tablet dissolution instruments in its commercial brand catalog.

제약테스터기 제품 | 국제엔지니어링

[E801] The Korean catalog of 국제엔지니어링 advertises KJ-DT-xx.xx KJ-DT-xx.xx and KJ-DT-xx.xx dissolution testers.

[E802] The Korean company catalog advertises KJ-DT dissolution instruments under the Kukje Engineering business identity. ([kjlab.co.kr](https://www.kjlab.co.kr/products/category-d0))

[E803] The page identifies a Paju, South Korea business address and describes equipment fabrication and supply.

Körber certifies q-doc by SOTAX for test data integration into PAS-X MES

[E804] Körber announced on September xx.xx 2025 that q-doc had been certified under its Technology Partner Program for PAS-X MES integration; this is a vendor-program status, not regulatory approval of an installation. ([koerber.com](https://www.koerber.com/en/about-us/news-and-press/q-doc-by-sotax-certification))

Dissolution Tester LX200DLT | Labdex

[E805] Advertises Dissolution Tester LX200DLT and identifies Labdex Ltd. in its commercial website footer.

Dissolution Tester | Labdex

[E806] Labdex maintains a dissolution-tester commercial offering. ([labdex.com](https://www.labdex.com/dissolution-tester/lx200dlt))

Tablet Dissolution Tester DS 14000 with Peristaltic Pump | Lab Dynamics

[E807] Lab Dynamics advertises a Labindia DS xx.xx sampling configuration. ([labdynamics.co.za](https://www.labdynamics.co.za/products/dissolution-and-tablet-testing/labindia-dissolution-apparatus/tablet-dissolution-tester-ds-xx.xx-with-peristaltic-pump))

Lab Dynamics - Tablet Dissolution Tester DS 14000 with Peristaltic Pump

[E808] Lab Dynamics advertises the Labindia DS xx.xx dissolution tester with a peristaltic-pump configuration.

[E809] The company describes supplying laboratory equipment and support to South Africa and Southern Africa.

Drug Dissolution Tester LMDDT-A101 | Labmate

[E810] Labmate advertises the named LMDDT-A101 dissolution instrument. ([labmate.com](https://www.labmate.com/drug-dissolution-tester/lmddt-a101))

[E811] Markets Drug Dissolution Tester LMDDT-A101 and identifies Labmate Scientific LLC with a Chicago business address.

Dissolutor de Comprimidos | Labor Estabille

[E812] Advertises tablet dissolution equipment and identifies Labor Estabille's address in Cotia, São Paulo, Brazil.

[E813] Labor Estabille maintains a dedicated tablet-dissolution equipment offering. ([laborestabille.com.br](https://www.laborestabille.com.br/dissolutor-de-comprimidos))

Dissolution Tester | Tablet Dissolution Tester | Labotronics

[E814] Advertises LB-series dissolution testers and identifies the Labotronics Scientific business with a Wilmington, Delaware address.

Dissolution Tester | Labotronics

[E815] Labotronics advertises named LB-series dissolution instruments. ([labotronics.com](https://www.labotronics.com/dissolution-tester))

Consumibles para Disolución | Lab Solutions

[E816] Lab Solutions advertises multibrand dissolution consumables and accessories. ([labsolutions.com.ar](https://www.labsolutions.com.ar/product-page/accesorios-y-consumibles-para-disolucion))

CONSUMIBLES PARA DISOLUCIÓN ¡TODAS LAS MARCAS! | lab-solutions

[E817] Offers dissolution consumables and accessories covering multiple equipment brands.

Disolutores USP App1 y App2 | lab-solutions

[E818] Advertises Logan Instruments dissolution systems through the Argentine Lab Solutions business.

Lambda Scientific - High-quality scientific instrumentation

[E819] Explicitly advertises SOTAX dissolution testing systems available through Lambda Scientific.

Electrolab Group - Company-authored business profile

[E820] The company-authored profile places staffing in the xx.xx-xx.xx range and distinguishes dissolution offerings from other physical-testing instruments and pumps, supporting a workforce range and a necessary product-scope deduction. ([linkedin.com](https://www.linkedin.com/company/electrolab-group/?originalSubdomain=in))

ERWEKA GmbH - Company-authored business profile

[E821] ERWEKA's company-authored profile describes more than xx.xx employees worldwide. The model uses xx.xx as an undated rounded workforce proxy, not an exact observed 2025 legal-entity count. ([linkedin.com](https://www.linkedin.com/company/erweka-gmbh/))

Quality Lab Accessories | LinkedIn

[E822] The company-authored profile reports an xx.xx-xx.xx employee size band and identifies its Telford location. This is a current scale constraint, not an audited or dated 2025 headcount; the working model's xx.xx employees remain assumed. ([linkedin.com](https://www.linkedin.com/company/quality-lab-accessories))

□□□□□ □□□□ □□□ □□□□□ □□□ □□□□□□ tablet dissolution tester | Electro Farmed Co.

[E823] A company-branded historical post promotes a tablet dissolution tester; it does not establish a current model or independently verified manufacturing.

Dissolution - Logan Instruments Corp

[E824] Logan Instruments Corp. markets dissolution testers across multiple apparatus categories and automated dissolution online-analysis systems.

[E826] The portfolio also includes media delivery, vessel washing, and calibration tools, and identifies its New Jersey headquarters.

Dissolution - Logan Instruments Corp.

[E825] Logan lists conventional, reciprocating, flow-through, online-analysis, media-delivery, vessel-washing, and qualification-tool offerings. ([loganinstruments.com](https://www.loganinstruments.com/dissolution/))

Contact Us | LS Scientific

[E827] The official contact page identifies LS Scientific Limited, its English registration information, and business addresses in the United Kingdom and Lagos, Nigeria.

ERWEKA | lsscientific

[E828] Its commercial page presents manual and automated dissolution-equipment categories and specialized dissolution systems.

[E829] LS Scientific states an ERWEKA partnership serving customers in Nigeria and Ghana.

Dissolution Instrument Product Listing | Matoli

[E830] Matoli advertises a named tablet and capsule dissolution instrument in its Brazilian catalog. ([matoli.com.br](https://www.matoli.com.br/?cat=xx.xx&codigo=xx.xx&dep=xx.xx&pagina=detalhes&scat=xx.xx))

Matoli

[E831] Offers the 060M017 tablet and capsule dissolution instrument and provides a Brazilian business address.

About Meditop Co., Ltd.

[E832] Meditop Co., Ltd.'s company page includes dissolution testers in its scientific-instrument business portfolio.

Products | MSS-Modern Scientific Supplies | Jordan

[E833] Modern Scientific Supplies lists a dissolution tester within its pharmaceutical-testing instrument portfolio.

[E835] The catalog identifies Modern Scientific Supplies and provides an Amman, Jordan address.

Products | Modern Scientific Supplies

[E834] Modern Scientific Supplies lists dissolution equipment in its pharmaceutical portfolio. ([mss-jo.com](https://www.mss-jo.com/products))

MYMSA-Pharma Test - Testing Equip. For Pharma.

[E836] MYMSA advertises Pharma Test tablet dissolution instruments, automated dissolution systems, sampling equipment, and dedicated support equipment.

[E838] The page identifies an Egyptian business address and describes equipment supply and after-sales services.

Pharma Test - Testing Equipment for Pharma | MYMSA

[E837] MYMSA presents Pharma Test dissolution instruments, automation, and supporting equipment. ([mymsa-eg.com](https://www.mymsa-eg.com/product.php?n=Pharma-Test----pharma))

Bidding Document for Laboratory Equipment - Schedule of Requirements

[E839] A validation kit is explicitly identified with the dissolution-equipment requirement. This supports qualification-related physical goods, but the procurement does not independently establish their separate selling price. ([naca.gov.ng](https://www.naca.gov.ng/wp-content/uploads/2021/xx.xx/xx.xx.xx.xx-Bidding-Document-for-Laboratory-Equipments.pdf))

[E840] The schedule identifies a dissolution tester with a validation kit, while listing general HPLC and UV instruments separately. This supports the distinction between dissolution equipment and general laboratory analytical instruments. ([naca.gov.ng](https://www.naca.gov.ng/wp-content/uploads/2021/xx.xx/xx.xx.xx.xx-Bidding-Document-for-Laboratory-Equipments.pdf))

Dissolution testing instruments - Norlab

[E841] Advertises Distek dissolution instruments, monitoring equipment, accessories, and support.

Dissolution Testing Instruments | Norlab

[E842] Norlab advertises Distek dissolution instruments, monitoring, and accessories. ([norlab.com](https://www.norlab.com/infocenter/xx.xx))

Support - Norlab

[E843] Offers dissolution accessories and provides Finnish and Danish business contacts.

The EEA Agreement | Norway and the EU

[E844] Norway's official explanation includes Norway and Iceland in the EEA internal market and expressly excludes the customs union from the EEA Agreement. Shared internal-market rules therefore do not establish identical customs treatment. ([norway.no](https://www.norway.no/en/missions/eu/areas-of-cooperation/the-eea-agreement/))

NOW Foods - NOW's World Class Labs

[E845] NOW describes in-house quality testing of incoming materials, in-process materials, and finished goods, with dissolution among its physical-testing capabilities. This supports a conformity-testing use rather than a claim of universal supplement-testing obligations. ([nowfoods.com](https://www.nowfoods.com/quality-safety/nows-world-class-labs))

[E846] NOW identifies dissolution among its own physical-testing capabilities, establishing a supplement-business laboratory setting without establishing another buyer's specifications or acquisition plans. ([nowfoods.com](https://www.nowfoods.com/quality-safety/nows-world-class-labs))

[E847] NOW identifies in-house dissolution capability and more than xx.xx monthly analyses/tests across its laboratories; the aggregate is not a dissolution workload or sales weight.

[E848] NOW identifies its own in-house laboratories and expressly includes dissolution among physical-testing capabilities. This provides buyer-side evidence of a supplement-business operating setting, without establishing equipment expenditure or global prevalence. ([nowfoods.com](https://www.nowfoods.com/quality-safety/nows-world-class-labs))

About Omicron | Omicron Research Limited

[E849] Omicron describes its UK instrument-distribution and support business and states that ORLEOT Ltd purchased the majority shareholding from its founder in 2021 under an employee-ownership arrangement. This supports reporting Omicron separately from the equipment manufacturers it represents. ([omicron-uk.com](https://www.omicron-uk.com/copy-of-about-us))

Dissolution Testing | NEW! Distek OLERA Series | Omicron

[E850] Identifies Omicron Research Limited and its Hungerford, UK address.

[E851] Markets the Distek OLERA dissolution series.

[E852] Omicron advertises the OLERA family through its own inquiry page, corroborating a UK commercial approach rather than completed delivery. ([omicron-uk.com](https://www.omicron-uk.com/distekolera))

[E853] Omicron markets OLERA, OLERA PLUS, and OLERA SELECT through its own customer-inquiry page, corroborating its advertised equipment-distribution role. ([omicron-uk.com](https://www.omicron-uk.com/distekolera))

[E854] Omicron's inspected commercial page offers all three Distek OLERA variants with a customer-inquiry facility and lists associated October and November 2026 promotional events. This corroborates current dissolution-equipment distribution rather than manufacturing. ([omicron-uk.com](https://www.omicron-uk.com/distekolera))

Support | omicron-research-ltd

[E855] Omicron advertises maintenance, repair, qualification, and support beyond its represented product lines. ([omicron-uk.com](https://www.omicron-uk.com/support))

[E856] Omicron advertises maintenance, repair, qualification, remote assistance, and customer-site training. ([omicron-uk.com](https://www.omicron-uk.com/support))

[E857] Omicron advertises preventive maintenance, repair, instrument qualification, remote assistance, and customer-site training, including service beyond its represented product lines. The page does not establish an enforceable response commitment for a particular customer. ([omicron-uk.com](https://www.omicron-uk.com/support))

[E858] Omicron advertises preventive maintenance, repair, qualification support, and customer-site training. These establish a potential partner contribution rather than an enforceable customer-specific response commitment. ([omicron-uk.com](https://www.omicron-uk.com/support))

[E859] The service portfolio supplies an evidenced potential partner contribution beyond a sales contact; enforceable site coverage remains contract-specific. ([omicron-uk.com](https://www.omicron-uk.com/support))

Pfizer - Scientist- Analytical Research and Development, job 4964243

[E860] Pfizer's own Groton analytical-research job posting identifies a laboratory-based drug-development role and lists dissolution among relevant analytical capabilities. It corroborates a pharmaceutical company's internal analytical demand setting, but recruitment requirements alone do not confirm owned equipment, a completed purchase, or 2025 expenditure. ([pfizer.com](https://www.pfizer.com/about/careers/job/xx.xx?langcode=en))

[E861] The role places analytical work and dissolution expertise within drug-product development, corroborating a development-oriented demand setting without establishing the primary purpose of any particular equipment purchase. ([pfizer.com](https://www.pfizer.com/about/careers/job/xx.xx?langcode=en))

Dissolution Testers | Pharma Alliance Group

[E862] Pharma Alliance Group lists AquaClear SF under dissolution testers; the listing does not establish equipment-origin arrangements.
([pharma-alliance-group.net](https://www.pharma-alliance-group.net/dissolution-testers-xx.xx))

Pharma Alliance Group. Dissolution Testers

[E863] Pharma Alliance Group's commercial catalog lists AquaClear SF under dissolution testers.

[E864] The catalog also lists automated sampling systems, media and degassing equipment, and flow-through apparatus.

Indonesia - Pharma Test

[E865] Pharma Test's own Indonesian partner page expressly describes PT. Pharma Test Indonesia as a subsidiary of Pharma Test Apparatebau AG.

[E866] The page describes its Indonesian pharmaceutical-equipment distribution and after-sales role and gives a Tangerang business address.

[E867] The undated relationship statement does not independently establish current shareholding percentages or current governance.

Dissolution Tester Archive - Pharma Test

[E868] Pharma Test maintains a dedicated dissolution-tester portfolio.
([pharma-test.de](https://www.pharma-test.de/en/products/dissolution-tester/))

PTWS 1220 - Pharma Test

[E869] Pharma Test markets the PTWS xx.xx tablet dissolution testing instrument for solid dosage forms.

[E870] The official page identifies the supplier as Pharma Test Apparatebau AG in Hainburg, Germany.

Imprint - Pharma Test

[E871] The inspected Pharma Test imprint identifies Pharma Test Apparatebau AG in Hainburg and supplies commercial-register number HRB xx.xx. The imprint does not establish the ownership relationship with PT. Pharma Test Indonesia or independently resolve the currency of all governance details.
([pharma-test.de](https://www.pharma-test.de/en/thepharmatestgroup/imprint/))

Locate a Distributor - Pion

[E872] Lists Biopharma Technologies France as its French distributor.

[E873] Lists LKB as a distributor for Serbia and Slovenia, without an inspectable product-specific allocation.

[E874] Pion's directory identifies Terralab as its distributor in Turkey.

[E875] Pion's directory lists Dubai-based Gulf Scientific Corporation for Bahrain, Kuwait, Oman, Qatar, and Saudi Arabia.

Locate a Distributor | Pion

[E876] Pion's directory lists Gulf Scientific Corporation for several Gulf destinations and corroborates its French distribution route. ([pion-inc.com](https://www.pion-inc.com/locate-a-distributor))

[E877] Pion's distributor directory names LKB Vertriebs Ges.m.b.H. for several destinations. The listing supports a manufacturer-named inquiry route, not a customer-specific product allocation or fulfillment agreement.

Pion Inc. Announces DissoSpec Fully Integrated Dissolution System - Pion

[E878] Pion Inc. announced the launch of DissoSpec on May xx.xx 2025.

[E886] The announced commercial system integrates dissolution equipment, Rainbow R6 optical monitoring, and DissoPRO software for pharmaceutical dissolution analysis.

Pion Inc. Announces DissoSpec Fully Integrated Dissolution System

[E879] Pion announced DissoSpec on May xx.xx 2025, combining a dissolution bath, Rainbow R6 in situ optical monitoring, and DissoPRO software. The announcement describes semi-automated operation; integrated packaging does not itself establish full automation.

[E880] Pion announced DissoSpec on May xx.xx 2025, combining a dissolution bath, Rainbow R6 optical monitoring, and DissoPRO software. Its announcement describes Semi-Automated operation, distinguishing integrated packaging from full automation. ([pion-inc.com](https://www.pion-inc.com/news/pion-inc-announces-dissospec-fully-integrated-dissolution-system))

[E881] Pion announced DissoSpec on May xx.xx 2025, combining apparatus, optical monitoring, and software, and described the offering as semi-automated. ([pion-inc.com](https://www.pion-inc.com/news/pion-inc-announces-dissospec-fully-integrated-dissolution-system))

[E882] Pion's May xx.xx 2025 announcement combines a dissolution bath, Rainbow R6 optical monitoring, and DissoPRO software, and explicitly describes DissoSpec as semi-automated. Integrated packaging does not establish full automation.

[E883] Pion's May xx.xx 2025 launch combines a dissolution bath, Rainbow R6 monitoring, and DissoPRO software, describing semi-automated operation. ([pion-inc.com](https://www.pion-inc.com/news/pion-inc-announces-dissospec-fully-integrated-dissolution-system))

[E884] The May xx.xx 2025 DissoSpec announcement establishes availability of an integrated dissolution-monitoring package. A product launch does not establish orders, realized labor savings, or market-wide adoption. ([pion-inc.com](https://www.pion-inc.com/news/pion-inc-announces-dissospec-fully-integrated-dissolution-system))

[E885] The May xx.xx 2025 announcement establishes an offered integrated fiber-optic dissolution package by the base year. It supports availability and a conditional adoption premise, not observed orders or the forecast conversion rate.

[E887] The integrated offering supports the commercial possibility of richer equipment packages, while the forecast's conversion rate and price-mix contribution remain assumptions rather than independently verified outcomes. ([pion-inc.com](https://www.pion-inc.com/news/pion-inc-announces-dissospec-fully-integrated-dissolution-system))

Pion - MicroDISS

[E888] MicroDISS is commercially presented with in situ fiber-optic UV monitoring, supporting category mapping rather than a measured shipment share.

[E889] MicroDISS is explicitly advertised with in situ fiber-optic UV monitoring, establishing a named commercial detection architecture. ([pion-inc.com](https://www.pion-inc.com/solutions/products/microdiss))

[E890] Pion advertises MicroDISS as a dedicated dissolution-monitoring instrument, supporting a commercial example for the accepted Stirred-Vial Apparatus category without establishing universal quality-control substitution. ([pion-inc.com](https://www.pion-inc.com/solutions/products/microdiss))

MicroDISS - Small-Volume Biorelevant Dissolution Testing Instrument

[E891] The inspected commercial page offers a dedicated small-volume, stirred dissolution instrument rather than only a general stirrer or solubility service. It supports the identified specialty family but not a universal cross-supplier definition of stirred-vial platforms. ([pion-inc.com](https://www.pion-inc.com/solutions/products/microdiss))

[E892] The instrument is explicitly marketed with in situ fiber-optic UV monitoring, establishing a commercial analytical architecture rather than an inference from generic spectroscopy capability. ([pion-inc.com](https://www.pion-inc.com/solutions/products/microdiss))

Pion - MicroFLUX

[E893] Pion advertises MicroFLUX as a combined dissolution-absorption assessment offering. This establishes a specialist portfolio role, not universal equivalence to conventional quality-control apparatus.

[E894] Pion advertises MicroFLUX as a combined dissolution-absorption offering, supporting a distinct commercial example within Membrane-Separated Cell Apparatus. No operational details or performance predictions are adopted. ([pion-inc.com](https://www.pion-inc.com/solutions/products/microflux))

[E895] Pion advertises MicroFLUX for combined dissolution and absorption assessment. ([pion-inc.com](https://www.pion-inc.com/solutions/products/microflux))

Pion - SDi2

[E896] Pion advertises SDi2 as a flow-through dissolution system combining UV and visible imaging with drug-release information, supporting its classification as a specialist analytical offering rather than recording-only surveillance.

[E897] Pion advertises SDi2 as a flow-through dissolution system with UV and visible imaging, supplying a distinct analytical-information proposition. ([pion-inc.com](https://www.pion-inc.com/solutions/products/sdi2))

[E898] Pion advertises SDi2 dissolution imaging as a specialist analytical platform. ([pion-inc.com](https://www.pion-inc.com/solutions/products/sdi2))

[E899] Pion advertises SDi2 with UV and visible imaging alongside drug-release and concentration information, supporting an analytical-imaging proposition distinct from recording-only observation. ([pion-inc.com](https://www.pion-inc.com/solutions/products/sdi2))

[E900] SDi2 combines UV/visible imaging with drug-release information, supporting analytical-imaging classification distinct from recording-only surveillance; category revenue and historical shipments are undisclosed.

[E901] SDi2's advertised analytical imaging supports a specialty peer group, not automatic substitution for conventional quality-control apparatus. ([pion-inc.com](https://www.pion-inc.com/solutions/products/sdi2))

SDi2 - Flow-Through Dissolution System with Visible and UV Imaging

[E902] The commercial offering supplies spatial UV/visible dissolution imaging alongside drug-release information, distinguishing quantitative analytical imaging from recording-only surveillance. ([pion-inc.com](https://www.pion-inc.com/solutions/products/sdi2))

[E903] The marketed system explicitly combines a flow-through dissolution architecture with quantitative UV and visible imaging. A specialized flow cell is not thereby asserted to be a compendially conforming USP apparatus. ([pion-inc.com](https://www.pion-inc.com/solutions/products/sdi2))

Implementation of PDG Harmonized Texts into Japanese Pharmacopoeia - General Chapters - PMDA

[E904] PMDA's dissolution harmonization table distinguishes implemented revisions from Revision xx.xx at Stage xx.xx supporting separation of effective and draft change signals. ([pmda.go.jp](https://www.pmda.go.jp/english/rs-sb-std/standards-development/jp/xx.xx.html))

Japanese Pharmacopoeia XVII - General Information: Harmonized Items for Dissolution 6.10

[E905] The Japanese Pharmacopoeia harmonization table distinguishes platform identity from local numbering: basket and paddle retain their named methods, while the flow-through cell is Japanese Apparatus xx.xx. This supports name-led global classification. ([pmda.go.jp](https://www.pmda.go.jp/files/xx.xx.pdf))

[E906] The table maps the harmonized flow-through-cell apparatus to Japanese Apparatus xx.xx and distinguishes it from the reciprocating-cylinder designation. ([pmda.go.jp](https://www.pmda.go.jp/files/xx.xx.pdf))

[E907] The table names the basket method as Japanese Apparatus xx.xx. ([pmda.go.jp](https://www.pmda.go.jp/files/xx.xx.pdf))

[E908] The table names the paddle method as Japanese Apparatus xx.xx. ([pmda.go.jp](https://www.pmda.go.jp/files/xx.xx.pdf))

Request Info - Prolyse B.V.

[E909] The June xx.xx 2014 inquiry page identifies Prolyse B.V. in the Netherlands and lists Labhut/QLA dissolution accessories.

Lab Consumables and Dissolution Tester Consumables | Quality Lab Solutions

[E910] Quality Lab Solutions identifies its Mumbai business and dedicated dissolution accessories and consumables catalog. ([qlsindia.co.in](https://www.qlsindia.co.in/lab-consumables-n-dissolution-tester-consumables.html))

Lab Consumables n Dissolution Tester Consumables - Quality Lab Solutions

[E911] Quality Lab Solutions maintains a dedicated dissolution-tester consumables and accessories catalog.

[E912] The catalog identifies the Mumbai supplier; it is not treated as proof of independent complete-tester manufacturing.

Quality Lab Solutions USA LLC - Company

[E913] Its commercial navigation includes dissolution accessories and a dedicated dissolution media degasser.

[E914] The company page identifies Quality Lab Solutions USA LLC as the business behind QLS-branded laboratory equipment and spare parts.

Dissolution Media Degasser | Quality Lab Solutions USA LLC

[E915] QLS USA maintains a dedicated dissolution-media degasser offering. ([qlsusa.com](https://www.qlsusa.com/dissolution-media-degasser.php))

Quality Lab Solutions USA LLC - Dissolution Media Degasser

[E916] QLS maintains a specific commercial product page for dissolution media degassing equipment.

[E917] The evidenced role is dissolution-specific peripheral equipment, not proof of complete dissolution-tester manufacturing.

Assistência Técnica - Quimis Aparelhos Científicos

[E918] QUIMIS publishes a state-selectable technical-assistance directory containing its own service contacts and other providers. The directory does not specify Q850 coverage or contract-specific response obligations for every entry. ([quimis.com.br](https://www.quimis.com.br/assistencia-tecnica/))

Quimis Aparelhos Científicos 48 anos

[E919] Describes QUIMIS as a Brazilian laboratory-equipment manufacturer with Brazilian capital and business facilities in Brazil.

[E920] QUIMIS describes itself as a Brazilian laboratory-equipment manufacturer with operations in Diadema and São Roque. Its nationality and manufacturing description do not establish buyer preference or delivery performance. ([quimis.com.br](https://www.quimis.com.br/empresa/))

Dissolutor de comprimidos automático Q850

[E921] Markets the Q850 automatic tablet dissolution instrument.

[E922] QUIMIS advertises the Q850 as an automatic tablet dissolution instrument through a dedicated commercial product page. That label does not establish an included sampling, detection, and records-management package. ([quimis.com.br](https://www.quimis.com.br/produto/dissolutor-de-comprimidos/))

[E923] QUIMIS advertises the Q850 automatic tablet dissolution instrument. ([quimis.com.br](https://www.quimis.com.br/produto/dissolutor-de-comprimidos/))

Qualificações - Quimis Aparelhos Científicos

[E924] QUIMIS separately advertises installation, operational, and performance qualification services and provides an equipment-model inquiry route. These are service offerings, not evidence of acceptance for a particular Q850 installation. ([quimis.com.br](https://www.quimis.com.br/servico/qualificacoes/))

About RAYTOR

[E925] The final share additionally depends on explicitly modeled period, product relevance, apparatus ownership, purchasing incidence, realized price and physical aftermarket capture.

[E926] The official company page reports more than xx.xx clients and describes dissolution and adjacent analytical-instrument operations. This is the supplier-reported reference scale for the customer-stock estimate, not verified 2025 revenue or an exact active customer census.

RT612 Automated Dissolution Tester: Advanced Automation

[E927] Its official product navigation also lists reciprocating and flow-through dissolution systems and media-handling equipment.

[E930] Raytor markets the RT612-ST automated pharmaceutical dissolution system.

RT612-ST Automated Dissolution Tester | Raytor

[E928] Raytor advertises RT612-ST and other dissolution apparatus families. ([raytor.com](https://www.raytor.com/product/rt612-st-automated-dissolution-tester/))

[E929] Raytor advertises RT612-ST dissolution equipment. Its product presentation does not establish an OEM, reseller, or ownership relationship with LEAD-TECH.

Производители - REATORG

[E931] A Russian supplier page connects Universal Lab-branded dissolution testers to REATORG's commercial portfolio.

[E932] Lists Universal Lab dissolution equipment within its represented supplier portfolio.

Производители | REATORG

[E933] REATORG lists Universal Lab within its represented portfolio; legal ownership and equipment origin remain separate questions. ([reatorg.ru](https://www.reatorg.ru/brands/))

Marcas Representadas por Ridaline

[E934] Identifies Ridaline S.A. and its Montevideo business location.

Roquette - Investment in Pharmaceutical Innovation Center in the US

[E935] Roquette's April xx.xx 2023 announcement describes an opened customer-facing Pharmaceutical Innovation Center with dissolution capability. ([roquette.com](https://www.roquette.com/press-releases/pharmaceutical-innovation-center-usa-investment))

[E936] Roquette's April xx.xx 2023 announcement identifies an opened Pharmaceutical Innovation Center serving pharmaceutical and nutraceutical customers and expressly includes dissolution capability. This supports an ingredient supplier's application-support setting, not universal ingredient-company purchasing behavior. ([roquette.com](https://www.roquette.com/press-releases/pharmaceutical-innovation-center-usa-investment))

[E937] Roquette's April xx.xx 2023 announcement identifies its pharmaceutical and nutraceutical excipient business and an opened research center with dissolution-testing capability. This is evidence about an ingredient supplier's own operating facility, not a dissolution-equipment supplier's customer portfolio. ([roquette.com](https://www.roquette.com/press-releases/pharmaceutical-innovation-center-usa-investment))

[E938] The announced center places dissolution capability within pharmaceutical research and formulation-development activities, supporting the development objective without establishing 2025 purchases or market share. ([roquette.com](https://www.roquette.com/press-releases/pharmaceutical-innovation-center-usa-investment))

Roquette - USD 25 Million Pharmaceutical Innovation Center in the USA, April 19, 2023

[E939] The opened USD xx.xx center includes dissolution capability, establishing ingredient-company operating relevance; the investment is not attributable dissolution-equipment revenue.

Raja Ramanna Centre for Advanced Technology - Purchase Orders, July-September 2020

[E940] A July xx.xx 2020 order records INR xx.xx for an autosampler-equipped apparatus. The explicitly adjusted proxy constrains the shared package-price envelope, not QC-purpose sales or forecast share. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E941] The July xx.xx 2020 order names Electrolab India Pvt. Ltd. as supplier of dissolution apparatus with an autosampler for INR xx.xx. It is a historical monetary check on manufacturer-direct purchasing, not a representative global allocation sample. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E942] The July xx.xx 2020 purchasing entry records INR xx.xx for dissolution apparatus with an autosampler. It constrains the common lower-price package envelope after inherited adjustments, but does not identify a basket-only configuration.

[E943] The July-September 2020 purchasing register records INR xx.xx for dissolution apparatus with an autosampler. It constrains the lower-priced partial-automation package proxy after explicit quantity, period, currency and scope assumptions; it does not establish either anchor share. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E944] The July-September 2020 register records INR xx.xx for dissolution apparatus with an autosampler. This is a historical lower-priced package anchor, subject to the predecessor's explicit period, currency and scope assumptions. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E945] The combined apparatus/autosampler order constrains regional package-price variation; it does not disclose a standalone sampler price or worldwide purchase incidence. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E946] The historical order constrains the lower-priced autosampler-equipped package assumption after explicitly modeled currency, period, and commercial-scope adjustments. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E947] The lower-priced configuration transaction constrains assumed comparative package values; its institutional buyer is not automatically classified as instructional. ([rrcat.gov.in](https://www.rrcat.gov.in/tenders/docs/PO_JUL_20_SEP_20.pdf))

[E948] The same observed order is a common commercial package-price check, not a paddle shipment count or direct platform numerator.

SADCAS - Quality Surveillance Laboratory Namibia: Certificate and Schedule of Accreditation, June 20, 2025

[E949] The certificate effective June xx.xx 2025 identifies Namibia's Quality Surveillance Laboratory under the Ministry of Health and Social Services; its pharmaceutical-analysis scope includes dissolution. This establishes dated operating scope, not an equipment transaction or WHO-prequalification status. ([sadcas.org](https://www.sadcas.org/sites/default/files/2025-xx.xx/Testing%xx.xx-%20QSL%xx.xx-%20Cert%xx.xx%20SoA%xx.xx%28Pharmaceuticals%xx.xx%xx.xx%28SoA%20Issue%2004%xx.xx%202025_Final.pdf))

Instrument Division - Saka International Ltd.

[E950] Saka International's instrument division advertises Electrolab dissolution testers and dissolution media-preparation equipment in Bangladesh.

Instrument Division | Saka International Ltd.

[E951] Saka International's instrument division lists Electrolab dissolution equipment. ([sakaint.com](https://www.sakaint.com/instrument_division.html))

SCINCO - Global: SCINCO Taiwan

[E952] SCINCO describes establishing its Taiwan branch and identifies a Taiwan distribution relationship with Distek.

Dissolution System - SCINCO Taiwan

[E953] SCINCO Taiwan's catalog advertises Model xx.xx dissolution systems and a DF-xx.xx flow-through dissolution tester.

[E954] The page identifies SCINCO TAIWAN CO., LTD. and Taiwanese business locations.

Dissolution Tester - Scitek

[E955] A dissolution-tester catalog identifies Scitek Global Co., Ltd.; the protected row's separate economic identity is unresolved.

[E956] It supports the common Scitek commercial identity but does not substantiate treating the two protected Co., Ltd. title variants as independent competitors.

[E957] Its footer identifies Scitek Global Co., Ltd. in Jinan, China, and separately identifies Scitek Global Inc. in Houston, United States.

[E958] SCITEK's catalog advertises DT dissolution testers and DSC automatic dissolution sampling and collection systems.

[E959] Scitek's dissolution catalog identifies Scitek Global Co., Ltd. in China and Scitek Global Inc. in the United States. It does not establish separate Co., Ltd. businesses corresponding to the captured punctuation variants or a UAE legal establishment.

[E960] The inspected Scitek dissolution catalog advertises dissolution testers and sampling systems.

[E961] The page does not establish a distinct company corresponding to the punctuation-only difference between the two retained Scitek titles, or a UAE legal establishment.

[E962] The page identifies Scitek Global Co., Ltd. in Jinan, China, and separately names a U.S. entity.

[E963] The same official catalog identifies the Chinese Scitek Global Co., Ltd. business and a separately named U.S. company while advertising dissolution equipment.

Mettler-Toledo International Inc. - 2025 Form 10-K

[E964] The company's own disclosure associates sophisticated instruments with direct selling and states that direct sales exceed indirect sales. This is a comparable commercial premise, not a dissolution-market share. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/mtd-xx.xx.htm))

[E965] The disclosure associates simpler products with indirect channels, supporting lower direct attribution for standardized physical goods. Exact capture fractions and future persistence remain assumptions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/mtd-xx.xx.htm))

Agilent Technologies, Inc. - Fiscal 2025 Form 10-K

[E966] Academia/government revenue fell from USD xx.xx to xx.xx, providing a broad funding counterforce rather than evidence of assured public-laboratory purchasing expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E967] Agilent's fiscal 2025 Form xx.xx-K establishes the public parent company's official identity and continuing consolidated operations. It does not separately establish dissolution revenue or market share. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E968] Distributors, resellers and representatives supplement direct selling. Their dissolution-specific revenue contribution is not disclosed; the indirect fractions are modeled. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E969] FY2025 pharmaceutical/biopharmaceutical revenue rose from USD xx.xx to xx.xx. This broad end-market signal qualifies differentiated demand assumptions but does not measure dissolution R&D purchasing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E970] FY2025 revenue was USD xx.xx, up approximately xx.xx%; tariff and shipping pressure coexisted with targeted pricing. These observations qualify recovery and pricing assumptions but do not isolate dissolution equipment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E971] The academia/government decline and stated dependence on capital and public-funding policies constrain the slower teaching-equipment activity assumption; they are not instructional sales weights. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E972] The filing describes primarily direct selling, with agents extending geographic and smaller-account coverage and multiple routes for consumables. It supports differentiated channel premises, not the modeled global percentage. Forecast persistence remains assumed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

[E973] The filing reports FY2024 revenue of USD xx.xx, down approximately xx.xx%, and identifies pharmaceutical customer capital-spending pressure. This broad-company observation supports a purchasing counterforce, not the modeled dissolution-market decline directly. ([sec.gov](https://www.sec.gov/Archives/edgar/data/xx.xx/xx.xx/a-xx.xx.htm))

SFW Capital Partners Completes A Strategic Recapitalization of Pion Inc.

[E974] SFW Capital Partners announced completion of a majority recapitalization of Pion Inc. on May xx.xx 2021, with the previous owners retaining an interest. This establishes a completed historical ownership event, not independently reconfirmed October 2026 shareholdings. ([sfwcap.com](https://www.sfwcap.com/news-article/sfw-capital-partners-completes-a-strategic-recapitalization-of-pion-inc-a-leading-instrumentation-provider-for-life-sciences))

High-Performance UV-Vis Spectrophotometers & Accessories | S.I. Photonics

[E975] It advertises xx.xx Series fiber-optic spectrophotometers and explicitly names dissolution testing as a commercial application.

[E976] The inspected product-focused business page identifies S.I. Photonics instruments as manufactured in Tucson, Arizona.

Fiber-Optic Dissolution Testing | S.I. Photonics

[E977] S.I. Photonics advertises dedicated fiber-optic dissolution analysis rather than a complete apparatus. ([siphotonics.com](https://www.siphotonics.com/fiber-optic-dissolution-testing))

Superior Dissolution Testing & Kinetic Reaction Performance | S.I. Photonics

[E978] S.I. Photonics markets its xx.xx Series spectrophotometers for in situ fiber-optic dissolution analysis.

[E979] The page advertises a dedicated optical analysis offering rather than a complete dissolution bath.

About us | Soltek

[E980] Soltek's official business page provides a Rosh Haayin, Israel address and company contact information.

q-doc - Data Management Software

[E981] Advertised multibrand connectivity counters inevitable hardware lock-in; software support remains a separate relationship. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E982] Advertised multibrand drivers counter inevitable hardware lock-in, while the support offering identifies a continuing supplier relationship. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E983] SOTAX advertises multibrand instrument interfaces, enterprise-system connections, and support contracts including update licenses. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E984] SOTAX advertises multibrand q-doc interfaces and software support contracts including update licenses. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E985] SOTAX advertises q-doc drivers for instruments from different brands and DataLink interfaces to LIMS, MES, ERP, and other data environments. The page does not establish compatibility for every proposed instrument-and-software configuration.

[E986] SOTAX advertises q-doc multibrand connectivity and interfaces to other laboratory and enterprise systems. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E987] SOTAX advertises q-doc multibrand instrument drivers and software-support contracts combining priority service with update licenses. These establish advertised continuing-entitlement and integration options. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E988] SOTAX describes q-doc as supplying structured data for a customer's AI model; this does not establish deployment of an autonomous dissolution application. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E989] Software support and update entitlements are distinct ongoing commitments to consider alongside equipment acquisition.
([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E990] q-doc advertises multibrand instrument drivers; configuration-specific software obligations remain a bounded contracting inference.
([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E991] q-doc support contracts combine priority service with update licenses, establishing a lifecycle bundle distinct from apparatus configuration.
([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E992] q-doc's advertised electronic audit trail supports the record-accountability proposition, not proven implementation outcomes.
([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E993] q-doc's advertised multibrand interfaces and support agreements support configuration-specific integration choices, not universal compatibility or guaranteed future deployment.
([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

[E994] q-doc's support-and-update offering establishes continuing software entitlements as a commercial package consideration. ([sotax.com](https://www.sotax.com/data_management/data_management_software_q_docr))

SOTAX - Flow-through Cell Dissolution Tester USP 4

[E995] CE 7smart is offered in offline, UV-online and combined configurations. These options support package-scope differentiation but disclose neither global sales nor the assumed relative price and growth factors.

[E996] SOTAX lists CE 7smart Flow-Through Cell Apparatus in Offline, UV Online, and combined analytical configurations, establishing a distinct advertised apparatus family.
([sotax.com](https://www.sotax.com/dissolution_testing/usp4_dissolution_testing/tester))

Manual and automated dissolution testing systems (USP 1/2/5/6) | SOTAX

[E997] SOTAX offers the Xtend dissolution line in manual, semi-automated, and fully automated configurations.

[E998] The official portfolio identifies AT Xtend, ATS Xtend, and ATF Xtend offerings.

SOTAX - Dissolution Automation and Integrated Analytical Configurations

[E999] Commercial configurations distinguish offline sample collection from analytical integration. This supports separate functional attribution and the forecast's bundling counterforce, not an observed adoption rate.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1001] Dissolution configurations include UV and chromatographic analytical integration. Only dissolution-attributable goods are included; general laboratory instrument sales are not substituted for this category.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1002] Integrated cleaning configurations are an alternative to independent cleaners; their existence supports a substitution premise, not quantified sales displacement.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1003] Integrated media-handling options provide a commercial alternative to separately purchased units, constraining the forecast standalone purchasing assumption.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1004] LC-connected configurations establish a commercial integration option; the model does not equate every interface with a newly supplied chromatographic detector.

[E1005] Offline collection for transfer to an external analytical device supports a substantive purchasing alternative without integrated detection.

[E1007] Separate offline and integrated-UV offerings support the supplied-detection attribution model, but disclose no global sales weights.

[E1011] The manufacturer distinguishes Semi-Automated equipment from both manual and fully automated configurations. This supports partial-automation category mapping, not the modeled worldwide purchasing proportion. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1012] The manufacturer maintains a distinct Manual offering, supporting classification by delivered automation responsibilities rather than treating basic equipment as commercially absent. No sales weight is disclosed.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1013] The manufacturer separately presents fully automated platforms and analytical-integration choices, supporting the model's distinction between automation breadth and detector integration. Availability does not establish adoption. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/automation))

[E1015] UV-online analysis of withdrawn samples supports the external-cell commercial architecture used in the allocation.

SOTAX Xtend - Automation and Integrated Analytical Finish

[E1000] Dissolution configurations can integrate analytical hardware separately from sample collection and the base apparatus. Only dissolution-specific modules or attributable integrated components enter the working goods perimeter. ([sotax.com](https://www.sotax.com/dissolution_testing/solutions/xtend_dissolution/))

[E1008] The LC configuration connects dissolution sample handling to HPLC or UPLC analysis, establishing a marketed integrated chromatographic architecture. ([sotax.com](https://www.sotax.com/dissolution_testing/solutions/xtend_dissolution/))

[E1009] The UV-online configuration measures withdrawn dissolution liquid using an integrated spectrophotometer, establishing an external analytical-cell architecture distinct from in-vessel probe monitoring. ([sotax.com](https://www.sotax.com/dissolution_testing/solutions/xtend_dissolution/))

[E1010] The inspected commercial configurations distinguish sample collection from integrated UV-Vis and liquid-chromatographic analysis. This corroborates functional modularity, not the market's complete offering taxonomy. ([sotax.com](https://www.sotax.com/dissolution_testing/solutions/xtend_dissolution/))

[E1014] The offline configuration collects samples for operator transfer to an analytical device without dedicating the dissolution system to an analytical method. This supports an explicit no-integrated-detection hardware state. ([sotax.com](https://www.sotax.com/dissolution_testing/solutions/xtend_dissolution/))

SOTAX - Automation

[E1006] SOTAX distinguishes Offline collection, integrated UV analysis of withdrawn samples, and HPLC or UPLC-connected configurations. These support different package choices, not proof that a detector is supplied under every interface offer. ([sotax.com](https://www.sotax.com/dissolution_testing/solutions/xtend_dissolution/))

AT-MD Offline - Fully automated self-cleaning benchtop dissolution tester

[E1016] AT-MD Offline supplies an evidenced broader-automation alternative for a workload-specific purchasing case. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1017] AT-MD Offline's unattended capability is a supplier proposition, not independently demonstrated staff benefits for a particular laboratory. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1018] SOTAX advertises AT-MD Offline as a fully automated, self-cleaning benchtop dissolution system supporting unattended sequences and automated collection for subsequent analytical work.

[E1019] SOTAX advertises AT-MD Offline as a fully automated, self-cleaning benchtop dissolution tester with unattended operation. These are supplier capability claims, not independently demonstrated customer outcomes. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1020] SOTAX advertises AT-MD Offline as a fully automated, self-cleaning benchtop dissolution tester. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1021] SOTAX advertises AT-MD Offline as a fully automated, self-cleaning dissolution tester with unattended operation and collection for subsequent analysis. This is a different package proposition from integrated optical analysis.

[E1022] SOTAX advertises AT-MD Offline as a fully automated, self-cleaning system for unattended sequences. This supports a broader automation offering without making online detection or realized staff benefits inherent to the category. ([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1023] SOTAX advertises AT-MD Offline as an unattended, fully automated dissolution offering; advertised capability does not establish realized buyer benefits.

([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1024] SOTAX advertises AT-MD Offline as fully automated and unattended; this establishes an offering rather than buyer acceptance.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1025] SOTAX advertises AT-MD Offline for unattended automation and collection for subsequent analysis.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1027] The advertised unattended AT-MD Offline supplies the assessed broader-automation proposition.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1028] The advertised unattended package supports comparing delivered automation scope with a narrower equipment addition.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1029] The supplier advertises unattended operation and reduced routine operator attention; these are offering claims, not independently established buyer benefits.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

[E1030] Unattended operation is a supplier-stated capability, providing a potential operator-attention benefit rather than proven economic savings.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

SOTAX - AT-MD Offline: Fully Automated Self-Cleaning Benchtop Dissolution Tester

[E1026] The AT-MD Offline is marketed as fully automated and capable of unattended sequences. This supports the commercial classification without requiring online analytical detection; it provides no revenue or market-share observation.
([sotax.com](https://www.sotax.com/dissolution_testing/usp_1_2_5_6/dissolution_tester/fully_automated_systems/fully_automated_benchtop_dissolution_offline))

METTLER TOLEDO and SOTAX Partnership

[E1031] A 2018 announcement describes a marketing and sales partnership integrating METTLER TOLEDO's UV7 Excellence spectrophotometer with SOTAX dissolution equipment.

[E1032] The announcement identifies SOTAX as the dissolution-equipment partner in the integrated system.

[E1033] The document establishes a dated integration role, not independently confirmed current availability or complete-tester manufacturing.

Legal Notices | SOTAX

[E1034] SOTAX's legal notice identifies SOTAX AG at Nordring xx.xx Aesch, Switzerland, and distinguishes its designated German representative. This supports the Swiss operating-entity reporting identity.
([sotax.com](https://www.sotax.com/legal_notice/legal_notices))

Your career with SOTAX

[E1035] SOTAX describes its worldwide workforce as close to xx.xx and identifies equipment, technical services and pharmaceutical services. The rounded workforce is a commercial-scale proxy, not measured 2025 dissolution revenue. ([sotax.com](https://www.sotax.com/sotax_group/career))

Contact SOTAX - find us worldwide connected | SOTAX

[E1036] Costa Rica entry names HTDS RDC and links to HTDS; local identity is not established.

[E1037] Listed contact.

[E1038] Listed contacts under related Labtim names.

[E1039] Listed regional contacts.

[E1040] Lists RGH partners in Dominican Republic, El Salvador, and Guatemala, linking each to the group website.

[E1042] Sales/service partner: Argentina.

[E1043] Sales/service partner: Bolivia.

[E1044] Sales/service partner: Brazil.

[E1045] Sales/service partner: Chile.

[E1046] Sales/service partner: Colombia.

[E1047] Sales/service partner: Ecuador.

SOTAX Worldwide - Sales and Service Partners

[E1041] SOTAX identifies the discussed businesses as sales-and-service contacts; the directory does not establish universally allocated models or customer contracts.
([sotax.com](https://www.sotax.com/sotax_group/contact/worldwide))

News | SOTAX

[E1048] SOTAX's inspected news page contains October 2026 business communications, including its INSIGHT conference and a pharmaceutical-development partnership, corroborating continuing operations. These records are not equipment-sales or market-share measurements. ([sotax.com](https://www.sotax.com/sotax_group/news))

SOTAX - Validate Dissolution Vessel Cleaning and Increase Lab Productivity!

[E1049] SOTAX's March xx.xx 2019 announcement identifies DVC-xx.xx as dedicated vessel-cleaning equipment usable with multiple dissolution systems. The historical announcement does not establish a new transaction's supply or support commitment.
([sotax.com](https://www.sotax.com/sotax_group/news/sotax_worldwide/new_dissolution_vessel_cleaner))

SOTAX - Validate Dissolution Vessel Cleaning and Increase Lab Productivity!, March 1, 2019

[E1050] The March xx.xx 2019 announcement distinguishes dedicated vessel-cleaning equipment and describes one cleaner serving four testers. This constrains commercial pooling assumptions, but does not establish current shipments or realized utilization.
([sotax.com](https://www.sotax.com/sotax_group/news/sotax_worldwide/new_dissolution_vessel_cleaner))

[E1051] The announcement separately identifies a media-preparation station, supporting a commercial boundary distinct from vessel cleaning. Category prices and penetration remain modeled.
([sotax.com](https://www.sotax.com/sotax_group/news/sotax_worldwide/new_dissolution_vessel_cleaner))

Validate Dissolution Vessel Cleaning and Increase Lab Productivity!

[E1052] The announcement separately identifies equipment for preparing and dispensing dissolution media, corroborating its functional distinction from vessel cleaning.
([sotax.com](https://www.sotax.com/sotax_group/news/sotax_worldwide/new_dissolution_vessel_cleaner))

[E1053] The commercial announcement distinguishes a dedicated dissolution-vessel cleaner from a media-preparation station. It establishes a separately identifiable cleaning offering, not independently measured global demand.
([sotax.com](https://www.sotax.com/sotax_group/news/sotax_worldwide/new_dissolution_vessel_cleaner))

Services & Support | SOTAX

[E1054] SOTAX advertises installation, qualification, training, repair, project management, and LIMS/MES/ERP integration services, with support routes involving direct subsidiaries and independent partners.

Dissolutor de Comprimidos QUIMIS Q850 para Testes Farmacêuticos Precisos e Automáticos

[E1055] Offers the QUIMIS Q850 dissolution instrument through its Brazilian commercial catalog.

Dissolutor de Comprimidos QUIMIS Q850 | SPMÉDICA

[E1056] SPMÉDICA advertises the QUIMIS Q850 dissolution instrument.
([spmedica.com](https://www.spmedica.com/laboratorial/dissolutor-de-comprimidos-quimis-cod-q850))

University of Strathclyde - Annual Procurement Report, August 2023-July 2024

[E1057] Strathclyde's August 2023-July 2024 procurement report records a Sotax Ltd contract for supply, delivery, and installation of an automated dissolution system. It does not establish realized staff benefits.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1058] Strathclyde's procurement report records Sotax Ltd as supplier under a contract for supply, delivery, and installation of an automated dissolution system, providing a university purchasing counterexample to a presumed Manual preference.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1068] The report establishes a recorded automated-system acquisition, but its description does not establish every unattended function or another buyer's acceptance.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

University of Strathclyde - Annual Procurement Report 2023-2024

[E1059] The GBP xx.xx automated-system contract constrains the upper package-price tier used in the common value-allocation model; it does not disclose UV attachment or a global mix.

[E1060] The automated-system contract supports distinguishing package richness from apparatus labels; its equipment/service attribution remains an inherited assumption rather than a reported paddle price.

[E1061] The bundled contract provides a common high-configuration monetary constraint after assumed scope and producer-realization adjustments, not direct LC revenue.

[E1062] The disclosed transaction provides an upper-configuration commercial anchor for the modeled fully automated package price after assumed service and channel deductions; it does not establish the global automation mix.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1063] The observed bundled purchasing amount constrains package valuation and supports distinguishing goods from delivery and continuing obligations.

[E1064] The procurement report records a GBP xx.xx automated dissolution-system contract beginning December xx.xx 2023. It constrains the upper package-price range; the multi-year contract is not annual equipment revenue or proof of forecast adoption.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1065] The procurement report records a GBP xx.xx contract with Sotax Ltd for an automated dissolution system, with a December xx.xx 2023 start and May xx.xx 2028 end. The amount is a bundled contract value, not annual equipment revenue.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1066] The procurement report records a GBP xx.xx automated dissolution-system contract. Its bundled scope constrains the upper configuration-price envelope but does not establish a basket platform mix or annual revenue.

[E1067] The register records a GBP xx.xx automated dissolution-system contract with Sotax, countering an assumed universal academic preference for basic equipment; it is not annual goods revenue.

[E1069] The report records GBP xx.xx for an automated dissolution-system contract with Sotax Ltd, running December xx.xx 2023-May xx.xx 2028. This bundled transaction constrains a high-configuration price proxy after modeled deductions, not annual revenue, functional completeness or global adoption.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1070] The report records a GBP xx.xx automated-dissolution-system contract spanning December xx.xx 2023 to May xx.xx 2028. After explicit assumed scope adjustments, it constrains the richer-package price envelope, not annual R&D revenue.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

[E1071] The university transaction demonstrates that an academic buyer can acquire a premium configuration; institutional identity alone cannot establish an instructional purpose or basic-system price.
([strath.ac.uk](https://www.strath.ac.uk/media/ps/purchasing/procurement-hp/UoS_Annual_Procurement_Report_AY2023-xx.xx.pdf))

dissoWASH&DOSE - Synersy

[E1072] Advertises dissoWASH&DOSE dedicated dissolution-support equipment and provides a Rivesaltes, France business address.

dissoWASH&DOSE | Synersy

[E1073] Synersy advertises dissoWASH&DOSE supporting equipment.
([synersy.fr](https://www.synersy.fr/product/dissowash-amp-dose/))

关于我们 - 天津市天大天发科技有限公司

[E1074] The official company material identifies the pharmaceutical-testing equipment business behind the Tianda Tianfa portfolio.

区域销售 - 天津市天大天发科技有限公司

[E1075] The supplier publishes instrument-purchasing contacts organized by Chinese provinces and regions. These advertised domestic routes do not establish a destination-specific international supply or service contract.

RC1209D 溶出仪- 天津市天大天发科技有限公司

[E1076] The Chinese-language supplier catalog advertises RC1209D and supporting equipment. Product presentation does not independently establish the exact English-named overseas contracting entity or export-service obligations.

[E1077] The Chinese-named Tianda Tianfa catalog advertises RC1209D and supporting categories. ([tdtf.cn](https://www.tdtf.cn/?products_22%2F495.html=))

[E1078] The catalog naming 天津市天大天发科技有限公司 advertises RC1209D dissolution apparatus and separately lists reciprocating apparatus, sampling systems, QX-xx.xx cleaning equipment, and dissolution accessories. It does not establish official English legal-name binding or export fulfillment.

[E1079] The page binds the offering to 天津市天大天发科技有限公司.

[E1080] Tianda Tianfa's official catalog markets the RC1209D dissolution instrument.

Teledyne Acquires Hanson Research Corporation

[E1081] Teledyne announced on December xx.xx 2016, that Teledyne Instruments, Inc. acquired Hanson Research Corporation.

[E1082] The announcement identifies Hanson Research's pharmaceutical dissolution and diffusion instrumentation business.

Teledyne Hanson is part of Teledyne LABS

[E1083] Teledyne identifies Hanson as a brand within Teledyne LABS.

[E1084] Teledyne presents Hanson as a Teledyne LABS brand supplying tablet-dissolution systems. ([teledynelabs.com](https://www.teledynelabs.com/brands/hanson))

[E1085] The brand relationship establishes corporate context, not an independent public parent or universal service agreement. ([teledynelabs.com](https://www.teledynelabs.com/brands/hanson))

[E1086] The business describes manufacture of tablet-dissolution test systems at its Chatsworth, California facility and an international customer-support network.

Dissolution Testers | Teledyne LABS

[E1087] Teledyne LABS markets Hanson dissolution testers, including the Vision G2 Classic xx.xx.

[E1088] The page describes dissolution instruments, operating software, and accessories for pharmaceutical development and quality control.

Teledyne LABS names new Hanson brand product line manager

[E1089] A November xx.xx 2025 announcement identifies Teledyne Hanson as a Teledyne LABS dissolution- and diffusion-instrument brand and confirms continuing product-line management and worldwide commercial support. The brand is not presented as an independent public parent. ([teledynelabs.com](https://www.teledynelabs.com/en-us/hector-bucaro))

Pion DissoSpec | Terralab

[E1090] Terralab advertises Pion DissoSpec through its Turkish commercial portfolio. ([terralab.com.tr](https://www.terralab.com.tr/urunler/pion-dissospec-gelismis-uv-vis-kontrollu-cozunme-test-sistemi))

Pion DissoSpec Gelişmiş UV-Vis Kontrollü Çözünme Test Sistemi | Terralab

[E1091] Terralab's Turkish-language catalog advertises the Pion DissoSpec dissolution-testing system.

International Agreements and Arrangements for GMP Clearance | TGA

[E1092] TGA describes arrangements with New Zealand's Medsafe for information exchange and mutual recognition of defined medicine-manufacturer GMP inspection outcomes, with explicit scope, exclusions, and territorial conditions. These are not apparatus approvals or shared equipment-service contracts.

([tga.gov.au](https://www.tga.gov.au/products/medicines/manufacturing/manufacture-medicine/good-manufacturing-practice-gmp/international-agreements-and-arrangements-gmp-clearance))

RT612-ST 12 Bit Automatic Sampling And Dissolution System - Lead-Tech

[E1093] LEAD-TECH separately advertises RT612-ST equipment, supplying an independent commercial attribution check against Raytor's advertised model designation.

[E1096] The listing does not establish ownership, an OEM agreement or realized revenue. It supports retaining the unresolved equipment-origin condition and excluding additional downstream resale value from the modeled producer numerator.

RT612-ST Automatic Sampling And Dissolution System | LEAD-TECH

[E1094] LEAD-TECH separately advertises RT612-ST equipment. A shared model designation does not establish the commercial relationship between its seller and Raytor.

RT612-ST Automatic Sampling And Dissolution System - Lead-Tech

[E1095] LEAD-TECH's RT612-ST dissolution-system page identifies its operator as Tianjin Lead-Tech Trade Co., Ltd.

[E1097] The page establishes an advertised commercial offering, not independent manufacturing or an ownership relationship with Raytor.

Dissolution Tester | Torontech

[E1098] The page identifies Torontech Inc. in Toronto, Canada, and a North American business presence.

[E1099] Torontech advertises ToronDISS standalone and sampling-equipped configurations; equipment origin is not established by catalog breadth. ([torontech.com](https://www.torontech.com/dissolution-tester/))

[E1100] Torontech markets ToronDISS-branded standalone and automated dissolution systems.

カタログ | 富山産業株式会社

[E1101] Toyama's catalog lists apparatus families, SAS-xx.xx sampling, and Di-LINQ software, not a destination-specific supply commitment. ([toyamas.co.jp](https://www.toyamas.co.jp/catalog/index.html))

会社情報 | 富山産業株式会社

[E1102] A published company action plan covers November 2024 through May 2027. It corroborates ongoing corporate activity, not current availability of a particular dissolution model. ([toyamas.co.jp](https://www.toyamas.co.jp/company/))

[E1103] The company describes pharmaceutical-instrument manufacturing and sales and its dissolution-testing business.

[E1104] The official corporate profile binds 富山産業株式会社 to TOYAMA SANGYO CO., LTD. and identifies Japanese business locations.

[E1105] Toyama's inspected corporate profile binds 富山産業株式会社 to TOYAMA SANGYO CO., LTD., identifies Japanese business locations, and expressly describes dissolution-instrument manufacture and sales.

ニュース | 富山産業株式会社

[E1106] Toyama's news page identifies a new-product announcement for the SAS-xx.xx autosampler dated September xx.xx 2025. This establishes a dated supplier announcement, not an integrated-package or destination-fulfillment commitment. ([toyamas.co.jp](https://www.toyamas.co.jp/news.php))

製品情報 | 富山産業株式会社

[E1107] The dated announcement establishes a named commercial offering and resolves the earlier absence of current model-level support; it does not establish sales volume or export availability.

[E1108] Toyama's official product-news page announces the NTR-xx.xx/xx.xx dissolution-instrument series on September xx.xx 2026.

International Trade Administration - SelectUSA Biopharmaceuticals Industry

[E1109] More than xx.xx pharmaceutical-manufacturing employees in mid-2024 corroborate substantial domestic customer activity. The national observation does not establish state equipment shares.

UCL Commercial and Procurement Services - Responsible Procurement

[E1110] UCL encourages supplier emissions disclosures in its 2025-xx.xx and 2026-xx.xx reporting years and specifies later requirements for suppliers meeting its eligibility threshold, with exceptions considered individually. ([ucl.ac.uk](https://www.ucl.ac.uk/commercial-procurement/responsible-procurement))

Veego Instrument Corporation - Know Us

[E1111] The business profile identifies Veego Instrument Corporation and includes tablet-dissolution equipment in its own advertised range. Its singular-name attribution does not establish the identity or obligations of a similarly named business.

Veego Instrument Corporation - Manufacturer from Mumbai, India | Know Us

[E1112] The profile describes the business as a proprietorship and names its proprietor.

[E1113] The singular-name Veego business's own profile identifies Veego Instrument Corporation, GST number 27AACPV8764G1Z5, and an Andheri East, Mumbai address.

[E1114] This is company-published identity information, not independent registry confirmation or proof that the separately observed plural-name business is the same entity.

Veego Instrument Corporation - Company and Product Catalog

[E1115] It provides an observed naming record, not proof that the singular and plural Veego businesses are the same legal entity.

[E1116] This company-hosted catalog uses the singular name Veego Instrument Corporation and lists tablet dissolution apparatus.

Microcontroler Based Dissolution Test Apparatus VDA 8D(ARM) - Veego Instruments Corporation

[E1117] The page identifies a Mumbai business, but its plural company name conflicts with the protected singular title.

[E1118] The product page advertises the VDA 8D(ARM) dissolution apparatus under VEEGO INSTRUMENTS CORPORATION.

Laboratory Instruments Supplier in Bangladesh | Vvon Technologies

[E1119] Vvon Technologies' Bangladesh catalog advertises ERWEKA DT xx.xx and DT xx.xx dissolution testers and related automated systems.

Laboratory Instruments in Bangladesh | Vvon Technologies

[E1120] Vvon advertises ERWEKA dissolution equipment in its Bangladesh laboratory-instruments catalog. ([vvon.com.bd](https://www.vvon.com.bd/catalogue/scientific/laboratory-instruments))

Dissolution Apparatus | VWR, part of Avantor

[E1121] Identifies VWR as Avantor's distribution channel.

[E1122] Lists QLA dissolution apparatus accessories, including vessels and qualification tools.

[E1123] VWR lists QLA dissolution accessories through its commercial category. ([vwr.com](https://www.vwr.com/uk/en/category/xx.xx/dissolution-apparatus))

DS-806AT Auto Sampling Dissolution - Wahyong

[E1124] The product page carries an April xx.xx 2018 date; continued supply is not independently established.

[E1126] Wahyong's catalog advertises the DS-806AT automated-sampling dissolution system and identifies a Shenzhen, China address.

DS-806AT Auto Sampling Dissolution | Wahyong

[E1125] Wahyong's DS-806AT page displays April xx.xx 2018. The dated presentation does not establish a present supply, manufacturer-authorization, or service commitment.

WHO - Laboratory Networks and Services

[E1127] WHO describes quality surveys, complaint-related testing, regulatory support, and monitoring of health products on the market as laboratory missions. This supports surveillance as a distinct objective, not a measured dissolution-equipment segment. ([who.int](https://www.who.int/teams/regulation-prequalification/regulation-and-safety/laboratory-networks-and-services))

[E1128] WHO identifies complaint-related laboratory testing, quality surveys, and regulatory support among its laboratory-network missions. These establish commissioning contexts, not dissolution-equipment awards. ([who.int](https://www.who.int/teams/regulation-prequalification/regulation-and-safety/laboratory-networks-and-services))

[E1129] WHO identifies quality-control laboratories' role in monitoring product quality in the market and responding to substandard and falsified products. The page does not identify dissolution-system purchases primarily allocated to that mission.

([who.int](https://www.who.int/teams/regulation-prequalification/regulation-and-safety/laboratory-networks-and-services))

About us - World of Labs

[E1130] The official business description uses the English name World of Labs Trading Establishment.

Digital DT 950 Series Dissolution Tester | World of Labs

[E1131] World of Labs advertises ERWEKA DT xx.xx equipment.
([wlabs.sa](https://www.wlabs.sa/case-study/digital-dt-xx.xx-series-dissolution-tester))

Digital DT 950 Series Dissolution Tester - Products - World of Labs

[E1132] World of Labs advertises the ERWEKA Digital DT xx.xx Series dissolution tester and provides a Riyadh business contact.

Contact | Worldoftest

[E1133] It lists a Canadian mailing, shipping, and corporate office in Richmond Hill, Ontario.

[E1134] Qualitest's contact page lists U.S. business addresses in Florida.

Dissolution Tester Sampling System - QualiPharma DIS SA 2008 | Qualitest

[E1135] Qualitest advertises the QualiPharma DIS SA 2008 dissolution sampling-system offering.
([worldoftest.com](https://www.worldoftest.com/dissolution-tester-sampling-system-qualipharmatm-dis-sa-2008/))

Dissolution Tester Sampling System - QualiPharma DIS SA 2008 | Worldoftest

[E1136] Qualitest advertises the QualiPharma DIS SA 2008 dissolution tester sampling system.

[E1137] The offering is explicitly marketed to pharmaceutical laboratories in the United States and Canada.

Agreement on Government Procurement - Coverage Schedules | WTO

[E1138] WTO explains that GPA obligations apply only to procurement covered by party schedules, including the relevant entities, purchasing categories, thresholds, and exceptions. Participation does not establish coverage of a particular dissolution-equipment tender.
([wto.org](https://www.wto.org/english/tratop_e/gproc_e/gp_app_agree_e.htm))

Agreement on Government Procurement - Parties and Observers | WTO

[E1139] WTO lists Canada, Japan, the United Kingdom, the United States, and the European Union as GPA parties. Brazil, China, India, the Russian Federation, and Türkiye are listed as observers. This supports different procurement-access assessments within the Americas, G7, NATO, and BRICS overlays.
([wto.org](https://www.wto.org/english/tratop_e/gproc_e/memobs_e.htm))

Tablet Dissolution Test Apparatus Manufacturer, Supplier India - Yatherm

[E1140] The product page identifies an Indian business address and describes a manufacturing and supply role.

[E1141] Yatherm Scientific advertises tablet dissolution apparatus and an automated-sampling workstation.

Tablet Dissolution Test Apparatus | Yatherm Scientific

[E1142] Yatherm advertises tablet-dissolution apparatus and sampling equipment.
([yatherm.com](https://yatherm.com/pharmaceutical-instruments/dissolution-test-apparatus))

List of Figures

Figure 1. Global Dissolution Equipment Market, Years Considered for the Study....11
Figure 2. Global Dissolution Equipment Market, Research Design....14
Figure 3. Global Dissolution Equipment Market, Research Framework....15
Figure 4. Global Dissolution Equipment Market, Data Triangulation....17
Figure 5. Global Dissolution Equipment Market Size, 2017-2040 (USD Million, Growth %)....22
Figure 6. Global Dissolution Equipment Market, Key Growth Contribution, by Region, 2025-2032 (USD Million)....23
Figure 7. Global Dissolution Equipment Market, Key Growth Contribution, by Country, 2025-2032 (CAGR %)....24
Figure 8. Global Dissolution Equipment Market Size, by Product Type, 2025 (%)....45
Figure 9. Global Dissolution Equipment Market, by Product Type, 2032 (USD Million)....45
Figure 10. Global Dissolution Equipment Market Size, by Apparatus Platform, 2025 (%)....74
Figure 11. Global Dissolution Equipment Market, by Apparatus Platform, 2032 (USD Million)....74
Figure 12. Global Dissolution Equipment Market Size, by Analytical Detection, 2025 (%)....117
Figure 13. Global Dissolution Equipment Market, by Analytical Detection, 2032 (USD Million)....118
Figure 14. Global Dissolution Equipment Market Size, by Testing Purpose, 2025 (%)....139
Figure 15. Global Dissolution Equipment Market, by Testing Purpose, 2032 (USD Million)....139
Figure 16. Global Dissolution Equipment Market Size, by End User, 2025 (%)....158
Figure 17. Global Dissolution Equipment Market, by End User, 2032 (USD Million)....158
Figure 18. Global Dissolution Equipment Market Size, by Automation Level, 2025 (%)....180
Figure 19. Global Dissolution Equipment Market, by Automation Level, 2032 (USD Million)....180
Figure 20. Global Dissolution Equipment Market Size, by Sales Channel, 2025 (%)....191
Figure 21. Global Dissolution Equipment Market, by Sales Channel, 2032 (USD Million)....192
Figure 22. Global Dissolution Equipment Market Size, by Tested Product, 2025 (%)....201
Figure 23. Global Dissolution Equipment Market, by Tested Product, 2032 (USD Million)....201
Figure 24. Global Dissolution Equipment Market, by Region: Market share evolution, 2025-2032....235
Figure 25. Global Dissolution Equipment Market, by Region: Market size by category, 2025 (USD Million)....235
Figure 26. Global Dissolution Equipment Market, Regional growth by End User, 2025-2032 (CAGR %)....236
Figure 27. Global Dissolution Equipment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)....279
Figure 28. Global Dissolution Equipment Market Size, by Country, 2025 vs 2032 (%)....322
Figure 29. Global Dissolution Equipment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)....323
Figure 30. Global Dissolution Equipment Market Share, by Key Player, 2025....406

List of Tables

Table 1. Global Dissolution Equipment Market Segmentation & Coverage 9
Table 2. Global Dissolution Equipment Market Size, 2017-2040 (USD Million, Growth %) 22
Table 3. Global Dissolution Equipment Market, Key Growth Contribution, 2025-2032 (USD Million) 24
Table 4. Global Dissolution Equipment Market, by Product Type growth contribution, 2025-2032 (USD Million) 46
Table 5. Global Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 47
Table 6. Global Dissolution Equipment Market Size, by Dissolution Test Systems, by Region, 2017-2040 (USD Million) 48
Table 7. Global Dissolution Equipment Market Size, by Dissolution Test Systems, by Group, 2017-2040 (USD Million) 48
Table 8. Global Dissolution Equipment Market Size, by Dissolution Test Systems, by Country, 2017-2040 (USD Million) 49
Table 9. Global Dissolution Equipment Market Size, by Accessories, Consumables, and Replacement Parts, by Region, 2017-2040 (USD Million) 51
Table 10. Global Dissolution Equipment Market Size, by Accessories, Consumables, and Replacement Parts, by Group, 2017-2040 (USD Million) 51
Table 11. Global Dissolution Equipment Market Size, by Accessories, Consumables, and Replacement Parts, by Country, 2017-2040 (USD Million) 52
Table 12. Global Dissolution Equipment Market Size, by Media-Handling Equipment, by Region, 2017-2040 (USD Million) 54
Table 13. Global Dissolution Equipment Market Size, by Media-Handling Equipment, by Group, 2017-2040 (USD Million) 54
Table 14. Global Dissolution Equipment Market Size, by Media-Handling Equipment, by Country, 2017-2040 (USD Million) 55
Table 15. Global Dissolution Equipment Market Size, by Sample-Handling Equipment, by Region, 2017-2040 (USD Million) 57
Table 16. Global Dissolution Equipment Market Size, by Sample-Handling Equipment, by Group, 2017-2040 (USD Million) 57
Table 17. Global Dissolution Equipment Market Size, by Sample-Handling Equipment, by Country, 2017-2040 (USD Million) 58
Table 18. Global Dissolution Equipment Market Size, by Analytical Detection Modules, by Region, 2017-2040 (USD Million) 60
Table 19. Global Dissolution Equipment Market Size, by Analytical Detection Modules, by Group, 2017-2040 (USD Million) 60
Table 20. Global Dissolution Equipment Market Size, by Analytical Detection Modules, by Country, 2017-2040 (USD Million) 61
Table 21. Global Dissolution Equipment Market Size, by Mechanical Qualification Equipment, by Region, 2017-2040 (USD Million) 63
Table 22. Global Dissolution Equipment Market Size, by Mechanical Qualification Equipment, by Group, 2017-2040 (USD Thousand) 63

Table 23. Global Dissolution Equipment Market Size, by Mechanical Qualification Equipment, by Country, 2017-2040 (USD Million) 64
Table 24. Global Dissolution Equipment Market Size, by Vessel-Cleaning Equipment, by Region, 2017-2040 (USD Thousand) 66
Table 25. Global Dissolution Equipment Market Size, by Vessel-Cleaning Equipment, by Group, 2017-2040 (USD Thousand) 66
Table 26. Global Dissolution Equipment Market Size, by Vessel-Cleaning Equipment, by Country, 2017-2040 (USD Thousand) 67
Table 27. Global Dissolution Equipment Market Size, by Visual Surveillance Equipment, by Region, 2017-2040 (USD Thousand) 69
Table 28. Global Dissolution Equipment Market Size, by Visual Surveillance Equipment, by Group, 2017-2040 (USD Thousand) 69
Table 29. Global Dissolution Equipment Market Size, by Visual Surveillance Equipment, by Country, 2017-2040 (USD Thousand) 70
Table 30. Global Dissolution Equipment Market, by Apparatus Platform growth contribution, 2025-2032 (USD Thousand) 75
Table 31. Global Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Million) 76
Table 32. Global Dissolution Equipment Market Size, by Paddle Apparatus, by Region, 2017-2040 (USD Million) 77
Table 33. Global Dissolution Equipment Market Size, by Paddle Apparatus, by Group, 2017-2040 (USD Million) 77
Table 34. Global Dissolution Equipment Market Size, by Paddle Apparatus, by Country, 2017-2040 (USD Million) 78
Table 35. Global Dissolution Equipment Market Size, by Basket Apparatus, by Region, 2017-2040 (USD Million) 80
Table 36. Global Dissolution Equipment Market Size, by Basket Apparatus, by Group, 2017-2040 (USD Million) 80
Table 37. Global Dissolution Equipment Market Size, by Basket Apparatus, by Country, 2017-2040 (USD Million) 81
Table 38. Global Dissolution Equipment Market Size, by Flow-Through Cell Apparatus, by Region, 2017-2040 (USD Million) 83
Table 39. Global Dissolution Equipment Market Size, by Flow-Through Cell Apparatus, by Group, 2017-2040 (USD Million) 83
Table 40. Global Dissolution Equipment Market Size, by Flow-Through Cell Apparatus, by Country, 2017-2040 (USD Million) 84
Table 41. Global Dissolution Equipment Market Size, by Reciprocating Cylinder Apparatus, by Region, 2017-2040 (USD Million) 86
Table 42. Global Dissolution Equipment Market Size, by Reciprocating Cylinder Apparatus, by Group, 2017-2040 (USD Million) 86
Table 43. Global Dissolution Equipment Market Size, by Reciprocating Cylinder Apparatus, by Country, 2017-2040 (USD Million) 87
Table 44. Global Dissolution Equipment Market Size, by Stirred-Vial Apparatus, by Region, 2017-2040 (USD Million) 89

Table 45. Global Dissolution Equipment Market Size, by Stirred-Vial Apparatus, by Group, 2017-2040 (USD Million) 89
Table 46. Global Dissolution Equipment Market Size, by Stirred-Vial Apparatus, by Country, 2017-2040 (USD Million) 90
Table 47. Global Dissolution Equipment Market Size, by Membrane-Separated Cell Apparatus, by Region, 2017-2040 (USD Million) 92
Table 48. Global Dissolution Equipment Market Size, by Membrane-Separated Cell Apparatus, by Group, 2017-2040 (USD Thousand) 92
Table 49. Global Dissolution Equipment Market Size, by Membrane-Separated Cell Apparatus, by Country, 2017-2040 (USD Thousand) 93
Table 50. Global Dissolution Equipment Market Size, by Reciprocating Holder Apparatus, by Region, 2017-2040 (USD Million) 95
Table 51. Global Dissolution Equipment Market Size, by Reciprocating Holder Apparatus, by Group, 2017-2040 (USD Thousand) 95
Table 52. Global Dissolution Equipment Market Size, by Reciprocating Holder Apparatus, by Country, 2017-2040 (USD Million) 96
Table 53. Global Dissolution Equipment Market Size, by Paddle Over Disk Apparatus, by Region, 2017-2040 (USD Thousand) 98
Table 54. Global Dissolution Equipment Market Size, by Paddle Over Disk Apparatus, by Group, 2017-2040 (USD Thousand) 98
Table 55. Global Dissolution Equipment Market Size, by Paddle Over Disk Apparatus, by Country, 2017-2040 (USD Thousand) 99
Table 56. Global Dissolution Equipment Market Size, by Rotating Cylinder Apparatus, by Region, 2017-2040 (USD Thousand) 101
Table 57. Global Dissolution Equipment Market Size, by Rotating Cylinder Apparatus, by Group, 2017-2040 (USD Thousand) 101
Table 58. Global Dissolution Equipment Market Size, by Rotating Cylinder Apparatus, by Country, 2017-2040 (USD Thousand) 102
Table 59. Global Dissolution Equipment Market Size, by Rotating-Disk Apparatus, by Region, 2017-2040 (USD Thousand) 104
Table 60. Global Dissolution Equipment Market Size, by Rotating-Disk Apparatus, by Group, 2017-2040 (USD Thousand) 104
Table 61. Global Dissolution Equipment Market Size, by Rotating-Disk Apparatus, by Country, 2017-2040 (USD Thousand) 105
Table 62. Global Dissolution Equipment Market Size, by Mechanical Chewing Apparatus, by Region, 2017-2040 (USD Thousand) 107
Table 63. Global Dissolution Equipment Market Size, by Mechanical Chewing Apparatus, by Group, 2017-2040 (USD Thousand) 107
Table 64. Global Dissolution Equipment Market Size, by Mechanical Chewing Apparatus, by Country, 2017-2040 (USD Thousand) 108
Table 65. Global Dissolution Equipment Market Size, by Stationary-Disk Apparatus, by Region, 2017-2040 (USD Thousand) 110
Table 66. Global Dissolution Equipment Market Size, by Stationary-Disk Apparatus, by Group, 2017-2040 (USD Thousand) 110

Table 67. Global Dissolution Equipment Market Size, by Stationary-Disk Apparatus, by Country, 2017-2040 (USD Thousand) 111
Table 68. Global Dissolution Equipment Market Size, by Agitated-Bottle Apparatus, by Region, 2017-2040 (USD Thousand) 113
Table 69. Global Dissolution Equipment Market Size, by Agitated-Bottle Apparatus, by Group, 2017-2040 (USD Thousand) 113
Table 70. Global Dissolution Equipment Market Size, by Agitated-Bottle Apparatus, by Country, 2017-2040 (USD Thousand) 114
Table 71. Global Dissolution Equipment Market, by Analytical Detection growth contribution, 2025-2032 (USD Million) 118
Table 72. Global Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 118
Table 73. Global Dissolution Equipment Market Size, by No Integrated Detection, by Region, 2017-2040 (USD Million) 119
Table 74. Global Dissolution Equipment Market Size, by No Integrated Detection, by Group, 2017-2040 (USD Million) 119
Table 75. Global Dissolution Equipment Market Size, by No Integrated Detection, by Country, 2017-2040 (USD Million) 120
Table 76. Global Dissolution Equipment Market, by Direct UV-Vis Detection growth contribution, 2025-2032 (USD Million) 122
Table 77. Global Dissolution Equipment Market Size, by Direct UV-Vis Detection, by Region, 2017-2040 (USD Million) 122
Table 78. Global Dissolution Equipment Market Size, by Direct UV-Vis Detection, by Group, 2017-2040 (USD Million) 123
Table 79. Global Dissolution Equipment Market Size, by Direct UV-Vis Detection, by Country, 2017-2040 (USD Million) 123
Table 80. Global Dissolution Equipment Market Size, by External-Cell UV-Vis Spectrophotometry, by Region, 2017-2040 (USD Million) 125
Table 81. Global Dissolution Equipment Market Size, by External-Cell UV-Vis Spectrophotometry, by Group, 2017-2040 (USD Million) 126
Table 82. Global Dissolution Equipment Market Size, by External-Cell UV-Vis Spectrophotometry, by Country, 2017-2040 (USD Million) 126
Table 83. Global Dissolution Equipment Market Size, by In Situ Fiber-Optic UV-Vis Spectrophotometry, by Region, 2017-2040 (USD Million) 128
Table 84. Global Dissolution Equipment Market Size, by In Situ Fiber-Optic UV-Vis Spectrophotometry, by Group, 2017-2040 (USD Million) 129
Table 85. Global Dissolution Equipment Market Size, by In Situ Fiber-Optic UV-Vis Spectrophotometry, by Country, 2017-2040 (USD Million) 129
Table 86. Global Dissolution Equipment Market Size, by UV-Vis Dissolution Imaging, by Region, 2017-2040 (USD Million) 131
Table 87. Global Dissolution Equipment Market Size, by UV-Vis Dissolution Imaging, by Group, 2017-2040 (USD Thousand) 132
Table 88. Global Dissolution Equipment Market Size, by UV-Vis Dissolution Imaging, by Country, 2017-2040 (USD Million) 132

Table 89. Global Dissolution Equipment Market Size, by Liquid Chromatography, by Region, 2017-2040 (USD Million) 134
Table 90. Global Dissolution Equipment Market Size, by Liquid Chromatography, by Group, 2017-2040 (USD Million) 135
Table 91. Global Dissolution Equipment Market Size, by Liquid Chromatography, by Country, 2017-2040 (USD Million) 135
Table 92. Global Dissolution Equipment Market, by Testing Purpose growth contribution, 2025-2032 (USD Million) 140
Table 93. Global Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 140
Table 94. Global Dissolution Equipment Market Size, by Batch Quality Control and Stability Testing, by Region, 2017-2040 (USD Million) 141
Table 95. Global Dissolution Equipment Market Size, by Batch Quality Control and Stability Testing, by Group, 2017-2040 (USD Million) 141
Table 96. Global Dissolution Equipment Market Size, by Batch Quality Control and Stability Testing, by Country, 2017-2040 (USD Million) 142
Table 97. Global Dissolution Equipment Market Size, by Research and Development, by Region, 2017-2040 (USD Million) 144
Table 98. Global Dissolution Equipment Market Size, by Research and Development, by Group, 2017-2040 (USD Million) 144
Table 99. Global Dissolution Equipment Market Size, by Research and Development, by Country, 2017-2040 (USD Million) 145
Table 100. Global Dissolution Equipment Market Size, by Regulatory Equivalence and Change Assessment, by Region, 2017-2040 (USD Million) 147
Table 101. Global Dissolution Equipment Market Size, by Regulatory Equivalence and Change Assessment, by Group, 2017-2040 (USD Million) 147
Table 102. Global Dissolution Equipment Market Size, by Regulatory Equivalence and Change Assessment, by Country, 2017-2040 (USD Million) 148
Table 103. Global Dissolution Equipment Market Size, by Education and Training, by Region, 2017-2040 (USD Million) 150
Table 104. Global Dissolution Equipment Market Size, by Education and Training, by Group, 2017-2040 (USD Thousand) 150
Table 105. Global Dissolution Equipment Market Size, by Education and Training, by Country, 2017-2040 (USD Thousand) 151
Table 106. Global Dissolution Equipment Market Size, by Post-Market Quality Surveillance, by Region, 2017-2040 (USD Thousand) 153
Table 107. Global Dissolution Equipment Market Size, by Post-Market Quality Surveillance, by Group, 2017-2040 (USD Thousand) 153
Table 108. Global Dissolution Equipment Market Size, by Post-Market Quality Surveillance, by Country, 2017-2040 (USD Thousand) 154
Table 109. Global Dissolution Equipment Market, by End User growth contribution, 2025-2032 (USD Million) 159
Table 110. Global Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 159
Table 111. Global Dissolution Equipment Market Size, by Pharmaceutical Product Companies, by Region, 2017-2040 (USD Million) 160

Table 112. Global Dissolution Equipment Market Size, by Pharmaceutical Product Companies, by Group, 2017-2040 (USD Million) 160
Table 113. Global Dissolution Equipment Market Size, by Pharmaceutical Product Companies, by Country, 2017-2040 (USD Million) 161
Table 114. Global Dissolution Equipment Market Size, by Contract Research and Testing Organizations, by Region, 2017-2040 (USD Million) 163
Table 115. Global Dissolution Equipment Market Size, by Contract Research and Testing Organizations, by Group, 2017-2040 (USD Million) 163
Table 116. Global Dissolution Equipment Market Size, by Contract Research and Testing Organizations, by Country, 2017-2040 (USD Million) 164
Table 117. Global Dissolution Equipment Market Size, by Pharmaceutical Ingredient Companies, by Region, 2017-2040 (USD Million) 166
Table 118. Global Dissolution Equipment Market Size, by Pharmaceutical Ingredient Companies, by Group, 2017-2040 (USD Million) 166
Table 119. Global Dissolution Equipment Market Size, by Pharmaceutical Ingredient Companies, by Country, 2017-2040 (USD Million) 167
Table 120. Global Dissolution Equipment Market Size, by Academic and Noncommercial Research Institutions, by Region, 2017-2040 (USD Million) 169
Table 121. Global Dissolution Equipment Market Size, by Academic and Noncommercial Research Institutions, by Group, 2017-2040 (USD Million) 169
Table 122. Global Dissolution Equipment Market Size, by Academic and Noncommercial Research Institutions, by Country, 2017-2040 (USD Million) 170
Table 123. Global Dissolution Equipment Market Size, by Dietary Supplement Companies, by Region, 2017-2040 (USD Million) 172
Table 124. Global Dissolution Equipment Market Size, by Dietary Supplement Companies, by Group, 2017-2040 (USD Million) 172
Table 125. Global Dissolution Equipment Market Size, by Dietary Supplement Companies, by Country, 2017-2040 (USD Million) 173
Table 126. Global Dissolution Equipment Market Size, by Public Medicines-Control Laboratories, by Region, 2017-2040 (USD Million) 175
Table 127. Global Dissolution Equipment Market Size, by Public Medicines-Control Laboratories, by Group, 2017-2040 (USD Thousand) 175
Table 128. Global Dissolution Equipment Market Size, by Public Medicines-Control Laboratories, by Country, 2017-2040 (USD Thousand) 176
Table 129. Global Dissolution Equipment Market, by Automation Level growth contribution, 2025-2032 (USD Million) 180
Table 130. Global Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 181
Table 131. Global Dissolution Equipment Market Size, by Semi-Automated, by Region, 2017-2040 (USD Million) 181
Table 132. Global Dissolution Equipment Market Size, by Semi-Automated, by Group, 2017-2040 (USD Million) 182
Table 133. Global Dissolution Equipment Market Size, by Semi-Automated, by Country, 2017-2040 (USD Million) 182

Table 134. Global Dissolution Equipment Market Size, by Fully Automated, by Region, 2017-2040 (USD Million) 184
Table 135. Global Dissolution Equipment Market Size, by Fully Automated, by Group, 2017-2040 (USD Million) 185
Table 136. Global Dissolution Equipment Market Size, by Fully Automated, by Country, 2017-2040 (USD Million) 185
Table 137. Global Dissolution Equipment Market Size, by Manual, by Region, 2017-2040 (USD Million) 187
Table 138. Global Dissolution Equipment Market Size, by Manual, by Group, 2017-2040 (USD Million) 188
Table 139. Global Dissolution Equipment Market Size, by Manual, by Country, 2017-2040 (USD Million) 188
Table 140. Global Dissolution Equipment Market, by Sales Channel growth contribution, 2025-2032 (USD Million) 192
Table 141. Global Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 192
Table 142. Global Dissolution Equipment Market Size, by Direct Sales, by Region, 2017-2040 (USD Million) 193
Table 143. Global Dissolution Equipment Market Size, by Direct Sales, by Group, 2017-2040 (USD Million) 193
Table 144. Global Dissolution Equipment Market Size, by Direct Sales, by Country, 2017-2040 (USD Million) 194
Table 145. Global Dissolution Equipment Market Size, by Indirect Sales, by Region, 2017-2040 (USD Million) 196
Table 146. Global Dissolution Equipment Market Size, by Indirect Sales, by Group, 2017-2040 (USD Million) 196
Table 147. Global Dissolution Equipment Market Size, by Indirect Sales, by Country, 2017-2040 (USD Million) 197
Table 148. Global Dissolution Equipment Market, by Tested Product growth contribution, 2025-2032 (USD Million) 201
Table 149. Global Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 202
Table 150. Global Dissolution Equipment Market, by Pharmaceutical Dosage Forms growth contribution, 2025-2032 (USD Million) 202
Table 151. Global Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, by Region, 2017-2040 (USD Million) 203
Table 152. Global Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, by Group, 2017-2040 (USD Million) 203
Table 153. Global Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, by Country, 2017-2040 (USD Million) 204
Table 154. Global Dissolution Equipment Market Size, by Oral Dosage Forms, by Region, 2017-2040 (USD Million) 206
Table 155. Global Dissolution Equipment Market Size, by Oral Dosage Forms, by Group, 2017-2040 (USD Million) 206

Table 156. Global Dissolution Equipment Market Size, by Oral Dosage Forms, by Country, 2017-2040 (USD Million) 207
Table 157. Global Dissolution Equipment Market Size, by Parenteral Dosage Forms, by Region, 2017-2040 (USD Million) 209
Table 158. Global Dissolution Equipment Market Size, by Parenteral Dosage Forms, by Group, 2017-2040 (USD Million) 209
Table 159. Global Dissolution Equipment Market Size, by Parenteral Dosage Forms, by Country, 2017-2040 (USD Million) 210
Table 160. Global Dissolution Equipment Market Size, by Transdermal Systems, by Region, 2017-2040 (USD Million) 212
Table 161. Global Dissolution Equipment Market Size, by Transdermal Systems, by Group, 2017-2040 (USD Million) 212
Table 162. Global Dissolution Equipment Market Size, by Transdermal Systems, by Country, 2017-2040 (USD Million) 213
Table 163. Global Dissolution Equipment Market Size, by Topical & Mucosal Dosage Forms, by Region, 2017-2040 (USD Million) 215
Table 164. Global Dissolution Equipment Market Size, by Topical & Mucosal Dosage Forms, by Group, 2017-2040 (USD Million) 215
Table 165. Global Dissolution Equipment Market Size, by Topical & Mucosal Dosage Forms, by Country, 2017-2040 (USD Million) 216
Table 166. Global Dissolution Equipment Market Size, by Inhalation Dosage Forms, by Region, 2017-2040 (USD Thousand) 218
Table 167. Global Dissolution Equipment Market Size, by Inhalation Dosage Forms, by Group, 2017-2040 (USD Thousand) 218
Table 168. Global Dissolution Equipment Market Size, by Inhalation Dosage Forms, by Country, 2017-2040 (USD Thousand) 219
Table 169. Global Dissolution Equipment Market, by Drug Substances & Excipients growth contribution, 2025-2032 (USD Million) 221
Table 170. Global Dissolution Equipment Market Size, by Drug Substances & Excipients, by Region, 2017-2040 (USD Million) 221
Table 171. Global Dissolution Equipment Market Size, by Drug Substances & Excipients, by Group, 2017-2040 (USD Million) 222
Table 172. Global Dissolution Equipment Market Size, by Drug Substances & Excipients, by Country, 2017-2040 (USD Million) 222
Table 173. Global Dissolution Equipment Market Size, by Drug Substances, by Region, 2017-2040 (USD Million) 224
Table 174. Global Dissolution Equipment Market Size, by Drug Substances, by Group, 2017-2040 (USD Million) 225
Table 175. Global Dissolution Equipment Market Size, by Drug Substances, by Country, 2017-2040 (USD Million) 225
Table 176. Global Dissolution Equipment Market Size, by Excipients, by Region, 2017-2040 (USD Million) 227
Table 177. Global Dissolution Equipment Market Size, by Excipients, by Group, 2017-2040 (USD Thousand) 228

Table 178. Global Dissolution Equipment Market Size, by Excipients, by Country, 2017-2040 (USD Thousand) 228
Table 179. Global Dissolution Equipment Market Size, by Dietary Supplements, by Region, 2017-2040 (USD Million) 230
Table 180. Global Dissolution Equipment Market Size, by Dietary Supplements, by Group, 2017-2040 (USD Million) 231
Table 181. Global Dissolution Equipment Market Size, by Dietary Supplements, by Country, 2017-2040 (USD Million) 231
Table 182. Global Dissolution Equipment Market, by Region growth contribution, 2025-2032 (USD Million) 236
Table 183. Global Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 236
Table 184. Asia-Pacific Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 238
Table 185. Asia-Pacific Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 238
Table 186. Asia-Pacific Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 239
Table 187. Asia-Pacific Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 240
Table 188. Asia-Pacific Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 240
Table 189. Asia-Pacific Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 241
Table 190. Asia-Pacific Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 241
Table 191. Asia-Pacific Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 241
Table 192. Asia-Pacific Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 242
Table 193. Asia-Pacific Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 242
Table 194. Asia-Pacific Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 242
Table 195. Asia-Pacific Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 242
Table 196. Asia-Pacific Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 243
Table 197. North America Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand) 244
Table 198. North America Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 244
Table 199. North America Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 245
Table 200. North America Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 246

Table 201. North America Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 246
Table 202. North America Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 247
Table 203. North America Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 247
Table 204. North America Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 248
Table 205. North America Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 248
Table 206. North America Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 248
Table 207. North America Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 249
Table 208. North America Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 249
Table 209. North America Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 249
Table 210. Europe Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 251
Table 211. Europe Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 252
Table 212. Europe Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 253
Table 213. Europe Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 254
Table 214. Europe Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 254
Table 215. Europe Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 255
Table 216. Europe Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 255
Table 217. Europe Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 255
Table 218. Europe Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 256
Table 219. Europe Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 256
Table 220. Europe Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 256
Table 221. Europe Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 256
Table 222. Europe Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 257
Table 223. Latin America Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 258

Table 224. Latin America Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 259
Table 225. Latin America Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 259
Table 226. Latin America Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 260
Table 227. Latin America Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 260
Table 228. Latin America Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 261
Table 229. Latin America Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 261
Table 230. Latin America Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 262
Table 231. Latin America Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 262
Table 232. Latin America Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 262
Table 233. Latin America Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 263
Table 234. Latin America Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 263
Table 235. Latin America Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 263
Table 236. Middle East Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 265
Table 237. Middle East Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 265
Table 238. Middle East Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 266
Table 239. Middle East Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 267
Table 240. Middle East Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 267
Table 241. Middle East Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 268
Table 242. Middle East Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 268
Table 243. Middle East Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 268
Table 244. Middle East Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 269
Table 245. Middle East Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 269

Table 246. Middle East Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 269
Table 247. Middle East Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 269
Table 248. Middle East Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 270
Table 249. Africa Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 271
Table 250. Africa Dissolution Equipment Market Size, by Region, 2017-2040 (USD Million) 271
Table 251. Africa Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 272
Table 252. Africa Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 273
Table 253. Africa Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 273
Table 254. Africa Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 274
Table 255. Africa Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Thousand) 274
Table 256. Africa Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 274
Table 257. Africa Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 275
Table 258. Africa Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 275
Table 259. Africa Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 275
Table 260. Africa Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 275
Table 261. Africa Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 276
Table 262. Global Dissolution Equipment Market Size, by Group, 2017-2040 (USD Million) 279
Table 263. NATO Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand) 280
Table 264. NATO Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand) 281
Table 265. NATO Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 282
Table 266. NATO Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Million) 283
Table 267. NATO Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 283
Table 268. NATO Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 284
Table 269. NATO Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 284

Table 270. NATO Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 284
Table 271. NATO Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 285
Table 272. NATO Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 285
Table 273. NATO Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 285
Table 274. NATO Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 285
Table 275. NATO Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 286
Table 276. G7 Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 288
Table 277. G7 Dissolution Equipment Market Size, by Group, 2017-2040 (USD Million) 288
Table 278. G7 Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 289
Table 279. G7 Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Million) 290
Table 280. G7 Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 290
Table 281. G7 Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 291
Table 282. G7 Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 291
Table 283. G7 Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 291
Table 284. G7 Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 292
Table 285. G7 Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 292
Table 286. G7 Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 292
Table 287. G7 Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 292
Table 288. G7 Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 293
Table 289. BRICS Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 294
Table 290. BRICS Dissolution Equipment Market Size, by Group, 2017-2040 (USD Million) 294
Table 291. BRICS Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 295
Table 292. BRICS Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 296
Table 293. BRICS Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 296
Table 294. BRICS Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 297

Table 295. BRICS Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 297
Table 296. BRICS Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 297
Table 297. BRICS Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 298
Table 298. BRICS Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 298
Table 299. BRICS Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 298
Table 300. BRICS Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 298
Table 301. BRICS Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 299
Table 302. European Union Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand) 301
Table 303. European Union Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand) 302
Table 304. European Union Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 303
Table 305. European Union Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 304
Table 306. European Union Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 304
Table 307. European Union Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 305
Table 308. European Union Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 305
Table 309. European Union Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 306
Table 310. European Union Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 306
Table 311. European Union Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 306
Table 312. European Union Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 307
Table 313. European Union Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 307
Table 314. European Union Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 307
Table 315. ASEAN Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand) 309
Table 316. ASEAN Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand) 309
Table 317. ASEAN Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 310

Table 318. ASEAN Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 311
Table 319. ASEAN Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 311
Table 320. ASEAN Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 312
Table 321. ASEAN Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 312
Table 322. ASEAN Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 312
Table 323. ASEAN Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 313
Table 324. ASEAN Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 313
Table 325. ASEAN Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 313
Table 326. ASEAN Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 313
Table 327. ASEAN Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 314
Table 328. GCC Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Thousand) 315
Table 329. GCC Dissolution Equipment Market Size, by Group, 2017-2040 (USD Thousand) 315
Table 330. GCC Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 316
Table 331. GCC Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 317
Table 332. GCC Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 317
Table 333. GCC Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Thousand) 318
Table 334. GCC Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Thousand) 318
Table 335. GCC Dissolution Equipment Market Size, by End User, 2017-2040 (USD Thousand) 318
Table 336. GCC Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 319
Table 337. GCC Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 319
Table 338. GCC Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 319
Table 339. GCC Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 319
Table 340. GCC Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 320

Table 341. Global Dissolution Equipment Market, by Country growth contribution, 2025-2032 (USD Million) 324
Table 342. Global Dissolution Equipment Market Size, by Country, 2017-2040 (USD Million) 325
Table 343. United States Dissolution Equipment Market Size, 2017-2040 (USD Million) 326
Table 344. United States Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 327
Table 345. United States Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 328
Table 346. United States Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 328
Table 347. United States Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 329
Table 348. United States Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 329
Table 349. United States Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 330
Table 350. United States Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 330
Table 351. United States Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 330
Table 352. United States Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 331
Table 353. United States Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 331
Table 354. United States Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 331
Table 355. China Dissolution Equipment Market Size, 2017-2040 (USD Million) 332
Table 356. China Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 333
Table 357. China Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 334
Table 358. China Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 334
Table 359. China Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 335
Table 360. China Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 335
Table 361. China Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 335
Table 362. China Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 336
Table 363. China Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 336
Table 364. China Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 336

Table 365. China Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 336
Table 366. China Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 337
Table 367. India Dissolution Equipment Market Size, 2017-2040 (USD Million) 337
Table 368. India Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 338
Table 369. India Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 339
Table 370. India Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 339
Table 371. India Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 340
Table 372. India Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 340
Table 373. India Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 340
Table 374. India Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 341
Table 375. India Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 341
Table 376. India Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 341
Table 377. India Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Million) 341
Table 378. India Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 342
Table 379. Germany Dissolution Equipment Market Size, 2017-2040 (USD Million) 342
Table 380. Germany Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 343
Table 381. Germany Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 344
Table 382. Germany Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 344
Table 383. Germany Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 345
Table 384. Germany Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 345
Table 385. Germany Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 345
Table 386. Germany Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 346
Table 387. Germany Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 346

Table 388. Germany Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 346
Table 389. Germany Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 346
Table 390. Germany Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 347
Table 391. Japan Dissolution Equipment Market Size, 2017-2040 (USD Million) 347
Table 392. Japan Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 348
Table 393. Japan Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 349
Table 394. Japan Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 349
Table 395. Japan Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 350
Table 396. Japan Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 350
Table 397. Japan Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 350
Table 398. Japan Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 351
Table 399. Japan Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 351
Table 400. Japan Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 351
Table 401. Japan Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 351
Table 402. Japan Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Million) 352
Table 403. France Dissolution Equipment Market Size, 2017-2040 (USD Million) 352
Table 404. France Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Million) 353
Table 405. France Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 354
Table 406. France Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 354
Table 407. France Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 355
Table 408. France Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 355
Table 409. France Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 355
Table 410. France Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 356
Table 411. France Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 356

Table 412. France Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 356
Table 413. France Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 356
Table 414. France Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 357
Table 415. Italy Dissolution Equipment Market Size, 2017-2040 (USD Million) 357
Table 416. Italy Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 358
Table 417. Italy Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 359
Table 418. Italy Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 359
Table 419. Italy Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 360
Table 420. Italy Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 360
Table 421. Italy Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 360
Table 422. Italy Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 361
Table 423. Italy Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 361
Table 424. Italy Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 361
Table 425. Italy Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 361
Table 426. Italy Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 362
Table 427. South Korea Dissolution Equipment Market Size, 2017-2040 (USD Million) 362
Table 428. South Korea Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 363
Table 429. South Korea Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 364
Table 430. South Korea Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 364
Table 431. South Korea Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 365
Table 432. South Korea Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 365
Table 433. South Korea Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 365
Table 434. South Korea Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 366

Table 435. South Korea Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 366
Table 436. South Korea Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 366
Table 437. South Korea Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 366
Table 438. South Korea Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 367
Table 439. Canada Dissolution Equipment Market Size, 2017-2040 (USD Million) 367
Table 440. Canada Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 368
Table 441. Canada Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 369
Table 442. Canada Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 369
Table 443. Canada Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 370
Table 444. Canada Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 370
Table 445. Canada Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 370
Table 446. Canada Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 371
Table 447. Canada Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 371
Table 448. Canada Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 371
Table 449. Canada Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 371
Table 450. Canada Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 372
Table 451. United Kingdom Dissolution Equipment Market Size, 2017-2040 (USD Million) 372
Table 452. United Kingdom Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 373
Table 453. United Kingdom Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 374
Table 454. United Kingdom Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 374
Table 455. United Kingdom Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 375
Table 456. United Kingdom Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 375
Table 457. United Kingdom Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 376

Table 458. United Kingdom Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 376
Table 459. United Kingdom Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 376
Table 460. United Kingdom Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 377
Table 461. United Kingdom Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 377
Table 462. United Kingdom Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 377
Table 463. Mexico Dissolution Equipment Market Size, 2017-2040 (USD Million) 378
Table 464. Mexico Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 379
Table 465. Mexico Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 380
Table 466. Mexico Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 380
Table 467. Mexico Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 381
Table 468. Mexico Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 381
Table 469. Mexico Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 381
Table 470. Mexico Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 382
Table 471. Mexico Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 382
Table 472. Mexico Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 382
Table 473. Mexico Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 382
Table 474. Mexico Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 383
Table 475. Spain Dissolution Equipment Market Size, 2017-2040 (USD Million) 383
Table 476. Spain Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 384
Table 477. Spain Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 385
Table 478. Spain Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 385
Table 479. Spain Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 386
Table 480. Spain Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 386
Table 481. Spain Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 386

Table 482. Spain Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 387
Table 483. Spain Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 387
Table 484. Spain Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 387
Table 485. Spain Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 387
Table 486. Spain Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 388
Table 487. Russia Dissolution Equipment Market Size, 2017-2040 (USD Million) 388
Table 488. Russia Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 389
Table 489. Russia Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 390
Table 490. Russia Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 390
Table 491. Russia Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 391
Table 492. Russia Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 391
Table 493. Russia Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 391
Table 494. Russia Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 392
Table 495. Russia Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 392
Table 496. Russia Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 392
Table 497. Russia Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 392
Table 498. Russia Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 393
Table 499. Brazil Dissolution Equipment Market Size, 2017-2040 (USD Million) 393
Table 500. Brazil Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 394
Table 501. Brazil Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 395
Table 502. Brazil Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 395
Table 503. Brazil Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 396
Table 504. Brazil Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Million) 396
Table 505. Brazil Dissolution Equipment Market Size, by End User, 2017-2040 (USD Million) 396

Table 506. Brazil Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 397
Table 507. Brazil Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 397
Table 508. Brazil Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 397
Table 509. Brazil Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 397
Table 510. Brazil Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 398
Table 511. Australia Dissolution Equipment Market Size, 2017-2040 (USD Million) 398
Table 512. Australia Dissolution Equipment Market Size, by Product Type, 2017-2040 (USD Thousand) 399
Table 513. Australia Dissolution Equipment Market Size, by Apparatus Platform, 2017-2040 (USD Thousand) 400
Table 514. Australia Dissolution Equipment Market Size, by Analytical Detection, 2017-2040 (USD Million) 400
Table 515. Australia Dissolution Equipment Market Size, by Direct UV-Vis Detection, 2017-2040 (USD Million) 401
Table 516. Australia Dissolution Equipment Market Size, by Testing Purpose, 2017-2040 (USD Thousand) 401
Table 517. Australia Dissolution Equipment Market Size, by End User, 2017-2040 (USD Thousand) 401
Table 518. Australia Dissolution Equipment Market Size, by Automation Level, 2017-2040 (USD Million) 402
Table 519. Australia Dissolution Equipment Market Size, by Sales Channel, 2017-2040 (USD Million) 402
Table 520. Australia Dissolution Equipment Market Size, by Tested Product, 2017-2040 (USD Million) 402
Table 521. Australia Dissolution Equipment Market Size, by Pharmaceutical Dosage Forms, 2017-2040 (USD Thousand) 402
Table 522. Australia Dissolution Equipment Market Size, by Drug Substances & Excipients, 2017-2040 (USD Thousand) 403
Table 523. Global Dissolution Equipment Market Share, by Key Player, 2025 406
Table 524. Global Dissolution Equipment Market, Companies Covered 421
Table 525. Global Dissolution Equipment Market, Key Experts 430

Contributors



Shikha Sachan

Chief Executive Officer

A transformational leader with a strong focus on integrating new technology frameworks into market research. She focuses on reshaping business models in line with evolving technologies and geopolitical shifts, while actively engaging with decision-makers and experts to deliver trustworthy insights, strategic clarity, and lasting business value.



Shraddha Bhirud

Research Manager

With extensive experience in market intelligence, leads complex client engagements by overseeing multiple research projects from initiation to delivery. Strengthens research operations timely through standardized methods, process optimization, and cross-functional collaboration while supporting sales initiatives. Her commitment to quality, and client success ensures the delivery of actionable insights.



Vivek Paymode

Research Lead

Oversees end-to-end research engagements by mentoring analysts and delivering reliable market intelligence. Specializes in industry analysis, company profiling, trend evaluation, opportunity assessment, and quality assurance. Collaborates closely with clients and internal teams to ensure actionable insights that support informed strategic business decisions.



Shailesh Sachan

Research Lead

Leads market intelligence projects by guiding research analysts and ensuring accurate, insight-driven deliverables. Specializes in competitive benchmarking, market assessment, research planning, data validation, and project execution. Delivers high-quality outcomes through effective client coordination, structured workflows, and consistent adherence to project timelines and quality standards.

360iResearch

Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

Global Information | RESEARCH AND MARKETS THE WORLD'S LARGEST MARKET RESEARCH STORE | Market Research.com

© 360iResearch 2026

All Rights Reserved. This document contains highly confidential information and is the sole property of 360iResearch. No part of it may be circulated, copied, quoted, or otherwise reproduced without the written approval of 360iResearch.